
<html lang="en"     class="pb-page"  data-request-id="9c91eca3-66f5-43f7-8282-35c55e99d27b"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2021.64.issue-5;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.0c01922;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Unique Molecular Interaction with the Histone Deacetylase 6 Catalytic Tunnel: Crystallographic and Biological Characterization of a Model Chemotype" /></meta><meta name="dc.Creator" content="Olasunkanmi O.  Olaoye" /></meta><meta name="dc.Creator" content="Paris R.  Watson" /></meta><meta name="dc.Creator" content="Nabanita  Nawar" /></meta><meta name="dc.Creator" content="Mulu  Geletu" /></meta><meta name="dc.Creator" content="Abootaleb  Sedighi" /></meta><meta name="dc.Creator" content="Shazreh  Bukhari" /></meta><meta name="dc.Creator" content="Yasir S.  Raouf" /></meta><meta name="dc.Creator" content="Pimyupa  Manaswiyoungkul" /></meta><meta name="dc.Creator" content="Fettah  Erdogan" /></meta><meta name="dc.Creator" content="Ayah  Abdeldayem" /></meta><meta name="dc.Creator" content="Aaron D.  Cabral" /></meta><meta name="dc.Creator" content="Muhammad Murtaza  Hassan" /></meta><meta name="dc.Creator" content="Krimo  Toutah" /></meta><meta name="dc.Creator" content="Andrew E.  Shouksmith" /></meta><meta name="dc.Creator" content="Justyna M.  Gawel" /></meta><meta name="dc.Creator" content="Johan  Israelian" /></meta><meta name="dc.Creator" content="Tudor B.  Radu" /></meta><meta name="dc.Creator" content="Niyati  Kachhiyapatel" /></meta><meta name="dc.Creator" content="Elvin D.  de Araujo" /></meta><meta name="dc.Creator" content="David W.  Christianson" /></meta><meta name="dc.Creator" content="Patrick T.  Gunning" /></meta><meta name="dc.Description" content="Histone deacetylase 6 (HDAC6) is involved in multiple regulatory processes, ranging from cellular stress to intracellular transport. Inhibition of aberrant HDAC6 activity in several cancers and neu..." /></meta><meta name="Description" content="Histone deacetylase 6 (HDAC6) is involved in multiple regulatory processes, ranging from cellular stress to intracellular transport. Inhibition of aberrant HDAC6 activity in several cancers and neu..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 12, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01922" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01922" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01922" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01922" /></link>
        
    
    

<title>Unique Molecular Interaction with the Histone Deacetylase 6 Catalytic Tunnel: Crystallographic and Biological Characterization of a Model Chemotype | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01922" /></meta><meta property="og:title" content="Unique Molecular Interaction with the Histone Deacetylase 6 Catalytic Tunnel: Crystallographic and Biological Characterization of a Model Chemotype" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/large/jm0c01922_0016.jpeg" /></meta><meta property="og:description" content="Histone deacetylase 6 (HDAC6) is involved in multiple regulatory processes, ranging from cellular stress to intracellular transport. Inhibition of aberrant HDAC6 activity in several cancers and neurological diseases has been shown to be efficacious in both preclinical and clinical studies. While selective HDAC6 targeting has been pursued as an alternative to pan-HDAC drugs, identifying truly selective molecular templates has not been trivial. Herein, we report a structure–activity relationship study yielding TO-317, which potently binds HDAC6 catalytic domain 2 (Ki = 0.7 nM) and inhibits the enzyme function (IC50 = 2 nM). TO-317 exhibits 158-fold selectivity for HDAC6 over other HDAC isozymes by binding the catalytic Zn2+ and, uniquely, making a never seen before direct hydrogen bond with the Zn2+ coordinating residue, His614. This novel structural motif targeting the second-sphere His614 interaction, observed in a 1.84 Å resolution crystal structure with drHDAC6 from zebrafish, can provide new pharmacophores for identifying enthalpically driven, high-affinity, HDAC6-selective inhibitors." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01922"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01922">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01922&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01922&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01922&amp;href=/doi/10.1021/acs.jmedchem.0c01922" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 5</span><span class="cit-fg-pageRange">, 2691-2704</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/5" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c01875" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c01957" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Unique Molecular Interaction with the Histone Deacetylase 6 Catalytic Tunnel: Crystallographic and Biological Characterization of a Model Chemotype</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Olasunkanmi O. Olaoye</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Olasunkanmi O. Olaoye</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemical and Physical Sciences, University of Toronto Mississauga, 3359 Mississauga Rd N., Mississauga, Ontario L5L 1C6, Canada</div><div class="loa-info-affiliations-info">Department of Chemistry, University of Toronto, 80 St. George Street, Toronto, Ontario M5S 3H6, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Olasunkanmi+O.++Olaoye">Olasunkanmi O. Olaoye</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Paris R. Watson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Paris R. Watson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Roy and Diana Vagelos Laboratories, Department of Chemistry, University of Pennsylvania, 231 South 34th Street, Philadelphia, Pennsylvania 19104-6323, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Paris+R.++Watson">Paris R. Watson</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Nabanita Nawar</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nabanita Nawar</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemical and Physical Sciences, University of Toronto Mississauga, 3359 Mississauga Rd N., Mississauga, Ontario L5L 1C6, Canada</div><div class="loa-info-affiliations-info">Department of Chemistry, University of Toronto, 80 St. George Street, Toronto, Ontario M5S 3H6, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nabanita++Nawar">Nabanita Nawar</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mulu Geletu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mulu Geletu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemical and Physical Sciences, University of Toronto Mississauga, 3359 Mississauga Rd N., Mississauga, Ontario L5L 1C6, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mulu++Geletu">Mulu Geletu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Abootaleb Sedighi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Abootaleb Sedighi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemical and Physical Sciences, University of Toronto Mississauga, 3359 Mississauga Rd N., Mississauga, Ontario L5L 1C6, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Abootaleb++Sedighi">Abootaleb Sedighi</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5974-1792" title="Orcid link">http://orcid.org/0000-0001-5974-1792</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Shazreh Bukhari</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shazreh Bukhari</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemical and Physical Sciences, University of Toronto Mississauga, 3359 Mississauga Rd N., Mississauga, Ontario L5L 1C6, Canada</div><div class="loa-info-affiliations-info">Department of Chemistry, University of Toronto, 80 St. George Street, Toronto, Ontario M5S 3H6, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shazreh++Bukhari">Shazreh Bukhari</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yasir S. Raouf</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yasir S. Raouf</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemical and Physical Sciences, University of Toronto Mississauga, 3359 Mississauga Rd N., Mississauga, Ontario L5L 1C6, Canada</div><div class="loa-info-affiliations-info">Department of Chemistry, University of Toronto, 80 St. George Street, Toronto, Ontario M5S 3H6, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yasir+S.++Raouf">Yasir S. Raouf</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Pimyupa Manaswiyoungkul</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Pimyupa Manaswiyoungkul</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemical and Physical Sciences, University of Toronto Mississauga, 3359 Mississauga Rd N., Mississauga, Ontario L5L 1C6, Canada</div><div class="loa-info-affiliations-info">Department of Chemistry, University of Toronto, 80 St. George Street, Toronto, Ontario M5S 3H6, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Pimyupa++Manaswiyoungkul">Pimyupa Manaswiyoungkul</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Fettah Erdogan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Fettah Erdogan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemical and Physical Sciences, University of Toronto Mississauga, 3359 Mississauga Rd N., Mississauga, Ontario L5L 1C6, Canada</div><div class="loa-info-affiliations-info">Department of Chemistry, University of Toronto, 80 St. George Street, Toronto, Ontario M5S 3H6, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Fettah++Erdogan">Fettah Erdogan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ayah Abdeldayem</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ayah Abdeldayem</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemical and Physical Sciences, University of Toronto Mississauga, 3359 Mississauga Rd N., Mississauga, Ontario L5L 1C6, Canada</div><div class="loa-info-affiliations-info">Department of Chemistry, University of Toronto, 80 St. George Street, Toronto, Ontario M5S 3H6, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ayah++Abdeldayem">Ayah Abdeldayem</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Aaron D. Cabral</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Aaron D. Cabral</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemical and Physical Sciences, University of Toronto Mississauga, 3359 Mississauga Rd N., Mississauga, Ontario L5L 1C6, Canada</div><div class="loa-info-affiliations-info">Department of Chemistry, University of Toronto, 80 St. George Street, Toronto, Ontario M5S 3H6, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Aaron+D.++Cabral">Aaron D. Cabral</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Muhammad Murtaza Hassan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Muhammad Murtaza Hassan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemical and Physical Sciences, University of Toronto Mississauga, 3359 Mississauga Rd N., Mississauga, Ontario L5L 1C6, Canada</div><div class="loa-info-affiliations-info">Department of Chemistry, University of Toronto, 80 St. George Street, Toronto, Ontario M5S 3H6, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Muhammad+Murtaza++Hassan">Muhammad Murtaza Hassan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Krimo Toutah</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Krimo Toutah</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemical and Physical Sciences, University of Toronto Mississauga, 3359 Mississauga Rd N., Mississauga, Ontario L5L 1C6, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Krimo++Toutah">Krimo Toutah</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Andrew E. Shouksmith</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Andrew E. Shouksmith</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemical and Physical Sciences, University of Toronto Mississauga, 3359 Mississauga Rd N., Mississauga, Ontario L5L 1C6, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Andrew+E.++Shouksmith">Andrew E. Shouksmith</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Justyna M. Gawel</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Justyna M. Gawel</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemical and Physical Sciences, University of Toronto Mississauga, 3359 Mississauga Rd N., Mississauga, Ontario L5L 1C6, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Justyna+M.++Gawel">Justyna M. Gawel</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Johan Israelian</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Johan Israelian</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemical and Physical Sciences, University of Toronto Mississauga, 3359 Mississauga Rd N., Mississauga, Ontario L5L 1C6, Canada</div><div class="loa-info-affiliations-info">Department of Chemistry, University of Toronto, 80 St. George Street, Toronto, Ontario M5S 3H6, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Johan++Israelian">Johan Israelian</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tudor B. Radu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tudor B. Radu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemical and Physical Sciences, University of Toronto Mississauga, 3359 Mississauga Rd N., Mississauga, Ontario L5L 1C6, Canada</div><div class="loa-info-affiliations-info">Department of Chemistry, University of Toronto, 80 St. George Street, Toronto, Ontario M5S 3H6, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tudor+B.++Radu">Tudor B. Radu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Niyati Kachhiyapatel</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Niyati Kachhiyapatel</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemical and Physical Sciences, University of Toronto Mississauga, 3359 Mississauga Rd N., Mississauga, Ontario L5L 1C6, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Niyati++Kachhiyapatel">Niyati Kachhiyapatel</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Elvin D. de Araujo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Elvin D. de Araujo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemical and Physical Sciences, University of Toronto Mississauga, 3359 Mississauga Rd N., Mississauga, Ontario L5L 1C6, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Elvin+D.++de+Araujo">Elvin D. de Araujo</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">David W. Christianson</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">David W. Christianson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Roy and Diana Vagelos Laboratories, Department of Chemistry, University of Pennsylvania, 231 South 34th Street, Philadelphia, Pennsylvania 19104-6323, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#1b78736972685b687a68356e6b7e7575357e7f6e"><span class="__cf_email__" data-cfemail="e7848f958e94a7948694c99297828989c9828392">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=David+W.++Christianson">David W. Christianson</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0194-5212" title="Orcid link">http://orcid.org/0000-0002-0194-5212</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Patrick T. Gunning</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Patrick T. Gunning</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemical and Physical Sciences, University of Toronto Mississauga, 3359 Mississauga Rd N., Mississauga, Ontario L5L 1C6, Canada</div><div class="loa-info-affiliations-info">Department of Chemistry, University of Toronto, 80 St. George Street, Toronto, Ontario M5S 3H6, Canada</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#0979687d7b606a62276e7c676760676e497c7d667b66677d66276a68"><span class="__cf_email__" data-cfemail="ec9c8d989e858f87c28b99828285828bac9998839e83829883c28f8d">[email protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Patrick+T.++Gunning">Patrick T. Gunning</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0654-735X" title="Orcid link">http://orcid.org/0000-0003-0654-735X</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01922&amp;href=/doi/10.1021%2Facs.jmedchem.0c01922" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 5</span><span class="cit-pageRange">, 2691–2704</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">February 12, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>6 November 2020</li><li><span class="item_label"><b>Published</b> online</span>12 February 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 11 March 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01922" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01922</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D2691%26pageCount%3D14%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DOlasunkanmi%2BO.%2BOlaoye%252C%2BParis%2BR.%2BWatson%252C%2BNabanita%2BNawar%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D5%26contentID%3Dacs.jmedchem.0c01922%26title%3DUnique%2BMolecular%2BInteraction%2Bwith%2Bthe%2BHistone%2BDeacetylase%2B6%2BCatalytic%2BTunnel%253A%2BCrystallographic%2Band%2BBiological%2BCharacterization%2Bof%2Ba%2BModel%2BChemotype%26numPages%3D14%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D2704%26publicationDate%3DMarch%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01922"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1126</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">1</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01922" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Unique Molecular Interaction with the Histone Deacetylase 6 Catalytic Tunnel: Crystallographic and Biological Characterization of a Model Chemotype&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Olasunkanmi&quot;,&quot;last_name&quot;:&quot;O. Olaoye&quot;},{&quot;first_name&quot;:&quot;Paris&quot;,&quot;last_name&quot;:&quot;R. Watson&quot;},{&quot;first_name&quot;:&quot;Nabanita&quot;,&quot;last_name&quot;:&quot;Nawar&quot;},{&quot;first_name&quot;:&quot;Mulu&quot;,&quot;last_name&quot;:&quot;Geletu&quot;},{&quot;first_name&quot;:&quot;Abootaleb&quot;,&quot;last_name&quot;:&quot;Sedighi&quot;},{&quot;first_name&quot;:&quot;Shazreh&quot;,&quot;last_name&quot;:&quot;Bukhari&quot;},{&quot;first_name&quot;:&quot;Yasir&quot;,&quot;last_name&quot;:&quot;S. Raouf&quot;},{&quot;first_name&quot;:&quot;Pimyupa&quot;,&quot;last_name&quot;:&quot;Manaswiyoungkul&quot;},{&quot;first_name&quot;:&quot;Fettah&quot;,&quot;last_name&quot;:&quot;Erdogan&quot;},{&quot;first_name&quot;:&quot;Ayah&quot;,&quot;last_name&quot;:&quot;Abdeldayem&quot;},{&quot;first_name&quot;:&quot;Aaron&quot;,&quot;last_name&quot;:&quot;D. Cabral&quot;},{&quot;first_name&quot;:&quot;Muhammad&quot;,&quot;last_name&quot;:&quot;Murtaza Hassan&quot;},{&quot;first_name&quot;:&quot;Krimo&quot;,&quot;last_name&quot;:&quot;Toutah&quot;},{&quot;first_name&quot;:&quot;Andrew&quot;,&quot;last_name&quot;:&quot;E. Shouksmith&quot;},{&quot;first_name&quot;:&quot;Justyna&quot;,&quot;last_name&quot;:&quot;M. Gawel&quot;},{&quot;first_name&quot;:&quot;Johan&quot;,&quot;last_name&quot;:&quot;Israelian&quot;},{&quot;first_name&quot;:&quot;Tudor&quot;,&quot;last_name&quot;:&quot;B. Radu&quot;},{&quot;first_name&quot;:&quot;Niyati&quot;,&quot;last_name&quot;:&quot;Kachhiyapatel&quot;},{&quot;first_name&quot;:&quot;Elvin&quot;,&quot;last_name&quot;:&quot;D. de Araujo&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;W. Christianson&quot;},{&quot;first_name&quot;:&quot;Patrick&quot;,&quot;last_name&quot;:&quot;T. Gunning&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;12&quot;,&quot;issue&quot;:&quot;5&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;2691-2704&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01922&quot;},&quot;abstract&quot;:&quot;Histone deacetylase 6 (HDAC6) is involved in multiple regulatory processes, ranging from cellular stress to intracellular transport. Inhibition of aberrant HDAC6 activity in several cancers and neurological diseases has been shown to be efficacious in both preclinical and clinical studies. While selective HDAC6 targeting has been pursued as an alternative to pan-HDAC drugs, identifying truly selective molecular templates has not been trivial. Herein, we report a structure–activity relationship study yielding TO-317, which potently binds HDAC6 catalytic domain 2 (Ki = 0.7 nM) and inhibits the enzyme function (IC50 = 2 nM). TO-317 exhibits 158-fold selectivity for HDAC6 over other HDAC isozymes by binding the catalytic Zn2+ and, uniquely, making a never seen before direct hydrogen bond with the Zn2+ coordinating residue, His614. This novel structural motif targeting the second-sphere His614 interaction, observed in a 1.84 Å resolution crystal structure with drHDAC6 from zebrafish, can provide new pharmacophores&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01922&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01922" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01922&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01922" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01922&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01922" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01922&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01922&amp;href=/doi/10.1021/acs.jmedchem.0c01922" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01922" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01922" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01922&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01922%26sid%3Dliteratum%253Aachs%26pmid%3D33576627%26genre%3Darticle%26aulast%3DOlaoye%26date%3D2021%26atitle%3DUnique%2BMolecular%2BInteraction%2Bwith%2Bthe%2BHistone%2BDeacetylase%2B6%2BCatalytic%2BTunnel%253A%2BCrystallographic%2Band%2BBiological%2BCharacterization%2Bof%2Ba%2BModel%2BChemotype%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D5%26spage%3D2691%26epage%3D2704%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (7)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/5" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/jmcmar.2021.64.issue-5/20210311/jmcmar.2021.64.issue-5.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/medium/jm0c01922_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/large/jm0c01922_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01922&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Histone deacetylase 6 (HDAC6) is involved in multiple regulatory processes, ranging from cellular stress to intracellular transport. Inhibition of aberrant HDAC6 activity in several cancers and neurological diseases has been shown to be efficacious in both preclinical and clinical studies. While selective HDAC6 targeting has been pursued as an alternative to pan-HDAC drugs, identifying truly selective molecular templates has not been trivial. Herein, we report a structure–activity relationship study yielding <b>TO-317</b>, which potently binds HDAC6 catalytic domain 2 (<i>K</i><sub>i</sub> = 0.7 nM) and inhibits the enzyme function (IC<sub>50</sub> = 2 nM). <b>TO-317</b> exhibits 158-fold selectivity for HDAC6 over other HDAC isozymes by binding the catalytic Zn<sup>2+</sup> and, uniquely, making a never seen before direct hydrogen bond with the Zn<sup>2+</sup> coordinating residue, His614. This novel structural motif targeting the second-sphere His614 interaction, observed in a 1.84 Å resolution crystal structure with <i>dr</i>HDAC6 from zebrafish, can provide new pharmacophores for identifying enthalpically driven, high-affinity, HDAC6-selective inhibitors.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06888" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06888" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Histone deacetylases (HDACs) are widely investigated as clinical targets due to their role as epigenetic modulators.<a onclick="showRef(event, 'ref1 ref2 ref3 ref4 ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3 ref4 ref5 ref6">(1−6)</a> There are 18 known HDACs, with 11 having Zn<sup>2+</sup>-dependent catalytic deacetylation activity and the remaining 7, referred to as sirtuins (class III HDACs), exhibiting NAD<sup>+</sup>-dependent deacetylation. The 11 Zn<sup>2+</sup>-dependent HDACs are further differentiated into 4 distinct classes based on phylogenetic analysis.<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7,8)</a> HDACs 1, 2, 3, and 8 are grouped into class I. HDACs 4, 5, 7, and 9 are grouped as class IIA. HDACs 6 and 10 belong to class IIB, while HDAC 11 individually occupies group IV.</div><div class="NLM_p">HDAC6 is unique among other Zn<sup>2+</sup>-dependent HDACs. While some HDACs reside in the nucleus and regulate gene transcription, HDAC6 is predominantly found in the cytoplasm and directly engages with a host of cytosolic proteins and substrates, including α-tubulin and β-tubulin, assembled microtubules, cortactin, and heat shock proteins.<a onclick="showRef(event, 'ref9 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref9 ref10 ref11">(9−11)</a> In addition, while histones are the primary substrates for most Zn<sup>2+</sup>-dependent HDACs, this is not the case for HDAC6 as α-tubulin is proposed to be the major substrate for HDAC6.<a onclick="showRef(event, 'ref12 ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref14">(12−14)</a> Notably, HDAC6 is structurally distinct from other HDACs, with two unique and independent catalytic domains (CDs) which have diverse roles and different substrate preferences and activities.<a onclick="showRef(event, 'ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref15 ref16">(15,16)</a> Catalytic domain 2 (CD2) is established as the tubulin deacetylase<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> and a critical target for drug design. HDAC6 also contains a Zn<sup>2+</sup>-finger ubiquitin binding domain through which it binds to polyubiquitinated proteins and shuttles them to dynein motors associated with microtubule cargo transport.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> From a therapeutic perspective, several knockout studies in mice lacking the HDAC6 gene have shown no survival dependency and that no lethality is associated with HDAC6 deletion.<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18,19)</a></div><div class="NLM_p">Currently, the US Food and Drug Administration (FDA) has approved several HDAC inhibitors for clinical treatment of different hematological cancers including cutaneous T-cell lymphoma (CTCL), peripheral T-cell lymphoma (PTCL), and multiple myeloma (MM). Vorinostat (SAHA) was the first FDA-approved HDAC inhibitor in 2006 for CTCL patients whose disease had persisted or worsened after two systemic therapies. As a result of severe side effects, all clinical HDAC inhibitors are approved only for cases where the patient does not respond to the first option treatment or at least two prior standard therapies (Romidepsin, approved in 2009 for CTCL patients and in 2011 for PTCL patients, with both only after at least one prior systemic therapy; Panobinostat, approved in 2016 for MM patients after two treatment regimens) or in cases of relapse or recurring disease (Belinostat, approved in 2014 for relapsed PTCL). All these inhibitors exhibit pan-HDAC inhibition which may contribute to their side effects.</div><div class="NLM_p">Since no lethal effects have been observed in HDAC6 knockout mice, it was hypothesized that selective inhibition may attenuate the toxicity of current clinical HDAC inhibitors, while retaining therapeutic efficacy. HDAC6 has been validated as an attractive therapeutic target with modestly selective inhibitors such as citarinostat and ricolinostat currently at different phases of clinical trials as single agents or combination therapies for several conditions, including refractory MM, malignant melanoma, non-small-cell lung cancer, lymphoid malignancies, metastatic breast cancer, and diabetic neuropathic pain.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> These inhibitors achieve selective HDAC6 inhibition by incorporating large bulky cap groups to a lysine hydroxamate mimic, similar to the first non-selective/pan HDAC inhibitor, SAHA (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). This scaffold is well tolerated at the outer surface of the HDAC6 binding pocket, unlike other HDAC homologues which are unable to favorably accommodate the cap groups due to steric clashes with the outer surfaces of the binding pockets.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> The selectivity afforded by these designs does not always translate to a safe therapeutic index, and some exhibit moderate to advanced toxicities at clinically efficacious doses.<a onclick="showRef(event, 'ref22 ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref22 ref23 ref24">(22−24)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/medium/jm0c01922_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/large/jm0c01922_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Currently known HDAC6 inhibitors. The structural features involve a hydroxamic acid which is required for Zn<sup>2+</sup> binding and a linker that connects the hydroxamic acid to a cap group. (a) Currently known inhibitors achieved HDAC6 selectivity by replacing the benzene substituent on SAHA with a bulkier, usually hydrophobic cap group. (b) Previous studies showed that compound <b>1</b> is a nM inhibitor against HDAC6 exhibiting minimal selectivity. (c) Current studies show that <b>TO-317</b> adopts a rotatable cap group with two aromatic substituents that occupy the HDAC6 surface, facilitating specific residue interactions. *IC<sub>50</sub> values were determined using an activity-based electrophoretic mobility shift assay (EMSA) by Nanosyn Inc., USA.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/large/jm0c01922_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01922&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The lead compound described in this study, <b>TO-317</b>, exhibits low nanomolar affinity for HDAC6 (<i>K</i><sub>i</sub> = 0.7 nM), low nanomolar inhibition of the HDAC6 function (IC<sub>50</sub> = 2 nM), and over 150-fold selectivity for HDAC6 across a panel of 11 Zn<sup>2+</sup>-dependent HDACs. The <i>in vitro</i> selectivity of <b>TO-317</b> for HDAC6 is translated <i>in cellulo</i> by Western blot analyses of both pan-HDAC and HDAC6-selective pharmacodynamic (PD) targets. Most interestingly, the X-ray crystal structure determination of <b>TO-317</b> bound to HDAC6 CD2 from <i>Danio rerio</i> (zebrafish, a well-studied surrogate of human HDAC6 CD2, and henceforth designated <i>dr</i>HDAC6) reveals a unique binding mode in which the inhibitor simultaneously coordinates to the catalytic Zn<sup>2+</sup> ion and participates in a “second shell” interaction with Zn<sup>2+</sup> by forming a direct hydrogen bond with the metal-coordinating residue, H614. A direct enzyme–inhibitor hydrogen bond with this residue has not been previously observed. Exploitation of this structural finding may lead to a new generation of HDAC6-targeting ligands.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47150" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47150" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Discovery of <b>TO-317</b>, A Potent and Highly Selective HDAC6 Inhibitor</h3><div class="NLM_p">Herein, we describe a rational, iterative approach to identifying potent and selective HDAC6 inhibitors with drug-like properties and acceptable pharmacokinetic profiles. Identification of novel inhibitors lacking the high-molecular-weight cap groups, which contribute to a reduced ligand efficiency (LE) and an increased molecular weight while not affording selectivity, was considered critical.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Examining the binding pocket of HDAC6 revealed a hydrophobic tunnel which opens to an outer cleft region flanked by two outer regions (L1 and L2, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01922/suppl_file/jm0c01922_si_002.pdf" class="ext-link">Figure S1B</a>) and an uneven surface topology consisting of polar residues.<a onclick="showRef(event, 'ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref26 ref27">(26,27)</a> This outer surface region is more expansive in HDAC6 (the rough dimensions of the tunnel entrance are 5.6 Å × 10.8 Å; PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5WGI">5WGI</a>, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01922/suppl_file/jm0c01922_si_002.pdf" class="ext-link">Figure S1C</a>) compared to other homologues: the rough dimensions of the tunnel entrance in HDAC3 are 5.6 Å × 5.5 Å (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4A69">4A69</a>) and those in HDAC8 are 4.9 Å × 6.4 Å (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T64">1T64</a>) (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01922/suppl_file/jm0c01922_si_002.pdf" class="ext-link">Figure S1C</a>). As a result, HDAC6 appears to tolerate inhibitors bearing sterically bulky cap groups and affords selectivity, as was found for ricolinostat and citarinostat.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> However, bulky cap groups are predominantly solvent-exposed with minimal residue interactions, thereby reducing their contributions to HDAC6 binding. From internal hit-to-lead HDACi development and lead optimization,<a onclick="showRef(event, 'ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref29 ref30">(29,30)</a> compound <b>1</b> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>B, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) was identified, which exhibited low micromolar activity against HDAC6 <i>in vitro</i>. Compound <b>1</b>, while limited by poor HDAC6 selectivity, poor cellular potency, and an undesirable pharmacokinetic profile, afforded a suitable starting point for optimization due to the presence of a free sulfonamide −NH. Virtual docking of N-alkylated derivatives was hypothesized to afford improved binding compounds with better HDAC6 selectivity. Initial docking studies with <b>1</b> suggested that F583 and F643 in <i>dr</i>HDAC6 CD2 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5WGI">5WGI</a>, corresponding to residues F620 and F680 in <i>Homo sapiens</i> (human) HDAC6, henceforth designated as <i>h</i>HDAC6, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EDU">5EDU</a>), which line the hydrophobic HDAC6 binding tunnel, form an offset aromatic π–π stacking interaction with the benzyl linker of compound <b>1</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01922/suppl_file/jm0c01922_si_002.pdf" class="ext-link">Figure S1A</a>). Maintaining this hydrophobic interaction required retention of the benzyl linker group. Linking groups in HDAC6 inhibitors usually direct the cap groups toward the L1 crevice, found in the exposed surface of the enzyme, to facilitate interactions with nearby residues.<a onclick="showRef(event, 'ref26 ref28 ref31'); return false;" href="javascript:void(0);" class="ref ref26 ref28 ref31">(26,28,31)</a> With the exception of a small subset of compounds, all reported HDAC6 inhibitors engage only at the L1 region and in some rare cases can alternate the positioning of the cap groups between the L1 and L2 crevices<a onclick="showRef(event, 'ref26 ref31'); return false;" href="javascript:void(0);" class="ref ref26 ref31">(26,31)</a> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01922/suppl_file/jm0c01922_si_002.pdf" class="ext-link">Figure S1B</a>). The pentafluorobenzene (PFB) ring of <b>1</b> was shown to be directed into the L2 region of HDAC6 and is nested on the outer surface with the ring partially exposed to water (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01922/suppl_file/jm0c01922_si_002.pdf" class="ext-link">Figure S1A</a>). The PFB ring is predicted to make a π–π aromatic interaction with F643. The sulfonamide −NH does not participate in binding to the protein despite the predicted interaction with S531, a residue which has previously been proposed to afford selectivity.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> N-alkylation was therefore not expected to have any disruptive consequences for HDAC6 binding. Water-mediated hydrogen bonding of the sulfonyl oxygen with L712 and the Zn<sup>2+</sup>-binding ligand, H614, completed the interactions observed with <b>1</b> and <i>dr</i>HDAC6. Structural insights into the binding pockets and the outer surface crevices of HDAC6 (<i>dr</i>HDAC6 CD2, PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5WGI">5WGI</a>) identified several aromatic residues lining the L1 outer surfaces (F642, F643, F583, H463, H573, H614, and Y745) and the HDAC6 binding pocket. N-alkylation of <b>1</b> with a benzyl substituent was proposed to improve binding by these hydrophobic residues <i>via</i> a windmill-type conformation (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01922/suppl_file/jm0c01922_si_002.pdf" class="ext-link">Figure S2</a>). Compound <b>2</b> was synthesized (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01922/suppl_file/jm0c01922_si_002.pdf" class="ext-link">Figure S2</a>) and assessed for its inhibitory activity against four representative HDAC homologues. HDACi <b>2</b> exhibited an improved selectivity window as compared to <b>1</b> and both citarinostat and ricolinostat. Next, scaffold optimization was attempted by differential substitution of the benzene ring of <b>2</b>. Compounds <b>4</b> [−CF<sub>3</sub>) and <b>5</b> (−N(CH<sub>3</sub>)<sub>2</sub>] provided insights into the electronic effects on activity and selectivity, while <b>6</b> (−CH<sub>3</sub>) and <b>7</b> (−<sup><i>t</i></sup>Bu) elucidated the role of incorporating bulk at the <i>para</i>-position. To investigate electron-deficient rings, compound <b>8</b>, containing a pyridine ring, was synthesized and was suggested to be the most promising HDAC6-selective inhibitor (>71 fold).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Activity of <b>1</b> and Derivatives against Four HDAC Homologues<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/medium/jm0c01922_0012.gif" alt="" id="gr11" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> values were determined by  EMSA using full-length hHDAC6 and a 6-carboxy fluorescein-aminohexyl amidite (FAM)-labeled acetylated peptide substrate of HDAC6 catalytic domain 2. IC<sub>50</sub> values are an average of duplicate experiments and are reported in μM, and the 95% confidence interval is italicized and reported in brackets close to the IC<sub>50</sub> values. Sigmoidal curves of inhibitor concentration (12 concentrations, 5.6 × 10<sup>–6</sup> to 1 μM) versus % inhibition were fitted using XLDB software (a four-parameter sigmoidal dose-response model). The full protocol is described in detail in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c01922/suppl_file/jm0c01922_si_002.pdf" class="ext-link">Supporting Information</a> procedure. Full IC<sub>50</sub> curves are shown in <a href="/doi/suppl/10.1021/acs.jmedchem.0c01922/suppl_file/jm0c01922_si_002.pdf" class="ext-link">Supporting Information</a> data.</p></div></div><div></div></div><div class="NLM_p">Tetrafluorobenzene (TFB) was previously identified as a bioisostere of PFB, improving phase II metabolic stability and contributing to improved selectivity for HDAC6.<a onclick="showRef(event, 'ref25 ref33'); return false;" href="javascript:void(0);" class="ref ref25 ref33">(25,33)</a> PFB was replaced on <b>8</b>, <b>2</b>, and <b>3</b> with a TFB to yield <b>9</b>, <b>10</b>, and <b>11</b>, respectively (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). The location of the fluorine substituent was varied to both the <i>ortho</i> (<b>13</b>)- and <i>meta</i> (<b>12</b>)-positions. Potency was marginally improved (two-fold) in both cases, although with a decrease in selectivity. Subsequently, modifications to the pyridine analogue were explored. The 2-picolyl substituted inhibitor (<b>14</b>) is two-fold more potent against HDAC6, with only minimal improvement in selectivity when compared to <b>9</b>. The 3-picolyl analogue, <b>TO-317</b> (<b>15</b>), showed significant improvements in both potency and selectivity.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Focused SAR Highlights the Substitution of the PFB Ring with TFB Analogues Showing Improvements in Selectivity for HDAC6<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/medium/jm0c01922_0013.gif" alt="" id="gr12" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">We have also shown that TFB analogues have superior metabolic profiles compared to their PFB isotypes. The substituent location on the cap group aromatic ring plays a significant role in targeted HDAC6 binding. The pyridine motifs displayed the most potent and discriminative activity against HDAC6. IC<sub>50</sub> values were determined as described in the caption of <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.0c01922/suppl_file/jm0c01922_si_002.pdf" class="ext-link">Supporting Information</a> procedures. IC<sub>50</sub> values are an average of duplicate experiments and are reported in μM, and their 95% confidence interval is italicized and reported in brackets under each IC<sub>50</sub> value. Full IC<sub>50</sub> curves are shown in <a href="/doi/suppl/10.1021/acs.jmedchem.0c01922/suppl_file/jm0c01922_si_002.pdf" class="ext-link">Supporting Information</a> data.</p></div></div><div></div></div><div class="NLM_p">In addition to the inhibitory activity in an EMSA, the binding was measured by an orthogonal fluorescence polarization (FP) assay (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01922/suppl_file/jm0c01922_si_002.pdf" class="ext-link">Figure S3</a>), which confirmed an interaction with a 4 nM potency between <b>TO-317</b> and <i>dr</i>HDAC6 CD2. This interaction was substantially tighter when compared to other compounds in the structure–activity relationship (SAR) (>20-fold stronger compared to the nearest analogue, <b>11</b> (IC<sub>50</sub> = 80 nM)). Based on the promising activity and binding data, the broader HDAC selectivity of <b>TO-317</b> against a panel of all 11 Zn<sup>2+</sup>-based HDACs was investigated (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). <b>TO-317</b> was determined to be selective for HDAC6 across all 11 HDAC homologues, showing relatively modest affinity for HDACs 3, 8, and 10 as compared to HDAC6. To further characterize HDAC6 selectivity, <b>TO-317</b> was evaluated against the other HDAC homologues at a top treatment concentration of 10 μM. The results, shown in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>, support the hypothesis that <b>TO-317</b> is a highly selective HDAC6 inhibitor. Further investigation of the selectivity of <b>TO-317</b> and its utility as a lead candidate was pursued in a series of structural and cellular biology experiments outlined below.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/medium/jm0c01922_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/large/jm0c01922_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Overlaid inhibition curves for <b>TO-317</b> against a panel of 11 Zn<sup>2+</sup>-based HDAC homologues. <b>TO-317</b> shows <i>in vitro</i> HDAC6 selectivity across all Zn<sup>2+</sup>-dependent HDAC homologues and becomes a viable candidate for further biological investigation of the HDAC6 enzyme.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/large/jm0c01922_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01922&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. IC<sub>50</sub> Values for <b>TO-317</b> against all HDAC Isoforms Determined with a Top Concentration of 10 μM<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/medium/jm0c01922_0014.gif" alt="" id="gr13" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last"><b>TO-317</b> maintains strong <i>in vitro</i> inhibitory preference for HDAC6, indicating a promising selectivity profile that is worthy of further biological characterization. IC<sub>50</sub> values are an average of duplicate experiments, and their 95% confidence interval is italicized and in brackets under each IC<sub>50</sub> value.</p></div></div><div></div></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> HDAC6 Selectivity Mediated by Unique Catalytic Domain Interactions</h3><div class="NLM_p">Computational modeling was employed to investigate the conformation of <b>TO-317</b> that afforded HDAC6 selectivity. For comparison, citarinostat and <b>TO-317</b> were docked with <i>dr</i>HDAC6 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5WGI">5WGI</a>, <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.0c01922/suppl_file/jm0c01922_si_002.pdf" class="ext-link">S4A</a>, respectively). Docking citarinostat showed the cap group to be largely solvent-exposed and directed away from the L1 and L2 outer surfaces. The crystal structure of ricolinostat with CD2 of <i>dr</i>HDAC6 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5WGL">5WGL</a>) was obtained, and an overlay of our docking image of citarinostat was performed (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01922/suppl_file/jm0c01922_si_002.pdf" class="ext-link">Figure S4A</a>). Both inhibitors adopt identical conformations with the tricyclic pyrimidine cap groups extending away from the L1 crevice without making any apparent interaction with nearby residues, validating the docking results. The authors indicated that water-mediated hydrogen bonding is possible with S531 and D460 residues of the L1 crevice.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> In contrast, <b>TO-317</b> was found to adopt a ligand–enzyme fit that showed scaffold engagement with both L1 and L2 outer crevices (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5WGI">5WGI</a>, <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). Furthermore, <b>TO-317</b> was predicted to adopt a conformation that engaged several residues through aromatic π–π interactions and hydrogen bonding. The benzyl linker retained the π–π interaction with F643 and F583 observed with compound <b>1</b>. The pyridyl ring was predicted to occupy the L2 crevice and engage in a π–π stacking interaction with F642 and H-bonding with the protonated Zn<sup>2+</sup>-bound, H614. These <i>in silico</i> HDAC6 enzyme engagements are absent in comparative HDAC8 studies (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T64">1T64</a>, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01922/suppl_file/jm0c01922_si_002.pdf" class="ext-link">Figure S4B, Table S1</a>).</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/medium/jm0c01922_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/large/jm0c01922_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Docking conformation of <b>TO-317</b> with <i>dr</i>HDAC6 CD2 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5WGI">5WGI</a>) reveals occupancy of both L1 and L2 crevices which facilitates a plethora of interactions. Deck A shows the pocket view of these interactions, while deck B shows how <b>TO-317</b> adopts a windmill conformation that allows both aromatic ring cap groups to engage with the L1 and L2 crevices of the HDAC6 outer surface.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/large/jm0c01922_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01922&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To validate these docking predictions, the X-ray crystal structure of the HDAC6–<b>TO-317</b> complex was solved at a 1.84 Å resolution (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). There are 2 monomers in the asymmetric unit in this orthorhombic crystal form, and the structures of each are essentially identical (root-mean-square deviation = 0.07 Å for 296 Cα atoms). Similarly, the inhibitor binding mode is essentially identical in both monomers, with the hydroxamate moiety coordinating to the catalytic Zn<sup>2+</sup> ion in a monodentate fashion as first observed for the binding of <i>N</i>-hydroxy-4-(2-[(2-hydroxyethyl)(phenyl)amino]-2-oxoethyl)benzamide.<a onclick="showRef(event, 'ref15 ref34'); return false;" href="javascript:void(0);" class="ref ref15 ref34">(15,34)</a> The hydroxamate N–O<sup>–</sup> group coordinates to Zn<sup>2+</sup> with an average separation of 2.4 Å and is hydrogen-bonded with Y745. The hydroxamate C═O hydrogen bonds with the Zn<sup>2+</sup>-bound water molecule, which further engages H573 and H574 in hydrogen bonding.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/medium/jm0c01922_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/large/jm0c01922_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Stereo-view of a Polder omit map (contoured at 4.0σ) showing the binding of <b>TO-317</b> in the active site of HDAC6 (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7JOM">7JOM</a>). The catalytic Zn<sup>2+</sup> ion is shown as a gray sphere, and the Zn<sup>2+</sup> bound water molecule is shown as a red sphere; metal coordination and hydrogen bond interactions are shown as solid and dashed black lines, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/large/jm0c01922_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01922&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Outside the active site cleft, the benzyl group of the phenylhydroxamate moiety packs between F583 and F643 and engages in favorable offset π–π interactions. Desolvation of this region may contribute an entropic advantage to the binding of inhibitors with aromatic linker groups.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> The capping group is bifurcated <i>via</i> the dialkyl sulfonamide nitrogen, with each substituent directed to different outer active site. Bifurcated capping groups enable the capture of additional affinity and selectivity interactions in the HDAC6 active site.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Notably, the pyridine ring binds in the L1 pocket and accepts a hydrogen bond from Zn<sup>2+</sup> ligand H614. While water-mediated enzyme–inhibitor hydrogen bonds with H614 have been observed,<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> a direct enzyme–inhibitor hydrogen bond with this residue has not been previously observed. As such, the inhibitor pyridine group serves as a “second shell” or indirect ligand to the catalytic Zn<sup>2+</sup> ion,<a onclick="showRef(event, 'ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref36 ref37">(36,37)</a> and chelation of the Zn<sup>2+</sup> ion by direct and indirect interactions through the hydroxamate group and the pyridine ring, respectively, presumably makes a substantial contribution to affinity. The sulfonamide group does not participate in any hydrogen bond interactions and is oriented such that the TFB ring is directed toward the solution. The closest residue to the TFB ring is S531, which at its closest point is 3.4 Å away.</div><div class="NLM_p last">The molecular residency of <b>TO-317</b> at the HDAC6 active site was investigated by kinetic experiments and mass spectrometry analysis. In a jump dilution experiment, <b>TO-317</b> exhibited a <i>K</i><sub>i</sub> of 0.7 nM and a residence time of 142 min in a two-step reversible inhibition model (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01922/suppl_file/jm0c01922_si_002.pdf" class="ext-link">Figure S5A</a>). This occupancy at the catalytic pocket could rationalize the IC<sub>50</sub> values exhibited by <b>TO-317</b> in enzyme preincubation studies (no preincubation IC<sub>50</sub> = 4 nM, 3 h preincubation IC<sub>50</sub> = 2 nM; IC<sub>50</sub>’s are an average of duplicate studies, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01922/suppl_file/jm0c01922_si_002.pdf" class="ext-link">Figure S5B</a>) as intact mass spectrometry analysis confirmed that no covalent modification of the enzyme was observed on treatment with <b>TO-317</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01922/suppl_file/jm0c01922_si_002.pdf" class="ext-link">Figure S5C</a>). These experiments suggest a reversible yet thermodynamically driven interaction between <b>TO-317</b> and HDAC6 whose stability is presumably driven by the observed dual Zn<sup>2+</sup> coordination at the active tunnel.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> <b>TO-317</b> Exhibits <i>In Cellulo</i> HDAC6 Target Engagement and Mediates Mechanistic Cell Proliferation in Leukemic Cancers</h3><div class="NLM_p">The cellular potency of <b>TO-317</b> was evaluated in a selection of indications where HDAC6 activity has been implicated and treated with HDAC6 inhibitors as single agents. Although HDAC6 has been validated as a clinical target in hematological cancers such as MM, HDAC6 knockout/deletion studies with siRNA or CRISPR/CAS9 show discrepancies in dependency. <b>TO-317</b> was assessed across 5 disease indications (12 cancer cell lines) previously validated by several research groups for their dependency on HDAC6 in growth and survival.<a onclick="showRef(event, 'ref1 ref38 ref39 ref40 ref41 ref42 ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref1 ref38 ref39 ref40 ref41 ref42 ref43 ref44">(1,38−44)</a> Assessment in acute myeloid leukemia (AML) cell lines was prioritized owing to growing evidence of HDAC6 playing a critical role in survival and resistance to various treatment regimens.<a onclick="showRef(event, 'ref1 ref42'); return false;" href="javascript:void(0);" class="ref ref1 ref42">(1,42)</a> As can be seen in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>, <b>TO-317</b> was active in several cancer cell lines but showed minimal activity in “normal” MRC9 lung fibroblasts. <b>TO-317</b> was shown to have anti-proliferative activity in all six leukemic cancer cells tested, having an average IC<sub>50</sub> of <2.0 μM. Sub-μM anti-proliferative activity was observed in both MM cell lines where HDAC6 inhibitors have been deployed clinically.<a onclick="showRef(event, 'ref2 ref38 ref40 ref45'); return false;" href="javascript:void(0);" class="ref ref2 ref38 ref40 ref45">(2,38,40,45)</a></div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/medium/jm0c01922_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/large/jm0c01922_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Cellular potency of <b>TO-317</b> and citarinostat (positive control) in 12 cell lines (1 heathy cell, MRC-9 included). <b>TO-317</b> shows anti-proliferative potency across different cancer cells with minimal activity in healthy cells. IC<sub>50</sub> values are indicated above each graph and reported in μM. IC<sub>50</sub> values with their 95% confidence intervals are reported in <a href="/doi/suppl/10.1021/acs.jmedchem.0c01922/suppl_file/jm0c01922_si_002.pdf" class="ext-link">Table S3</a>. Citarinostat was not tested in Ramos cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/large/jm0c01922_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01922&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Acetylation levels of α-tubulin are used as a clinical biomarker for HDAC6 inhibition.<a onclick="showRef(event, 'ref46 ref47'); return false;" href="javascript:void(0);" class="ref ref46 ref47">(46,47)</a> Inhibition of other HDACs leads to an increase in histone H3K9 and H3K27 acetylation.<a onclick="showRef(event, 'ref48 ref49'); return false;" href="javascript:void(0);" class="ref ref48 ref49">(48,49)</a> Comparative acetylation of both substrates provides a robust biomarker of HDAC6 inhibition. Treatment of MV4-11 cells with <b>TO-317</b> induced a significant increase in Ac-α-tubulin levels even at 0.25 μM, with only minimal accumulation of Ac-histones (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A). From comparative Western blots in <b>TO-317</b> and citarinostat-treated MV4-11 cells (0.25–1.0 μM), it was determined that <b>TO-317</b> is marginally more potent for HDAC6 (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A) with strong increases in Ac-α-tubulin at a concentration of 0.25 μM. Citarinostat appears more selective than <b>TO-317</b> in a cellular environment, with accumulation of Ac-histone H3K27 between 0.75 and 1.00 μM in both AML and MM cells. Similar results were observed in MM cell lines (MM.1S cell lines, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B) where <b>TO-317</b> was more potent for HDAC6 over the range of concentrations assayed. These results recapitulate the selectivity and potency of <b>TO-317</b> for HDAC6 <i>in cellulo</i>. However, at higher concentrations, the effects and cytotoxicity observed may be partially due to nuclear HDAC inhibition.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/medium/jm0c01922_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/large/jm0c01922_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. <b>TO-317</b> shows superior HDAC6 selectivity and potency in MV4-11 and MM.1S cells. (A) MV4-11 cells treated with increasing doses (0.25–1 μM) of citarinostat and <b>TO-317</b> show accumulation of Ac-α-tubulin for <b>TO-317</b> at 0.25 μM but not for citarinostat. (B) Similar dose-dependent responses were observed for both inhibitors in MM.1S cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/large/jm0c01922_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01922&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Immunofluorescence was employed as a secondary bioorthogonal assay to validate the <i>in cellulo</i> HDAC6 selectivity of <b>TO-317</b>. HeLa cells were incubated with two different concentrations of <b>TO-317</b> or citarinostat at 0.1 and 2 μM. Treatment with <b>TO-317</b> led to significant accumulation of Ac-α-tubulin (red stain) at 2 μM. These effects were slightly less prominent with citarinostat at the same concentration (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.0c01922/suppl_file/jm0c01922_si_002.pdf" class="ext-link">S7</a>). The levels of Ac-histone (green stain) do not change significantly upon treatment with either the 0.1 or 2 μM concentration of <b>TO-317</b> (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). A 4′,6-diamidino-2-phenylindole (DAPI) nuclear stain (blue, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01922/suppl_file/jm0c01922_si_002.pdf" class="ext-link">Figure S6</a>) confirmed cell viability during the 6 h incubation period assessed. An overlay of both acetylated tubulin and histone stains also showed preferential Ac-α-tubulin accumulation over Ac-H3K27 histones at all concentrations of <b>TO-317</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01922/suppl_file/jm0c01922_si_002.pdf" class="ext-link">Figure S6</a>). In conjunction with initial Western blots, immunofluorescence further recapitulated the <i>in cellulo</i> HDAC6 target engagement exhibited by <b>TO-317</b>.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/medium/jm0c01922_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/large/jm0c01922_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Quantification of Ac-α-tubulin and Ac-histone levels in the immunofluorescence assay. DMSO was used as a negative control in each cohort, and citarinostat was the positive control. The result indicates that <b>TO-317</b> induces a clear dose-dependent increase in acetylated α-tubulin with minimal cellular accumulation of acetylated histones under the same dosing concentrations. The data reported above are an average of duplicate experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/large/jm0c01922_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01922&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To characterize the mechanism of inhibition and cell death by <b>TO-317</b>, fluorescence-activated cell sorting (FACS) flow cytometry was employed to sort the populations of treated leukemic cells at different stages of the cell cycle <i>via</i> their differential staining with annexin and propidium iodide (PI) fluorophore. Cells in the sub-population UL (upper level, red stain) are necrotic cells, and an increase in cell population in this quadrant is indicative of a toxic inhibitor lacking a defined mechanism. <b>TO-317</b> does not show statistically different changes to necrosis as this sub-population is consistent across the range of inhibitor concentrations tested and comparable to the DMSO control (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). The LL sub-population (lower level, green stain) shows viable cells where the fluorophore cannot access the cytosol (green stain) and is representative of intact and healthy cancer cells. The healthy cell count dramatically decreases from 88% with no inhibitor present to 35% at a 2 μM inhibitor concentration. The loss in healthy cells is compensated in the LR and UR quadrants (blue stains) showing cell populations undergoing early and late apoptosis, respectively. These quadrants show an increase in the respective populations as the concentration of <b>TO-317</b> is increased. Early and late apoptotic cell populations increased from a combined 11% at 0.25 μM to 65% at 2 μM and to 73% at 4 μM (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01922/suppl_file/jm0c01922_si_002.pdf" class="ext-link">Figure S8A</a>). A similar trend was observed for citarinostat (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>B,; <a href="/doi/suppl/10.1021/acs.jmedchem.0c01922/suppl_file/jm0c01922_si_002.pdf" class="ext-link">Figure S8B</a>), albeit with reduced potency, as was seen with <b>TO-317</b>. This systematic disruption and arrest of the cell cycle is the signature of a mechanistic-based inhibitor and strongly supports the hypothesis that <b>TO-317</b> achieves cell death in leukemia cells through programmed cell death.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/medium/jm0c01922_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/large/jm0c01922_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. MV4-11 cells treated with <b>TO-317</b> (A) and citarinostat (B) leads to dose-dependent programmed cell death. Death by necrosis (Q1) is minimal and consistent at all doses. Dose-dependent cell death by <b>TO-317</b> is consistent with a mechanistic approach of cell cycle arrest leading to apoptosis and corroborates the previously observed superior anti-proliferative activity of <b>TO-317</b> over citarinostat, the positive control. The data reported above are an average of duplicate experiments, and quantification of each cell population with the associated standard deviation is reported graphically in <a href="/doi/suppl/10.1021/acs.jmedchem.0c01922/suppl_file/jm0c01922_si_002.pdf" class="ext-link">Figure S8A,B</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/large/jm0c01922_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01922&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The role of reactive oxygen species (ROS) in the progression and survival of leukemic cells has been very contentious.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> NADPH oxidases (NOXs) are elevated in several AML mutations including FLT3-ITD AML and Ras.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> These mutations are known to be associated with poor prognosis and a high resistance and relapse rates whose mechanism depends on over-secretion of ROS. Several models of AML also show increased ROS generation-induced redox dysregulation and oxidative stress that is strongly linked to promotion of cellular proliferation, survival, and immune evasion.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> However, several studies also indicate that the persistence of elevated ROS levels may significantly strengthen oxidative DNA damage leading to single- and double-strand breaks and lipid peroxidation, which further leads to cellular damage. Since HDAC inhibitors are known to generate ROS and induce cell cycle arrest in cancer cells,<a onclick="showRef(event, 'ref53 ref54 ref55'); return false;" href="javascript:void(0);" class="ref ref53 ref54 ref55">(53−55)</a><b>TO-317</b>-treated MV4-11 cells were investigated. As expected, <b>TO-317</b>-treated cells showed increased ROS generation when compared to the DMSO control over a 4 h period (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>). This is consistent with previously reported HDAC inhibitors and may implicate ROS accumulation as a possible mechanism for the induction of apoptosis observed with <b>TO-317</b>.</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/medium/jm0c01922_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/large/jm0c01922_0010.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. ROS generation in MV4-11 cells following incubation with 10 μM <b>TO-317</b> for up to 4 h. <b>TO-317</b> shows markedly increased levels of ROS after 2 h incubation which continue to increase up to the 4 h incubation time tested. Data reported are an average of duplicate studies.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/large/jm0c01922_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01922&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> <b>TO-317</b><i>In Vitro</i> and <i>In Vivo</i> Stability Profiles</h3><div class="NLM_p">Pharmacokinetic profiles of <b>TO-317</b> were assessed in both <i>in vitro</i> and <i>in vivo</i> experiments. Plasma and whole blood stability assays were used to determine the stability of <b>TO-317</b> in biological fluids. Several studies have shown reduction of hydroxamic acids in whole blood but not in plasma.<a onclick="showRef(event, 'ref56 ref57'); return false;" href="javascript:void(0);" class="ref ref56 ref57">(56,57)</a> After 1 h incubation in mouse plasma, 68% of <b>TO-317</b> remained with a calculated <i>t</i><sub>1/2</sub> of 110 min (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). In pooled human whole blood samples, ∼69% of <b>TO-317</b> was present after 1 h with a calculated <i>t</i><sub>1/2</sub> of 108 min, indicating collectively that <b>TO-317</b> does not suffer from the previously reported high clearance rates and metabolic degradation of <i>N</i>-hydroxamic acids in biological fluids.<a onclick="showRef(event, 'ref58 ref59'); return false;" href="javascript:void(0);" class="ref ref58 ref59">(58,59)</a><b>TO-317</b> was advanced for a preclinical pharmacokinetic study employing a dose of 50 mg/kg <i>via</i> intraperitoneal (i.p.) injection in male MALB/c mice. Consistent with previous plasma and whole blood studies, <b>TO-317</b> displayed modest stability <i>in vivo</i> (<i>t</i><sub>1/2</sub> = 1.7 h) as compared to known HDAC inhibitors, reaching a <i>C</i><sub>max</sub> of 95.1 ng/mL in 1 h (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>). However, given the dose, 50 mg/kg, significantly higher plasma concentrations were anticipated, indicating either a metabolic instability <i>in vivo</i> or poor solubility/permeability, which limits systemic bioavailability and further progression as a therapeutic agent.</div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/medium/jm0c01922_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/large/jm0c01922_0011.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. <b>TO-317</b> is stable <i>in vivo</i> with a <i>t</i><sub>1/2 (avg)</sub> = 1.7 h. Male BALB/c mice were dosed with <b>TO-317</b> intraperitoneally (50 mg/mL solution 5% DMSO, 30% PEG400, 1% Tween 80, and 64% saline) and peaks were detected and quantified from collected blood samples at different time concentrations using a triple-quad LC–MS/MS.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/large/jm0c01922_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01922&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. <b>TO-317</b> Showed Extended Lifetimes in Both Mouse Plasma and Pooled Human Blood Stability Assays<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="5" align="center" char=".">remaining percentage <b>TO-317</b> concentration</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">assay</th><th class="colsep0 rowsep0" align="center" char=".">0 min (%)</th><th class="colsep0 rowsep0" align="center" char=".">15 min (%)</th><th class="colsep0 rowsep0" align="center" char=".">30 min (%)</th><th class="colsep0 rowsep0" align="center" char=".">60 min (%)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>1/2</sub> (min)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mouse plasma</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="char" char=".">88.1</td><td class="colsep0 rowsep0" align="char" char=".">79.8</td><td class="colsep0 rowsep0" align="char" char=".">68.0</td><td class="colsep0 rowsep0" align="char" char=".">110</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human whole blood</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="char" char=".">88.0</td><td class="colsep0 rowsep0" align="char" char=".">80.8</td><td class="colsep0 rowsep0" align="char" char=".">68.9</td><td class="colsep0 rowsep0" align="char" char=".">108</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Assay values reported are an average of triplicate studies.</p></div></div></div><div class="NLM_p">Kinetic solubility experiments (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01922/suppl_file/jm0c01922_si_002.pdf" class="ext-link">Figure S9</a>) showed <b>TO-317</b> to exhibit solubility in PBS, pH 7.4, with a saturation concentration of 161.50 ± 33.20 μM (<i>n</i> = 3), ruling out solubility as a likely cause for its poor <i>in vivo</i> exposure. Parallel artificial membrane permeability <i>assay</i><i>(</i>PAMPA) studies (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01922/suppl_file/jm0c01922_si_002.pdf" class="ext-link">Table S2</a>) revealed poor permeability profiles which may be responsible for the limited availability observed <i>in vivo</i> with <b>TO-317</b>, with an average permeability score of −log <i>P</i><sub>e</sub> = 6.71. Membrane-permeable molecules generally exhibit permeability scores with −log <i>P</i><sub>e</sub> ≤ 6.0. It is interesting that <b>TO-317</b> can elicit PD in proliferating cells such as AML and MM but is unable to passively diffuse in the i.p.-dosed preclinical experiments.</div><div class="NLM_p last">Future studies will therefore be directed toward improving the permeability properties of <b>TO-317</b><i>in vivo</i>, while retaining HDAC6 potency, selectivity, and biological activity.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52857" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52857" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The push for selective HDAC6 inhibitors has been on the rise due to the promising clinical efficacy and the lower toxicity profile exhibited in trials. For example, citarinostat (ACY-241, in combination with lenadomide) is currently in clinical trials for smoldering MM; ricolinostat (ACY-1215) is enrolled in multiple clinical trials for a variety of conditions such as breast cancer, MM, and diabetic neuropathic pain, among others.<a onclick="showRef(event, 'ref20 ref39 ref43 ref60'); return false;" href="javascript:void(0);" class="ref ref20 ref39 ref43 ref60">(20,39,43,60)</a> Recent clinical candidates have selectivity windows that are 5–6-fold for HDAC6 as compared to off-target HDACs. While it has been previously reported that HDAC6 has conformational predilections that discriminate between different structural motifs and imposes requirements for inhibitors to achieve maximum ligand-enzyme fit and interactions,<a onclick="showRef(event, 'ref26 ref31'); return false;" href="javascript:void(0);" class="ref ref26 ref31">(26,31)</a> the clinical HDAC6 inhibitors have instead opted for bulky cap groups to confer selectivity. In this study, by X-ray crystallography, we have shown that <b>TO-317</b>, employing a bifurcated approach, using a pyridyl cap group in concert with the traditional <i>N</i>-hydroxamic acid occupies the L1 outer crevice and makes a strong direct H-bonding with the Zn<sup>2+</sup>–ligand, H614. To the best of our knowledge, there has been no previous report of a direct H-bonding interaction with a Zn<sup>2+</sup>–ligand at the HDAC6 active site. <b>TO-317</b> is shown to adopt an induced fit model which may facilitate this direct residue interaction and thereby stabilize the enzyme–inhibitor complex. This unique structural motif, which engages the second-shell interactions with the catalytic Zn<sup>2+</sup> metal, can provide novel pharmacophores for identifying tighter binding HDAC6-selective inhibitors.</div><div class="NLM_p">The selectivity of <b>TO-317</b> was demonstrated <i>in vitro</i> through several orthogonal cell biology experiments. We showed in a dose-dependent manner the preferential increase in acetylated α-tubulin on incubation with concentrations as low as 50 nM of <b>TO-317</b>. Furthermore, ∼0.75 μM was required to observe distinct acetylation of H3 histone, validating the <i>in vitro</i> preferential HDAC6 selectivity of <b>TO-317</b>. <b>TO-317</b> was found to be biologically active in several cancer cell lines, while not eliciting any meaningful cell-killing activity in normal cells, indicating an appreciable therapeutic window, which was attributed to the observed HDAC6 selectivity. <b>TO-317</b> mediates programmed cancer cell apoptosis, which may be associated with ROS generation along the mechanistic pathway. Preliminary stability assays in various biological fluids highlighted potential bioavailability issues <i>in vivo</i> with this inhibitor. Future studies will attempt to improve the poor bioavailability exhibited by <b>TO-317</b>.</div><div class="NLM_p last">Collectively, we have demonstrated a novel approach to selective HDAC6 inhibition, achieving a low nM potency against HDAC6. Structural studies have revealed a unique binding mode in which <b>TO-317</b> simultaneously coordinates to Zn<sup>2+</sup> and the H614 residue in the catalytic tunnel, affording >150-fold selectivity for HDAC6. Optimized pharmacokinetic properties might yield a preclinical candidate HDAC6 inhibitor from this compound. Finally, the <b>TO-317</b> model presents a structural model that can be incorporated for the selective targeting of HDAC6.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86256" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86256" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Chemistry</h3><div class="NLM_p">All chemicals and reagents were purchased from any of the following suppliers: Combi-Blocks, Sigma-Aldrich, Enamine, Alfa-Aesar, and Oakwood Chemicals. Solvents such as DCM were obtained in anhydrous forms from our in-house Mbraun solvent dispensary system. Other solvents such as acetonitrile and DMF were used in their dry forms from 100 mL Sigma-Aldrich bottles. Reactions were carried out in oven-dried glassware, and reaction progress was monitored using a TLC silica gel 60 F254 and a 254 nM UV lamp. Purification of intermediates was carried out using a Biotage automated flash chromatography instrument in prepacked SNAP KP-SIL cartridges supplied by Biotage in sizes of 12G, 25G, 50G, and 100G packings. Characterization for intermediates includes <sup>1</sup>H, <sup>19</sup>F, and <sup>13</sup>C NMR obtained using a 400 MHz Bruker NMR spectrometer and low-resolution mass spectrometry obtained using a Waters LC–MS Micromass ZQ using ESI positive and negative ionization modes. Purifications of final compounds were carried out using a Waters prep-HPLC system equipped with a Waters 2545 quaternary gradient pump system, an XSelect 300G CSH Phenyl-Hexyl C18 column, and a 2489 dual-absorbance UV detector and ran using the mobile phases acetonitrile and water spiked with 0.1% trifluoroacetic acid (TFA). Characterization for final compounds includes <sup>1</sup>H, <sup>19</sup>F, and <sup>13</sup>C NMR and is obtained like that of the intermediates, and high-resolution mass spectrometry was performed using a quadrupole time-of-flight liquid chromatography–mass spectrometry (LC–MS) system at the Advanced Instrumentation for Molecular Structure (AIMS) facility at the University of Toronto; purity checks for all final compounds satisfy a ≥95% purity requirement, and traces were obtained using an HP 1100 series analytical HPLC using gradient 5–100% acetonitrile in water for 40 min/60 min. The retention times (<i>T</i><sub>R</sub>) and purity as calculated from the peak area of the compound/total area of all peaks in spectra X 100% were reported as automatically calculated by the analytical HPLC instrument.</div><div class="NLM_p">Details for protein crystallographic methods are provided in detail in the online <a href="/doi/suppl/10.1021/acs.jmedchem.0c01922/suppl_file/jm0c01922_si_001.csv" class="ext-link">Supporting Information</a>.</div><div class="NLM_p last">All intermediates and final product characterizations and their yields are reported in the online <a href="/doi/suppl/10.1021/acs.jmedchem.0c01922/suppl_file/jm0c01922_si_001.csv" class="ext-link">Supporting Information</a>.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Synthesis of Product A′ (Tetrafluorobenzenesulfonyl Chloride)</h3><div class="NLM_p last">Tetrafluorobenzene (TFB, 1.0 g, 6.6 mmol) was carefully added into chlorosulfonic acid (3.88 g, 33.3 mmol), and the mixture was refluxed for 3 h. The reaction vessel was cooled to 0 °C, and the solution was slowly pipetted into ice-cold water. This aqueous solution was extracted with 20 mL of EtOAc twice. Combined EtOAc fractions were washed with brine and dried over MgSO<sub>4</sub>. The clear solution was concentrated under vacuum and purified using flash chromatography, isocratic condition 10% EtOAc in hexane. The pure product was obtained as a clear oil, with a 95% yield. <sup>1</sup>H NMR (400 MHz, acetonitrile-<i>d</i><sub>3</sub>): δ 7.92–7.66 (m, 1H), <sup>19</sup>F NMR (376 MHz, acetonitrile-<i>d</i><sub>3</sub>): δ −133.82 (dtd, <i>J</i> = 20.7, 12.0, 5.9 Hz), −135.65 to 136.10 (m), −142.87 (tdd, <i>J</i> = 19.2, 12.0, 7.8 Hz), −151.06 to 151.57 (m). <sup>13</sup>C NMR (101 MHz, acetonitrile-<i>d</i><sub>3</sub>): δ 147.8 (ddd, <i>J</i> = 10.7, 3.8, 1.8 Hz), 147.3 (ddd, <i>J</i> = 15.8, 12.3, 3.1 Hz), 146.7 (dt, <i>J</i> = 12.7, 3.3 Hz), 145.3 (ddd, <i>J</i> = 10.8, 3.9, 1.8 Hz), 144.6 (ddd, <i>J</i> = 15.9, 12.3, 3.1 Hz), 144.1 (dt, <i>J</i> = 12.7, 3.3 Hz), 143.1 (ddd, <i>J</i> = 16.0, 13.0, 3.2 Hz), 140.5 (ddd, <i>J</i> = 16.1, 12.9, 3.2 Hz), 127.4 (ddd, <i>J</i> = 11.6, 6.8, 4.4 Hz), 116.6, 111.8 (dd, <i>J</i> = 23.4, 3.5 Hz). MS ESI-found 229.04 corresponding to M – 1 for the acid showing rapid compound hydrolysis under MS conditions. Also found 459.0 (M + M + 1 peak).<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/medium/jm0c01922_0015.gif" alt="" id="dgr1" /></img></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Synthesis of Product A (Secondary Sulfonamides)</h3><div class="NLM_p last">In an oven-dried round-bottom flask charged with a magnetic stirring bar were added 1 M equiv of the corresponding sulfonyl chloride and 1.1 M equiv of the corresponding amine in 0.1 M DCM solution, and the mixture was stirred at room temperature (RT) under inert conditions for 1 h or until TLC confirms complete consumption of starting materials. An insoluble precipitate is usually formed corresponding to the protonated quaternary sulfonamide product which is neutralized on addition of 2 M equiv of the triethylamine base, usually leading to dissolution of the precipitate and a clear solution. This clear solution is further stirred for an additional 10 min. Reaction solvents are removed under vacuum, and residue obtained is dissolved in a 2:1 mixture of EtOAc/H<sub>2</sub>O. The organic layer is washed with brine and dried over MgSO<sub>4</sub>. The organic solution is evaporated and purified by flash chromatography using conditions as determined by TLC.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Synthesis of Product B (Tertiary Sulfonamide, Ester Derivatives)</h3><div class="NLM_p last">To the corresponding secondary sulfonamides (1 equiv) were added under inert conditions 1.1 M equiv of <i>tert</i>-butyl 4-(bromomethyl) benzoate and K<sub>2</sub>CO<sub>3</sub> (2 equiv) in 0.25 M acetonitrile solution. The mixture was stirred for 6 h at RT, then the acetonitrile solvent was removed, and the solid residue obtained was dissolved in EtOAc and washed with H<sub>2</sub>O. The organic layer is further washed with brine and dried over MgSO<sub>4</sub>. The clear solution obtained is concentrated and purified using flash chromatography under the appropriate conditions as determined by TLC.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Synthesis of Product C (Tertiary Sulfonamides, Acid Derivatives)</h3><div class="NLM_p last">The corresponding ester is dissolved in 1:4 TFA/DCM (0.1 M solution) and stirred for 3 h or until TLC indicates complete deprotection of the ester. The acidic solution is then neutralized with sodium bicarbonate to a pH of ∼8 before extracting 3x using appropriate amounts of DCM. The combined organic phase is washed once with brine and dried over MgSO<sub>4</sub>. The clear organic solution is evaporated under vacuum to give the required acid which is carried forward to the next step without any further purification.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Synthesis of Compound D <i>O</i>-(Tetrahydro-2<i>H</i>-pyran-2-yl) Protected Hyrodoxamate Esters</h3><div class="NLM_p last">In an oven-dried round-bottom flask was added the corresponding acid dissolved in 0.2 M DCM containing a few drops of DMF. This solution is cooled to 0 °C, and 5 M equiv oxalic chloride is added, resulting in wild evolution of CO<sub>2</sub> gas. On complete effervescence, the solution is warmed to RT and then allowed to stir for 1 h. After stirring for 1 h, the solvents are removed by evaporation and the residue usually obtained is dried under vacuum for 1 h. The dried chloride residue is further taken up in 0.5 M DCM and 1.5 M equiv of <i>O</i>-(tetrahydro-2<i>H</i>-pyran-2-yl)hydroxylamine, resulting in a cloudy mixture which is stirred for 15 min before the addition of 2 M equiv triethylamine, which results in a clear solution. The reaction solution is further stirred for 1 h or as judged to be completion of reaction by TLC. The DCM solvent is then removed under vacuum, dissolved in H<sub>2</sub>O, and extracted with EtOAc. The organic layer is washed with brine and then dried over MgSO<sub>4</sub> before being purified using flash chromatography based on conditions as determined by TLC.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Synthesis of Final Compounds the Corresponding Hydroxamic Acids</h3><div class="NLM_p last">The precursor hydroxamate ester is dissolved in 0.1 M solution of 4 M HCl in dioxane, and the acidic solution is stirred for 3 h or until TLC indicates complete consumption of the starting material. The acid solution is removed under vacuum, and the crude hydroxamic acid is taken up in 2–5 mL of the mixture of H<sub>2</sub>O: acetonitrile in proportions that is suitable for dissolution. A 200 mL aliquot is subjected to an analytical HPLC trial run (5–100% acetonitrile in H<sub>2</sub>O) to determine appropriate conditions for preparatory HPLC purification runs. About 2–5 mL of the reaction mixture is then subjected to a preparatory HPLC run, with 5–95% acetonitrile or gradient conditions as determined from the analytical HPLC trial run. Fractions from prep-HPLC are further checked by analytical HPLC for purity check and then analyzed by LC–MS for identity check before pure fractions are pooled together and lyophilized overnight to give the pure dry hydroxamic acids.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Cytotoxicity Assays</h3><div class="NLM_p last">HeLa cells were grown in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum (FBS) (Sigma-Aldrich). MV4-11 and AML3 were maintained in Iscove’s modified Dulbecco’s medium supplemented with 10% FBS. MOLM-13, MRC-9, MM.1S, MM.1R, Jukat, BV-173, and RPMI 8226 cells were maintained in RPMI-1640 and supplemented with 10% FBS. U87G cells were maintained in Eagle’s minimum essential medium and supplemented with 10% FBS. AR230 cells were maintained in RPMI-1640 and supplemented with 10% FBS, 2 mM <span class="smallcaps smallerCapital">l</span>-glutamine, and 1 μM imatinib. Normal human fibroblasts (NHFs) were purchased from Cell System and grown in a Cell System growth medium, supplemented with Culture Boost. HUVEC cells were purchased from ATCC and cultured in the Vascular Cell Basal Medium supplemented with Endothelial Cell Grow Kit-VEGF. An appropriate number of cells were plated per well in 96-well flat-bottom sterile culture plates with low-evaporation lids (Costar #3997) for these cell lines. After 24 h, inhibitors and a vehicle control (0.5% DMSO) were added. Wells were treated with Cell Titer-Blue (Promega #G808A) (20 μL/well) after 72 h, and fluorescence was recorded at 560/590 nm using a Cytation S63 spectrophotometer. IC<sub>50</sub> values were determined using non-linear regression analysis with GraphPad Prism 6.0 (GraphPad Software Inc.).</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> FACS Apoptosis Detection Assay</h3><div class="NLM_p last">MV4-11 cells were cultured, dosed, and washed twice with cold 1X PBS. Using FITC Annexin V Apoptosis Detection Kit I (BD Pharmingen), cell pellets were resuspended in the 1× binding buffer at a density of 1 × 10<sup>6</sup> cells/ml. 5 μL of FITC Annexin V and 5 μL of PI were added to 250 μL of the solution (2.5 × 10<sup>5</sup> cells). Cells were vortexed and incubated in the dark for 15 min, followed by addition of 250 μL of the 1× binding buffer. Cells were analyzed by flow cytometry within 1 h using a Cytoflex S (Beckman Coulter).</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Western Blotting</h3><div class="NLM_p last">MV4-11 and MM.1S cells were incubated with compounds for 6 h before lysing with the radioimmunoprecipitation assay buffer [20 mM Tris pH 7.4, 150 mM NaCl, 0.5% deoxycholate, 1% Triton X-100, and 0.1% sodium dodecyl sulfate (SDS)]. The total protein was measured using a bicinchoninic acid assay (Thermo Fisher), in which the clarified protein was resolved on a 4–20% polyacrylamide SDS gel and transferred to a nitrocellulose membrane (Bio-Rad). The membranes were blocked with a 5% solution of skimmed milk powder in PBS with Tween 20, followed by an overnight incubation at 4 °C in the primary antibody (1:1000 dilution). Blots were probed with antibodies against acetylated α-tubulin mouse monoclonal (EMD Millipore), acetylated histone H3 (Ac-Lys18, Sigma), and HSC70 (Santa Cruz). The horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG secondary antibody (Cell Signaling) or the HRP-linked anti-rabbit IgG secondary antibody (Cell Signaling) was applied to the membrane (1:5000 dilution), and bands were visualized using clarity western ECL substrate luminal/enhancer solution and peroxide solution 1:1 ratio for the HRP-conjugated secondary antibody (Bio-Rad) and analyzed using Image Lab software (Bio-Rad).</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Detection of ROS Generation</h3><div class="NLM_p last">MV4-11 cells were treated with the relevant compounds and analyzed for production of ROS using 2’,7’-dichlorodihydrofluorescein diacetate (DCFDA) (Abcam 113851 DCFDA Cellular ROS detection Assay Kit). Briefly, cells were collected and washed with 1× PBS once and incubated with DCFDA (33 μM) at 37 °C for 30 min in the dark. The cells were then washed and resuspended in the 1× supplemental buffer, seeded in a clear bottom black 96-well plate (Fisher Scientific), and dosed with the compound, and the fluorescence at Ex/Em = 485/535 was measured using a Cytation S63 spectrophotometer.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Immunofluorescence Assay</h3><div class="NLM_p">HeLa cells were plated to sub-confluency on a clear bottom black 96-well plate (Fisher Scientific) and treated with the compound after 24 h. Samples were washed with 1× PBS, fixed with 4% formaldehyde (Millipore Sigma), permeabilized with 1% Triton X-100 (Millipore Sigma), and blocked in 5% bovine serum albumin (BioShop) for 1 h at RT. The cells were incubated in an antibody cocktail made up of acetylated α-tubulin mouse monoclonal (1:100 dilution, MD Millipore) and acetylated histone H3 (1:50 dilution, Ac-Lys18, Sigma). Cells were counterstained for nucleic acids using DAPI (Thermo Fisher Scientific). Images were obtained using a Cytation S63 spectrophotometer.</div><div class="NLM_p last">Further protocols have been provided in <a href="/doi/suppl/10.1021/acs.jmedchem.0c01922/suppl_file/jm0c01922_si_002.pdf" class="ext-link">Supporting Information</a> methods.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i26"><a href="/doi/suppl/10.1021/acs.jmedchem.0c01922" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57228" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57228" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c01922?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01922</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01922/suppl_file/jm0c01922_si_001.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">HDAC binding and inhibition profiles using FP and enzymatic activity assays; PAMPA, kinetic solubility, and pharmacokinetic data; cell population sorting; cell viability screens; mass spectrometry; immunofluorescence; and synthetic schemes, experimental procedures, and compound characterization (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01922/suppl_file/jm0c01922_si_002.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Docking of <b>TO-317</b> with drHDAC6 (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01922/suppl_file/jm0c01922_si_003.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Docking of 1 with drHDAC6 (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01922/suppl_file/jm0c01922_si_004.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Docking of 2 with drHDAC6 (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01922/suppl_file/jm0c01922_si_005.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Docking of citarinostat with drHDAC6 (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01922/suppl_file/jm0c01922_si_006.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Docking of <b>TO-317</b> with HDAC8 (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01922/suppl_file/jm0c01922_si_007.pdb" class="ext-link">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01922/suppl_file/jm0c01922_si_001.csv">jm0c01922_si_001.csv (2.29 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01922/suppl_file/jm0c01922_si_002.pdf">jm0c01922_si_002.pdf (11.59 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01922/suppl_file/jm0c01922_si_003.pdb">jm0c01922_si_003.pdb (60.23 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01922/suppl_file/jm0c01922_si_004.pdb">jm0c01922_si_004.pdb (4.92 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01922/suppl_file/jm0c01922_si_005.pdb">jm0c01922_si_005.pdb (5.05 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01922/suppl_file/jm0c01922_si_006.pdb">jm0c01922_si_006.pdb (5.11 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01922/suppl_file/jm0c01922_si_007.pdb">jm0c01922_si_007.pdb (6.31 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c01922" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_88662" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_88662" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David W. Christianson</span> - <span class="hlFld-Affiliation affiliation">Roy
and Diana Vagelos Laboratories, Department of Chemistry, University of Pennsylvania, 231 South 34th Street, Philadelphia, Pennsylvania 19104-6323, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0194-5212" title="Orcid link">http://orcid.org/0000-0002-0194-5212</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#57343f253e241724362479222732393979323322"><span class="__cf_email__" data-cfemail="2e4d465c475d6e5d4f5d005b5e4b4040004b4a5b">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Patrick T. Gunning</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemical and Physical Sciences, University
of Toronto Mississauga, 3359 Mississauga Rd N., Mississauga, Ontario L5L 1C6, Canada</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Chemistry, University of Toronto, 80 St. George Street, Toronto, Ontario M5S 3H6, Canada</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0654-735X" title="Orcid link">http://orcid.org/0000-0003-0654-735X</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#c5b5a4b1b7aca6aeeba2b0ababacaba285b0b1aab7aaabb1aaeba6a4"><span class="__cf_email__" data-cfemail="23534257514a40480d44564d4d4a4d446356574c514c4d574c0d4042">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Olasunkanmi O. Olaoye</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemical and Physical Sciences, University
of Toronto Mississauga, 3359 Mississauga Rd N., Mississauga, Ontario L5L 1C6, Canada</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Chemistry, University of Toronto, 80 St. George Street, Toronto, Ontario M5S 3H6, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paris R. Watson</span> - <span class="hlFld-Affiliation affiliation">Roy
and Diana Vagelos Laboratories, Department of Chemistry, University of Pennsylvania, 231 South 34th Street, Philadelphia, Pennsylvania 19104-6323, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nabanita Nawar</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemical and Physical Sciences, University
of Toronto Mississauga, 3359 Mississauga Rd N., Mississauga, Ontario L5L 1C6, Canada</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Chemistry, University of Toronto, 80 St. George Street, Toronto, Ontario M5S 3H6, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mulu Geletu</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemical and Physical Sciences, University
of Toronto Mississauga, 3359 Mississauga Rd N., Mississauga, Ontario L5L 1C6, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Abootaleb Sedighi</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemical and Physical Sciences, University
of Toronto Mississauga, 3359 Mississauga Rd N., Mississauga, Ontario L5L 1C6, Canada</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5974-1792" title="Orcid link">http://orcid.org/0000-0001-5974-1792</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shazreh Bukhari</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemical and Physical Sciences, University
of Toronto Mississauga, 3359 Mississauga Rd N., Mississauga, Ontario L5L 1C6, Canada</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Chemistry, University of Toronto, 80 St. George Street, Toronto, Ontario M5S 3H6, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yasir S. Raouf</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemical and Physical Sciences, University
of Toronto Mississauga, 3359 Mississauga Rd N., Mississauga, Ontario L5L 1C6, Canada</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Chemistry, University of Toronto, 80 St. George Street, Toronto, Ontario M5S 3H6, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pimyupa Manaswiyoungkul</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemical and Physical Sciences, University
of Toronto Mississauga, 3359 Mississauga Rd N., Mississauga, Ontario L5L 1C6, Canada</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Chemistry, University of Toronto, 80 St. George Street, Toronto, Ontario M5S 3H6, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fettah Erdogan</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemical and Physical Sciences, University
of Toronto Mississauga, 3359 Mississauga Rd N., Mississauga, Ontario L5L 1C6, Canada</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Chemistry, University of Toronto, 80 St. George Street, Toronto, Ontario M5S 3H6, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ayah Abdeldayem</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemical and Physical Sciences, University
of Toronto Mississauga, 3359 Mississauga Rd N., Mississauga, Ontario L5L 1C6, Canada</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Chemistry, University of Toronto, 80 St. George Street, Toronto, Ontario M5S 3H6, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Aaron D. Cabral</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemical and Physical Sciences, University
of Toronto Mississauga, 3359 Mississauga Rd N., Mississauga, Ontario L5L 1C6, Canada</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Chemistry, University of Toronto, 80 St. George Street, Toronto, Ontario M5S 3H6, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Muhammad Murtaza Hassan</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemical and Physical Sciences, University
of Toronto Mississauga, 3359 Mississauga Rd N., Mississauga, Ontario L5L 1C6, Canada</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Chemistry, University of Toronto, 80 St. George Street, Toronto, Ontario M5S 3H6, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Krimo Toutah</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemical and Physical Sciences, University
of Toronto Mississauga, 3359 Mississauga Rd N., Mississauga, Ontario L5L 1C6, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrew E. Shouksmith</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemical and Physical Sciences, University
of Toronto Mississauga, 3359 Mississauga Rd N., Mississauga, Ontario L5L 1C6, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Justyna M. Gawel</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemical and Physical Sciences, University
of Toronto Mississauga, 3359 Mississauga Rd N., Mississauga, Ontario L5L 1C6, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Johan Israelian</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemical and Physical Sciences, University
of Toronto Mississauga, 3359 Mississauga Rd N., Mississauga, Ontario L5L 1C6, Canada</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Chemistry, University of Toronto, 80 St. George Street, Toronto, Ontario M5S 3H6, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tudor B. Radu</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemical and Physical Sciences, University
of Toronto Mississauga, 3359 Mississauga Rd N., Mississauga, Ontario L5L 1C6, Canada</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Chemistry, University of Toronto, 80 St. George Street, Toronto, Ontario M5S 3H6, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Niyati Kachhiyapatel</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemical and Physical Sciences, University
of Toronto Mississauga, 3359 Mississauga Rd N., Mississauga, Ontario L5L 1C6, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Elvin D. de Araujo</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemical and Physical Sciences, University
of Toronto Mississauga, 3359 Mississauga Rd N., Mississauga, Ontario L5L 1C6, Canada</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>O.O.O., A.E.S., K.T., E.D.d.A., and P.T.G. designed this study. O.O.O., E.D.d.A., P.R.W., D.W.C., and P.T.G. drafted the manuscript. O.O.O. synthesized the chemical compounds. P.R.W. and D.W.C. performed the X-ray crystallography studies, data collection, and X-ray structure analysis. N.N., M.G., S.B., P.M., A.D.C., J.M.G, and A.A. conducted the cellular biology and biophysical experiments. Y.R. and O.O.O. carried out the in silico docking simulations. A.S., T.B.R., and J.I. conducted the PAMPA, plasma, blood stability, and toxicity assays. O.O.O., F.E., M.M.H., N.K., and E.D.A. expressed and purified the recombinant protein used for biophysical studies.</p></li><li><span class="author-information-subsection-header">Funding</span><p>P.T.G. is supported by research grants from NSERC (RGPIN-2014-05767), CIHR (MOP-130424, MOP-137036), Canada Research Chair (950-232042), the Canadian Cancer Society (703963), the Canadian Breast Cancer Foundation (705456), and the Leukaemia and Lymphoma Society of Canada and infrastructure grants from CFI (33536) and the Ontario Research Fund (34876). D.W.C. is supported by grant GM49758 from the US National Institutes of Health. O.O.O. is supported by an OGS Fellowship. Y.S.R and N.N. are supported by grants from Jesse’s Journey, and A.D.C is supported by NSERC CGS. This work utilized beamline 17-ID-1 (AMX) of the National Synchroton Light Source II, a US Department of Energy (DOE) Office of Science User Facility operated for the DOE office of Science by Brookhaven National Laboratory under contract DE-SC0012704. The Center for BioMolecular Structure (CBMS) is primarily supported by the National Institute of General Medical Sciences (NIGMS) of the National Institutes of Health through a Center Core P30 Grant (P30GM133893) and by the DOE Office of Biological and Environmental Research (KP1605010). The authors would also like to thank Andrew Sedmihradsky and family, who have raised funds and awareness for Duchenne muscular dystrophy and generated support for Max’s Big Fellowship.</p></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br><p class="inlineNote">Atomic coordinates and structure factor amplitudes for the drHDAC6-<b>TO-317</b> complex are deposited in the Protein Data Bank (<a href="http://www.rcsb.org" class="extLink">www.rcsb.org</a>) with accession code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7JOM">7JOM</a>. The authors will release the atomic coordinates and experimental data upon article publication.</p></div></li></ul></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">CAS9</td><td class="NLM_def"><p class="first last">CRISPR associated protein 9</p></td></tr><tr><td class="NLM_term">CD</td><td class="NLM_def"><p class="first last">catalytic domain</p></td></tr><tr><td class="NLM_term">CRISPR</td><td class="NLM_def"><p class="first last">clustered regularly interspaced short palindromic repeats</p></td></tr><tr><td class="NLM_term">CTCL</td><td class="NLM_def"><p class="first last">cutaneous T-cell lymphoma</p></td></tr><tr><td class="NLM_term">DAPI</td><td class="NLM_def"><p class="first last">4′,6-diamidino-2-phenylindole</p></td></tr><tr><td class="NLM_term"><i>dr</i>HDAC6</td><td class="NLM_def"><p class="first last"><i>danio rerio</i> histone deacetylase 6</p></td></tr><tr><td class="NLM_term">EMSA</td><td class="NLM_def"><p class="first last">electrophoretic mobility shift assay</p></td></tr><tr><td class="NLM_term">FAM</td><td class="NLM_def"><p class="first last">6-carboxy fluorescein-aminohexyl amidite</p></td></tr><tr><td class="NLM_term">FP</td><td class="NLM_def"><p class="first last">fluorescence polarization</p></td></tr><tr><td class="NLM_term">HDAC</td><td class="NLM_def"><p class="first last">histone deacetylase</p></td></tr><tr><td class="NLM_term">HDAC6</td><td class="NLM_def"><p class="first last">histone deacetylase 6</p></td></tr><tr><td class="NLM_term">LE</td><td class="NLM_def"><p class="first last">ligand efficiency</p></td></tr><tr><td class="NLM_term">LL</td><td class="NLM_def"><p class="first last">lower left</p></td></tr><tr><td class="NLM_term">LR</td><td class="NLM_def"><p class="first last">lower right</p></td></tr><tr><td class="NLM_term">MM</td><td class="NLM_def"><p class="first last">multiple myeloma</p></td></tr><tr><td class="NLM_term">PFB</td><td class="NLM_def"><p class="first last">pentafluoro benzene</p></td></tr><tr><td class="NLM_term">PI</td><td class="NLM_def"><p class="first last">propidium iodide</p></td></tr><tr><td class="NLM_term">PTCL</td><td class="NLM_def"><p class="first last">peripheral T-cell lymphoma</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">TFB</td><td class="NLM_def"><p class="first last">tetrafluoro benzene</p></td></tr><tr><td class="NLM_term">UL</td><td class="NLM_def"><p class="first last">upper left</p></td></tr><tr><td class="NLM_term">UR</td><td class="NLM_def"><p class="first last">upper right</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i30">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60180" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60180" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 60 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hackanson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rimmele, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benkißer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdelkarim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fliegauf, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lübbert, M.</span></span> <span> </span><span class="NLM_article-title">HDAC6 as a Target for Antileukemic Drugs in Acute Myeloid Leukemia</span>. <i>Leuk. Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">1055</span>– <span class="NLM_lpage">1062</span>, <span class="refDoi"> DOI: 10.1016/j.leukres.2012.02.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1016%2Fj.leukres.2012.02.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=22464548" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvFSmsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2012&pages=1055-1062&author=B.+Hackansonauthor=L.+Rimmeleauthor=M.+Benki%C3%9Ferauthor=M.+Abdelkarimauthor=M.+Fliegaufauthor=M.+Jungauthor=M.+L%C3%BCbbert&title=HDAC6+as+a+Target+for+Antileukemic+Drugs+in+Acute+Myeloid+Leukemia&doi=10.1016%2Fj.leukres.2012.02.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC6 as a target for antileukemic drugs in acute myeloid leukemia</span></div><div class="casAuthors">Hackanson, Bjoern; Rimmele, Leander; Benkisser, Marco; Abdelkarim, Mahmoud; Fliegauf, Manfred; Jung, Manfred; Luebbert, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1055-1062</span>CODEN:
                <span class="NLM_cas:coden">LEREDD</span>;
        ISSN:<span class="NLM_cas:issn">0145-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Inhibition of histone deacetylases (HDACs) by drugs such as vorinostat or depsipeptide has become treatment strategy under study in acute myeloid leukemia.  Most preclinically and clin. investigated HDACi target classes I, II and IV, but only few are selective in inhibiting specific HDACs.  Here we analyzed the in vitro antileukemic activity of three novel hydroxamate derivs., the pan-HDAC-inhibitors ST13, ST34 and the known HDAC6 inhibitor ST80, treating leukemia cell lines HL60, Kasumi-1, NB-4, THP-1, K562, U937, Jurkat as well as primary AML blasts.  In cell lines all three compds. exerted a strong growth-inhibitory effect at low micromolar concns.  ST13 increased acetylation of H3, H4 and α-tubulin, while ST34 preferentially acetylated histones H3 and H4.  Interestingly, ST80 preferentially induced α-tubulin acetylation at low micromolar doses, confirming a selective inhibition of HDAC6 by ST80 in leukemic cells.  These observations were also confirmed in primary AML blasts cultured ex vivo.  Growth-inhibition by ST80 was independent of pre-treatment HDAC6 protein expression and in contrast to ST13 and ST34, ST80 did not result in induction of p21/WAF.  Immunofluorescence imaging confirmed that ST80 treatment both increased the abundance and resulted in unilateral local accumulation of acetylated α-tubulin.  In conclusion, the three novel HDACi show potent antileukemic activity in myeloid cell lines and primary AML blasts at low micromolar concns.  Preferential acetylation of α-tubulin implies that ST80 might exert its antileukemic effect not through histone reacetylation but rather through inhibition of HDAC6.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogNxuKC1ZPdrVg90H21EOLACvtfcHk0ljdJw2DXj1DSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvFSmsLo%253D&md5=26085ecb4905806c84bc90900c820db5</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.leukres.2012.02.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.leukres.2012.02.026%26sid%3Dliteratum%253Aachs%26aulast%3DHackanson%26aufirst%3DB.%26aulast%3DRimmele%26aufirst%3DL.%26aulast%3DBenki%25C3%259Fer%26aufirst%3DM.%26aulast%3DAbdelkarim%26aufirst%3DM.%26aulast%3DFliegauf%26aufirst%3DM.%26aulast%3DJung%26aufirst%3DM.%26aulast%3DL%25C3%25BCbbert%26aufirst%3DM.%26atitle%3DHDAC6%2520as%2520a%2520Target%2520for%2520Antileukemic%2520Drugs%2520in%2520Acute%2520Myeloid%2520Leukemia%26jtitle%3DLeuk.%2520Res.%26date%3D2012%26volume%3D36%26spage%3D1055%26epage%3D1062%26doi%3D10.1016%2Fj.leukres.2012.02.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Santo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hideshima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarpe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Duzer, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazitschek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogier, W. C.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Preclinical Activity, Pharmacodynamic, and Pharmacokinetic Properties of a Selective HDAC6 Inhibitor, ACY-1215, in Combination with Bortezomib in Multiple Myeloma</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">2579</span>– <span class="NLM_lpage">2589</span>, <span class="refDoi"> DOI: 10.1182/blood-2011-10-387365</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1182%2Fblood-2011-10-387365" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=22262760" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BC38XltVOntb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2012&pages=2579-2589&author=L.+Santoauthor=T.+Hideshimaauthor=A.+L.+Kungauthor=J.-C.+Tsengauthor=D.+Tamangauthor=M.+Yangauthor=M.+Jarpeauthor=J.+H.+Van+Duzerauthor=R.+Mazitschekauthor=W.+C.+Ogier&title=Preclinical+Activity%2C+Pharmacodynamic%2C+and+Pharmacokinetic+Properties+of+a+Selective+HDAC6+Inhibitor%2C+ACY-1215%2C+in+Combination+with+Bortezomib+in+Multiple+Myeloma&doi=10.1182%2Fblood-2011-10-387365"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma</span></div><div class="casAuthors">Santo, Loredana; Hideshima, Teru; Kung, Andrew L.; Tseng, Jen-Chieh; Tamang, David; Yang, Min; Jarpe, Matthew; van Duzer, John H.; Mazitschek, Ralph; Ogier, Walter C.; Cirstea, Diana; Rodig, Scott; Eda, Homare; Scullen, Tyler; Canavese, Miriam; Bradner, James; Anderson, Kenneth C.; Jones, Simon S.; Raje, Noopur</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2579-2589</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Histone deacetylase (HDAC) enzymic activity has been linked to the transcription of DNA in cancers including multiple myeloma (MM).  Therefore, HDAC inhibitors used alone and in combination are being actively studied as novel therapies in MM.  In the present study, we investigated the preclin. activity of ACY-1215, an HDAC6-selective inhibitor, alone and in combination with bortezomib in MM.  Low doses of ACY-1215 combined with bortezomib triggered synergistic anti-MM activity, resulting in protracted endoplasmic reticulum stress and apoptosis via activation of caspase-3, caspase-8, and caspase-9 and poly (ADP) ribosome polymerase.  In vivo, the anti-MM activity of ACY-1215 in combination with bortezomib was confirmed using 2 different xenograft SCID mouse models: human MM injected s.c. (the plasmacytoma model) and luciferase-expressing human MM injected i.v. (the disseminated MM model).  Tumor growth was significantly delayed and overall survival was significantly prolonged in animals treated with the combination therapy.  Pharmacokinetic data showed peak plasma levels of ACY-1215 at 4 h after treatment coincident with an increase in acetylated α-tubulin, a marker of HDAC6 inhibition, by immunohistochem. and Western blot anal.  These studies provide preclin. rationale for acetylated α-tubulin use as a pharmacodynamic biomarker in future clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoelmsk1wo_LVg90H21EOLACvtfcHk0ljts5D5_IFhxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XltVOntb4%253D&md5=094298bdd3d5b91c7060d8b294857846</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1182%2Fblood-2011-10-387365&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2011-10-387365%26sid%3Dliteratum%253Aachs%26aulast%3DSanto%26aufirst%3DL.%26aulast%3DHideshima%26aufirst%3DT.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DTseng%26aufirst%3DJ.-C.%26aulast%3DTamang%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DM.%26aulast%3DJarpe%26aufirst%3DM.%26aulast%3DVan%2BDuzer%26aufirst%3DJ.%2BH.%26aulast%3DMazitschek%26aufirst%3DR.%26aulast%3DOgier%26aufirst%3DW.%2BC.%26atitle%3DPreclinical%2520Activity%252C%2520Pharmacodynamic%252C%2520and%2520Pharmacokinetic%2520Properties%2520of%2520a%2520Selective%2520HDAC6%2520Inhibitor%252C%2520ACY-1215%252C%2520in%2520Combination%2520with%2520Bortezomib%2520in%2520Multiple%2520Myeloma%26jtitle%3DBlood%26date%3D2012%26volume%3D119%26spage%3D2579%26epage%3D2589%26doi%3D10.1182%2Fblood-2011-10-387365" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, C.</span></span> <span> </span><span class="NLM_article-title">HDAC6 Promotes Cell Proliferation and Confers Resistance to Gefitinib in Lung Adenocarcinoma</span>. <i>Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">589</span>– <span class="NLM_lpage">597</span>, <span class="refDoi"> DOI: 10.3892/or.2016.4811</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.3892%2For.2016.4811" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=27221381" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtl2mtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2016&pages=589-597&author=Z.+Wangauthor=F.+Tangauthor=P.+Huauthor=Y.+Wangauthor=J.+Gongauthor=S.+Sunauthor=C.+Xie&title=HDAC6+Promotes+Cell+Proliferation+and+Confers+Resistance+to+Gefitinib+in+Lung+Adenocarcinoma&doi=10.3892%2For.2016.4811"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC6 promotes cell proliferation and confers resistance to gefitinib in lung adenocarcinoma</span></div><div class="casAuthors">Wang, Zhihao; Tang, Fang; Hu, Pengchao; Wang, Ying; Gong, Jun; Sun, Shaoxing; Xie, Conghua</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">589-597</span>CODEN:
                <span class="NLM_cas:coden">OCRPEW</span>;
        ISSN:<span class="NLM_cas:issn">1791-2431</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) are promising targets for cancer therapy, and first-generation HDAC inhibitors are currently in clin. trials for the treatment of cancer patients.  HDAC6, which is a key regulator of many signaling pathways that are linked to cancer, has recently emerged as an attractive target for the treatment of cancer.  In the present study, HDAC6 was found to be overexpressed in lung adenocarcinoma cell lines and was neg. correlated with the prognosis of patients with lung adenocarcinoma.  Overexpression of HDAC6 promoted the proliferation of lung adenocarcinoma cells in a deacetylase activity-dependent manner.  HDAC6 overexpression conferred resistance to gefitinib via the stabilization of epidermal growth factor receptor (EGFR).  The inhibition of HDAC6 by CAY10603, a potent and selective inhibitor of HDAC6, inhibited the proliferation of lung adenocarcinoma cells and induced apoptosis.  CAY10603 downregulated the levels of EGFR protein, which in turn inhibited activation of the EGFR signaling pathway.  Moreover, CAY10603 synergized with gefitinib to induce apoptosis of the lung adenocarcinoma cell lines via the destabilization of EGFR.  Taken together, our results suggest that the inhibition of HDAC6 may be a promising strategy for the treatment of lung adenocarcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4lXuah65G6bVg90H21EOLACvtfcHk0ljts5D5_IFhxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtl2mtLk%253D&md5=3a2778e81b86443b5e4fcc37bc11f11e</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.3892%2For.2016.4811&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For.2016.4811%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DTang%26aufirst%3DF.%26aulast%3DHu%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DGong%26aufirst%3DJ.%26aulast%3DSun%26aufirst%3DS.%26aulast%3DXie%26aufirst%3DC.%26atitle%3DHDAC6%2520Promotes%2520Cell%2520Proliferation%2520and%2520Confers%2520Resistance%2520to%2520Gefitinib%2520in%2520Lung%2520Adenocarcinoma%26jtitle%3DOncol.%2520Rep.%26date%3D2016%26volume%3D36%26spage%3D589%26epage%3D597%26doi%3D10.3892%2For.2016.4811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ho, T. C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, A. H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganesan, A.</span></span> <span> </span><span class="NLM_article-title">Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">12460</span>– <span class="NLM_lpage">12484</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00830</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00830" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlSisrzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=12460-12484&author=T.+C.+S.+Hoauthor=A.+H.+Y.+Chanauthor=A.+Ganesan&title=Thirty+Years+of+HDAC+Inhibitors%3A+2020+Insight+and+Hindsight&doi=10.1021%2Facs.jmedchem.0c00830"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight</span></div><div class="casAuthors">Ho, Terence C. S.; Chan, Alex H. Y.; Ganesan, A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">12460-12484</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  It is now 30 years since the first report of a potent zinc-dependent histone deacetylase (HDAC) inhibitor appeared.  Since then, five HDAC inhibitors have received regulatory approval for cancer chemotherapy while many others are in clin. development for oncol. as well as other therapeutic indications.  This Perspective reviews the biol. and medicinal chem. advances over the past 3 decades with an emphasis on the design of selective inhibitors that discriminate between the 11 human HDAC isoforms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrES4d2gbkB17Vg90H21EOLACvtfcHk0ljIwvdhLMcZ1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlSisrzP&md5=1deb2ad5787797a9ee98dcf7bdade52c</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00830%26sid%3Dliteratum%253Aachs%26aulast%3DHo%26aufirst%3DT.%2BC.%2BS.%26aulast%3DChan%26aufirst%3DA.%2BH.%2BY.%26aulast%3DGanesan%26aufirst%3DA.%26atitle%3DThirty%2520Years%2520of%2520HDAC%2520Inhibitors%253A%25202020%2520Insight%2520and%2520Hindsight%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D12460%26epage%3D12484%26doi%3D10.1021%2Facs.jmedchem.0c00830" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span> <span> </span><span class="NLM_article-title">Role of HDACs in Normal and Malignant Hematopoiesis</span>. <i>Mol. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">5</span>, <span class="refDoi"> DOI: 10.1186/s12943-019-1127-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1186%2Fs12943-019-1127-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=31910827" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A280%3ADC%252BB3MbnsVartw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2020&pages=5&author=P.+Wangauthor=Z.+Wangauthor=J.+Liu&title=Role+of+HDACs+in+Normal+and+Malignant+Hematopoiesis&doi=10.1186%2Fs12943-019-1127-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Role of HDACs in normal and malignant hematopoiesis</span></div><div class="casAuthors">Wang Pan; Wang Zi; Wang Pan; Wang Zi; Liu Jing</div><div class="citationInfo"><span class="NLM_cas:title">Molecular cancer</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Normal hematopoiesis requires the accurate orchestration of lineage-specific patterns of gene expression at each stage of development, and epigenetic regulators play a vital role.  Disordered epigenetic regulation has emerged as a key mechanism contributing to hematological malignancies.  Histone deacetylases (HDACs) are a series of key transcriptional cofactors that regulate gene expression by deacetylation of lysine residues on histone and nonhistone proteins.  In normal hematopoiesis, HDACs are widely involved in the development of various lineages.  Their functions involve stemness maintenance, lineage commitment determination, cell differentiation and proliferation, etc.  Deregulation of HDACs by abnormal expression or activity and oncogenic HDAC-containing transcriptional complexes are involved in hematological malignancies.  Currently, HDAC family members are attractive targets for drug design, and a variety of HDAC-based combination strategies have been developed for the treatment of hematological malignancies.  Drug resistance and limited therapeutic efficacy are key issues that hinder the clinical applications of HDAC inhibitors (HDACis).  In this review, we summarize the current knowledge of how HDACs and HDAC-containing complexes function in normal hematopoiesis and highlight the etiology of HDACs in hematological malignancies.  Moreover, the implication and drug resistance of HDACis are also discussed.  This review presents an overview of the physiology and pathology of HDACs in the blood system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQuj8DxhH9_I9LIORRPd5lbfW6udTcc2earZF4ofGNgsbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MbnsVartw%253D%253D&md5=96b7cff9ffdde16fca3e2b6e79e51078</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1186%2Fs12943-019-1127-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12943-019-1127-7%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DJ.%26atitle%3DRole%2520of%2520HDACs%2520in%2520Normal%2520and%2520Malignant%2520Hematopoiesis%26jtitle%3DMol.%2520Cancer%26date%3D2020%26volume%3D19%26spage%3D5%26doi%3D10.1186%2Fs12943-019-1127-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase (HDAC) Inhibitors in Cancer: A Patent Review (2017-Present)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">263</span>– <span class="NLM_lpage">274</span>, <span class="refDoi"> DOI: 10.1080/13543776.2020.1725470</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1080%2F13543776.2020.1725470" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=32008402" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BB3cXit1CitbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=263-274&author=C.+Zhaoauthor=H.+Dongauthor=Q.+Xuauthor=Y.+Zhang&title=Histone+Deacetylase+%28HDAC%29+Inhibitors+in+Cancer%3A+A+Patent+Review+%282017-Present%29&doi=10.1080%2F13543776.2020.1725470"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase (HDAC) inhibitors in cancer: a patent review (2017-present)</span></div><div class="casAuthors">Zhao, Chunlong; Dong, Hang; Xu, Qifu; Zhang, Yingjie</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">263-274</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase (HDAC) inhibitors play a crucial role in restoring the balance of acetylation and deacetylation of lysine residues of histones and non-histone proteins, which are applied to treat several diseases including cancer.  This review covers recent efforts in the synthesis and applications of inhibitors and hybrid inhibitors targeting HDAC from 2017 to 2019.  HDACs are important epigenetic targets and HDAC inhibitors have become important biol. active compds. for the treatment of cancers.  Among the recent patents available, most of them place emphasis on HDAC selective inhibitors and multitarget HDAC inhibitors.  Although great accomplishments have been achieved in developing HDAC selective inhibitors, there is still an urgent need for discovery of novel HDAC inhibitors with new zinc-binding groups avoiding the unfavorable pharmacokinetics profiles of hydroxamic acid.  Apart from cancer therapy, HDAC inhibitors have recently been considered as a new strategy in treating other human diseases, such as alc. use disorder (AUD), neurol. disorders, age-related diseases, and so forth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdA-S5sLkahbVg90H21EOLACvtfcHk0ljIwvdhLMcZ1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXit1CitbY%253D&md5=8c3d1f76892b3d33fb6b41d22d561e96</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1080%2F13543776.2020.1725470&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2020.1725470%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DC.%26aulast%3DDong%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DHistone%2520Deacetylase%2520%2528HDAC%2529%2520Inhibitors%2520in%2520Cancer%253A%2520A%2520Patent%2520Review%2520%25282017-Present%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2020%26volume%3D30%26spage%3D263%26epage%3D274%26doi%3D10.1080%2F13543776.2020.1725470" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leipe, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landsman, D.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylases, Acetoin Utilization Proteins and Acetylpolyamine Amidohydrolases Are Members of an Ancient Protein Superfamily</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">3693</span>– <span class="NLM_lpage">3697</span>, <span class="refDoi"> DOI: 10.1093/nar/25.18.3693</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1093%2Fnar%2F25.18.3693" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=9278492" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADyaK2sXmsVahsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1997&pages=3693-3697&author=D.+D.+Leipeauthor=D.+Landsman&title=Histone+Deacetylases%2C+Acetoin+Utilization+Proteins+and+Acetylpolyamine+Amidohydrolases+Are+Members+of+an+Ancient+Protein+Superfamily&doi=10.1093%2Fnar%2F25.18.3693"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylases, acetoin utilization proteins and acetylpolyamine amidohydrolases are members of an ancient protein superfamily</span></div><div class="casAuthors">Leipe, Detlef D.; Landsman, David</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3693-3697</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Searches of several sequence databases reveal that human HD1, yeast HDA1, yeast RPD3 and other eukaryotic histone deacetylases share nine motifs with archaeal and eubacterial enzymes, including acetoin utilization protein (acuC) and acetylpolyamine amidohydrolase.  Histone deacetylase and acetylpolyamine amidohydrolase also share profound functional similarities in that both: (i) recognize an acetylated aminoalkyl group; (ii) catalyze the removal of the acetyl group by cleaving an amide bond; (iii) increase the pos. charge of the substrate.  Stabilization of nucleosomal DNA-histone interaction brought about by the change in charge has been implicated as the underlying cause for histone deacetylase-mediated transcriptional repression.  We speculate that the eukaryotic histone deacetylases originated from a prokaryotic enzyme similar to the acetylpolyamine amidohydrolases that relied on reversible acetylation and deacetylation of the aminoalkyl group of a DNA binding mol. to achieve a gene regulatory effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrN74VTsfnnb7Vg90H21EOLACvtfcHk0liznamz3uaL1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmsVahsbw%253D&md5=8e62f421b69cbaf52640fdc066ac8df2</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1093%2Fnar%2F25.18.3693&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252F25.18.3693%26sid%3Dliteratum%253Aachs%26aulast%3DLeipe%26aufirst%3DD.%2BD.%26aulast%3DLandsman%26aufirst%3DD.%26atitle%3DHistone%2520Deacetylases%252C%2520Acetoin%2520Utilization%2520Proteins%2520and%2520Acetylpolyamine%2520Amidohydrolases%2520Are%2520Members%2520of%2520an%2520Ancient%2520Protein%2520Superfamily%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D1997%26volume%3D25%26spage%3D3693%26epage%3D3697%26doi%3D10.1093%2Fnar%2F25.18.3693" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gregoretti, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodson, H. V.</span></span> <span> </span><span class="NLM_article-title">Molecular Evolution of the Histone Deacetylase Family: Functional Implications of Phylogenetic Analysis</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>338</i></span>,  <span class="NLM_fpage">17</span>– <span class="NLM_lpage">31</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2004.02.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1016%2Fj.jmb.2004.02.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=15050820" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BD2cXisFyksro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=338&publication_year=2004&pages=17-31&author=I.+Gregorettiauthor=Y.-M.+Leeauthor=H.+V.+Goodson&title=Molecular+Evolution+of+the+Histone+Deacetylase+Family%3A+Functional+Implications+of+Phylogenetic+Analysis&doi=10.1016%2Fj.jmb.2004.02.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Evolution of the Histone Deacetylase Family: Functional Implications of Phylogenetic Analysis</span></div><div class="casAuthors">Gregoretti, Ivan V.; Lee, Yun-Mi; Goodson, Holly V.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">338</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17-31</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) modify core histones and participate in large regulatory complexes that both suppress and enhance transcription.  Recent studies indicate that some HDACs can act on non-histone proteins as well.  Interest in these enzymes is growing because HDAC inhibitors appear to be promising therapeutic agents against cancer and a variety of other diseases.  Thus far, 11 members of the HDAC family have been identified in humans, but few have been characterized in detail.  To better define the biol. function of these proteins, make maximal use of studies performed in other systems, and assist in drug development efforts, we have performed a phylogenetic anal. of all HDAC-related proteins in all fully sequenced free-living organisms.  Previous analyses have divided non-sirtuin HDACs into two groups, classes 1 and 2.  We find that HDACs can be divided into three equally distinct groups: class 1, class 2, and a third class consisting of proteins related to the recently identified human HDAC11 gene.  We term this novel group "class 4" to distinguish it from the unrelated "class 3" sirtuin deacetylases.  Anal. of gene duplication events indicates that the common ancestor of metazoan organisms contained two class 1, two class 2, and a single class 4 HDAC.  Examn. of HDAC characteristics in light of these evolutionary relationships leads to functional predictions, among them that self-assocn. is common among HDAC proteins.  All three HDAC classes (including class 4) exist in eubacteria.  Phylogenetic anal. of bacterial HDAC relatives suggests that all three HDAC classes precede the evolution of histone proteins and raises the possibility that the primary activity of some "histone deacetylase" enzymes is directed against non-histone substrates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVqdtToKvZgLVg90H21EOLACvtfcHk0liznamz3uaL1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXisFyksro%253D&md5=1748e3b88d8f3b774db50eb19799f63c</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2004.02.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2004.02.006%26sid%3Dliteratum%253Aachs%26aulast%3DGregoretti%26aufirst%3DI.%26aulast%3DLee%26aufirst%3DY.-M.%26aulast%3DGoodson%26aufirst%3DH.%2BV.%26atitle%3DMolecular%2520Evolution%2520of%2520the%2520Histone%2520Deacetylase%2520Family%253A%2520Functional%2520Implications%2520of%2520Phylogenetic%2520Analysis%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2004%26volume%3D338%26spage%3D17%26epage%3D31%26doi%3D10.1016%2Fj.jmb.2004.02.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rossaert, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Den Bosch, L.</span></span> <span> </span><span class="NLM_article-title">HDAC6 Inhibitors: Translating Genetic and Molecular Insights into a Therapy for Axonal CMT</span>. <i>Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>1733</i></span>,  <span class="NLM_fpage">146692</span>, <span class="refDoi"> DOI: 10.1016/j.brainres.2020.146692</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1016%2Fj.brainres.2020.146692" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=32006555" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjsVOksbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1733&publication_year=2020&pages=146692&author=E.+Rossaertauthor=L.+Van+Den+Bosch&title=HDAC6+Inhibitors%3A+Translating+Genetic+and+Molecular+Insights+into+a+Therapy+for+Axonal+CMT&doi=10.1016%2Fj.brainres.2020.146692"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC6 inhibitors: Translating genetic and molecular insights into a therapy for axonal CMT</span></div><div class="casAuthors">Rossaert, Elisabeth; Van Den Bosch, Ludo</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">1733</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">146692</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase 6 (HDAC6) plays a central role in various processes that are key for neuronal survival.  In this review, we summarize the current evidence related to disease pathways in the axonal form of Charcot-Marie-Tooth disease (CMT) and highlight the role of HDAC6 in these pathways.  We hypothesize that HDAC6 might in fact actively contribute to the pathogenesis of certain forms of axonal CMT.  HDAC6 plays a deacetylase activity-dependent, neg. role in axonal transport and axonal regeneration, which are both processes implicated in axonal CMT.  On the other hand, HDAC6 coordinates a protective response during elimination of toxic misfolded proteins, but this is mostly mediated independent of its deacetylase activity.  The current mechanistic insights on these functions of HDAC6 in axonal CMT, along with the selective druggability against its deacetylase activity, make the targeting of HDAC6 particularly attractive.  We elaborate on the preclin. studies that demonstrated beneficial effects of HDAC6 inhibitors in axonal CMT models and outline possible modes of action.  Overall, this overview ultimately provides a rationale for the use of small-mol. HDAC6 inhibitors as a therapeutic strategy for this devastating disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLQPvMw55ppbVg90H21EOLACvtfcHk0liznamz3uaL1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjsVOksbw%253D&md5=3005fe78c94cf2a719d6e031573320c5</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.brainres.2020.146692&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.brainres.2020.146692%26sid%3Dliteratum%253Aachs%26aulast%3DRossaert%26aufirst%3DE.%26aulast%3DVan%2BDen%2BBosch%26aufirst%3DL.%26atitle%3DHDAC6%2520Inhibitors%253A%2520Translating%2520Genetic%2520and%2520Molecular%2520Insights%2520into%2520a%2520Therapy%2520for%2520Axonal%2520CMT%26jtitle%3DBrain%2520Res.%26date%3D2020%26volume%3D1733%26spage%3D146692%26doi%3D10.1016%2Fj.brainres.2020.146692" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Auzmendi-Iriarte, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saenz-Antoñanzas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikelez-Alonso, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrasco-Garcia, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tellaetxe-Abete, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrie, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampron, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortajarena, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matheu, A.</span></span> <span> </span><span class="NLM_article-title">Characterization of a New Small-Molecule Inhibitor of HDAC6 in Glioblastoma</span>. <i>Cell Death Dis.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">417</span>, <span class="refDoi"> DOI: 10.1038/s41419-020-2586-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1038%2Fs41419-020-2586-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=32488056" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFemt7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=417&author=J.+Auzmendi-Iriarteauthor=A.+Saenz-Anto%C3%B1anzasauthor=I.+Mikelez-Alonsoauthor=E.+Carrasco-Garciaauthor=M.+Tellaetxe-Abeteauthor=C.+H.+Lawrieauthor=N.+Sampronauthor=A.+L.+Cortajarenaauthor=A.+Matheu&title=Characterization+of+a+New+Small-Molecule+Inhibitor+of+HDAC6+in+Glioblastoma&doi=10.1038%2Fs41419-020-2586-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of a new small-molecule inhibitor of HDAC6 in glioblastoma</span></div><div class="casAuthors">Auzmendi-Iriarte, Jaione; Saenz-Antonanzas, Ander; Mikelez-Alonso, Idoia; Carrasco-Garcia, Estefania; Tellaetxe-Abete, Maitena; Lawrie, Charles H.; Sampron, Nicolas; Cortajarena, Aitziber L.; Matheu, Ander</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Disease</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">417</span>CODEN:
                <span class="NLM_cas:coden">CDDEA4</span>;
        ISSN:<span class="NLM_cas:issn">2041-4889</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: Histone deacetylase 6 (HDAC6) is an epigenetic modifier that is an attractive pharmacol. target in cancer.  In this work, we show that HDAC6 is elevated in glioblastoma, the most malignant and common brain tumor in adults, in which its high levels correlate with poor patient survival and is more abundant in glioma stem cell subpopulation.  Moreover, we identified a new small-mol. inhibitor of HDAC6, which presents strong sensitivity for HDAC6 inhibition and exerts high cytotoxic activity, alone or in combination with temozolomide.  It is also able to significantly reduce tumor growth in vivo.  Transcriptomic anal. of patient-derived glioma stem cells revealed an increase in cell differentiation and cell death pathways, as well as a decrease in cell-cycle activity and cell division by the treatment with the compd.  Finally, the comparison with a pan-HDAC inhibitor, Vorinostat (SAHA), or HDAC6-specific inhibitor, Tubastatin A, showed higher target specificity and antitumor activity of the new HDAC6 inhibitor.  In conclusion, our data reveal the efficacy of a novel HDAC6 inhibitor in glioblastoma preclin. setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp53nM_XMZC7LVg90H21EOLACvtfcHk0liznamz3uaL1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFemt7%252FM&md5=fd4fad040bffea9191e1a00e9268a3b5</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fs41419-020-2586-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41419-020-2586-x%26sid%3Dliteratum%253Aachs%26aulast%3DAuzmendi-Iriarte%26aufirst%3DJ.%26aulast%3DSaenz-Anto%25C3%25B1anzas%26aufirst%3DA.%26aulast%3DMikelez-Alonso%26aufirst%3DI.%26aulast%3DCarrasco-Garcia%26aufirst%3DE.%26aulast%3DTellaetxe-Abete%26aufirst%3DM.%26aulast%3DLawrie%26aufirst%3DC.%2BH.%26aulast%3DSampron%26aufirst%3DN.%26aulast%3DCortajarena%26aufirst%3DA.%2BL.%26aulast%3DMatheu%26aufirst%3DA.%26atitle%3DCharacterization%2520of%2520a%2520New%2520Small-Molecule%2520Inhibitor%2520of%2520HDAC6%2520in%2520Glioblastoma%26jtitle%3DCell%2520Death%2520Dis.%26date%3D2020%26volume%3D11%26spage%3D417%26doi%3D10.1038%2Fs41419-020-2586-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bae, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ha, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Youn, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. Y.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Therapeutic Potential of CKD-506, a Novel Selective Histone Deacetylase 6 Inhibitor, in a Murine Model of Rheumatoid Arthritis</span>. <i>Arthritis Res. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1</span>, <span class="refDoi"> DOI: 10.1186/s13075-020-02258-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1186%2Fs13075-020-02258-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=31898524" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2020&pages=1&author=J.+K.+Parkauthor=Y.+J.+Jangauthor=B.+R.+Ohauthor=J.+Shinauthor=D.+Baeauthor=N.+Haauthor=Y.+I.+Choiauthor=G.+S.+Younauthor=J.+Parkauthor=E.+Y.+Lee&title=Therapeutic+Potential+of+CKD-506%2C+a+Novel+Selective+Histone+Deacetylase+6+Inhibitor%2C+in+a+Murine+Model+of+Rheumatoid+Arthritis&doi=10.1186%2Fs13075-020-02258-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1186%2Fs13075-020-02258-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13075-020-02258-0%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DJ.%2BK.%26aulast%3DJang%26aufirst%3DY.%2BJ.%26aulast%3DOh%26aufirst%3DB.%2BR.%26aulast%3DShin%26aufirst%3DJ.%26aulast%3DBae%26aufirst%3DD.%26aulast%3DHa%26aufirst%3DN.%26aulast%3DChoi%26aufirst%3DY.%2BI.%26aulast%3DYoun%26aufirst%3DG.%2BS.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DE.%2BY.%26atitle%3DTherapeutic%2520Potential%2520of%2520CKD-506%252C%2520a%2520Novel%2520Selective%2520Histone%2520Deacetylase%25206%2520Inhibitor%252C%2520in%2520a%2520Murine%2520Model%2520of%2520Rheumatoid%2520Arthritis%26jtitle%3DArthritis%2520Res.%2520Ther.%26date%3D2020%26volume%3D22%26spage%3D1%26doi%3D10.1186%2Fs13075-020-02258-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boyault, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadoul, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pabion, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khochbin, S.</span></span> <span> </span><span class="NLM_article-title">HDAC6, at the Crossroads between Cytoskeleton and Cell Signaling by Acetylation and Ubiquitination</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">5468</span>– <span class="NLM_lpage">5476</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1210614</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1038%2Fsj.onc.1210614" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=17694087" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BD2sXovFersrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=5468-5476&author=C.+Boyaultauthor=K.+Sadoulauthor=M.+Pabionauthor=S.+Khochbin&title=HDAC6%2C+at+the+Crossroads+between+Cytoskeleton+and+Cell+Signaling+by+Acetylation+and+Ubiquitination&doi=10.1038%2Fsj.onc.1210614"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination</span></div><div class="casAuthors">Boyault, C.; Sadoul, K.; Pabion, M.; Khochbin, S.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">5468-5476</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase 6 (HDAC6) is a unique enzyme with specific structural and functional features.  It is actively or stably maintained in the cytoplasm and is the only member, within the HDAC family, that harbors a full duplication of its deacetylase homol. region followed by a specific ubiquitin-binding domain at the C-terminus end.  Accordingly, this deacetylase functions at the heart of a cellular regulatory mechanism capable of coordinating various cellular functions largely relying on the microtubule network.  Moreover, HDAC6 action as a regulator of HSP90 chaperone activity adds to the multifunctionality of the protein, and allows the authors to propose a crit. role for HDAC6 in mediating and coordinating various cellular events in response to different stressful stimuli.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9IYNSqbx5pbVg90H21EOLACvtfcHk0lj2iYufgYRB0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXovFersrw%253D&md5=3796fc81a6b403bf2c6d08122d3e94c8</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1210614&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1210614%26sid%3Dliteratum%253Aachs%26aulast%3DBoyault%26aufirst%3DC.%26aulast%3DSadoul%26aufirst%3DK.%26aulast%3DPabion%26aufirst%3DM.%26aulast%3DKhochbin%26aufirst%3DS.%26atitle%3DHDAC6%252C%2520at%2520the%2520Crossroads%2520between%2520Cytoskeleton%2520and%2520Cell%2520Signaling%2520by%2520Acetylation%2520and%2520Ubiquitination%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26spage%3D5468%26epage%3D5476%26doi%3D10.1038%2Fsj.onc.1210614" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moreno-Gonzalo, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayor, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sánchez-Madrid, F.</span></span> <span> </span><span class="NLM_article-title">HDAC6 at Crossroads of Infection and Innate Immunity</span>. <i>Trends Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">591</span>– <span class="NLM_lpage">595</span>, <span class="refDoi"> DOI: 10.1016/j.it.2018.05.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1016%2Fj.it.2018.05.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=29937401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFCmtL%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2018&pages=591-595&author=O.+Moreno-Gonzaloauthor=F.+Mayorauthor=F.+S%C3%A1nchez-Madrid&title=HDAC6+at+Crossroads+of+Infection+and+Innate+Immunity&doi=10.1016%2Fj.it.2018.05.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC6 at Crossroads of Infection and Innate Immunity</span></div><div class="casAuthors">Moreno-Gonzalo, Olga; Mayor, Federico; Sanchez-Madrid, Francisco</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Immunology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">591-595</span>CODEN:
                <span class="NLM_cas:coden">TIRMAE</span>;
        ISSN:<span class="NLM_cas:issn">1471-4906</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase 6 (HDAC6) acts by enzyme-dependent and -independent mechanisms to regulate diverse cellular processes including autophagy, the ubiquitin proteasome system, and cell migration.  HDAC6 also has emerging roles in innate immunity, including pathogen sensing and destruction, thus placing this enzyme at the crossroads of infection and innate immunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq57jhEg9ljw7Vg90H21EOLACvtfcHk0lj2iYufgYRB0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFCmtL%252FJ&md5=06ef7cff747e0af6a67b138ad6ef3074</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.it.2018.05.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.it.2018.05.004%26sid%3Dliteratum%253Aachs%26aulast%3DMoreno-Gonzalo%26aufirst%3DO.%26aulast%3DMayor%26aufirst%3DF.%26aulast%3DS%25C3%25A1nchez-Madrid%26aufirst%3DF.%26atitle%3DHDAC6%2520at%2520Crossroads%2520of%2520Infection%2520and%2520Innate%2520Immunity%26jtitle%3DTrends%2520Immunol.%26date%3D2018%26volume%3D39%26spage%3D591%26epage%3D595%26doi%3D10.1016%2Fj.it.2018.05.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Depetter, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geurs, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Vreese, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goethals, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandoorn, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laevens, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steenbrugge, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Tullio, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bracke, M.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Selective Pharmacological Inhibitors of HDAC6 Reveal Biochemical Activity but Functional Tolerance in Cancer Models</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>145</i></span>,  <span class="NLM_fpage">735</span>– <span class="NLM_lpage">747</span>, <span class="refDoi"> DOI: 10.1002/ijc.32169</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1002%2Fijc.32169" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=30694564" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtlCrsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=145&publication_year=2019&pages=735-747&author=Y.+Depetterauthor=S.+Geursauthor=R.+De+Vreeseauthor=S.+Goethalsauthor=E.+Vandoornauthor=A.+Laevensauthor=J.+Steenbruggeauthor=E.+Meyerauthor=P.+de+Tullioauthor=M.+Bracke&title=Selective+Pharmacological+Inhibitors+of+HDAC6+Reveal+Biochemical+Activity+but+Functional+Tolerance+in+Cancer+Models&doi=10.1002%2Fijc.32169"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Selective pharmacological inhibitors of HDAC6 reveal biochemical activity but functional tolerance in cancer models</span></div><div class="casAuthors">Depetter, Yves; Geurs, Silke; De Vreese, Rob; Goethals, Sophie; Vandoorn, Elien; Laevens, Alien; Steenbrugge, Jonas; Meyer, Evelyne; de Tullio, Pascal; Bracke, Marc; D'hooghe, Matthias; De Wever, Olivier</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">145</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">735-747</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Our study investigates the biochem. and functional impact of selective histone deacetylase 6 (HDAC6) inhibitors, a promising class of novel therapeutics, in several cancer models.  Selective HDAC6 inhibitors (Tubathian A, Tubastatin A, Tubacin and Ricolinostat) and a non-selective HDAC inhibitor (Vorinostat) were evaluated on cancer cell lines derived from multiple tumor types in both an in vitro and in vivo setting as potential cancer therapeutics.  Selective HDAC6 inhibitors resulted in a-tubulin acetylation with no impact on histone acetylation but failed to show any anti-cancer properties.  Only the use of high concns. of selective HDAC6 inhibitors resulted in co-inhibition of other HDAC enzymes and consequently in reduced growth, migratory and/or invasive activity of cancer cells in vitro as well as in vivo.  The specificity of HDAC6 inhibition was confirmed using a CRISPR/Cas9 knockout cell line.  Our results suggest that selective HDAC6 inhibitors may fall short as potential single agent anti-cancer drugs and prove that many previous data regarding this promising class of compds. need to be interpreted with great care due to their use in high concns. resulting in low selectivity and potential off-target effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYUTbDIiyPkLVg90H21EOLACvtfcHk0liQPtWABT6n5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtlCrsro%253D&md5=8fd1520da407ccdefed627de78c4ed2a</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1002%2Fijc.32169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.32169%26sid%3Dliteratum%253Aachs%26aulast%3DDepetter%26aufirst%3DY.%26aulast%3DGeurs%26aufirst%3DS.%26aulast%3DDe%2BVreese%26aufirst%3DR.%26aulast%3DGoethals%26aufirst%3DS.%26aulast%3DVandoorn%26aufirst%3DE.%26aulast%3DLaevens%26aufirst%3DA.%26aulast%3DSteenbrugge%26aufirst%3DJ.%26aulast%3DMeyer%26aufirst%3DE.%26aulast%3Dde%2BTullio%26aufirst%3DP.%26aulast%3DBracke%26aufirst%3DM.%26atitle%3DSelective%2520Pharmacological%2520Inhibitors%2520of%2520HDAC6%2520Reveal%2520Biochemical%2520Activity%2520but%2520Functional%2520Tolerance%2520in%2520Cancer%2520Models%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2019%26volume%3D145%26spage%3D735%26epage%3D747%26doi%3D10.1002%2Fijc.32169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase 6 Structure and Molecular Basis of Catalysis and Inhibition</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">741</span>– <span class="NLM_lpage">747</span>, <span class="refDoi"> DOI: 10.1038/nchembio.2134</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1038%2Fnchembio.2134" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=27454933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Kmu7rJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=741-747&author=Y.+Haiauthor=D.+W.+Christianson&title=Histone+Deacetylase+6+Structure+and+Molecular+Basis+of+Catalysis+and+Inhibition&doi=10.1038%2Fnchembio.2134"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase 6 structure and molecular basis of catalysis and inhibition</span></div><div class="casAuthors">Hai, Yang; Christianson, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">741-747</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Histone deacetylase 6 (HDAC6) is a crit. target for drug design because of its role in oncogenic transformation and cancer metastasis, and is unique among all histone deacetylases in that it contains tandem catalytic domains designated CD1 and CD2.  We now report the crystal structures of CD2 from Homo sapiens HDAC6 and of CD1 and CD2 from Danio rerio HDAC6.  We correlated these structures with activity measurements using 13 different substrates.  The catalytic activity of CD2 from both species exhibited broad substrate specificity, whereas that of CD1 was highly specific for substrates bearing C-terminal acetyllysine residues.  Crystal structures of substrate complexes yielded unprecedented snapshots of the catalytic mechanism.  Addnl., crystal structures of complexes with eight different inhibitors, including belinostat and panobinostat (currently used in cancer chemotherapy), the macrocyclic tetrapeptide HC toxin, and the HDAC6-specific inhibitor N-hydroxy-4-(2-((2-hydroxyethyl)(phenyl)amino)-2-oxoethyl)benzamide, revealed surprising new insight regarding changes in Zn2+ coordination and isoenzyme-specific inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqCfziGBHBRLVg90H21EOLACvtfcHk0liQPtWABT6n5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Kmu7rJ&md5=e167bc6f66e00923da4f2bced2b306b9</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.2134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.2134%26sid%3Dliteratum%253Aachs%26aulast%3DHai%26aufirst%3DY.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26atitle%3DHistone%2520Deacetylase%25206%2520Structure%2520and%2520Molecular%2520Basis%2520of%2520Catalysis%2520and%2520Inhibition%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2016%26volume%3D12%26spage%3D741%26epage%3D747%26doi%3D10.1038%2Fnchembio.2134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miyake, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keusch, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melancon, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helquist, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gut, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthias, P.</span></span> <span> </span><span class="NLM_article-title">Structural Insights into HDAC6 Tubulin Deacetylation and Its Selective Inhibition</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">748</span>– <span class="NLM_lpage">754</span>, <span class="refDoi"> DOI: 10.1038/nchembio.2140</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1038%2Fnchembio.2140" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=27454931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Kmu7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=748-754&author=Y.+Miyakeauthor=J.+J.+Keuschauthor=L.+Wangauthor=M.+Saitoauthor=D.+Hessauthor=X.+Wangauthor=B.+J.+Melanconauthor=P.+Helquistauthor=H.+Gutauthor=P.+Matthias&title=Structural+Insights+into+HDAC6+Tubulin+Deacetylation+and+Its+Selective+Inhibition&doi=10.1038%2Fnchembio.2140"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Structural insights into HDAC6 tubulin deacetylation and its selective inhibition</span></div><div class="casAuthors">Miyake, Yasuyuki; Keusch, Jeremy J.; Wang, Longlong; Saito, Makoto; Hess, Daniel; Wang, Xiaoning; Melancon, Bruce J.; Helquist, Paul; Gut, Heinz; Matthias, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">748-754</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The authors report crystal structures of zebrafish histone deacetylase 6 (HDAC6) catalytic domains in tandem or as single domains in complex with the (R) and (S) enantiomers of trichostatin A (TSA) or with the HDAC6-specific inhibitor, nexturastat A.  The tandem domains formed, together with the inter-domain linker, an ellipsoid-shaped complex with pseudo-twofold symmetry.  The authors identified important active site differences between both catalytic domains and revealed the binding mode of HDAC6 selective inhibitors.  HDAC inhibition assays with (R)- and (S)-TSA showed that (R)-TSA was a broad-range inhibitor, whereas (S)-TSA had moderate selectivity for HDAC6.  The authors identified a uniquely positioned α-helix and a flexible Trp residue in the loop joining α-helixes H20 to H21 as crit. for deacetylation of the physiol. substrate, tubulin.  Using single-mol. measurements and biochem. assays, the authors demonstrated that HDAC6 catalytic domain 2 deacetylated α-tubulin Lys-40 in the lumen of microtubules, but that its preferred substrate was unpolymd. tubulin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpERJRurS1cC7Vg90H21EOLACvtfcHk0lh2BNYYkV3_vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Kmu7rM&md5=4abe529ab89615df33f54350a1a8c69a</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.2140&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.2140%26sid%3Dliteratum%253Aachs%26aulast%3DMiyake%26aufirst%3DY.%26aulast%3DKeusch%26aufirst%3DJ.%2BJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DSaito%26aufirst%3DM.%26aulast%3DHess%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DMelancon%26aufirst%3DB.%2BJ.%26aulast%3DHelquist%26aufirst%3DP.%26aulast%3DGut%26aufirst%3DH.%26aulast%3DMatthias%26aufirst%3DP.%26atitle%3DStructural%2520Insights%2520into%2520HDAC6%2520Tubulin%2520Deacetylation%2520and%2520Its%2520Selective%2520Inhibition%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2016%26volume%3D12%26spage%3D748%26epage%3D754%26doi%3D10.1038%2Fnchembio.2140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haggarty, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koeller, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grozinger, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S. L.</span></span> <span> </span><span class="NLM_article-title">Domain-Selective Small-Molecule Inhibitor of Histone Deacetylase 6 (HDAC6)-Mediated Tubulin Deacetylation</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">4389</span>– <span class="NLM_lpage">4394</span>, <span class="refDoi"> DOI: 10.1073/pnas.0430973100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1073%2Fpnas.0430973100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=12677000" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjt12gtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2003&pages=4389-4394&author=S.+J.+Haggartyauthor=K.+M.+Koellerauthor=J.+C.+Wongauthor=C.+M.+Grozingerauthor=S.+L.+Schreiber&title=Domain-Selective+Small-Molecule+Inhibitor+of+Histone+Deacetylase+6+%28HDAC6%29-Mediated+Tubulin+Deacetylation&doi=10.1073%2Fpnas.0430973100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation</span></div><div class="casAuthors">Haggarty, Stephen J.; Koeller, Kathryn M.; Wong, Jason C.; Grozinger, Christina M.; Schreiber, Stuart L.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4389-4394</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Protein acetylation, esp. histone acetylation, is the subject of both research and clin. investigation.  At least four small-mol. histone deacetylase inhibitors are currently in clin. trials for the treatment of cancer.  These and other inhibitors also affect microtubule acetylation.  A multidimensional, chem. genetic screen of 7392 small mols. was used to discover "tubacin," which inhibits α-tubulin deacetylation in mammalian cells.  Tubacin does not affect the level of histone acetylation, gene-expression patterns, or cell-cycle progression.  We provide evidence that class II histone deacetylase 6 (HDAC6) is the intracellular target of tubacin.  Only one of the two catalytic domains of HDAC6 possesses tubulin deacetylase activity, and only this domain is bound by tubacin.  Tubacin treatment did not affect the stability of microtubules but did decrease cell motility.  HDAC6 overexpression disrupted the localization of p58, a protein that mediates binding of Golgi elements to microtubules.  Our results highlight the role of α-tubulin acetylation in mediating the localization of microtubule-assocd. proteins.  They also suggest that small mols. that selectively inhibit HDAC6-mediated α-tubulin deacetylation, a first example of which is tubacin, might have therapeutic applications as antimetastatic and antiangiogenic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbQBWjEZr47rVg90H21EOLACvtfcHk0lh2BNYYkV3_vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjt12gtL0%253D&md5=260da1ede64782ddbddda31b740b9782</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0430973100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0430973100%26sid%3Dliteratum%253Aachs%26aulast%3DHaggarty%26aufirst%3DS.%2BJ.%26aulast%3DKoeller%26aufirst%3DK.%2BM.%26aulast%3DWong%26aufirst%3DJ.%2BC.%26aulast%3DGrozinger%26aufirst%3DC.%2BM.%26aulast%3DSchreiber%26aufirst%3DS.%2BL.%26atitle%3DDomain-Selective%2520Small-Molecule%2520Inhibitor%2520of%2520Histone%2520Deacetylase%25206%2520%2528HDAC6%2529-Mediated%2520Tubulin%2520Deacetylation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2003%26volume%3D100%26spage%3D4389%26epage%3D4394%26doi%3D10.1073%2Fpnas.0430973100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cubizolles, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rousseaux, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kneissel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chua, K.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Mice Lacking Histone Deacetylase 6 Have Hyperacetylated Tubulin but Are Viable and Develop Normally</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">1688</span>– <span class="NLM_lpage">1701</span>, <span class="refDoi"> DOI: 10.1128/mcb.01154-06</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1128%2FMCB.01154-06" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=18180281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BD1cXivVajtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2008&pages=1688-1701&author=Y.+Zhangauthor=S.+Kwonauthor=T.+Yamaguchiauthor=F.+Cubizollesauthor=S.+Rousseauxauthor=M.+Kneisselauthor=C.+Caoauthor=N.+Liauthor=H.-L.+Chengauthor=K.+Chua&title=Mice+Lacking+Histone+Deacetylase+6+Have+Hyperacetylated+Tubulin+but+Are+Viable+and+Develop+Normally&doi=10.1128%2Fmcb.01154-06"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally</span></div><div class="casAuthors">Zhang, Yu; Kwon, SoHee; Yamaguchi, Teppei; Cubizolles, Fabien; Rousseaux, Sophie; Kneissel, Michaela; Cao, Chun; Li, Na; Cheng, Hwei-Ling; Chua, Katrin; Lombard, David; Mizeracki, Adam; Matthias, Gabriele; Alt, Frederick W.; Khochbin, Saadi; Matthias, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1688-1701</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Posttranslational modifications play important roles in regulating protein structure and function.  Histone deacetylase 6 (HDAC6) is a mostly cytoplasmic class II HDAC, which has a unique structure with two catalytic domains and a domain binding ubiquitin with high affinity.  This enzyme was recently identified as a multisubstrate protein deacetylase that can act on acetylated histone tails, α-tubulin and Hsp90.  To investigate the in vivo functions of HDAC6 and the relevance of tubulin acetylation/deacetylation, we targeted the HDAC6 gene by homologous recombination in embryonic stem cells and generated knockout mice.  HDAC6-deficient mice are viable and fertile and show hyperacetylated tubulin in most tissues.  The highest level of expression of HDAC6 is seen in the testis, yet development and function of this organ are normal in the absence of HDAC6.  Likewise, lymphoid development is normal, but the immune response is moderately affected.  Furthermore, the lack of HDAC6 results in a small increase in cancellous bone mineral d., indicating that this deacetylase plays a minor role in bone biol.  HDAC6-deficient mouse embryonic fibroblasts show apparently normal microtubule organization and stability and also show increased Hsp90 acetylation correlating with impaired Hsp90 function.  Collectively, these data demonstrate that mice survive well without HDAC6 and that tubulin hyperacetylation is not detrimental to normal mammalian development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1on7_hqKefrVg90H21EOLACvtfcHk0ljytXSJ8DU2qA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXivVajtLo%253D&md5=9c83b56ee31ea67a04357b31467ed655</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1128%2FMCB.01154-06&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.01154-06%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DKwon%26aufirst%3DS.%26aulast%3DYamaguchi%26aufirst%3DT.%26aulast%3DCubizolles%26aufirst%3DF.%26aulast%3DRousseaux%26aufirst%3DS.%26aulast%3DKneissel%26aufirst%3DM.%26aulast%3DCao%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DCheng%26aufirst%3DH.-L.%26aulast%3DChua%26aufirst%3DK.%26atitle%3DMice%2520Lacking%2520Histone%2520Deacetylase%25206%2520Have%2520Hyperacetylated%2520Tubulin%2520but%2520Are%2520Viable%2520and%2520Develop%2520Normally%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2008%26volume%3D28%26spage%3D1688%26epage%3D1701%26doi%3D10.1128%2Fmcb.01154-06" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Messaoudi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishaq, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palazzo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sliwa, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bluteau, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Souquère, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diop, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rameau, P.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Critical Role of the HDAC6-Cortactin Axis in Human Megakaryocyte Maturation Leading to a Proplatelet-Formation Defect</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1786</span>, <span class="refDoi"> DOI: 10.1038/s41467-017-01690-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1038%2Fs41467-017-01690-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=29176689" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A280%3ADC%252BC1M3ltV2qsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1786&author=K.+Messaoudiauthor=A.+Aliauthor=R.+Ishaqauthor=A.+Palazzoauthor=D.+Sliwaauthor=O.+Bluteauauthor=S.+Souqu%C3%A8reauthor=D.+Mullerauthor=K.+M.+Diopauthor=P.+Rameau&title=Critical+Role+of+the+HDAC6-Cortactin+Axis+in+Human+Megakaryocyte+Maturation+Leading+to+a+Proplatelet-Formation+Defect&doi=10.1038%2Fs41467-017-01690-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Critical role of the HDAC6-cortactin axis in human megakaryocyte maturation leading to a proplatelet-formation defect</span></div><div class="casAuthors">Messaoudi Kahia; Ali Ashfaq; Ishaq Rameez; Palazzo Alberta; Sliwa Dominika; Bluteau Olivier; Muller Delphine; Godin Isabelle; Droin Nathalie; Vainchenker William; Plo Isabelle; Raslova Hana; Debili Najet; Messaoudi Kahia; Ali Ashfaq; Ishaq Rameez; Palazzo Alberta; Sliwa Dominika; Bluteau Olivier; Muller Delphine; Godin Isabelle; Droin Nathalie; Vainchenker William; Plo Isabelle; Raslova Hana; Debili Najet; Messaoudi Kahia; Ali Ashfaq; Ishaq Rameez; Palazzo Alberta; Sliwa Dominika; Bluteau Olivier; Muller Delphine; Godin Isabelle; Droin Nathalie; Vainchenker William; Plo Isabelle; Raslova Hana; Debili Najet; Messaoudi Kahia; Ali Ashfaq; Ishaq Rameez; Palazzo Alberta; Souquere Sylvie; Pierron Gerard; Diop Khadija M; Droin Nathalie; Rameau Philippe; Lapierre Valerie; Marolleau Jean-Pierre; Matthias Patrick; Thomas Steven G; Watson Stephen P; Thomas Steven G; Watson Stephen P</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1786</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Thrombocytopenia is a major side effect of a new class of anticancer agents that target histone deacetylase (HDAC).  Their mechanism is poorly understood.  Here, we show that HDAC6 inhibition and genetic knockdown lead to a strong decrease in human proplatelet formation (PPF).  Unexpectedly, HDAC6 inhibition-induced tubulin hyperacetylation has no effect on PPF.  The PPF decrease induced by HDAC6 inhibition is related to cortactin (CTTN) hyperacetylation associated with actin disorganization inducing important changes in the distribution of megakaryocyte (MK) organelles.  CTTN silencing in human MKs phenocopies HDAC6 inactivation and knockdown leads to a strong PPF defect.  This is rescued by forced expression of a deacetylated CTTN mimetic.  Unexpectedly, unlike human-derived MKs, HDAC6 and CTTN are shown to be dispensable for mouse PPF in vitro and platelet production in vivo.  Our results highlight an unexpected function of HDAC6-CTTN axis as a positive regulator of human but not mouse MK maturation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQBGBYr4SlFFu_Q9URG6Dx8fW6udTcc2eZhcOlts8jzYbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M3ltV2qsg%253D%253D&md5=919c53df63b715bc6cc3caa7a042981c</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fs41467-017-01690-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-017-01690-2%26sid%3Dliteratum%253Aachs%26aulast%3DMessaoudi%26aufirst%3DK.%26aulast%3DAli%26aufirst%3DA.%26aulast%3DIshaq%26aufirst%3DR.%26aulast%3DPalazzo%26aufirst%3DA.%26aulast%3DSliwa%26aufirst%3DD.%26aulast%3DBluteau%26aufirst%3DO.%26aulast%3DSouqu%25C3%25A8re%26aufirst%3DS.%26aulast%3DMuller%26aufirst%3DD.%26aulast%3DDiop%26aufirst%3DK.%2BM.%26aulast%3DRameau%26aufirst%3DP.%26atitle%3DCritical%2520Role%2520of%2520the%2520HDAC6-Cortactin%2520Axis%2520in%2520Human%2520Megakaryocyte%2520Maturation%2520Leading%2520to%2520a%2520Proplatelet-Formation%2520Defect%26jtitle%3DNat.%2520Commun.%26date%3D2017%26volume%3D8%26spage%3D1786%26doi%3D10.1038%2Fs41467-017-01690-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">A Patent Review of Histone Deacetylase 6 Inhibitors in Neurodegenerative Diseases (2014-2019)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">121</span>– <span class="NLM_lpage">136</span>, <span class="refDoi"> DOI: 10.1080/13543776.2019.1708901</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1080%2F13543776.2019.1708901" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=31865813" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVKnsb3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=121-136&author=S.+Shenauthor=A.+P.+Kozikowski&title=A+Patent+Review+of+Histone+Deacetylase+6+Inhibitors+in+Neurodegenerative+Diseases+%282014-2019%29&doi=10.1080%2F13543776.2019.1708901"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">A patent review of histone deacetylase 6 inhibitors in neurodegenerative diseases (2014-2019)</span></div><div class="casAuthors">Shen, Sida; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">121-136</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase 6 (HDAC6) is unique in comparison with other zinc-dependent HDAC family members.  An increasing amt. of evidence from clin. and preclin. research demonstrates the potential of HDAC6 inhibition as an effective therapeutic approach for the treatment of cancer, autoimmune diseases, as well as neurol. disorders.  The recently disclosed crystal structures of HDAC6-ligand complexes offer further means for achieving pharmacophore refinement, thus further accelerating the pace of HDAC6 inhibitor discovery in the last few years.: This review summarizes the latest clin. status of HDAC6 inhibitors, discusses pharmacol. applications of selective HDAC6 inhibitors in neurodegenerative diseases, and describes the patent applications dealing with HDAC6 inhibitors from 2014-2019 that have not been reported in research articles.: Phenylhydroxamate has proven a very useful scaffold in the discovery of potent and selective HDAC6 inhibitors.  However, weaknesses of the hydroxamate function such as metabolic instability and mutagenic potential limit its application in the neurol. field, where long-term administration is required.  The recent invention of oxadiazole-based ligands by pharmaceutical companies may provide a new opportunity to optimize the druglike properties of HDAC6 inhibitors for the treatment of neurodegenerative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCWThC7SH8r7Vg90H21EOLACvtfcHk0ljytXSJ8DU2qA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVKnsb3J&md5=926d00ce3a0153953eb2f933599500b9</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1080%2F13543776.2019.1708901&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2019.1708901%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DS.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DA%2520Patent%2520Review%2520of%2520Histone%2520Deacetylase%25206%2520Inhibitors%2520in%2520Neurodegenerative%2520Diseases%2520%25282014-2019%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2020%26volume%3D30%26spage%3D121%26epage%3D136%26doi%3D10.1080%2F13543776.2019.1708901" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mackwitz, M. K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamacher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osko, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Held, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schöler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kassack, M. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, F. K.</span></span> <span> </span><span class="NLM_article-title">Multicomponent Synthesis and Binding Mode of Imidazo[1,2- a]Pyridine-Capped Selective HDAC6 Inhibitors</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">3255</span>– <span class="NLM_lpage">3258</span>, <span class="refDoi"> DOI: 10.1021/acs.orglett.8b01118</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.orglett.8b01118" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpvVCnsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2018&pages=3255-3258&author=M.+K.+W.+Mackwitzauthor=A.+Hamacherauthor=J.+D.+Oskoauthor=J.+Heldauthor=A.+Sch%C3%B6lerauthor=D.+W.+Christiansonauthor=M.+U.+Kassackauthor=F.+K.+Hansen&title=Multicomponent+Synthesis+and+Binding+Mode+of+Imidazo%5B1%2C2-+a%5DPyridine-Capped+Selective+HDAC6+Inhibitors&doi=10.1021%2Facs.orglett.8b01118"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Multicomponent Synthesis and Binding Mode of Imidazo[1,2-a]pyridine-Capped Selective HDAC6 Inhibitors</span></div><div class="casAuthors">Mackwitz, Marcel K. W.; Hamacher, Alexandra; Osko, Jeremy D.; Held, Jana; Schoeler, Andrea; Christianson, David W.; Kassack, Matthias U.; Hansen, Finn K.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3255-3258</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7052</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The multicomponent synthesis of a mini-library of histone deacetylase inhibitors with imidazo[1,2-a]pyridine-based cap groups is presented.  The biol. evaluation led to the discovery of the hit compd. MAIP-032 as a selective HDAC6 inhibitor with promising anticancer activity.  The X-ray structure of catalytic domain 2 from Danio rerio HDAC6 complexed with MAIP-032 revealed a monodentate zinc-binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4rI48LyncTrVg90H21EOLACvtfcHk0lhJFU0aHHV8tw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpvVCnsbw%253D&md5=0c53331fabd83781717e0678a56dab7e</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Facs.orglett.8b01118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.orglett.8b01118%26sid%3Dliteratum%253Aachs%26aulast%3DMackwitz%26aufirst%3DM.%2BK.%2BW.%26aulast%3DHamacher%26aufirst%3DA.%26aulast%3DOsko%26aufirst%3DJ.%2BD.%26aulast%3DHeld%26aufirst%3DJ.%26aulast%3DSch%25C3%25B6ler%26aufirst%3DA.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26aulast%3DKassack%26aufirst%3DM.%2BU.%26aulast%3DHansen%26aufirst%3DF.%2BK.%26atitle%3DMulticomponent%2520Synthesis%2520and%2520Binding%2520Mode%2520of%2520Imidazo%255B1%252C2-%2520a%255DPyridine-Capped%2520Selective%2520HDAC6%2520Inhibitors%26jtitle%3DOrg.%2520Lett.%26date%3D2018%26volume%3D20%26spage%3D3255%26epage%3D3258%26doi%3D10.1021%2Facs.orglett.8b01118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chia, P. L.</span>; <span class="NLM_string-name">Mukhopadhyay, P.</span>; <span class="NLM_string-name">Kelly, S.</span>; <span class="NLM_string-name">Wu, R.</span>; <span class="NLM_string-name">Fenn, K.</span>; <span class="NLM_string-name">Trivedi, M. S.</span></span> <span> </span><span class="NLM_article-title">Network-Based Assessment of HDAC6 Activity Is Highly Predictive of Pre-Clinical and Clinical Responses to the HDAC Inhibitor Ricolinostat</span>. <span class="NLM_year" style="font-weight: bold;">2020</span>, medRxiv.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=P.+L.+Chia&author=P.+Mukhopadhyay&author=S.+Kelly&author=R.+Wu&author=K.+Fenn&author=M.+S.+Trivedi&title=Network-Based+Assessment+of+HDAC6+Activity+Is+Highly+Predictive+of+Pre-Clinical+and+Clinical+Responses+to+the+HDAC+Inhibitor+Ricolinostat"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChia%26aufirst%3DP.%2BL.%26atitle%3DNetwork-Based%2520Assessment%2520of%2520HDAC6%2520Activity%2520Is%2520Highly%2520Predictive%2520of%2520Pre-Clinical%2520and%2520Clinical%2520Responses%2520to%2520the%2520HDAC%2520Inhibitor%2520Ricolinostat%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jochems, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boulden, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blendy, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarpe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazitschek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Duzer, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berton, O.</span></span> <span> </span><span class="NLM_article-title">Antidepressant-like Properties of Novel HDAC6-Selective Inhibitors with Improved Brain Bioavailability</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">389</span>– <span class="NLM_lpage">400</span>, <span class="refDoi"> DOI: 10.1038/npp.2013.207</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1038%2Fnpp.2013.207" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=23954848" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFyntbjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2014&pages=389-400&author=J.+Jochemsauthor=J.+Bouldenauthor=B.+G.+Leeauthor=J.+A.+Blendyauthor=M.+Jarpeauthor=R.+Mazitschekauthor=J.+H.+Van+Duzerauthor=S.+Jonesauthor=O.+Berton&title=Antidepressant-like+Properties+of+Novel+HDAC6-Selective+Inhibitors+with+Improved+Brain+Bioavailability&doi=10.1038%2Fnpp.2013.207"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Antidepressant-Like Properties of Novel HDAC6-Selective Inhibitors with Improved Brain Bioavailability</span></div><div class="casAuthors">Jochems, Jeanine; Boulden, Janette; Lee, Bridgin G.; Blendy, Julie A.; Jarpe, Matthew; Mazitschek, Ralph; Van Duzer, John H.; Jones, Simon; Berton, Olivier</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">389-400</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">HDAC inhibitors have been reported to produce antidepressant and pro-cognitive effects in animal models, however, poor brain bioavailability or lack of isoform selectivity of current probes has limited our understanding of their mode of action.  We report the characterization of novel pyrimidine hydroxyl amide small mol. inhibitors of HDAC6, brain bioavailable upon systemic administration.  We show that two compds. in this family, ACY-738 and ACY-775, inhibit HDAC6 with low nanomolar potency and a selectivity of 60- to 1500-fold over class I HDACs.  In contrast to tubastatin A, a ref. HDAC6 inhibitor with similar potency and peripheral activity, but more limited brain bioavailability, ACY-738 and ACY-775 induce dramatic increases in α-tubulin acetylation in brain and stimulate mouse exploratory behaviors in novel, but not familiar environments.  Interestingly, despite a lack of detectable effect on histone acetylation, we show that ACY-738 and ACY-775 share the antidepressant-like properties of other HDAC inhibitors, such as SAHA and MS-275, in the tail suspension test and social defeat paradigm.  These effects of ACY-738 and ACY-775 are directly attributable to the inhibition of HDAC6 expressed centrally, as they are fully abrogated in mice with a neural-specific loss of function of HDAC6.  Furthermore, administered in combination, a behaviorally inactive dose of ACY-738 markedly potentiates the anti-immobility activity of a subactive dose of the selective serotonin reuptake inhibitor citalopram.  Our results validate new isoform-selective probes for in vivo pharmacol. studies of HDAC6 in the CNS and reinforce the viability of this HDAC isoform as a potential target for antidepressant development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5yEjJGIv3jbVg90H21EOLACvtfcHk0lhJFU0aHHV8tw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFyntbjN&md5=9e0f4d3856c84e629602b589161eb4ab</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2013.207&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2013.207%26sid%3Dliteratum%253Aachs%26aulast%3DJochems%26aufirst%3DJ.%26aulast%3DBoulden%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DB.%2BG.%26aulast%3DBlendy%26aufirst%3DJ.%2BA.%26aulast%3DJarpe%26aufirst%3DM.%26aulast%3DMazitschek%26aufirst%3DR.%26aulast%3DVan%2BDuzer%26aufirst%3DJ.%2BH.%26aulast%3DJones%26aufirst%3DS.%26aulast%3DBerton%26aufirst%3DO.%26atitle%3DAntidepressant-like%2520Properties%2520of%2520Novel%2520HDAC6-Selective%2520Inhibitors%2520with%2520Improved%2520Brain%2520Bioavailability%26jtitle%3DNeuropsychopharmacology%26date%3D2014%26volume%3D39%26spage%3D389%26epage%3D400%26doi%3D10.1038%2Fnpp.2013.207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vergani, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandrone, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ripamonti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cellupica, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galbiati, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caprini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavich, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rocchio, I.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Novel Benzohydroxamate-Based Potent and Selective Histone Deacetylase 6 (HDAC6) Inhibitors Bearing a Pentaheterocyclic Scaffold: Design, Synthesis, and Biological Evaluation</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">10711</span>– <span class="NLM_lpage">10739</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01194</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01194" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFeqs77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=10711-10739&author=B.+Verganiauthor=G.+Sandroneauthor=M.+Marchiniauthor=C.+Ripamontiauthor=E.+Cellupicaauthor=E.+Galbiatiauthor=G.+Capriniauthor=G.+Pavichauthor=G.+Porroauthor=I.+Rocchio&title=Novel+Benzohydroxamate-Based+Potent+and+Selective+Histone+Deacetylase+6+%28HDAC6%29+Inhibitors+Bearing+a+Pentaheterocyclic+Scaffold%3A+Design%2C+Synthesis%2C+and+Biological+Evaluation&doi=10.1021%2Facs.jmedchem.9b01194"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Benzohydroxamate-Based Potent and Selective Histone Deacetylase 6 (HDAC6) Inhibitors Bearing a Pentaheterocyclic Scaffold: Design, Synthesis, and Biological Evaluation</span></div><div class="casAuthors">Vergani, Barbara; Sandrone, Giovanni; Marchini, Mattia; Ripamonti, Chiara; Cellupica, Edoardo; Galbiati, Elisabetta; Caprini, Gianluca; Pavich, Gianfranco; Porro, Giulia; Rocchio, Ilaria; Lattanzio, Maria; Pezzuto, Marcello; Skorupska, Malgorzata; Cordella, Paola; Pagani, Paolo; Pozzi, Pietro; Pomarico, Roberta; Modena, Daniela; Leoni, Flavio; Perego, Raffaella; Fossati, Gianluca; Steinkuhler, Christian; Stevenazzi, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10711-10739</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Histone deacetylase 6 (HDAC6) is a peculiar HDAC isoform whose expression and functional alterations were correlated with a variety of pathologies such as autoimmune disorders, neurodegenerative diseases, and cancer.  It is primarily a cytoplasmic protein, and its deacetylase activity is focused mainly on non-histone substrates such as tubulin, heat shock protein (HSP)90, Foxp3 and cortactin, to name a few.  Selective inhibition of HDAC6 does not show cytotoxic effects in healthy cells, normally assocd. with the inhibition of Class I HDAC isoforms.  Here the authors describe the design and synthesis of a new class of potent and selective HDAC6 inhibitors that bear a pentaheterocyclic central core.  These compds. show a remarkably low toxicity both in vitro and in vivo and are able to increase the function of regulatory T cells (Tregs) at well tolerated concns., suggesting a potential clin. use for the treatment of degenerative, auto-immune diseases and organ transplantation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpV3O384uJCkLVg90H21EOLACvtfcHk0liLm-UNj8HrQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFeqs77I&md5=efc978e814193713983d2239a821cfd7</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01194&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01194%26sid%3Dliteratum%253Aachs%26aulast%3DVergani%26aufirst%3DB.%26aulast%3DSandrone%26aufirst%3DG.%26aulast%3DMarchini%26aufirst%3DM.%26aulast%3DRipamonti%26aufirst%3DC.%26aulast%3DCellupica%26aufirst%3DE.%26aulast%3DGalbiati%26aufirst%3DE.%26aulast%3DCaprini%26aufirst%3DG.%26aulast%3DPavich%26aufirst%3DG.%26aulast%3DPorro%26aufirst%3DG.%26aulast%3DRocchio%26aufirst%3DI.%26atitle%3DNovel%2520Benzohydroxamate-Based%2520Potent%2520and%2520Selective%2520Histone%2520Deacetylase%25206%2520%2528HDAC6%2529%2520Inhibitors%2520Bearing%2520a%2520Pentaheterocyclic%2520Scaffold%253A%2520Design%252C%2520Synthesis%252C%2520and%2520Biological%2520Evaluation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D10711%26epage%3D10739%26doi%3D10.1021%2Facs.jmedchem.9b01194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shouksmith, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimard, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gawel, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raouf, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geletu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger-Becvar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Araujo, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luchman, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heaton, W. L.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Identification and Characterization of AES-135, a Hydroxamic Acid-Based HDAC Inhibitor That Prolongs Survival in an Orthotopic Mouse Model of Pancreatic Cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">2651</span>– <span class="NLM_lpage">2665</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01957</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01957" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjt1Slu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=2651-2665&author=A.+E.+Shouksmithauthor=F.+Shahauthor=M.+L.+Grimardauthor=J.+M.+Gawelauthor=Y.+S.+Raoufauthor=M.+Geletuauthor=A.+Berger-Becvarauthor=E.+D.+De+Araujoauthor=H.+A.+Luchmanauthor=W.+L.+Heaton&title=Identification+and+Characterization+of+AES-135%2C+a+Hydroxamic+Acid-Based+HDAC+Inhibitor+That+Prolongs+Survival+in+an+Orthotopic+Mouse+Model+of+Pancreatic+Cancer&doi=10.1021%2Facs.jmedchem.8b01957"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and characterization of AES-135, a hydroxamic acid-based HDAC inhibitor that prolongs survival in an orthotopic mouse model of pancreatic cancer</span></div><div class="casAuthors">Shouksmith, Andrew E.; Shah, Fenil; Grimard, Michelle L.; Gawel, Justyna M.; Raouf, Yasir S.; Geletu, Mulu; Berger-Becvar, Angelika; de Araujo, Elvin D.; Luchman, H. Artee; Heaton, William L.; Bakhshinyan, David; Adile, Ashley A.; Venugopal, Chitra; O'Hare, Thomas; Deininger, Michael W.; Singh, Sheila K.; Konieczny, Stephen F.; Weiss, Samuel; Fishel, Melissa L.; Gunning, Patrick T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2651-2665</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Pancreatic ductal adenocarcinoma (PDAC) is an aggressive, incurable cancer with a 20% 1 yr survival rate.  While std.-of-care therapy can prolong life in a small fraction of cases, PDAC is inherently resistant to current treatments, and novel therapies are urgently required.  Histone deacetylase (HDAC) inhibitors are effective in killing pancreatic cancer cells in in vitro PDAC studies, and although there are a few clin. studies investigating combination therapy including HDAC inhibitors, no HDAC drug or combination therapy with an HDAC drug has been approved for the treatment of PDAC.  We developed an inhibitor of HDACs, AES-135, that exhibits nanomolar inhibitory activity against HDAC3, HDAC6, and HDAC11 in biochem. assays.  In a three-dimensional coculture model, AES-135 kills low-passage patient-derived tumor spheroids selectively over surrounding cancer-assocd. fibroblasts and has excellent pharmacokinetic properties in vivo.  In an orthotopic murine model of pancreatic cancer, AES-135 prolongs survival significantly, therefore representing a candidate for further preclin. testing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsx6K4JeAb-bVg90H21EOLACvtfcHk0liLm-UNj8HrQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjt1Slu78%253D&md5=2b90becae883cc5552a701a614d8c452</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01957%26sid%3Dliteratum%253Aachs%26aulast%3DShouksmith%26aufirst%3DA.%2BE.%26aulast%3DShah%26aufirst%3DF.%26aulast%3DGrimard%26aufirst%3DM.%2BL.%26aulast%3DGawel%26aufirst%3DJ.%2BM.%26aulast%3DRaouf%26aufirst%3DY.%2BS.%26aulast%3DGeletu%26aufirst%3DM.%26aulast%3DBerger-Becvar%26aufirst%3DA.%26aulast%3DDe%2BAraujo%26aufirst%3DE.%2BD.%26aulast%3DLuchman%26aufirst%3DH.%2BA.%26aulast%3DHeaton%26aufirst%3DW.%2BL.%26atitle%3DIdentification%2520and%2520Characterization%2520of%2520AES-135%252C%2520a%2520Hydroxamic%2520Acid-Based%2520HDAC%2520Inhibitor%2520That%2520Prolongs%2520Survival%2520in%2520an%2520Orthotopic%2520Mouse%2520Model%2520of%2520Pancreatic%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D2651%26epage%3D2665%26doi%3D10.1021%2Facs.jmedchem.8b01957" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Porter, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osko, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diedrich, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hooker, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, F. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase 6-Selective Inhibitors and the Influence of Capping Groups on Hydroxamate-Zinc Denticity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">8054</span>– <span class="NLM_lpage">8060</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01013</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01013" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFansLnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=8054-8060&author=N.+J.+Porterauthor=J.+D.+Oskoauthor=D.+Diedrichauthor=T.+Kurzauthor=J.+M.+Hookerauthor=F.+K.+Hansenauthor=D.+W.+Christianson&title=Histone+Deacetylase+6-Selective+Inhibitors+and+the+Influence+of+Capping+Groups+on+Hydroxamate-Zinc+Denticity&doi=10.1021%2Facs.jmedchem.8b01013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase 6-Selective Inhibitors and the Influence of Capping Groups on Hydroxamate-Zinc Denticity</span></div><div class="casAuthors">Porter, Nicholas J.; Osko, Jeremy D.; Diedrich, Daniela; Kurz, Thomas; Hooker, Jacob M.; Hansen, Finn K.; Christianson, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">8054-8060</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Four crystal structures are presented of histone deacetylase 6 (HDAC6) complexes with para-substituted phenylhydromaxamate inhibitors, including bulky peptoids.  These structures provide insight regarding the design of capping groups that confer selectivity for binding to HDAC6, specifically with regard to interactions in a pocket formed by the L1 loop.  Capping group interactions may also influence hydroxamate-Zn2+ coordination with monodentate or bidentate geometry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq54PM6p6wpnrVg90H21EOLACvtfcHk0lgdwNuYPECSvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFansLnE&md5=f1d227d7668d09e121e5967b2d65f1a5</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01013%26sid%3Dliteratum%253Aachs%26aulast%3DPorter%26aufirst%3DN.%2BJ.%26aulast%3DOsko%26aufirst%3DJ.%2BD.%26aulast%3DDiedrich%26aufirst%3DD.%26aulast%3DKurz%26aufirst%3DT.%26aulast%3DHooker%26aufirst%3DJ.%2BM.%26aulast%3DHansen%26aufirst%3DF.%2BK.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26atitle%3DHistone%2520Deacetylase%25206-Selective%2520Inhibitors%2520and%2520the%2520Influence%2520of%2520Capping%2520Groups%2520on%2520Hydroxamate-Zinc%2520Denticity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D8054%26epage%3D8060%26doi%3D10.1021%2Facs.jmedchem.8b01013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svoboda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavasin, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Motlova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKinsey, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eubanks, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bařinka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">Structural and in Vivo Characterization of Tubastatin A, a Widely Used Histone Deacetylase 6 Inhibitor</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">706</span>– <span class="NLM_lpage">712</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00560</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00560" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFarsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=706-712&author=S.+Shenauthor=M.+Svobodaauthor=G.+Zhangauthor=M.+A.+Cavasinauthor=L.+Motlovaauthor=T.+A.+McKinseyauthor=J.+H.+Eubanksauthor=C.+Ba%C5%99inkaauthor=A.+P.+Kozikowski&title=Structural+and+in+Vivo+Characterization+of+Tubastatin+A%2C+a+Widely+Used+Histone+Deacetylase+6+Inhibitor&doi=10.1021%2Facsmedchemlett.9b00560"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and in Vivo Characterization of Tubastatin A, a Widely Used Histone Deacetylase 6 Inhibitor</span></div><div class="casAuthors">Shen, Sida; Svoboda, Michal; Zhang, Guangming; Cavasin, Maria A.; Motlova, Lucia; McKinsey, Timothy A.; Eubanks, James H.; Barinka, Cyril; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">706-712</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tubastatin A, a tetrahydro-γ-carboline-capped selective HDAC6 inhibitor (HDAC6i), was rationally designed 10 years ago, and has become the best investigated HDAC6i to date.  It shows efficacy in various neurol. disease animal models, as HDAC6 plays a crucial regulatory role in axonal transport deficits, protein aggregation, as well as oxidative stress.  In this work, we provide new insights into this HDAC6i by investigating the mol. basis of its interactions with HDAC6 through X-ray crystallog., detg. its functional capability to elevate the levels of acetylated α-tubulin in vitro and in vivo, correlating PK/PD profiles to det. EDs in plasma and brain, and finally assessing its therapeutic potential toward psychiatric diseases through use of the SmartCube screening platform.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpi67K0VhCsP7Vg90H21EOLACvtfcHk0lgdwNuYPECSvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFarsr8%253D&md5=431ff199537a679fc09f19f95e528219</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00560&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00560%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DS.%26aulast%3DSvoboda%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DCavasin%26aufirst%3DM.%2BA.%26aulast%3DMotlova%26aufirst%3DL.%26aulast%3DMcKinsey%26aufirst%3DT.%2BA.%26aulast%3DEubanks%26aufirst%3DJ.%2BH.%26aulast%3DBa%25C5%2599inka%26aufirst%3DC.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DStructural%2520and%2520in%2520Vivo%2520Characterization%2520of%2520Tubastatin%2520A%252C%2520a%2520Widely%2520Used%2520Histone%2520Deacetylase%25206%2520Inhibitor%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26spage%3D706%26epage%3D712%26doi%3D10.1021%2Facsmedchemlett.9b00560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Porter, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahendran, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breslow, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span> <span> </span><span class="NLM_article-title">Unusual Zinc-Binding Mode of HDAC6-Selective Hydroxamate Inhibitors</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">13459</span>– <span class="NLM_lpage">13464</span>, <span class="refDoi"> DOI: 10.1073/pnas.1718823114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1073%2Fpnas.1718823114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=29203661" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFWgsrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2017&pages=13459-13464&author=N.+J.+Porterauthor=A.+Mahendranauthor=R.+Breslowauthor=D.+W.+Christianson&title=Unusual+Zinc-Binding+Mode+of+HDAC6-Selective+Hydroxamate+Inhibitors&doi=10.1073%2Fpnas.1718823114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors</span></div><div class="casAuthors">Porter, Nicholas J.; Mahendran, Adaickapillai; Breslow, Ronald; Christianson, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">51</span>),
    <span class="NLM_cas:pages">13459-13464</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) regulate myriad cellular processes by catalyzing the hydrolysis of acetyl-L-lysine residues in histone and nonhistone proteins.  The Zn2+-dependent class IIb enzyme HDAC6 regulates microtubule function by deacetylating α-tubulin, which suppresses microtubule dynamics and leads to cell cycle arrest and apoptosis.  Accordingly, HDAC6 is a target for the development of selective inhibitors that might be useful in new therapeutic approaches for the treatment of cancer, neurodegenerative diseases, and other disorders.  Here, we present high-resoln. structures of catalytic domain 2 from Danio rerio HDAC6 (henceforth simply "HDAC6") complexed with compds. that selectively inhibit HDAC6 while maintaining nanomolar inhibitory potency: N-hydroxy-4-((N(2-hydroxyethyl)-2-phenylacetamido)methyl)-benzamide (HPB), ACY-1215 (Ricolinostat), and ACY-1083.  These structures reveal that an unusual monodentate Zn2+ coordination mode is exploited by sterically bulky HDAC6-selective phenylhydroxamate inhibitors.  We addnl. report the ultrahigh-resoln. structure of the HDAC6-trichostatin A complex, which reveals two Zn2+-binding conformers for the inhibitor: a major conformer (70%) with canonical bidentate hydroxamate-Zn2+ coordination geometry and a minor conformer (30%) with monodentate hydroxamate-Zn2+ coordination geometry, reflecting a free energy difference of only 0.5 kcal/mol.  The minor conformer is not visible in lower resoln. structure detns.  Structural comparisons of HDAC6-inhibitor complexes with class I HDACs suggest active site features that contribute to the isoenzyme selectivity obsd. in biochem. assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0oUH1X_04p7Vg90H21EOLACvtfcHk0ljoMXQMK2r1Vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFWgsrbI&md5=07180756239eac4891642cf59a2e6992</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1718823114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1718823114%26sid%3Dliteratum%253Aachs%26aulast%3DPorter%26aufirst%3DN.%2BJ.%26aulast%3DMahendran%26aufirst%3DA.%26aulast%3DBreslow%26aufirst%3DR.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26atitle%3DUnusual%2520Zinc-Binding%2520Mode%2520of%2520HDAC6-Selective%2520Hydroxamate%2520Inhibitors%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2017%26volume%3D114%26spage%3D13459%26epage%3D13464%26doi%3D10.1073%2Fpnas.1718823114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gawel, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shouksmith, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raouf, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nawar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toutah, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bukhari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manaswiyoungkul, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olaoye, O. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Israelian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radu, T. B.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">PTG-0861: A Novel HDAC6-Selective Inhibitor as a Therapeutic Strategy in Acute Myeloid Leukaemia</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>201</i></span>,  <span class="NLM_fpage">112411</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112411</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1016%2Fj.ejmech.2020.112411" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=32615502" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlSht73E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=201&publication_year=2020&pages=112411&author=J.+M.+Gawelauthor=A.+E.+Shouksmithauthor=Y.+S.+Raoufauthor=N.+Nawarauthor=K.+Toutahauthor=S.+Bukhariauthor=P.+Manaswiyoungkulauthor=O.+O.+Olaoyeauthor=J.+Israelianauthor=T.+B.+Radu&title=PTG-0861%3A+A+Novel+HDAC6-Selective+Inhibitor+as+a+Therapeutic+Strategy+in+Acute+Myeloid+Leukaemia&doi=10.1016%2Fj.ejmech.2020.112411"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">PTG-0861: A novel HDAC6-selective inhibitor as a therapeutic strategy in acute myeloid leukaemia</span></div><div class="casAuthors">Gawel, Justyna M.; Shouksmith, Andrew E.; Raouf, Yasir S.; Nawar, Nabanita; Toutah, Krimo; Bukhari, Shazreh; Manaswiyoungkul, Pimyupa; Olaoye, Olasunkanmi O.; Israelian, Johan; Radu, Tudor B.; Cabral, Aaron D.; Sina, Diana; Sedighi, Abootaleb; de Araujo, Elvin D.; Gunning, Patrick T.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">201</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112411</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Dysregulated Histone Deacetylase (HDAC) activity across multiple human pathologies have highlighted this family of epigenetic enzymes as crit. druggable targets, amenable to small mol. intervention.  While efficacious, current approaches using non-selective HDAC inhibitors (HDACi) have been shown to cause a range of undesirable clin. toxicities.  To circumvent this, recent efforts have focused on the design of highly selective HDACi as a novel therapeutic strategy.  Beyond roles in regulating transcription, the unique HDAC6 (with two catalytic domains) regulates the deacetylation of α-tubulin; promoting growth factor-controlled cell motility, cell division, and metastatic hallmarks.  Recent studies have linked aberrant HDAC6 function in various hematol. cancers including acute myeloid leukemia and multiple myeloma.  Herein, we report the discovery, in vitro characterization, and biol. evaluation of PTG-0861 (JG-265), a novel HDAC6-selective inhibitor with strong isoenzyme-selectivity (∼36x ) and low nanomolar potency (IC50 = 5.92 nM) against HDAC6.  This selectivity profile was rationalized via in silico docking studies and also obsd. in cellulo through cellular target engagement.  Moreover, PTG-0861 achieved relevant potency against several blood cancer cell lines (e.g. MV4-11, MM1S), while showing limited cytotoxicity against non-malignant cells (e.g. NHF, HUVEC) and CD-1 mice.  In examg. compd. stability and cellular permeability, PTG-0861 revealed a promising in vitro pharmacokinetic (PK) profile.  Altogether, in this study we identified a novel and potent HDAC6-selective inhibitor (∼4x more selective than current clin. stds. - citarinostat, ricolinostat), which achieves cellular target engagement, efficacy in hematol. cancer cells with a promising safety profile and in vitro PK.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGUpACNMyWt7Vg90H21EOLACvtfcHk0ljoMXQMK2r1Vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlSht73E&md5=c5b2e399be96a785b52019f04e1c08b8</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112411&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112411%26sid%3Dliteratum%253Aachs%26aulast%3DGawel%26aufirst%3DJ.%2BM.%26aulast%3DShouksmith%26aufirst%3DA.%2BE.%26aulast%3DRaouf%26aufirst%3DY.%2BS.%26aulast%3DNawar%26aufirst%3DN.%26aulast%3DToutah%26aufirst%3DK.%26aulast%3DBukhari%26aufirst%3DS.%26aulast%3DManaswiyoungkul%26aufirst%3DP.%26aulast%3DOlaoye%26aufirst%3DO.%2BO.%26aulast%3DIsraelian%26aufirst%3DJ.%26aulast%3DRadu%26aufirst%3DT.%2BB.%26atitle%3DPTG-0861%253A%2520A%2520Novel%2520HDAC6-Selective%2520Inhibitor%2520as%2520a%2520Therapeutic%2520Strategy%2520in%2520Acute%2520Myeloid%2520Leukaemia%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D201%26spage%3D112411%26doi%3D10.1016%2Fj.ejmech.2020.112411" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shouksmith, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gawel, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nawar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sina, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raouf, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bukhari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johns, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manaswiyoungkul, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olaoye, O. O.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">56</span>– <span class="NLM_lpage">64</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00471</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00471" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlygtLrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=56-64&author=A.+E.+Shouksmithauthor=J.+M.+Gawelauthor=N.+Nawarauthor=D.+Sinaauthor=Y.+S.+Raoufauthor=S.+Bukhariauthor=L.+Heauthor=A.+E.+Johnsauthor=P.+Manaswiyoungkulauthor=O.+O.+Olaoye&title=Class+I%2FIIb-Selective+HDAC+Inhibitor+Exhibits+Oral+Bioavailability+and+Therapeutic+Efficacy+in+Acute+Myeloid+Leukemia&doi=10.1021%2Facsmedchemlett.9b00471"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia</span></div><div class="casAuthors">Shouksmith, Andrew E.; Gawel, Justyna M.; Nawar, Nabanita; Sina, Diana; Raouf, Yasir S.; Bukhari, Shazreh; He, Liying; Johns, Alexandra E.; Manaswiyoungkul, Pimyupa; Olaoye, Olasunkanmi O.; Cabral, Aaron D.; Sedighi, Abootaleb; de Araujo, Elvin D.; Gunning, Patrick T.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">56-64</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The HDAC inhibitor 4-tert-butyl-N-(4-(hydroxycarbamoyl)phenyl)benzamide (AES-350, I) was identified as a promising preclin. candidate for the treatment of acute myeloid leukemia (AML), an aggressive malignancy with a meagre 24% 5-yr survival rate.  Through screening of low-mol.-wt. analogs derived from the previously discovered novel HDAC inhibitor, AES-135 (II), compd. I demonstrated greater HDAC isoform selectivity, higher cytotoxicity in MV4-11 cells, an improved therapeutic window, and more efficient absorption through cellular and lipid membranes.  Compd. I also demonstrated improved oral bioavailability compared to SAHA in mouse models.  A broad spectrum of expts., including FACS, ELISA, and Western blotting, were performed to support our hypothesis that I dose-dependently triggers apoptosis in AML cells through HDAC inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8ikqWn7KZc7Vg90H21EOLACvtfcHk0lgL8q1HeNUytA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlygtLrK&md5=3c21f11cda2a27e00f30a7cd3c700785</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00471&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00471%26sid%3Dliteratum%253Aachs%26aulast%3DShouksmith%26aufirst%3DA.%2BE.%26aulast%3DGawel%26aufirst%3DJ.%2BM.%26aulast%3DNawar%26aufirst%3DN.%26aulast%3DSina%26aufirst%3DD.%26aulast%3DRaouf%26aufirst%3DY.%2BS.%26aulast%3DBukhari%26aufirst%3DS.%26aulast%3DHe%26aufirst%3DL.%26aulast%3DJohns%26aufirst%3DA.%2BE.%26aulast%3DManaswiyoungkul%26aufirst%3DP.%26aulast%3DOlaoye%26aufirst%3DO.%2BO.%26atitle%3DClass%2520I%252FIIb-Selective%2520HDAC%2520Inhibitor%2520Exhibits%2520Oral%2520Bioavailability%2520and%2520Therapeutic%2520Efficacy%2520in%2520Acute%2520Myeloid%2520Leukemia%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26spage%3D56%26epage%3D64%26doi%3D10.1021%2Facsmedchemlett.9b00471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Osko, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span> <span> </span><span class="NLM_article-title">Structural Basis of Catalysis and Inhibition of HDAC6 CD1, the Enigmatic Catalytic Domain of Histone Deacetylase 6</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">4912</span>– <span class="NLM_lpage">4924</span>, <span class="refDoi"> DOI: 10.1021/acs.biochem.9b00934</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.9b00934" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1Snsb3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2019&pages=4912-4924&author=J.+D.+Oskoauthor=D.+W.+Christianson&title=Structural+Basis+of+Catalysis+and+Inhibition+of+HDAC6+CD1%2C+the+Enigmatic+Catalytic+Domain+of+Histone+Deacetylase+6&doi=10.1021%2Facs.biochem.9b00934"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis of Catalysis and Inhibition of HDAC6 CD1, the Enigmatic Catalytic Domain of Histone Deacetylase 6</span></div><div class="casAuthors">Osko, Jeremy D.; Christianson, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">4912-4924</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Histone deacetylase 6 (HDAC6) is emerging as a target for inhibition in therapeutic strategies aimed at treating cancer, neurodegenerative disease, and other disorders.  Among the metal-dependent HDAC isoenzymes, HDAC6 is unique in that it contains two catalytic domains, CD1 and CD2.  CD2 is a tubulin deacetylase and a tau deacetylase, and the development of HDAC6-selective inhibitors has focused exclusively on this domain.  In contrast, there is a dearth of structural and functional information regarding CD1, which exhibits much narrower substrate specificity in comparison with CD2.  As the first step in addressing the CD1 information gap, we now present X-ray crystal structures of seven inhibitor complexes with wild-type, Y363F, and K330L HDAC6 CD1.  These structures broaden our understanding of mol. features important for catalysis and inhibitor binding.  The active site of HDAC6 CD1 is wider than that of CD2, which is unexpected in view of the narrow substrate specificity of CD1.  Amino acid substitutions between HDAC6 CD1 and CD2, as well as conformational differences in conserved residues, define striking differences in active site contours.  Catalytic activity measurements with HDAC6 CD1 confirm the preference for peptide substrates contg. C-terminal acetyllysine residues.  However, these measurements also show that CD1 exhibits weak activity for peptide substrates bearing certain small amino acids on the carboxyl side of the scissile acetyllysine residue.  Taken together, these results establish a foundation for understanding the structural basis of HDAC6 CD1 catalysis and inhibition, pointing to possible avenues for the development of HDAC6 CD1-selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrk6bd_6kU9erVg90H21EOLACvtfcHk0lgL8q1HeNUytA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1Snsb3P&md5=4bebfc15825270bceeb7b87ca61c0f10</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.9b00934&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.9b00934%26sid%3Dliteratum%253Aachs%26aulast%3DOsko%26aufirst%3DJ.%2BD.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26atitle%3DStructural%2520Basis%2520of%2520Catalysis%2520and%2520Inhibition%2520of%2520HDAC6%2520CD1%252C%2520the%2520Enigmatic%2520Catalytic%2520Domain%2520of%2520Histone%2520Deacetylase%25206%26jtitle%3DBiochemistry%26date%3D2019%26volume%3D58%26spage%3D4912%26epage%3D4924%26doi%3D10.1021%2Facs.biochem.9b00934" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Osko, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span> <span> </span><span class="NLM_article-title">Structural Determinants of Affinity and Selectivity in the Binding of Inhibitors to Histone Deacetylase 6</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">127023</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2020.127023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1016%2Fj.bmcl.2020.127023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=32067866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjtFGqs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=127023&author=J.+D.+Oskoauthor=D.+W.+Christianson&title=Structural+Determinants+of+Affinity+and+Selectivity+in+the+Binding+of+Inhibitors+to+Histone+Deacetylase+6&doi=10.1016%2Fj.bmcl.2020.127023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Structural determinants of affinity and selectivity in the binding of inhibitors to histone deacetylase 6</span></div><div class="casAuthors">Osko, Jeremy D.; Christianson, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">127023</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review. Digest.  Histone deacetylase 6 (HDAC6) is assocd. with multiple neurol. disorders as well as aggressive cancers, making its selective inhibition highly desirable for therapeutic purposes.  The basic mol. design of an effective HDAC6 inhibitor consists of a zinc-binding group, a linker, and a capping group capable of making interactions at the mouth of the active site.  To date, more than 50 high-resoln. X-ray crystal structures of HDAC6-inhibitor complexes have been reported, many of which reveal intermol. interactions that contribute to isoenzyme affinity and selectivity.  Here, we review the key features of HDAC6 inhibitor design illuminated by these structural studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEHMdvmF9TPLVg90H21EOLACvtfcHk0lhE0dRo06Oduw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjtFGqs70%253D&md5=df46fa5e4720d8340d728e6269dadb90</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2020.127023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2020.127023%26sid%3Dliteratum%253Aachs%26aulast%3DOsko%26aufirst%3DJ.%2BD.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26atitle%3DStructural%2520Determinants%2520of%2520Affinity%2520and%2520Selectivity%2520in%2520the%2520Binding%2520of%2520Inhibitors%2520to%2520Histone%2520Deacetylase%25206%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D30%26spage%3D127023%26doi%3D10.1016%2Fj.bmcl.2020.127023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ali, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gómez-Biagi, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosa, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, P.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heaton, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eiring, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vellore, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Araujo, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ball, D. P.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Disarming an Electrophilic Warhead: Retaining Potency in Tyrosine Kinase Inhibitor (TKI)-Resistant CML Lines While Circumventing Pharmacokinetic Liabilities</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">850</span>– <span class="NLM_lpage">861</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201600021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1002%2Fcmdc.201600021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=27028877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BC28XltVOitL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=850-861&author=A.+M.+Aliauthor=R.+F.+G%C3%B3mez-Biagiauthor=D.+A.+Rosaauthor=P.-S.+Laiauthor=W.+L.+Heatonauthor=J.+S.+Parkauthor=A.+M.+Eiringauthor=N.+A.+Velloreauthor=E.+D.+de+Araujoauthor=D.+P.+Ball&title=Disarming+an+Electrophilic+Warhead%3A+Retaining+Potency+in+Tyrosine+Kinase+Inhibitor+%28TKI%29-Resistant+CML+Lines+While+Circumventing+Pharmacokinetic+Liabilities&doi=10.1002%2Fcmdc.201600021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Disarming an Electrophilic Warhead: Retaining Potency in Tyrosine Kinase Inhibitor (TKI)-Resistant CML Lines While Circumventing Pharmacokinetic Liabilities</span></div><div class="casAuthors">Ali, Ahmed M.; Gomez-Biagi, Rodolfo F.; Rosa, David A.; Lai, Ping-Shan; Heaton, William L.; Park, Ji Sung; Eiring, Anna M.; Vellore, Nadeem A.; de Araujo, Elvin D.; Ball, Dan P.; Shouksmith, Andrew E.; Patel, Ami B.; Deininger, Michael W.; O'Hare, Thomas; Gunning, Patrick T.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">850-861</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Pharmacol. blockade of the activation of signal transducer and activator of transcription 3 (STAT3) in tyrosine kinase inhibitor (TKI)-resistant chronic myeloid leukemia (CML) cell lines characterized by kinase-independent resistance was shown to re-sensitize CML cells to TKI therapy, suggesting that STAT3 inhibitors in combination with TKIs are an effective combinatorial therapeutic for the treatment of CML.  Benzoic acid- and hydroxamic acid-based STAT3 inhibitors SH-4-054 and SH-5-007, developed previously in our lab., demonstrated promising activity against these resistant CML cell lines.  However, pharmacokinetic studies in murine models (CD-1 mice) revealed that both SH-4-054 and SH-5-007 are susceptible to glutathione conjugation at the para position of the pentafluorophenyl group via nucleophilic arom. substitution (SNAr).  To det. whether the electrophilicity of the pentafluorophenyl sulfonamide could be tempered, an in-depth structure-activity relationship (SAR) study of the SH-4-054 scaffold was conducted.  These studies revealed that AM-1-124, possessing a 2,3,5,6-tetrafluorophenylsulfonamide group, retained STAT3 protein affinity (Ki=15 μm), as well as selectivity over STAT1 (Ki>250 μm).  Moreover, in both hepatocytes and in in vivo pharmacokinetic studies (CD-1 mice), AM-1-124 was found to be dramatically more stable than SH-4-054 (t1/2=1.42 h cf. 10 min, resp.).  AM-1-124 is a promising STAT3-targeting inhibitor with demonstrated bioavailability, suitable for evaluation in preclin. cancer models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqS38duOD8NmLVg90H21EOLACvtfcHk0lhE0dRo06Oduw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XltVOitL4%253D&md5=f356ee9c2078e878e2756c885f099d55</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201600021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201600021%26sid%3Dliteratum%253Aachs%26aulast%3DAli%26aufirst%3DA.%2BM.%26aulast%3DG%25C3%25B3mez-Biagi%26aufirst%3DR.%2BF.%26aulast%3DRosa%26aufirst%3DD.%2BA.%26aulast%3DLai%26aufirst%3DP.-S.%26aulast%3DHeaton%26aufirst%3DW.%2BL.%26aulast%3DPark%26aufirst%3DJ.%2BS.%26aulast%3DEiring%26aufirst%3DA.%2BM.%26aulast%3DVellore%26aufirst%3DN.%2BA.%26aulast%3Dde%2BAraujo%26aufirst%3DE.%2BD.%26aulast%3DBall%26aufirst%3DD.%2BP.%26atitle%3DDisarming%2520an%2520Electrophilic%2520Warhead%253A%2520Retaining%2520Potency%2520in%2520Tyrosine%2520Kinase%2520Inhibitor%2520%2528TKI%2529-Resistant%2520CML%2520Lines%2520While%2520Circumventing%2520Pharmacokinetic%2520Liabilities%26jtitle%3DChemMedChem%26date%3D2016%26volume%3D11%26spage%3D850%26epage%3D861%26doi%3D10.1002%2Fcmdc.201600021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Porter, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span> <span> </span><span class="NLM_article-title">Structure, Mechanism, and Inhibition of the Zinc-Dependent Histone Deacetylases</span>. <i>Curr. Opin. Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">9</span>– <span class="NLM_lpage">18</span>, <span class="refDoi"> DOI: 10.1016/j.sbi.2019.01.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1016%2Fj.sbi.2019.01.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=30743180" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVGit7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2019&pages=9-18&author=N.+J.+Porterauthor=D.+W.+Christianson&title=Structure%2C+Mechanism%2C+and+Inhibition+of+the+Zinc-Dependent+Histone+Deacetylases&doi=10.1016%2Fj.sbi.2019.01.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Structure, mechanism, and inhibition of the zinc-dependent histone deacetylases</span></div><div class="casAuthors">Porter, Nicholas J.; Christianson, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Structural Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">9-18</span>CODEN:
                <span class="NLM_cas:coden">COSBEF</span>;
        ISSN:<span class="NLM_cas:issn">0959-440X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Zinc-dependent histone deacetylases (HDACs) regulate the biol. function of histone and non-histone proteins through the hydrolysis of acetyllysine side chains to yield free lysine and acetate.  Certain HDAC isoenzymes exhibit alternative catalytic activities, such as polyamine deacetylase or lysine fatty acid deacylase activity.  To date, crystal structures have been reported for class I HDACs (1-3, and 8), class IIa HDACs (4 and 7), and class IIb HDACs (6 and 10).  Conserved active site residues mediate the chem. of substrate activation and hydrolysis in these isoenzymes through a metal-activated water mol. assisted by general base-general acid catalysis.  Upregulated HDAC activity is obsd. in cancer and neurodegenerative disease, and four HDAC inhibitors are currently approved for use in cancer chemotherapy.  Crystal structures of HDAC-inhibitor complexes guide the design of new inhibitors with high affinity and selectivity for specific HDAC isoenzymes implicated in human disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2Vx86t86y6rVg90H21EOLACvtfcHk0lgXxZAmk3GNxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVGit7o%253D&md5=1dd392837f88a1f079861d44a3f529f5</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.sbi.2019.01.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.sbi.2019.01.004%26sid%3Dliteratum%253Aachs%26aulast%3DPorter%26aufirst%3DN.%2BJ.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26atitle%3DStructure%252C%2520Mechanism%252C%2520and%2520Inhibition%2520of%2520the%2520Zinc-Dependent%2520Histone%2520Deacetylases%26jtitle%3DCurr.%2520Opin.%2520Struct.%2520Biol.%26date%3D2019%26volume%3D59%26spage%3D9%26epage%3D18%26doi%3D10.1016%2Fj.sbi.2019.01.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Porter, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span> <span> </span><span class="NLM_article-title">Entropy as a Driver of Selectivity for Inhibitor Binding to Histone Deacetylase 6</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">3916</span>– <span class="NLM_lpage">3924</span>, <span class="refDoi"> DOI: 10.1021/acs.biochem.8b00367</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.8b00367" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BC1cXps1Onsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=3916-3924&author=N.+J.+Porterauthor=F.+F.+Wagnerauthor=D.+W.+Christianson&title=Entropy+as+a+Driver+of+Selectivity+for+Inhibitor+Binding+to+Histone+Deacetylase+6&doi=10.1021%2Facs.biochem.8b00367"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Entropy as a Driver of Selectivity for Inhibitor Binding to Histone Deacetylase 6</span></div><div class="casAuthors">Porter, Nicholas J.; Wagner, Florence F.; Christianson, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">3916-3924</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Among the metal-dependent histone deacetylases, the class IIb isoenzyme HDAC6 is remarkable due to its role in the regulation of microtubule dynamics in the cytosol.  Selective inhibition of HDAC6 results in microtubule hyperacetylation, leading to cell cycle arrest and apoptosis, which is a validated strategy for cancer chemotherapy and the treatment of other disorders.  HDAC6 inhibitors generally consist of a Zn2+-binding group such as a hydroxamate, a linker, and a capping group; the capping group is a crit. determinant of isoenzyme selectivity.  Surprisingly, however, even "capless" inhibitors exhibit appreciable HDAC6 selectivity.  To probe the chem. basis for this selectivity, we now report high-resoln. crystal structures of HDAC6 complexed with capless cycloalkylhydroxamate inhibitors 1-4.  Each inhibitor hydroxamate group coordinates to the catalytic Zn2+ ion with canonical bidentate geometry.  Addnl., the olefin moieties of compds. 2 and 4 bind in an arom. crevice between the side chains of F583 and F643.  Reasoning that similar binding could be achieved in the representative class I isoenzyme HDAC8, we employed isothermal titrn. calorimetry to study the thermodn. of inhibitor binding.  These measurements indicate that the entropy of inhibitor binding is generally pos. for binding to HDAC6 and neg. for binding to HDAC8, resulting in up to 313-fold selectivity for binding to HDAC6 relative to HDAC8.  Thus, favorable binding entropy contributes to HDAC6 selectivity.  Notably, cyclohexenylhydroxamate 2 represents a promising lead for derivatization with capping groups that may further enhance its impressive 313-fold thermodn. selectivity for HDAC6 inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5MmbdoXXUqrVg90H21EOLACvtfcHk0lgXxZAmk3GNxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXps1Onsrg%253D&md5=0da8abf0ee7f012db41c620101551442</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.8b00367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.8b00367%26sid%3Dliteratum%253Aachs%26aulast%3DPorter%26aufirst%3DN.%2BJ.%26aulast%3DWagner%26aufirst%3DF.%2BF.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26atitle%3DEntropy%2520as%2520a%2520Driver%2520of%2520Selectivity%2520for%2520Inhibitor%2520Binding%2520to%2520Histone%2520Deacetylase%25206%26jtitle%3DBiochemistry%26date%3D2018%26volume%3D57%26spage%3D3916%26epage%3D3924%26doi%3D10.1021%2Facs.biochem.8b00367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fierke, C. A.</span></span> <span> </span><span class="NLM_article-title">Carbonic Anhydrase: Evolution of the Zinc Binding Site by Nature and by Design</span>. <i>Acc. Chem. Res.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">331</span>– <span class="NLM_lpage">339</span>, <span class="refDoi"> DOI: 10.1021/ar9501232</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ar9501232" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADyaK28Xjs1GktLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=1996&pages=331-339&author=D.+W.+Christiansonauthor=C.+A.+Fierke&title=Carbonic+Anhydrase%3A+Evolution+of+the+Zinc+Binding+Site+by+Nature+and+by+Design&doi=10.1021%2Far9501232"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Carbonic anhydrase: Evolution of the zinc binding site by nature and by design</span></div><div class="casAuthors">Christianson, David W.; Fierke, Carol A.</div><div class="citationInfo"><span class="NLM_cas:title">Accounts of Chemical Research</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">331-339</span>CODEN:
                <span class="NLM_cas:coden">ACHRE4</span>;
        ISSN:<span class="NLM_cas:issn">0001-4842</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review and discussion with 89 refs., of the evolution of the Zn-binding site of erythrocyte carbonic anhydrase II and its redesign by protein engineering.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGCjLbhEYyq7Vg90H21EOLACvtfcHk0lgXxZAmk3GNxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xjs1GktLk%253D&md5=e86dc0ab1affce3505364767ad3efcb9</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Far9501232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Far9501232%26sid%3Dliteratum%253Aachs%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26aulast%3DFierke%26aufirst%3DC.%2BA.%26atitle%3DCarbonic%2520Anhydrase%253A%2520Evolution%2520of%2520the%2520Zinc%2520Binding%2520Site%2520by%2520Nature%2520and%2520by%2520Design%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D1996%26volume%3D29%26spage%3D331%26epage%3D339%26doi%3D10.1021%2Far9501232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dudev, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudev, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, C.</span></span> <span> </span><span class="NLM_article-title">First-Second Shell Interactions in Metal Binding Sites in Proteins: A PDB Survey and DFT/CDM Calculations</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">3168</span>– <span class="NLM_lpage">3180</span>, <span class="refDoi"> DOI: 10.1021/ja0209722</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja0209722" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BD3sXht1Sgt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2003&pages=3168-3180&author=T.+Dudevauthor=Y.+Linauthor=M.+Dudevauthor=C.+Lim&title=First-Second+Shell+Interactions+in+Metal+Binding+Sites+in+Proteins%3A+A+PDB+Survey+and+DFT%2FCDM+Calculations&doi=10.1021%2Fja0209722"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">First-Second Shell Interactions in Metal Binding Sites in Proteins: A PDB Survey and DFT/CDM Calculations</span></div><div class="casAuthors">Dudev, Todor; Lin, Yen-lin; Dudev, Minko; Lim, Carmay</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3168-3180</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The role of the second shell in the process of metal binding and selectivity in metalloproteins has been elucidated by combining Protein Data Bank (PDB) surveys of Mg, Mn, Ca, and Zn binding sites with d. functional theory/continuum dielec. methods (DFT/CDM).  Peptide backbone groups were found to be the most common second-shell ligand in Mg, Mn, Ca, and Zn binding sites, followed (in decreasing order) by Asp/Glu, Lys/Arg, Asn/Gln, and Ser/Thr side chains.  Arom. oxygen- or nitrogen-contg. side chains (Tyr, His, and Trp) and sulfur-contg. side chains (Cys and Met) are seldom found in the second coordination layer.  The backbone and Asn/Gln side chain are ubiquitous in the metal second coordination layer as their carbonyl oxygen and amide hydrogen can act as a hydrogen-bond acceptor and donor, resp., and can therefore partner practically every first-shell ligand.  The second most common outer-shell ligand, Asp/Glu, predominantly hydrogen bonds to a metal-bound water or Zn-bound histidine and polarizes the H-O or H-N bond.  In certain cases, a second-shell Asp/Glu could affect the protonation state of the metal ligand.  It could also energetically stabilize a pos. charged metal complex more than a neutral ligand such as the backbone and Asn/Gln side chain.  As for the first shell, the second shell is predicted to contribute to the metal selectivity of the binding site by discriminating between metal cations of different ionic radii and coordination geometries.  The first-shell-second-shell interaction energies decay rapidly with increasing solvent exposure of the metal binding site.  They are less favorable but are of the same order of magnitude as compared to the resp. metal-first-shell interaction energies. Altogether, the results indicate that the structure and properties of the second shell are dictated by those of the first layer.  The outer shell is apparently designed to stabilize/protect the inner-shell and complement/enhance its properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGof_Unc1bR69rVg90H21EOLACvtfcHk0lj63pn3JABl1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXht1Sgt7w%253D&md5=6f36bae58c3d9f8b4d4ffb3dd5efaceb</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fja0209722&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja0209722%26sid%3Dliteratum%253Aachs%26aulast%3DDudev%26aufirst%3DT.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DDudev%26aufirst%3DM.%26aulast%3DLim%26aufirst%3DC.%26atitle%3DFirst-Second%2520Shell%2520Interactions%2520in%2520Metal%2520Binding%2520Sites%2520in%2520Proteins%253A%2520A%2520PDB%2520Survey%2520and%2520DFT%252FCDM%2520Calculations%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2003%26volume%3D125%26spage%3D3168%26epage%3D3180%26doi%3D10.1021%2Fja0209722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ray, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hideshima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tai, Y.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chauhan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. C.</span></span> <span> </span><span class="NLM_article-title">Combination of a Novel HDAC6 Inhibitor ACY-241 and Anti-PD-L1 Antibody Enhances Anti-Tumor Immunity and Cytotoxicity in Multiple Myeloma</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">843</span>– <span class="NLM_lpage">846</span>, <span class="refDoi"> DOI: 10.1038/leu.2017.322</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1038%2Fleu.2017.322" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=29104288" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjvFWrtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2018&pages=843-846&author=A.+Rayauthor=D.+S.+Dasauthor=Y.+Songauthor=T.+Hideshimaauthor=Y.-T.+Taiauthor=D.+Chauhanauthor=K.+C.+Anderson&title=Combination+of+a+Novel+HDAC6+Inhibitor+ACY-241+and+Anti-PD-L1+Antibody+Enhances+Anti-Tumor+Immunity+and+Cytotoxicity+in+Multiple+Myeloma&doi=10.1038%2Fleu.2017.322"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma</span></div><div class="casAuthors">Ray, A.; Das, D. S.; Song, Y.; Hideshima, T.; Tai, Y.-T.; Chauhan, D.; Anderson, K. C.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">843-846</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) are attractive therapeutic targets, and selective HDAC inhibitors (HDACi), alone or in combination with other anti-cancer agents, are promising treatment strategies in multiple myeloma (MM).1234To date, however, the effect of HDACi on immune regulation in the MM bone marrow (BM) microenvironment, as well as the therapeutic potential of combining selective HDACi with immune-based therapies, is undefined.  Recent studies showed that besides histone modification, HDACs also modulate non-histone targets including immune regulatory mols.5, 6 For example, blockade of HDACs upregulates immunecheckpoints such as PD-1 ligand (PD-L1).6 Moreover, the combination of HDACi with PD-1/PD-L1 checkpoint blockade significantly improves immunotherapy in a murine B16F10 model.6 In MM, PD-L1 expression directly correlates with progression of disease, with highest levels in patients with relapsed/refractory MM.7, 8 Here, we utilized an orally bioavalable HDAC6 selective inhibitor ACY-241, currently in clin. trials,9 to examine whether the combination of ACY-241 with anti-PD-L1 antibody enhances anti-MM immunity in the MM BM microenvironment.  For our studies, we utilized a co-culture model of immune effector cells (plasmacytoid dendritic cells (pDCs), T cells, NK cells) and MM cells.7, 10 Specifically, we have identified that interactions of MM cells with innate and adaptive immune cells in the BM milieu confer immune suppression via PD-1/PD-L1 signaling axis (Figure 1a: Schema).7, 10 This is exemplified in our studies demonstrating a novel functional interaction between pDCs (Lin- MHC-II+ CD123+ CD4+ CD303/BDCA-2+ CD304/BDCA-4+) and MM cells, implicating pDCs in both MM pathogenesis and immune suppression.  We showed that increased nos. of pDCs are present in MM patient BM vs. normal BM.  Importantly, pDCs in MM BM are relatively resistant to current therapies; protect tumor cells from therapy-induced cytotoxicity; promote tumor growth and survival; and confer immune dysfunction.7, 10 Using our co-culture model, we further delineated the immunosuppressive mechanism(s) that have a role during pDC-T-NK cell interactions with tumor cells.  Specifically, we found that: (1) MM cells and pDCs expressed high surface levels of PD-L1, whereas T cells showed high PD-1 levels; and (2) PD-L1 on MM pDCs suppresses PD-1 expressing T-cell and NK cell immune function; and (3) blockade of PD-L1-PD-1 signaling axis by anti-PD-L1 Ab generates MM-specific CD8+ ctotoxic T lymphocyte (CTL) activity, as well as enhances NK cell-mediated MM cell cytolytic activity.  Importantly, our co-culture model allows for evaluation of the effect of anti-MM drugs on immune regulatory mols. expressed on immune cells and tumor cells, as well as provides a platform for validating all immune-based combination strategies, esp. in the context of immune cells within the MM BM microenvironment.  In the current study, we utilized these models to specifically examine whether the combination of ACY-241 with anti-PD-L1 Ab increases anti-tumor immunity and cytotoxicity in MM.  We first evaluated whether the combination of ACY-241 and anti-PD-L1 Ab enhances MM patient NK cell-mediated cytolytic activity.  For these studies, we utilized low concn. of ACY-241 that do not significantly affect the viability of pDCs, T cells or NK cells (Supplementary Figure 1 A-C).  Freshly isolated NK cells from MM patient BM (n=7) were co-cultured with autologous pDCs in the presence of anti-PD-L1 Ab (5 μg/mL), ACY-241 (0.2 μ) or ACY-241 plus anti-PD-L1 Ab for 5 days.  Cells were washed and resuspended in complete medium without drugs and cultured with autologous MM cells prestained with Celltrace violet for 24 h, followed by 7-AAD staining and quantification of MM cell lysis by flow cytometry.  The combination of ACY-241 and anti-PD-L1 Ab triggered a more robust NK cell-mediated cytotlytic activity against MM cells than either agent alone (Figure 1b and c).  No significant NK cell-mediated cytotoxicity was noted in the absence of pDCs in these expts. (Supplementary Figure 2B), confirming a key role of pDCs in NK cell functioning in response to treatment with ACY-241 and/or anti-PD-L1 Ab.  To further confirm our findings, we next performed anal. of CD107a as a marker of NK cell function.  MM patient pDCs and autologous NK cells were treated with ACY-241, anti-PD-L1 Ab or ACY-241 plus anti-PD-L1 Ab, followed by degranulation assay to assess surface CD107a expressing CD3-/CD56+ NK cells by multi-parameter flow cytometry.  In concert with our finding shown in Figures 1b and c, ACY-241 plus anti-PD-L1 Ab increases CD107a+ degranulated cytolytic NK cells (Supplementary Figure 3).  As in our prior study,7 anti-PD-L1 Ab alone restored NK cell-mediated anti-MM activity.  Interestingly, treatment of pDC-NK cells co-cultured with ACY-241 alone triggerred NK cell cytolytic activity against MM cells (Figures 1b and c).  In this context, a recent study showed a role of HDAC6 in the regulation of PD-L1 in melanoma.11 We hypothesized that ACY-241 may downregulate PD-L1/PD-1-mediated NK cell immune suppression during pDC-NK cell interactions.  Indeed, ACY-241 significantly decreases PD-L1 expression on pDCs (Supplementary Figure 5), which in turn attentuates PD-L1/PD-1-mediated NK suppression and thereby enhances NK cell-mediated MM cell cytotoxicity.  Although not examd. here, other possibilities may account for ACY-241 activity.  Similar to immunomodulatory agent Lenalidomide, ACY-241 may skew effector cytokine (IFN-γ; TNFα) prodn. toward enhancing NK cell anti-MM activity.  Alternatively, ACY-241 may act as reported for HDACi LBH589, which upregulates activation marker CD69 on NK cells.12 Finally, ACY-241 may enhance NK cell anti-MM activity by altering receptor-ligand (for example, NKG2D or KIR) expression-mediated tumor cell killing.  These issues remain to be examd.  Nonetheless, we here show that: (1) pDC-MM cell interactions modulate NK cell cytotoxic activity; (2) combined ACY-241 and anti-PD-L1 Ab enhances MM patient pDC-induced NK cell-mediated cytolytic activities against autologous MM cells; (3) ACY-241 or anti-PD-L1 alone have the ability to stimulate NK cell effector function, albiet to a lesser extent than in combination; and (4) ACY-241 is an immune-modulating agent as it triggers significant NK cell anti-MM activity.  A recent study showed that a HDAC6i ricolinostat triggers T-cell activation and APC function.13 We therefore next examd. whether ACY-241, anti-PD-L1 or their combination triggers the generation of MM-specific CTLs ex vivo.  MM patient BM CD8+T cells (n=7) were co-cultured with autologous pDCs (pDC:T; 1:10 ratio) in the presence of anti-PD-L1 Ab, ACY-241 or ACY-241 plus anti-PD-L1 Ab for 5 days.  Cells were washed and resuspended in complete medium without drugs and cultured with autologous MM cells that were prestained with CellTracker Green for 24 h, followed by 7-AAD staining and quantification of CTLs-mediated MM cell lysis by FACS.  The combination of ACY-241 and anti-PD-L1 Ab triggered a more robust autologous MM-specific CD8+ CTL activity than either agent alone, evidenced by decreased no. of viable CellTracker Green-pos. MM cells (Figure 2a and Supplementary Figure 4).  MM cells were also cultured alone without immune effector cells for the same time period, and data obtained from flow anal. were used for normalization to account for the spontaneous MM cells death.  We next performed CD107a degranulation assays to confirm the generation of CD8+ T-cell cytolytic activity.  MM patient pDCs were co-cultured with autologous T cells and treated with ACY-241, anti-PD-L1 Ab, or ACY-241 plus anti-PD-L1 Ab, followed by degranulation assay to measure CD107a on the cell surface of activated CD3+/CD8+ T cells using flow cytometry.  In agreement with our findings from CTL assays (Figure 2a and Supplementary Figure 4), a more robust increase in surface CD107a+ cytotoxic T cells was noted upon treatment with combined ACY-241 and anti-PD-L1 Ab vs. either ACY-241 or anti-PD-L1 Ab alone (Figure 2b).  No significant MM patient CTL activity was noticed in the absence of pDCs (Supplementary Figure 2C).  Collectively, our data show that combination of selective HDAC6 inhibitor ACY-241 with anti-PD-L1 Ab triggers both CTLs- and NK cells-mediated MM cell killing (Supplementary Figures 6 and 7; Schema).  Mechanistic studies show that combined activity of ACY-241 and anti-PD-L1 is due to downregulation of immunosuppressive PD-L1/PD-1 signaling during pDC-T cells and pDC-NK cells interactions.  It is likely that besides blockade of PD-L1/PD-1, this combination regimen also abrogates other immunosuppressive mechanisms and/or activates immune-activating pathways among pDCs, NK or T cells that together contribute in restoration of anti-MM immunity.  Ongoing studies are focused on investigating these immune mechanism(s).  Finally, recent data indicate potential toxicity assocd. with checkpoint inhibitors in MM.  However, in contrast to inhibitor of checkpoint PD-1 (pembrolizumab), clin. trials of anti-PD-L1 Abs to date show safety, without any significant adverse events in MM patients.14 Moreover, a recent study found a better response rate in patients with higher PD-L1 levels on MM cells, and PD-1 expression on lymphocytes correlated weakly with progression-free survival in a small subset of patients.15 These findings, coupled with our data, support translation of combined ACY-241 and anti-PD-L1 Ab into clin. trials to restore immune function, enhance MM cytotoxicity and improve patient outcome in MM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiLF586f3pxrVg90H21EOLACvtfcHk0lj63pn3JABl1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjvFWrtr0%253D&md5=b186fa9563c1e48519b4831dc3cebc3e</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fleu.2017.322&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2017.322%26sid%3Dliteratum%253Aachs%26aulast%3DRay%26aufirst%3DA.%26aulast%3DDas%26aufirst%3DD.%2BS.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DHideshima%26aufirst%3DT.%26aulast%3DTai%26aufirst%3DY.-T.%26aulast%3DChauhan%26aufirst%3DD.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26atitle%3DCombination%2520of%2520a%2520Novel%2520HDAC6%2520Inhibitor%2520ACY-241%2520and%2520Anti-PD-L1%2520Antibody%2520Enhances%2520Anti-Tumor%2520Immunity%2520and%2520Cytotoxicity%2520in%2520Multiple%2520Myeloma%26jtitle%3DLeukemia%26date%3D2018%26volume%3D32%26spage%3D843%26epage%3D846%26doi%3D10.1038%2Fleu.2017.322" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yee, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bensinger, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voorhees, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berdeja, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Supko, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wheeler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markelewicz, R. J.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, in Combonation with Lenalidomide and Dexamethasone in Patients with Relapsed and Relapsed-and-Refractory Multiple Myeloma: Phase 1b Results (ACE-MM-101 Study)</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">3055</span>, <span class="refDoi"> DOI: 10.1182/blood.v126.23.3055.3055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1182%2Fblood.V126.23.3055.3055" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2015&pages=3055&author=A.+J.+Yeeauthor=W.+Bensingerauthor=P.+M.+Voorheesauthor=J.+G.+Berdejaauthor=P.+G.+Richardsonauthor=J.+Supkoauthor=D.+Tamangauthor=S.+S.+Jonesauthor=C.+Wheelerauthor=R.+J.+Markelewicz&title=Ricolinostat+%28ACY-1215%29%2C+the+First+Selective+HDAC6+Inhibitor%2C+in+Combonation+with+Lenalidomide+and+Dexamethasone+in+Patients+with+Relapsed+and+Relapsed-and-Refractory+Multiple+Myeloma%3A+Phase+1b+Results+%28ACE-MM-101+Study%29&doi=10.1182%2Fblood.v126.23.3055.3055"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1182%2Fblood.V126.23.3055.3055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.V126.23.3055.3055%26sid%3Dliteratum%253Aachs%26aulast%3DYee%26aufirst%3DA.%2BJ.%26aulast%3DBensinger%26aufirst%3DW.%26aulast%3DVoorhees%26aufirst%3DP.%2BM.%26aulast%3DBerdeja%26aufirst%3DJ.%2BG.%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26aulast%3DSupko%26aufirst%3DJ.%26aulast%3DTamang%26aufirst%3DD.%26aulast%3DJones%26aufirst%3DS.%2BS.%26aulast%3DWheeler%26aufirst%3DC.%26aulast%3DMarkelewicz%26aufirst%3DR.%2BJ.%26atitle%3DRicolinostat%2520%2528ACY-1215%2529%252C%2520the%2520First%2520Selective%2520HDAC6%2520Inhibitor%252C%2520in%2520Combonation%2520with%2520Lenalidomide%2520and%2520Dexamethasone%2520in%2520Patients%2520with%2520Relapsed%2520and%2520Relapsed-and-Refractory%2520Multiple%2520Myeloma%253A%2520Phase%25201b%2520Results%2520%2528ACE-MM-101%2520Study%2529%26jtitle%3DBlood%26date%3D2015%26volume%3D126%26spage%3D3055%26doi%3D10.1182%2Fblood.v126.23.3055.3055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hideshima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paranal, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colling, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estiu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazitschek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, J. A.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Discovery of Selective Small-Molecule HDAC6 Inhibitor for Overcoming Proteasome Inhibitor Resistance in Multiple Myeloma</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">13162</span>– <span class="NLM_lpage">13167</span>, <span class="refDoi"> DOI: 10.1073/pnas.1608067113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1073%2Fpnas.1608067113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=27799547" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslKnu73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2016&pages=13162-13167&author=T.+Hideshimaauthor=J.+Qiauthor=R.+M.+Paranalauthor=W.+Tangauthor=E.+Greenbergauthor=N.+Westauthor=M.+E.+Collingauthor=G.+Estiuauthor=R.+Mazitschekauthor=J.+A.+Perry&title=Discovery+of+Selective+Small-Molecule+HDAC6+Inhibitor+for+Overcoming+Proteasome+Inhibitor+Resistance+in+Multiple+Myeloma&doi=10.1073%2Fpnas.1608067113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma</span></div><div class="casAuthors">Hideshima, Teru; Qi, Jun; Paranal, Ronald M.; Tang, Weiping; Greenberg, Edward; West, Nathan; Colling, Meaghan E.; Estiu, Guillermina; Mazitschek, Ralph; Perry, Jennifer A.; Ohguchi, Hiroto; Cottini, Francesca; Mimura, Naoya; Gorgun, Gullu; Tai, Yu-Tzu; Richardson, Paul G.; Carrasco, Ruben D.; Wiest, Olaf; Schreiber, Stuart L.; Anderson, Kenneth C.; Bradner, James E.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">46</span>),
    <span class="NLM_cas:pages">13162-13167</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Multiple myeloma (MM) has proven clin. susceptible to modulation of pathways of protein homeostasis.  Blockade of proteasomal degrdn. of polyubiquitinated misfolded proteins by the proteasome inhibitor bortezomib (BTZ) achieves responses and prolongs survival in MM, but long-term treatment with BTZ leads to drug-resistant relapse in most patients.  In a proof-of-concept study, the authors previously demonstrated that blocking aggresomal breakdown of polyubiquitinated misfolded proteins with the histone deacetylase 6 (HDAC6) inhibitor tubacin enhances BTZ-induced cytotoxicity in MM cells in vitro.  However, these foundational studies were limited by the pharmacol. liabilities of tubacin as a chem. probe with only in vitro utility.  Emerging from a focused library synthesis, a potent, selective, and bioavailable HDAC6 inhibitor, WT161, was created to study the mechanism of action of HDAC6 inhibition in MM alone and in combination with BTZ.  WT161 in combination with BTZ triggers significant accumulation of polyubiquitinated proteins and cell stress, followed by caspase activation and apoptosis.  More importantly, this combination treatment was effective in BTZ-resistant cells and in the presence of bone marrow stromal cells, which have been shown to mediate MM cell drug resistance.  The activity of WT161 was confirmed in the human MM cell xenograft mouse model and established the framework for clin. trials of the combination treatment to improve patient outcomes in MM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxE_VYaPFUSbVg90H21EOLACvtfcHk0lgno-TW8x_ECg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslKnu73M&md5=2515fcba03631917d0ca7656d1f62a7e</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1608067113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1608067113%26sid%3Dliteratum%253Aachs%26aulast%3DHideshima%26aufirst%3DT.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DParanal%26aufirst%3DR.%2BM.%26aulast%3DTang%26aufirst%3DW.%26aulast%3DGreenberg%26aufirst%3DE.%26aulast%3DWest%26aufirst%3DN.%26aulast%3DColling%26aufirst%3DM.%2BE.%26aulast%3DEstiu%26aufirst%3DG.%26aulast%3DMazitschek%26aufirst%3DR.%26aulast%3DPerry%26aufirst%3DJ.%2BA.%26atitle%3DDiscovery%2520of%2520Selective%2520Small-Molecule%2520HDAC6%2520Inhibitor%2520for%2520Overcoming%2520Proteasome%2520Inhibitor%2520Resistance%2520in%2520Multiple%2520Myeloma%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2016%26volume%3D113%26spage%3D13162%26epage%3D13167%26doi%3D10.1073%2Fpnas.1608067113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, C.</span></span> <span> </span><span class="NLM_article-title">HDAC6 Promotes Cell Proliferation and Confers Resistance to Temozolomide in Glioblastoma</span>. <i>Canc. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>379</i></span>,  <span class="NLM_fpage">134</span>– <span class="NLM_lpage">142</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2016.06.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1016%2Fj.canlet.2016.06.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=27267806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BC28Xptl2hu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=379&publication_year=2016&pages=134-142&author=Z.+Wangauthor=P.+Huauthor=F.+Tangauthor=H.+Lianauthor=X.+Chenauthor=Y.+Zhangauthor=X.+Heauthor=W.+Liuauthor=C.+Xie&title=HDAC6+Promotes+Cell+Proliferation+and+Confers+Resistance+to+Temozolomide+in+Glioblastoma&doi=10.1016%2Fj.canlet.2016.06.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC6 promotes cell proliferation and confers resistance to temozolomide in glioblastoma</span></div><div class="casAuthors">Wang, Zhihao; Hu, Pengchao; Tang, Fang; Lian, Haiwei; Chen, Xiong; Zhang, Yingying; He, Xiaohua; Liu, Wanhong; Xie, Conghua</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">379</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">134-142</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Histone deacetylases are considered to be among the most promising targets in drug development for cancer therapy.  Histone deacetylase 6 (HDAC6) is a unique cytoplasmic enzyme that regulates many biol. processes involved in tumorigenesis through its deacetylase and ubiquitin-binding activities.  Here, we report that HDAC6 is overexpressed in glioblastoma tissues and cell lines.  Overexpression of HDAC6 promotes the proliferation and spheroid formation of glioblastoma cells.  HDAC6 overexpression confers resistance to temozolomide (TMZ) mediated cell proliferation inhibition and apoptosis induction.  Conversely, knockdown of HDAC6 inhibits cell proliferation, impairs spheroid formation and sensitizes glioblastoma cells to TMZ.  The inhibition of HDAC6 deacetylase activity by selective inhibitors inhibits the proliferation of glioblastoma cells and induces apoptosis.  HDAC6 selective inhibitors can sensitize glioblastoma cells to TMZ.  Moreover, we showed that HDAC6 mediated EGFR stabilization might partly account for its oncogenic role in glioblastoma.  TMZ resistant glioblastoma cells showed higher expression of HDAC6 and more activation of EGFR.  HDAC6 inhibitors decrease EGFR protein levels and impair the activation of the EGFR pathway.  Taken together, our results suggest that the inhibition of HDAC6 may be a promising strategy for the treatment of glioblastoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6MAz69kW6cLVg90H21EOLACvtfcHk0ljNEtq5HWbbLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xptl2hu7o%253D&md5=683ba6217cf86e9834fc826be4ddc4fd</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2016.06.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2016.06.001%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DHu%26aufirst%3DP.%26aulast%3DTang%26aufirst%3DF.%26aulast%3DLian%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DXie%26aufirst%3DC.%26atitle%3DHDAC6%2520Promotes%2520Cell%2520Proliferation%2520and%2520Confers%2520Resistance%2520to%2520Temozolomide%2520in%2520Glioblastoma%26jtitle%3DCanc.%2520Lett.%26date%3D2016%26volume%3D379%26spage%3D134%26epage%3D142%26doi%3D10.1016%2Fj.canlet.2016.06.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maharaj, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Achille, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fonseca, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pabon-Saldana, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quayle, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villagra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotomayor, E. M.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Silencing of HDAC6 as a Therapeutic Target in Chronic Lymphocytic Leukemia</span>. <i>Blood Adv.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">3012</span>– <span class="NLM_lpage">3024</span>, <span class="refDoi"> DOI: 10.1182/bloodadvances.2018020065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1182%2Fbloodadvances.2018020065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=30425065" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1aqu7fF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2018&pages=3012-3024&author=K.+Maharajauthor=J.+J.+Powersauthor=A.+Achilleauthor=S.+Dengauthor=R.+Fonsecaauthor=M.+Pabon-Saldanaauthor=S.+N.+Quayleauthor=S.+S.+Jonesauthor=A.+Villagraauthor=E.+M.+Sotomayor&title=Silencing+of+HDAC6+as+a+Therapeutic+Target+in+Chronic+Lymphocytic+Leukemia&doi=10.1182%2Fbloodadvances.2018020065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Silencing of HDAC6 as a therapeutic target in chronic lymphocytic leukemia</span></div><div class="casAuthors">Maharaj, Kamira; Powers, John J.; Achille, Alex; Deng, Susan; Fonseca, Renee; Pabon-Saldana, Mibel; Quayle, Steven N.; Jones, Simon S.; Villagra, Alejandro; Sotomayor, Eduardo M.; Sahakian, Eva; Pinilla-Ibarz, Javier</div><div class="citationInfo"><span class="NLM_cas:title">Blood Advances</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">3012-3024</span>CODEN:
                <span class="NLM_cas:coden">BALDBA</span>;
        ISSN:<span class="NLM_cas:issn">2473-9537</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">We report for the first time that expression of epigenetic modifier histone deacetylase 6 (HDAC6) is upregulated in CLL patient samples, cell lines, and euTCL1 transgenic mouse models compared with HDAC6 in normal controls.  Genetic silencing of HDAC6 conferred survival benefit in euTCL1 mice.  Administration of isoform-specific HDAC6 inhibitor ACY738 in the euTCL1 aging and adoptive transfer models deterred proliferation of CLL B cells, delayed disease onset via disruption of B-cell receptor signaling, and sensitized CLL B cells to apoptosis.  Furthermore, coadministration of ACY738 and ibrutinib displayed synergistic cell kill against CLL cell lines and improved overall survival compared with either single agent in vivo.  These results demonstrate for the first time the therapeutic efficacy of selective HDAC6 inhibition in preclin. CLL models and suggest a rationale for the clin. development of HDAC6 inhibitors for CLL treatment, either alone or in combination with Bruton tyrosine kinase inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0IBtltKjkVrVg90H21EOLACvtfcHk0ljNEtq5HWbbLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1aqu7fF&md5=14a25be6448658246df510db8259c20c</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1182%2Fbloodadvances.2018020065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fbloodadvances.2018020065%26sid%3Dliteratum%253Aachs%26aulast%3DMaharaj%26aufirst%3DK.%26aulast%3DPowers%26aufirst%3DJ.%2BJ.%26aulast%3DAchille%26aufirst%3DA.%26aulast%3DDeng%26aufirst%3DS.%26aulast%3DFonseca%26aufirst%3DR.%26aulast%3DPabon-Saldana%26aufirst%3DM.%26aulast%3DQuayle%26aufirst%3DS.%2BN.%26aulast%3DJones%26aufirst%3DS.%2BS.%26aulast%3DVillagra%26aufirst%3DA.%26aulast%3DSotomayor%26aufirst%3DE.%2BM.%26atitle%3DSilencing%2520of%2520HDAC6%2520as%2520a%2520Therapeutic%2520Target%2520in%2520Chronic%2520Lymphocytic%2520Leukemia%26jtitle%3DBlood%2520Adv.%26date%3D2018%26volume%3D2%26spage%3D3012%26epage%3D3024%26doi%3D10.1182%2Fbloodadvances.2018020065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cosenza, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Civallero, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quayle, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pozzi, S.</span></span> <span> </span><span class="NLM_article-title">Ricolinostat (ACY-1215), a Selective HDAC6 Inhibitor, Alone and in Combination with Bendamustine Is Effective in Preclinical Studies in Lymphoma Cell Lines</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">2772</span>, <span class="refDoi"> DOI: 10.1182/blood.v128.22.2772.2772</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1182%2Fblood.V128.22.2772.2772" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2016&pages=2772&author=M.+Cosenzaauthor=M.+Civalleroauthor=S.+N.+Quayleauthor=S.+Sacchiauthor=S.+Pozzi&title=Ricolinostat+%28ACY-1215%29%2C+a+Selective+HDAC6+Inhibitor%2C+Alone+and+in+Combination+with+Bendamustine+Is+Effective+in+Preclinical+Studies+in+Lymphoma+Cell+Lines&doi=10.1182%2Fblood.v128.22.2772.2772"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1182%2Fblood.V128.22.2772.2772&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.V128.22.2772.2772%26sid%3Dliteratum%253Aachs%26aulast%3DCosenza%26aufirst%3DM.%26aulast%3DCivallero%26aufirst%3DM.%26aulast%3DQuayle%26aufirst%3DS.%2BN.%26aulast%3DSacchi%26aufirst%3DS.%26aulast%3DPozzi%26aufirst%3DS.%26atitle%3DRicolinostat%2520%2528ACY-1215%2529%252C%2520a%2520Selective%2520HDAC6%2520Inhibitor%252C%2520Alone%2520and%2520in%2520Combination%2520with%2520Bendamustine%2520Is%2520Effective%2520in%2520Preclinical%2520Studies%2520in%2520Lymphoma%2520Cell%2520Lines%26jtitle%3DBlood%26date%3D2016%26volume%3D128%26spage%3D2772%26doi%3D10.1182%2Fblood.v128.22.2772.2772" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cosenza, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Civallero, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcheselli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pozzi, S.</span></span> <span> </span><span class="NLM_article-title">Ricolinostat, a Selective HDAC6 Inhibitor, Shows Anti-Lymphoma Cell Activity Alone and in Combination with Bendamustine</span>. <i>Apoptosis</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">827</span>– <span class="NLM_lpage">840</span>, <span class="refDoi"> DOI: 10.1007/s10495-017-1364-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1007%2Fs10495-017-1364-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=28315173" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkslKktr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=827-840&author=M.+Cosenzaauthor=M.+Civalleroauthor=L.+Marcheselliauthor=S.+Sacchiauthor=S.+Pozzi&title=Ricolinostat%2C+a+Selective+HDAC6+Inhibitor%2C+Shows+Anti-Lymphoma+Cell+Activity+Alone+and+in+Combination+with+Bendamustine&doi=10.1007%2Fs10495-017-1364-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine</span></div><div class="casAuthors">Cosenza, Maria; Civallero, Monica; Marcheselli, Luigi; Sacchi, Stefano; Pozzi, Samantha</div><div class="citationInfo"><span class="NLM_cas:title">Apoptosis</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">827-840</span>CODEN:
                <span class="NLM_cas:coden">APOPFN</span>;
        ISSN:<span class="NLM_cas:issn">1360-8185</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Histone deacetylase inhibitors (HDACis) have emerged as a new class of anticancer agents, targeting the biol. process including cell cycle and apoptosis.  We investigated and explained the anticancer effects of an HDAC6 inhibitor, ricolinostat alone and in combination with bendamustine in lymphoma cell lines.  Cell viability was measured by MTT assay.  Apoptosis, reactive oxygen species (ROS) generation, Bcl-2 protein expression, cell cycle progression and tubuline expression were detd. by flow cytometry.  The effects of ricolinostat alone and in combination on the caspases, PI3K/Akt, Bcl-2 pathways, ER stress and UPR were assessed by immunoblotting.  Ricolinostat shows anti lymphoma activity when used as single agent and its capability to induce apoptosis is synergistically potentiated by the bendamustine in lymphoma cell lines.  Drug combination reduced the proportion of cells in the G0/G1 and S phases and caused an increase of "sub-G0/G1" peak.  The synergistic effect accompanied with the increased ROS, activation of caspase-8, -9, and -3, the cleavage of PARP and modulated by Bcl-2 proteins family.  In addn., the exposure of ricolinostat induced the acetylation level of α-tubulin, the extend of which was not further modified by bendamustine.  Finally, the apoptosis effect of ricolinostat/bendamustine may be mediated by a corresponding effect on microtubule stabilization.  Our data suggest that ricolinostat in combination with bendamustine may be a novel combination with potential for use as an antitumor agent in lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhV5zrMw5A6rVg90H21EOLACvtfcHk0ljOtUCEveQdQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkslKktr8%253D&md5=6ac58def2f10c37fe434c78dd074dcfd</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1007%2Fs10495-017-1364-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10495-017-1364-4%26sid%3Dliteratum%253Aachs%26aulast%3DCosenza%26aufirst%3DM.%26aulast%3DCivallero%26aufirst%3DM.%26aulast%3DMarcheselli%26aufirst%3DL.%26aulast%3DSacchi%26aufirst%3DS.%26aulast%3DPozzi%26aufirst%3DS.%26atitle%3DRicolinostat%252C%2520a%2520Selective%2520HDAC6%2520Inhibitor%252C%2520Shows%2520Anti-Lymphoma%2520Cell%2520Activity%2520Alone%2520and%2520in%2520Combination%2520with%2520Bendamustine%26jtitle%3DApoptosis%26date%3D2017%26volume%3D22%26spage%3D827%26epage%3D840%26doi%3D10.1007%2Fs10495-017-1364-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guha, M.</span></span> <span> </span><span class="NLM_article-title">HDAC Inhibitors Still Need a Home Run, despite Recent Approval</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">225</span>– <span class="NLM_lpage">226</span>, <span class="refDoi"> DOI: 10.1038/nrd4583</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1038%2Fnrd4583" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=25829268" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BC2MXls1artLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=225-226&author=M.+Guha&title=HDAC+Inhibitors+Still+Need+a+Home+Run%2C+despite+Recent+Approval&doi=10.1038%2Fnrd4583"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC inhibitors still need a home run, despite recent approval</span></div><div class="casAuthors">Guha, Malini</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">225-226</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A beleaguered class of epigenetic modulators continues to struggle for oncol. success, but new insights into their mechanisms in cancer may yet offer hope.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotdd1X74wEP7Vg90H21EOLACvtfcHk0ljOtUCEveQdQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXls1artLs%253D&md5=011db36451b31bc7d19e8ffab8281af8</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Fnrd4583&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4583%26sid%3Dliteratum%253Aachs%26aulast%3DGuha%26aufirst%3DM.%26atitle%3DHDAC%2520Inhibitors%2520Still%2520Need%2520a%2520Home%2520Run%252C%2520despite%2520Recent%2520Approval%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26spage%3D225%26epage%3D226%26doi%3D10.1038%2Fnrd4583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hubbert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guardiola, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawaguchi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nixon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, T.-P.</span></span> <span> </span><span class="NLM_article-title">HDAC6 Is a Microtubule-Associated Deacetylase</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>417</i></span>,  <span class="NLM_fpage">455</span>– <span class="NLM_lpage">458</span>, <span class="refDoi"> DOI: 10.1038/417455a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1038%2F417455a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=12024216" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BD38XjvVersr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=417&publication_year=2002&pages=455-458&author=C.+Hubbertauthor=A.+Guardiolaauthor=R.+Shaoauthor=Y.+Kawaguchiauthor=A.+Itoauthor=A.+Nixonauthor=M.+Yoshidaauthor=X.-F.+Wangauthor=T.-P.+Yao&title=HDAC6+Is+a+Microtubule-Associated+Deacetylase&doi=10.1038%2F417455a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC6 is a microtubule-associated deacetylase</span></div><div class="casAuthors">Hubbert, Charlotte; Guardiola, Amaris; Shao, Rong; Kawaguchi, Yoshiharu; Ito, Akihiro; Nixon, Andrew; Yoshida, Minoru; Wang, Xiao-Fan; Yao, Tso-Pang</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">417</span>
        (<span class="NLM_cas:issue">6887</span>),
    <span class="NLM_cas:pages">455-458</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Reversible acetylation of α-tubulin has been implicated in regulating microtubule stability and function.  The distribution of acetylated α-tubulin is tightly controlled and stereotypic.  Acetylated α-tubulin is most abundant in stable microtubules but is absent from dynamic cellular structures such as neuronal growth cones and the leading edges of fibroblasts.  However, the enzymes responsible for regulating tubulin acetylation and deacetylation are not known.  Here we report that a member of the histone deacetylase family, HDAC6, functions as a tubulin deacetylase.  HDAC6 is localized exclusively in the cytoplasm, where it assocs. with microtubules and localizes with the microtubule motor complex contg. p150glued.  In vivo, the overexpression of HDAC6 leads to a global deacetylation of α-tubulin, whereas a decrease in HDAC6 increases α-tubulin acetylation.  In vitro, purified HDAC6 potently deacetylates α-tubulin in assembled microtubules.  Furthermore, overexpression of HDAC6 promotes chemotactic cell movement, supporting the idea that HDAC6-mediated deacetylation regulates microtubule-dependent cell motility.  Our results show that HDAC6 is the tubulin deacetylase, and provide evidence that reversible acetylation regulates important biol. processes beyond histone metab. and gene transcription.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp76Er3MrWtO7Vg90H21EOLACvtfcHk0lhMqenxK3nNwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjvVersr4%253D&md5=f18cbb0af388925c606e822358ba3da6</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2F417455a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F417455a%26sid%3Dliteratum%253Aachs%26aulast%3DHubbert%26aufirst%3DC.%26aulast%3DGuardiola%26aufirst%3DA.%26aulast%3DShao%26aufirst%3DR.%26aulast%3DKawaguchi%26aufirst%3DY.%26aulast%3DIto%26aufirst%3DA.%26aulast%3DNixon%26aufirst%3DA.%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DX.-F.%26aulast%3DYao%26aufirst%3DT.-P.%26atitle%3DHDAC6%2520Is%2520a%2520Microtubule-Associated%2520Deacetylase%26jtitle%3DNature%26date%3D2002%26volume%3D417%26spage%3D455%26epage%3D458%26doi%3D10.1038%2F417455a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Catley, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiziltepe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tai, Y.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hideshima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tassone, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atadja, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chauhan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munshi, N. C.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Aggresome Induction by Proteasome Inhibitor Bortezomib and α-Tubulin Hyperacetylation by Tubulin Deacetylase (TDAC) Inhibitor LBH589 Are Synergistic in Myeloma Cells</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">3441</span>– <span class="NLM_lpage">3449</span>, <span class="refDoi"> DOI: 10.1182/blood-2006-04-016055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1182%2Fblood-2006-04-016055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=16728695" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1ahsLzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2006&pages=3441-3449&author=L.+Catleyauthor=E.+Weisbergauthor=T.+Kiziltepeauthor=Y.-T.+Taiauthor=T.+Hideshimaauthor=P.+Neriauthor=P.+Tassoneauthor=P.+Atadjaauthor=D.+Chauhanauthor=N.+C.+Munshi&title=Aggresome+Induction+by+Proteasome+Inhibitor+Bortezomib+and+%CE%B1-Tubulin+Hyperacetylation+by+Tubulin+Deacetylase+%28TDAC%29+Inhibitor+LBH589+Are+Synergistic+in+Myeloma+Cells&doi=10.1182%2Fblood-2006-04-016055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Aggresome induction by proteasome inhibitor bortezomib and α-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells</span></div><div class="casAuthors">Catley, Laurence; Weisberg, Ellen; Kiziltepe, Tanyel; Tai, Yu-Tzu; Hideshima, Teru; Neri, Paola; Tassone, Pierfrancesco; Atadja, Peter; Chauhan, Dharminder; Munshi, Nikhil C.; Anderson, Kenneth C.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3441-3449</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Histone deacetylase (HDAC) inhibitors have shown cytotoxicity as single agents in preclin. studies for multiple myeloma (MM) cells.  LBH589 is a novel hydroxamic acid deriv. that at low nanomolar concns. induces apoptosis in MM cells resistant to conventional therapies via caspase activation and poly-(ADP-ribose) polymerase (PARP) cleavage.  Significant synergistic cytotoxicity was obsd. with LBH589 in combination with bortezomib against MM cells that were sensitive and resistant to dexamethasone (Dex), as well as primary patient MM cells.  LBH589 at low nanomolar concns. also induced α-tubulin hyperacetylation.  Aggresome formation was obsd. in the presence of bortezomib, and the combination of LBH589 plus bortezomib induced the formation of abnormal bundles of hyeracetylated α-tubulin but with diminished aggresome size and apoptotic nuclei.  These data confirm the potential clin. benefit of combining HDAC inhibitors with proteasome inhibitors, and provide insight into the mechanisms of synergistic anti-MM activity of bortezomib in combination with LBH589.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoc6Qs12jXniLVg90H21EOLACvtfcHk0lhMqenxK3nNwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1ahsLzM&md5=3e50cf4c9f257e27dc9beb422963c99d</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1182%2Fblood-2006-04-016055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2006-04-016055%26sid%3Dliteratum%253Aachs%26aulast%3DCatley%26aufirst%3DL.%26aulast%3DWeisberg%26aufirst%3DE.%26aulast%3DKiziltepe%26aufirst%3DT.%26aulast%3DTai%26aufirst%3DY.-T.%26aulast%3DHideshima%26aufirst%3DT.%26aulast%3DNeri%26aufirst%3DP.%26aulast%3DTassone%26aufirst%3DP.%26aulast%3DAtadja%26aufirst%3DP.%26aulast%3DChauhan%26aufirst%3DD.%26aulast%3DMunshi%26aufirst%3DN.%2BC.%26atitle%3DAggresome%2520Induction%2520by%2520Proteasome%2520Inhibitor%2520Bortezomib%2520and%2520%25CE%25B1-Tubulin%2520Hyperacetylation%2520by%2520Tubulin%2520Deacetylase%2520%2528TDAC%2529%2520Inhibitor%2520LBH589%2520Are%2520Synergistic%2520in%2520Myeloma%2520Cells%26jtitle%3DBlood%26date%3D2006%26volume%3D108%26spage%3D3441%26epage%3D3449%26doi%3D10.1182%2Fblood-2006-04-016055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunker, E. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karman, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azofeifa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnett, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wheeler, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toomey, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Genome-Wide Dose-Dependent Inhibition of Histone Deacetylases Studies Reveal Their Roles in Enhancer Remodeling and Suppression of Oncogenic Super-Enhancers</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">1756</span>– <span class="NLM_lpage">1776</span>, <span class="refDoi"> DOI: 10.1093/nar/gkx1225</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1093%2Fnar%2Fgkx1225" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=29240919" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlGisbbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2018&pages=1756-1776&author=G.+J.+Sanchezauthor=P.+A.+Richmondauthor=E.+N.+Bunkerauthor=S.+S.+Karmanauthor=J.+Azofeifaauthor=A.+T.+Garnettauthor=Q.+Xuauthor=G.+E.+Wheelerauthor=C.+M.+Toomeyauthor=Q.+Zhang&title=Genome-Wide+Dose-Dependent+Inhibition+of+Histone+Deacetylases+Studies+Reveal+Their+Roles+in+Enhancer+Remodeling+and+Suppression+of+Oncogenic+Super-Enhancers&doi=10.1093%2Fnar%2Fgkx1225"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Genome-wide dose-dependent inhibition of histone deacetylases studies reveal their roles in enhancer remodeling and suppression of oncogenic super-enhancers</span></div><div class="casAuthors">Sanchez, Gilson J.; Richmond, Phillip A.; Bunker, Eric N.; Karman, Samuel S.; Azofeifa, Joseph; Garnett, Aaron T.; Xu, Quanbin; Wheeler, Graycen E.; Toomey, Cathryn M.; Zhang, Qinghong; Dowell, Robin D.; Liu, Xuedong</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1756-1776</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">1362-4962</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Histone deacetylase inhibitors (HDACIs) are known to alter gene expression by both up- and downregulation of protein-coding genes in normal and cancer cells.  However, the exact regulatory mechanisms of action remain uncharacterized.  Here we investigated genome wide dose-dependent epigenetic and transcriptome changes in response to HDACI largazole in a transformed and a non-transformed cell line.  Exposure to low nanomolar largazole concns. (<GI50) predominantly resulted in upregulation of gene transcripts whereas higher largazole doses (≥GI50) triggered a general decrease in mRNA accumulation.  Largazole induces elevation of histone H3 acetylation at Lys-9 and Lys-27 along many gene bodies but does not correlate with upor down-regulation of the assocd. transcripts.  A higher dose of largazole results in more RNA polymerase II pausing at the promoters of actively transcribed genes and cell death.  The most prevalent changes assocd. with transcriptional regulation occur at distal enhancer elements.  Largazole promotes H3K27 acetylation at a subset of poised enhancers and unexpectedly, we also found active enhancers that become decommissioned in a dose and cell type-dependent manner.  In particular, largazole decreases RNA polymerase II accumulation at superenhancers (SEs) and preferentially suppresses SEdriven transcripts that are assocd. with oncogenic activities in transformed cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2YBkoOboN_LVg90H21EOLACvtfcHk0lg9o-6mIiP2_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlGisbbN&md5=12517cc4cf615407f6f9698cde886e38</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkx1225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkx1225%26sid%3Dliteratum%253Aachs%26aulast%3DSanchez%26aufirst%3DG.%2BJ.%26aulast%3DRichmond%26aufirst%3DP.%2BA.%26aulast%3DBunker%26aufirst%3DE.%2BN.%26aulast%3DKarman%26aufirst%3DS.%2BS.%26aulast%3DAzofeifa%26aufirst%3DJ.%26aulast%3DGarnett%26aufirst%3DA.%2BT.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DWheeler%26aufirst%3DG.%2BE.%26aulast%3DToomey%26aufirst%3DC.%2BM.%26aulast%3DZhang%26aufirst%3DQ.%26atitle%3DGenome-Wide%2520Dose-Dependent%2520Inhibition%2520of%2520Histone%2520Deacetylases%2520Studies%2520Reveal%2520Their%2520Roles%2520in%2520Enhancer%2520Remodeling%2520and%2520Suppression%2520of%2520Oncogenic%2520Super-Enhancers%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2018%26volume%3D46%26spage%3D1756%26epage%3D1776%26doi%3D10.1093%2Fnar%2Fgkx1225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lue, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prabhu, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mundi, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abshiru, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camarillo, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, E. I.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">5271</span>– <span class="NLM_lpage">5283</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.ccr-18-3989</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1158%2F1078-0432.CCR-18-3989" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=30979734" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BB3cXltVegt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2019&pages=5271-5283&author=J.+K.+Lueauthor=S.+A.+Prabhuauthor=Y.+Liuauthor=Y.+Gonzalezauthor=A.+Vermaauthor=P.+S.+Mundiauthor=N.+Abshiruauthor=J.+M.+Camarilloauthor=S.+Mehtaauthor=E.+I.+Chen&title=Precision+Targeting+with+EZH2+and+HDAC+Inhibitors+in+Epigenetically+Dysregulated+Lymphomas&doi=10.1158%2F1078-0432.ccr-18-3989"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Precision targeting with EZH2 and HDAC inhibitors in epigenetically dysregulated lymphomas</span></div><div class="casAuthors">Lue, Jennifer K.; Prabhu, Sathyen A.; Liu, Yuxuan; Gonzalez, Yulissa; Verma, Akanksha; Mundi, Prabhjot S.; Abshiru, Nebiyu; Camarillo, Jeannie M.; Mehta, Swasti; Chen, Emily I.; Qiao, Changhong; Nandakumar, Renu; Cremers, Serge; Kelleher, Neil L.; Elemento, Olivier; Amengual, Jennifer E.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5271-5283</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Both gain-of-function enhancer of zeste homolog 2 (EZH2) mutations and inactivating histone acetyltransferases mutations, such as CREBBP and EP300, have been implicated in the pathogenesis of germinal center (GC)-derived lymphomas.  We hypothesized that direct inhibition of EZH2 and histone deacetyltransferase (HDAC) would be synergistic in GC-derived lymphomas.  Exptl. Design: Lymphoma cell lines (n = 21) were exposed to GSK126, an EZH2 inhibitor, and romidepsin, a pan-HDAC inhibitor.  Synergy was assessed by excess over bliss.  Western blot, mass spectrometry, and coimmunopptn. were performed.  A SU-DHL-10 xenograft model was utilized to validate in vitro findings.  Pretreatment RNA-sequencing of cell lines was performed.  MetaVIPER anal. was used to infer protein activity.  Results: Exposure to GSK126 and romidepsin demonstrated potent synergy in lymphoma cell lines with EZH2 dysregulation.  Combination of romidepsin with other EZH2 inhibitors also demonstrated synergy suggesting a class effect of EZH2 inhibition with romidepsin.  Dual inhibition of EZH2 and HDAC led to modulation of acetylation and methylation of H3K27.  The synergistic effects of the combination were due to disruption of the PRC2 complex secondary to acetylation of RbAP 46/48.  A common basal gene signature was shared among synergistic lymphoma cell lines and was characterized by upregulation in chromatin remodeling genes and transcriptional regulators.  This finding was supported by metaVIPER anal. which also revealed that HDAC 1/2 and DNA methyltransferase were assocd. with EZH2 activation.  Conclusions: Inhibition of EZH2 and HDAC is synergistic and leads to the dissocn. of PRC2 complex.  Our findings support the clin. translation of the combination of EZH2 and HDAC inhibition in EZH2 dysregulated lymphomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqpLROkJyGLLVg90H21EOLACvtfcHk0lg9o-6mIiP2_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXltVegt7c%253D&md5=c0a9c8babc8838b2b1c629e6578f9456</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-18-3989&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-18-3989%26sid%3Dliteratum%253Aachs%26aulast%3DLue%26aufirst%3DJ.%2BK.%26aulast%3DPrabhu%26aufirst%3DS.%2BA.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DGonzalez%26aufirst%3DY.%26aulast%3DVerma%26aufirst%3DA.%26aulast%3DMundi%26aufirst%3DP.%2BS.%26aulast%3DAbshiru%26aufirst%3DN.%26aulast%3DCamarillo%26aufirst%3DJ.%2BM.%26aulast%3DMehta%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DE.%2BI.%26atitle%3DPrecision%2520Targeting%2520with%2520EZH2%2520and%2520HDAC%2520Inhibitors%2520in%2520Epigenetically%2520Dysregulated%2520Lymphomas%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2019%26volume%3D25%26spage%3D5271%26epage%3D5283%26doi%3D10.1158%2F1078-0432.ccr-18-3989" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villani, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, X.</span></span> <span> </span><span class="NLM_article-title">The Role of Cellular Reactive Oxygen Species in Cancer Chemotherapy</span>. <i>J. Exp. Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">266</span>, <span class="refDoi"> DOI: 10.1186/s13046-018-0909-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1186%2Fs13046-018-0909-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=30382874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BC1MXptlWnsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2018&pages=266&author=H.+Yangauthor=R.+M.+Villaniauthor=H.+Wangauthor=M.+J.+Simpsonauthor=M.+S.+Robertsauthor=M.+Tangauthor=X.+Liang&title=The+Role+of+Cellular+Reactive+Oxygen+Species+in+Cancer+Chemotherapy&doi=10.1186%2Fs13046-018-0909-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">The role of cellular reactive oxygen species in cancer chemotherapy</span></div><div class="casAuthors">Yang, Haotian; Villani, Rehan M.; Wang, Haolu; Simpson, Matthew J.; Roberts, Michael S.; Tang, Min; Liang, Xiaowen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental & Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">266</span>CODEN:
                <span class="NLM_cas:coden">JECRDN</span>;
        ISSN:<span class="NLM_cas:issn">1756-9966</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Most chemotherapeutics elevate intracellular levels of reactive oxygen species (ROS), and many can alter redox-homeostasis of cancer cells.  It is widely accepted that the anticancer effect of these chemotherapeutics is due to the induction of oxidative stress and ROS-mediated cell injury in cancer.  However, various new therapeutic approaches targeting intracellular ROS levels have yielded mixed results.  Since it is impossible to quant. detect dynamic ROS levels in tumors during and after chemotherapy in clin. settings, it is of increasing interest to apply math. modeling techniques to predict ROS levels for understanding complex tumor biol. during chemotherapy.  This review outlines the current understanding of the role of ROS in cancer cells during carcinogenesis and during chemotherapy, provides a crit. anal. of the methods used for quant. ROS detection and discusses the application of math. modeling in predicting treatment responses.  Finally, we provide insights on and perspectives for future development of effective therapeutic ROS-inducing anticancer agents or antioxidants for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq93LfhPJogR7Vg90H21EOLACvtfcHk0lh8lBgffS3LGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXptlWnsbg%253D&md5=f790a63bc1d67df0a465872a166fa378</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1186%2Fs13046-018-0909-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13046-018-0909-x%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DH.%26aulast%3DVillani%26aufirst%3DR.%2BM.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DSimpson%26aufirst%3DM.%2BJ.%26aulast%3DRoberts%26aufirst%3DM.%2BS.%26aulast%3DTang%26aufirst%3DM.%26aulast%3DLiang%26aufirst%3DX.%26atitle%3DThe%2520Role%2520of%2520Cellular%2520Reactive%2520Oxygen%2520Species%2520in%2520Cancer%2520Chemotherapy%26jtitle%3DJ.%2520Exp.%2520Clin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D37%26spage%3D266%26doi%3D10.1186%2Fs13046-018-0909-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jayavelu, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Böhmer, S.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lässig, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerny-Reiterer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sperr, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valent, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriggl, R.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">NOX4-Driven ROS Formation Mediates PTP Inactivation and Cell Transformation in FLT3ITD-Positive AML Cells</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">473</span>– <span class="NLM_lpage">483</span>, <span class="refDoi"> DOI: 10.1038/leu.2015.234</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1038%2Fleu.2015.234" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=26308771" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsF2ru7rJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=473-483&author=A.+K.+Jayaveluauthor=J.+P.+M%C3%BCllerauthor=R.+Bauerauthor=S.-A.+B%C3%B6hmerauthor=J.+L%C3%A4ssigauthor=S.+Cerny-Reitererauthor=W.+R.+Sperrauthor=P.+Valentauthor=B.+Maurerauthor=R.+Moriggl&title=NOX4-Driven+ROS+Formation+Mediates+PTP+Inactivation+and+Cell+Transformation+in+FLT3ITD-Positive+AML+Cells&doi=10.1038%2Fleu.2015.234"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">NOX4-driven ROS formation mediates PTP inactivation and cell transformation in FLT3ITD-positive AML cells</span></div><div class="casAuthors">Jayavelu, A. K.; Mueller, J. P.; Bauer, R.; Boehmer, S.-A.; Laessig, J.; Cerny-Reiterer, S.; Sperr, W. R.; Valent, P.; Maurer, B.; Moriggl, R.; Schroeder, K.; Shah, A. M.; Fischer, M.; Scholl, S.; Barth, J.; Oellerich, T.; Berg, T.; Serve, H.; Frey, S.; Fischer, T.; Heidel, F. H.; Boehmer, F.-D.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">473-483</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Activating mutations of FMS-like tyrosine kinase 3 (FLT3), notably internal tandem duplications (ITDs), are assocd. with a grave prognosis in acute myeloid leukemia (AML).  Transforming FLT3ITD signal transduction causes formation of reactive oxygen species (ROS) and inactivation of the protein-tyrosine phosphatase (PTP) DEP-1/PTPRJ, a neg. regulator of FLT3 signaling.  Here we addressed the underlying mechanisms and biol. consequences.  NADPH oxidase 4 (NOX4) mRNA and protein expression was found to be elevated in FLT3ITD-pos. cells and to depend on FLT3ITD signaling and STAT5-mediated activation of the NOX4 promoter.  NOX4 knockdown reduced ROS levels, restored DEP-1 PTP activity and attenuated FLT3ITD-driven transformation.  Moreover, Nox4 knockout (Nox4-/-) murine hematopoietic progenitor cells were refractory to FLT3ITD-mediated transformation in vitro.  Development of a myeloproliferative-like disease (MPD) caused by FLT3ITD-transformed 32D cells in C3H/HeJ mice, and of a leukemia-like disease in mice transplanted with MLL-AF9/ FLT3ITD-transformed murine hematopoietic stem cells were strongly attenuated by NOX4 downregulation.  NOX4-targeting compds. were found to counteract proliferation of FLT3ITD-pos. AML blasts and MPD development in mice.  These findings reveal a previously unrecognized mechanism of oncoprotein-driven PTP oxidn., and suggest that interference with FLT3ITD-STAT5-NOX4-mediated overprodn. of ROS and PTP inactivation may have therapeutic potential in a subset of AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlyRxwdJm4YLVg90H21EOLACvtfcHk0lh8lBgffS3LGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsF2ru7rJ&md5=c002a51936b7f1fad8c49b2a2910dfab</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1038%2Fleu.2015.234&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2015.234%26sid%3Dliteratum%253Aachs%26aulast%3DJayavelu%26aufirst%3DA.%2BK.%26aulast%3DM%25C3%25BCller%26aufirst%3DJ.%2BP.%26aulast%3DBauer%26aufirst%3DR.%26aulast%3DB%25C3%25B6hmer%26aufirst%3DS.-A.%26aulast%3DL%25C3%25A4ssig%26aufirst%3DJ.%26aulast%3DCerny-Reiterer%26aufirst%3DS.%26aulast%3DSperr%26aufirst%3DW.%2BR.%26aulast%3DValent%26aufirst%3DP.%26aulast%3DMaurer%26aufirst%3DB.%26aulast%3DMoriggl%26aufirst%3DR.%26atitle%3DNOX4-Driven%2520ROS%2520Formation%2520Mediates%2520PTP%2520Inactivation%2520and%2520Cell%2520Transformation%2520in%2520FLT3ITD-Positive%2520AML%2520Cells%26jtitle%3DLeukemia%26date%3D2016%26volume%3D30%26spage%3D473%26epage%3D483%26doi%3D10.1038%2Fleu.2015.234" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claret, F. X.</span></span> <span> </span><span class="NLM_article-title">Novel Roles of Reactive Oxygen Species in the Pathogenesis of Acute Myeloid Leukemia</span>. <i>J. Leukocyte Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">423</span>– <span class="NLM_lpage">429</span>, <span class="refDoi"> DOI: 10.1189/jlb.0113006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1189%2Fjlb.0113006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=23715741" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlyqu7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2013&pages=423-429&author=F.+Zhouauthor=Q.+Shenauthor=F.+X.+Claret&title=Novel+Roles+of+Reactive+Oxygen+Species+in+the+Pathogenesis+of+Acute+Myeloid+Leukemia&doi=10.1189%2Fjlb.0113006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Novel roles of reactive oxygen species in the pathogenesis of acute myeloid leukemia</span></div><div class="casAuthors">Zhou, Fuling; Shen, Qiang; Claret, Francois X.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Leukocyte Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">423-429</span>CODEN:
                <span class="NLM_cas:coden">JLBIE7</span>;
        ISSN:<span class="NLM_cas:issn">0741-5400</span>.
    
            (<span class="NLM_cas:orgname">Society for Leukocyte Biology</span>)
        </div><div class="casAbstract">A review.  It has become apparent that regulation of ROS is important in cell signaling and homeostasis.  Accumulation of ROS triggers oxidative stress in various cell types and contributes to the development, progression, and persistence of cancer.  Recent research has demonstrated that redox dysregulation caused by ROS promotes proliferation, differentiation, genomic, and epigenetic alterations; immune evasion; and survival in leukemic cells.  ROS act as signaling mols. to regulate redox-sensitive transcriptional factors, enzymes, oncogenes, and other downstream effectors.  Thus, a thorough understanding the role of ROS as key mediators in leukemogenesis is likely to provide opportunities for improved pharmacol. intervention.  In this review, we summarize the recent findings that support a role for ROS in the pathogenesis of AML and outline innovative approaches in the implementation of redox therapies for myeloid malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEUyDAttsKZrVg90H21EOLACvtfcHk0lgeFOaKiAUllA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlyqu7nK&md5=b72a5fde8eb9a10bca275795f9ce3d2e</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1189%2Fjlb.0113006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1189%252Fjlb.0113006%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DF.%26aulast%3DShen%26aufirst%3DQ.%26aulast%3DClaret%26aufirst%3DF.%2BX.%26atitle%3DNovel%2520Roles%2520of%2520Reactive%2520Oxygen%2520Species%2520in%2520the%2520Pathogenesis%2520of%2520Acute%2520Myeloid%2520Leukemia%26jtitle%3DJ.%2520Leukocyte%2520Biol.%26date%3D2013%26volume%3D94%26spage%3D423%26epage%3D429%26doi%3D10.1189%2Fjlb.0113006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eckschlager, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stiborova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hrabeta, J.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase Inhibitors as Anticancer Drugs</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1414</span>, <span class="refDoi"> DOI: 10.3390/ijms18071414</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.3390%2Fijms18071414" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=28671573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVGgt73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=1414&author=T.+Eckschlagerauthor=J.+Plchauthor=M.+Stiborovaauthor=J.+Hrabeta&title=Histone+Deacetylase+Inhibitors+as+Anticancer+Drugs&doi=10.3390%2Fijms18071414"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors as anticancer drugs</span></div><div class="casAuthors">Eckschlager, Tomas; Plch, Johana; Stiborova, Marie; Hrabeta, Jan</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1414/1-1414/25</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Carcinogenesis cannot be explained only by genetic alterations, but also involves epigenetic processes.  Modification of histones by acetylation plays a key role in epigenetic regulation of gene expression and is controlled by the balance between histone deacetylases (HDAC) and histone acetyltransferases (HAT).  HDAC inhibitors induce cancer cell cycle arrest, differentiation and cell death, reduce angiogenesis and modulate immune response.  Mechanisms of anticancer effects of HDAC inhibitors are not uniform; they may be different and depend on the cancer type, HDAC inhibitors, doses, etc.  HDAC inhibitors seem to be promising anti-cancer drugs particularly in the combination with other anti-cancer drugs and/or radiotherapy.  HDAC inhibitors vorinostat, romidepsin and belinostat have been approved for some T-cell lymphoma and panobinostat for multiple myeloma.  Other HDAC inhibitors are in clin. trials for the treatment of hematol. and solid malignancies.  The results of such studies are promising but further larger studies are needed.  Because of the reversibility of epigenetic changes during cancer development, the potency of epigenetic therapies seems to be of great importance.  Here, we summarize the data on different classes of HDAC inhibitors, mechanisms of their actions and discuss novel results of preclin. and clin. studies, including the combination with other therapeutic modalities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPNVhoLBAHnrVg90H21EOLACvtfcHk0lgeFOaKiAUllA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVGgt73P&md5=6018c7709a09548214bfe34bd91107a9</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.3390%2Fijms18071414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms18071414%26sid%3Dliteratum%253Aachs%26aulast%3DEckschlager%26aufirst%3DT.%26aulast%3DPlch%26aufirst%3DJ.%26aulast%3DStiborova%26aufirst%3DM.%26aulast%3DHrabeta%26aufirst%3DJ.%26atitle%3DHistone%2520Deacetylase%2520Inhibitors%2520as%2520Anticancer%2520Drugs%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2017%26volume%3D18%26spage%3D1414%26doi%3D10.3390%2Fijms18071414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Debeb, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacerda, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolfe, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnamurthy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reuben, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueno, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilcrease, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodward, W. A.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase Inhibitor-Induced Cancer Stem Cells Exhibit High Pentose Phosphate Pathway Metabolism</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">28329</span>– <span class="NLM_lpage">28339</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.8631</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.18632%2Foncotarget.8631" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=27078845" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A280%3ADC%252BC28fpvVeiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=28329-28339&author=B.+G.+Debebauthor=L.+Lacerdaauthor=R.+Larsonauthor=A.+R.+Wolfeauthor=S.+Krishnamurthyauthor=J.+M.+Reubenauthor=N.+T.+Uenoauthor=M.+Gilcreaseauthor=W.+A.+Woodward&title=Histone+Deacetylase+Inhibitor-Induced+Cancer+Stem+Cells+Exhibit+High+Pentose+Phosphate+Pathway+Metabolism&doi=10.18632%2Foncotarget.8631"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitor-induced cancer stem cells exhibit high pentose phosphate pathway metabolism</span></div><div class="casAuthors">Debeb Bisrat G; Lacerda Lara; Larson Richard; Wolfe Adam R; Woodward Wendy A; Debeb Bisrat G; Lacerda Lara; Larson Richard; Wolfe Adam R; Krishnamurthy Savitri; Reuben James M; Ueno Naoto T; Woodward Wendy A; Krishnamurthy Savitri; Gilcrease Michael; Reuben James M; Ueno Naoto T</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">28329-39</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  We recently demonstrated that histone deacetylase (HDAC) inhibitors can "reprogram" differentiated triple-negative breast cancer cells to become quiescent stem-like cancer cells.  We hypothesized that the metabolic state of such cells differs from that of their differentiated progeny.  RESULTS:  In untreated cells, glucose uptake was higher in ALDH+ cells than in ALDH- cells (p = 0.01) but lactate production was not different; treating ALDH- or ALDH+ cells with VA or SAHA similarly increased glucose uptake without changing lactate production but upregulated G6PD, a rate-limiting enzyme in pentose phosphate pathway metabolism.  NADPH production was higher in HDAC inhibitor-treated stem-like cells than in vehicle-treated cells (p < 0.05).  Two G6PD inhibitors, 6-aminonicotinamide and dehydroepiandrosterone, decreased mammosphere formation efficiency and ALDH activity and 6-aminonicotinamide reduced the VA-induced increase in ALDH+ cells.  Finally, patients expressing high G6PD mRNA had significantly worse overall survival (p < 0.001), and patients with high G6PD protein showed a similar trend towards worse disease-specific survival (p = 0.06).  METHODS:  Glucose consumption, lactate and NADPH production, and reactive oxygen species generation were compared in aldehyde dehydrogenase (ALDH)-positive and -negative cells in the presence or absence of the HDAC inhibitors valproic acid (VA) or suberoylanilide hydroxamic acid (SAHA).  Glucose-6-phosphate dehydrogenase (G6PD) expression was evaluated in a tissue microarray from 94 patients with node-positive invasive breast carcinoma and in two publically available databases and correlated with overall survival.  CONCLUSIONS:  Energy metabolism in HDAC inhibitor-induced stem-like cancer cells differed sharply from that of differentiated cell types.  HDAC inhibitor-induced dedifferentiation promoted metabolic reprogramming into the pentose phosphate pathway, which is targeted effectively by G6PD inhibition.  These findings highlight a potential dual-therapy approach to targeting bulk differentiated cells with HDAC inhibitors and CSCs with G6PD inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcReIsQmOZOPkzW1zwg2yUK5fW6udTcc2eaSTZ7IiJ23DLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28fpvVeiuw%253D%253D&md5=4570baed154999960cf18e0478566516</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.8631&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.8631%26sid%3Dliteratum%253Aachs%26aulast%3DDebeb%26aufirst%3DB.%2BG.%26aulast%3DLacerda%26aufirst%3DL.%26aulast%3DLarson%26aufirst%3DR.%26aulast%3DWolfe%26aufirst%3DA.%2BR.%26aulast%3DKrishnamurthy%26aufirst%3DS.%26aulast%3DReuben%26aufirst%3DJ.%2BM.%26aulast%3DUeno%26aufirst%3DN.%2BT.%26aulast%3DGilcrease%26aufirst%3DM.%26aulast%3DWoodward%26aufirst%3DW.%2BA.%26atitle%3DHistone%2520Deacetylase%2520Inhibitor-Induced%2520Cancer%2520Stem%2520Cells%2520Exhibit%2520High%2520Pentose%2520Phosphate%2520Pathway%2520Metabolism%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26spage%3D28329%26epage%3D28339%26doi%3D10.18632%2Foncotarget.8631" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Valdez, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brammer, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosing, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nieto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Champlin, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, B. S.</span></span> <span> </span><span class="NLM_article-title">Romidepsin Targets Multiple Survival Signaling Pathways in Malignant T Cells</span>. <i>Blood Canc. J.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>, <span class="NLM_elocation-id">e357</span> <span class="refDoi"> DOI: 10.1038/bcj.2015.83</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1038%2Fbcj.2015.83" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=26473529" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&author=B.+C.+Valdezauthor=J.+E.+Brammerauthor=Y.+Liauthor=D.+Murrayauthor=Y.+Liuauthor=C.+Hosingauthor=Y.+Nietoauthor=R.+E.+Champlinauthor=B.+S.+Andersson&title=Romidepsin+Targets+Multiple+Survival+Signaling+Pathways+in+Malignant+T+Cells&doi=10.1038%2Fbcj.2015.83"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1038%2Fbcj.2015.83&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbcj.2015.83%26sid%3Dliteratum%253Aachs%26aulast%3DValdez%26aufirst%3DB.%2BC.%26aulast%3DBrammer%26aufirst%3DJ.%2BE.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DMurray%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DHosing%26aufirst%3DC.%26aulast%3DNieto%26aufirst%3DY.%26aulast%3DChamplin%26aufirst%3DR.%2BE.%26aulast%3DAndersson%26aufirst%3DB.%2BS.%26atitle%3DRomidepsin%2520Targets%2520Multiple%2520Survival%2520Signaling%2520Pathways%2520in%2520Malignant%2520T%2520Cells%26jtitle%3DBlood%2520Canc.%2520J.%26date%3D2015%26volume%3D5%26doi%3D10.1038%2Fbcj.2015.83" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Freisleben, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brudny-Klöppel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulder, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Vries, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Zwart, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timmerman, P.</span></span> <span> </span><span class="NLM_article-title">Blood Stability Testing: European Bioanalysis Forum View on Current Challenges for Regulated Bioanalysis</span>. <i>Bioanalysis</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1333</span>– <span class="NLM_lpage">1336</span>, <span class="refDoi"> DOI: 10.4155/bio.11.121</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.4155%2Fbio.11.121" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=21679027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BC3MXns1Shtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=1333-1336&author=A.+Freislebenauthor=M.+Brudny-Kl%C3%B6ppelauthor=H.+Mulderauthor=R.+De+Vriesauthor=M.+De+Zwartauthor=P.+Timmerman&title=Blood+Stability+Testing%3A+European+Bioanalysis+Forum+View+on+Current+Challenges+for+Regulated+Bioanalysis&doi=10.4155%2Fbio.11.121"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Blood stability testing: European Bioanalysis Forum view on current challenges for regulated bioanalysis</span></div><div class="casAuthors">Freisleben, Achim; Brudny-Kloeoeppel, Margarete; Mulder, Hans; de Vries, Ronald; de Zwart, Marcel; Timmerman, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Bioanalysis</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1333-1336</span>CODEN:
                <span class="NLM_cas:coden">BIOAB4</span>;
        ISSN:<span class="NLM_cas:issn">1757-6180</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">Since 2008, blood stability testing has gained considerable attention in the European Bioanal. Forum (EBF) with discussions aiming to align processes, timing and reporting of analyte stability testing in blood as part of method development and validation.  In this recommendation, EBF summarizes the conclusions reached to date and aims to provide recommendation for the exptl. conduct of such assays as well as the inclusion of stability testing into the scope of method development and validation.  Besides considering a step-wise approach for blood stability testing, recommendation is made to analyze the blood fraction using a qualified assay in order to circumvent important exptl. hurdles.  This article will provide an increased understanding of the impact of blood stability testing but furthermore invites scientists to share their views in order to refine the thinking to reach a global harmonized view.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmPhqXZlITKbVg90H21EOLACvtfcHk0liWZdBKamBbTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXns1Shtrc%253D&md5=366af8b550deb578f763c77e4d84b899</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.4155%2Fbio.11.121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Fbio.11.121%26sid%3Dliteratum%253Aachs%26aulast%3DFreisleben%26aufirst%3DA.%26aulast%3DBrudny-Kl%25C3%25B6ppel%26aufirst%3DM.%26aulast%3DMulder%26aufirst%3DH.%26aulast%3DDe%2BVries%26aufirst%3DR.%26aulast%3DDe%2BZwart%26aufirst%3DM.%26aulast%3DTimmerman%26aufirst%3DP.%26atitle%3DBlood%2520Stability%2520Testing%253A%2520European%2520Bioanalysis%2520Forum%2520View%2520on%2520Current%2520Challenges%2520for%2520Regulated%2520Bioanalysis%26jtitle%3DBioanalysis%26date%3D2011%26volume%3D3%26spage%3D1333%26epage%3D1336%26doi%3D10.4155%2Fbio.11.121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sugihara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitamura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatsumi, K.</span></span> <span> </span><span class="NLM_article-title">Reduction of Hydroxamic Acids to the Corresponding Amides Catalyzed by Rabbit Blood</span>. <i>Xenobiotica</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">457</span>– <span class="NLM_lpage">467</span>, <span class="refDoi"> DOI: 10.1080/004982500237479</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1080%2F004982500237479" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10875680" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BD3cXktF2ltbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2000&pages=457-467&author=K.+Sugiharaauthor=S.+Kitamuraauthor=S.+Ohtaauthor=K.+Tatsumi&title=Reduction+of+Hydroxamic+Acids+to+the+Corresponding+Amides+Catalyzed+by+Rabbit+Blood&doi=10.1080%2F004982500237479"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Reduction of hydroxamic acids to the corresponding amides catalyzed by rabbit blood</span></div><div class="casAuthors">Sugihara, K.; Kitamura, S.; Ohta, S.; Tatsumi, K.</div><div class="citationInfo"><span class="NLM_cas:title">Xenobiotica</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">457-467</span>CODEN:
                <span class="NLM_cas:coden">XENOBH</span>;
        ISSN:<span class="NLM_cas:issn">0049-8254</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">The hydroxamic acids N-hydroxyphenacetin and N-hydroxy-2-acetylamino-fluorene were reduced to the corresponding amides, phenacetin and 2-acetylaminofluorene resp. by rabbit blood supplemented with both NAD(P)H and FAD.  These reducing activities were found in erythrocytes but not in plasma, and were sensitive to inhibition by carbon monoxide and oxygen.  When blood or erythrocytes were boiled, these activities were not abolished.  Hemoproteins such as Hb and catalase exhibited the reductase activity in the presence of both NAD(P)H and FAD under anaerobic conditions.  The activity was not abolished when the hemoproteins were boiled.  Hematin showed a significant reducing activity in the presence of these cofactors.  The activity of hematin was also obsd. with the photochem. reduced form of FAD.  The redn. system in blood was composed of NAD(P)H, FAD and Hb.  Redn. appears to proceed in two steps, i.e. the redn. of FAD by NADH or NADPH, followed by the non-enzymic redn. of the hydroxamic acids to the amides by reduce FAD, catalyzed by the hem group of Hb in rabbit erythrocytes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgLx6hWIY9CLVg90H21EOLACvtfcHk0lgg2lO2EBaxfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXktF2ltbk%253D&md5=4c17b4499a670cb515c3c94edc4757ef</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1080%2F004982500237479&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F004982500237479%26sid%3Dliteratum%253Aachs%26aulast%3DSugihara%26aufirst%3DK.%26aulast%3DKitamura%26aufirst%3DS.%26aulast%3DOhta%26aufirst%3DS.%26aulast%3DTatsumi%26aufirst%3DK.%26atitle%3DReduction%2520of%2520Hydroxamic%2520Acids%2520to%2520the%2520Corresponding%2520Amides%2520Catalyzed%2520by%2520Rabbit%2520Blood%26jtitle%3DXenobiotica%26date%3D2000%26volume%3D30%26spage%3D457%26epage%3D467%26doi%3D10.1080%2F004982500237479" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hermant, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosc, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piveteau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gealageas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ronco, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roignant, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolojanahary, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jean, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renard, P.-Y.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Controlling Plasma Stability of Hydroxamic Acids: A MedChem Toolbox</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">9067</span>– <span class="NLM_lpage">9089</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01444</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01444" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1amurbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=9067-9089&author=P.+Hermantauthor=D.+Boscauthor=C.+Piveteauauthor=R.+Gealageasauthor=B.+Lamauthor=C.+Roncoauthor=M.+Roignantauthor=H.+Tolojanaharyauthor=L.+Jeanauthor=P.-Y.+Renard&title=Controlling+Plasma+Stability+of+Hydroxamic+Acids%3A+A+MedChem+Toolbox&doi=10.1021%2Facs.jmedchem.7b01444"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Controlling Plasma Stability of Hydroxamic Acids: A MedChem Toolbox</span></div><div class="casAuthors">Hermant, Paul; Bosc, Damien; Piveteau, Catherine; Gealageas, Ronan; Lam, BaoVy; Ronco, Cyril; Roignant, Matthieu; Tolojanahary, Hasina; Jean, Ludovic; Renard, Pierre-Yves; Lemdani, Mohamed; Bourotte, Marilyne; Herledan, Adrien; Bedart, Corentin; Biela, Alexandre; Leroux, Florence; Deprez, Benoit; Deprez-Poulain, Rebecca</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9067-9089</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Hydroxamic acids are outstanding zinc chelating groups that can be used to design potent and selective metalloenzyme inhibitors in various therapeutic areas.  Some hydroxamic acids display a high plasma clearance resulting in poor in vivo activity, though they may be very potent compds. in vitro.  The authors designed a 57-member library of hydroxamic acids to explore the structure-plasma stability relationships in these series and to identify which enzyme(s) and which pharmacophores are crit. for plasma stability.  Arylesterases and carboxylesterases were identified as the main metabolic enzymes for hydroxamic acids.  Finally, the authors suggest structural features to be introduced or removed to improve stability.  This work thus provides the first medicinal chem. toolbox (exptl. procedures and structural guidance) to assess and control the plasma stability of hydroxamic acids and realize their full potential as in vivo pharmacol. probes and therapeutic agents.  This study is particularly relevant to preclin. development as it allows obtaining compds. equally stable in human and rodent models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpp13iDBW5DnrVg90H21EOLACvtfcHk0lgg2lO2EBaxfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1amurbE&md5=a7314d840db2c12c7fb769d0b8d52236</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01444&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01444%26sid%3Dliteratum%253Aachs%26aulast%3DHermant%26aufirst%3DP.%26aulast%3DBosc%26aufirst%3DD.%26aulast%3DPiveteau%26aufirst%3DC.%26aulast%3DGealageas%26aufirst%3DR.%26aulast%3DLam%26aufirst%3DB.%26aulast%3DRonco%26aufirst%3DC.%26aulast%3DRoignant%26aufirst%3DM.%26aulast%3DTolojanahary%26aufirst%3DH.%26aulast%3DJean%26aufirst%3DL.%26aulast%3DRenard%26aufirst%3DP.-Y.%26atitle%3DControlling%2520Plasma%2520Stability%2520of%2520Hydroxamic%2520Acids%253A%2520A%2520MedChem%2520Toolbox%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D9067%26epage%3D9089%26doi%3D10.1021%2Facs.jmedchem.7b01444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flipo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hocine, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dassonneville, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deprez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deprez-Poulain, R.</span></span> <span> </span><span class="NLM_article-title">Hydroxamates: Relationships between Structure and Plasma Stability</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">6790</span>– <span class="NLM_lpage">6802</span>, <span class="refDoi"> DOI: 10.1021/jm900648x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900648x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1GgsbnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6790-6802&author=M.+Flipoauthor=J.+Chartonauthor=A.+Hocineauthor=S.+Dassonnevilleauthor=B.+Deprezauthor=R.+Deprez-Poulain&title=Hydroxamates%3A+Relationships+between+Structure+and+Plasma+Stability&doi=10.1021%2Fjm900648x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Hydroxamates: Relationships between Structure and Plasma Stability</span></div><div class="casAuthors">Flipo, Marion; Charton, Julie; Hocine, Akila; Dassonneville, Sandrine; Deprez, Benoit; Deprez-Poulain, Rebecca</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6790-6802</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Hydroxamates are valuable tools for chem. biol. as well as interesting leads for medicinal chem.  Although many hydroxamates display nanomolar activities against metalloproteases, only three hydroxamates have reached the market, among which is the HDAC inhibitor vorinostat.  Failures in development are generally attributed to lack of selectivity, toxicity, or poor stability.  To help medicinal chemists with respect to plasma stability, the authors have performed the first and preliminary study on structure-plasma stability for hydroxamates.  The authors define some structural rules to predict or improve the plasma stability in the preclin. stage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrk66ooWU1NhbVg90H21EOLACvtfcHk0li4Fqq2he7TXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1GgsbnJ&md5=069a87988fbeb68a248d006c7f6307a0</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Fjm900648x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900648x%26sid%3Dliteratum%253Aachs%26aulast%3DFlipo%26aufirst%3DM.%26aulast%3DCharton%26aufirst%3DJ.%26aulast%3DHocine%26aufirst%3DA.%26aulast%3DDassonneville%26aufirst%3DS.%26aulast%3DDeprez%26aufirst%3DB.%26aulast%3DDeprez-Poulain%26aufirst%3DR.%26atitle%3DHydroxamates%253A%2520Relationships%2520between%2520Structure%2520and%2520Plasma%2520Stability%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D6790%26epage%3D6802%26doi%3D10.1021%2Fjm900648x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarantopoulos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juric, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connarn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruchec, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harvey, R. D.</span></span> <span> </span><span class="NLM_article-title">A Phase 1b Study of the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Citarinostat (ACY-241) in Combination with Paclitaxel (Pac) in Patients (Pts) with Advanced Solid Tumors (AST)</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">2547</span>, <span class="refDoi"> DOI: 10.1200/JCO.2018.36.15_suppl.2547</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1200%2FJCO.2018.36.15_suppl.2547" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2018&pages=2547&author=M.+S.+Gordonauthor=G.+Shapiroauthor=J.+Sarantopoulosauthor=D.+Juricauthor=B.+Luauthor=P.+Chenauthor=J.+Connarnauthor=Y.+L.+Bruchecauthor=R.+D.+Harvey&title=A+Phase+1b+Study+of+the+Safety%2C+Pharmacokinetics%2C+and+Preliminary+Antitumor+Activity+of+Citarinostat+%28ACY-241%29+in+Combination+with+Paclitaxel+%28Pac%29+in+Patients+%28Pts%29+with+Advanced+Solid+Tumors+%28AST%29&doi=10.1200%2FJCO.2018.36.15_suppl.2547"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1200%2FJCO.2018.36.15_suppl.2547&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2018.36.15_suppl.2547%26sid%3Dliteratum%253Aachs%26aulast%3DGordon%26aufirst%3DM.%2BS.%26aulast%3DShapiro%26aufirst%3DG.%26aulast%3DSarantopoulos%26aufirst%3DJ.%26aulast%3DJuric%26aufirst%3DD.%26aulast%3DLu%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DConnarn%26aufirst%3DJ.%26aulast%3DBruchec%26aufirst%3DY.%2BL.%26aulast%3DHarvey%26aufirst%3DR.%2BD.%26atitle%3DA%2520Phase%25201b%2520Study%2520of%2520the%2520Safety%252C%2520Pharmacokinetics%252C%2520and%2520Preliminary%2520Antitumor%2520Activity%2520of%2520Citarinostat%2520%2528ACY-241%2529%2520in%2520Combination%2520with%2520Paclitaxel%2520%2528Pac%2529%2520in%2520Patients%2520%2528Pts%2529%2520with%2520Advanced%2520Solid%2520Tumors%2520%2528AST%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2018%26volume%3D36%26spage%3D2547%26doi%3D10.1200%2FJCO.2018.36.15_suppl.2547" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 1 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Krimo Toutah, Nabanita Nawar, Sanna Timonen, Helena Sorger, Yasir S. Raouf, Shazreh Bukhari, Jana von Jan, Aleksandr Ianevski, Justyna M. Gawel, Olasunkanmi O. Olaoye, Mulu Geletu, Ayah Abdeldayem, Johan Israelian, Tudor B. Radu, Abootaleb Sedighi, Muzaffar N. Bhatti, Muhammad Murtaza Hassan, Pimyupa Manaswiyoungkul, Andrew E. Shouksmith, Heidi A. Neubauer, Elvin D. de Araujo, Tero Aittokallio, Oliver H. Krämer, Richard Moriggl, Satu Mustjoki, Marco Herling, <span class="NLM_string-name hlFld-ContribAuthor">Patrick T. Gunning</span>. </span><span class="cited-content_cbyCitation_article-title">Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (12)
                                     , 8486-8509. <a href="https://doi.org/10.1021/acs.jmedchem.1c00420" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00420</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00420&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00420%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDevelopment%252Bof%252BHDAC%252BInhibitors%252BExhibiting%252BTherapeutic%252BPotential%252Bin%252BT-Cell%252BProlymphocytic%252BLeukemia%26aulast%3DToutah%26aufirst%3DKrimo%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D08032021%26date%3D08062021%26volume%3D64%26issue%3D12%26spage%3D8486%26epage%3D8509" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/medium/jm0c01922_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/large/jm0c01922_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01922&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/medium/jm0c01922_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/large/jm0c01922_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Currently known HDAC6 inhibitors. The structural features involve a hydroxamic acid which is required for Zn<sup>2+</sup> binding and a linker that connects the hydroxamic acid to a cap group. (a) Currently known inhibitors achieved HDAC6 selectivity by replacing the benzene substituent on SAHA with a bulkier, usually hydrophobic cap group. (b) Previous studies showed that compound <b>1</b> is a nM inhibitor against HDAC6 exhibiting minimal selectivity. (c) Current studies show that <b>TO-317</b> adopts a rotatable cap group with two aromatic substituents that occupy the HDAC6 surface, facilitating specific residue interactions. *IC<sub>50</sub> values were determined using an activity-based electrophoretic mobility shift assay (EMSA) by Nanosyn Inc., USA.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/large/jm0c01922_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01922&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/medium/jm0c01922_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/large/jm0c01922_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Overlaid inhibition curves for <b>TO-317</b> against a panel of 11 Zn<sup>2+</sup>-based HDAC homologues. <b>TO-317</b> shows <i>in vitro</i> HDAC6 selectivity across all Zn<sup>2+</sup>-dependent HDAC homologues and becomes a viable candidate for further biological investigation of the HDAC6 enzyme.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/large/jm0c01922_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01922&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/medium/jm0c01922_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/large/jm0c01922_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Docking conformation of <b>TO-317</b> with <i>dr</i>HDAC6 CD2 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5WGI">5WGI</a>) reveals occupancy of both L1 and L2 crevices which facilitates a plethora of interactions. Deck A shows the pocket view of these interactions, while deck B shows how <b>TO-317</b> adopts a windmill conformation that allows both aromatic ring cap groups to engage with the L1 and L2 crevices of the HDAC6 outer surface.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/large/jm0c01922_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01922&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/medium/jm0c01922_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/large/jm0c01922_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Stereo-view of a Polder omit map (contoured at 4.0σ) showing the binding of <b>TO-317</b> in the active site of HDAC6 (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7JOM">7JOM</a>). The catalytic Zn<sup>2+</sup> ion is shown as a gray sphere, and the Zn<sup>2+</sup> bound water molecule is shown as a red sphere; metal coordination and hydrogen bond interactions are shown as solid and dashed black lines, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/large/jm0c01922_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01922&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/medium/jm0c01922_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/large/jm0c01922_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Cellular potency of <b>TO-317</b> and citarinostat (positive control) in 12 cell lines (1 heathy cell, MRC-9 included). <b>TO-317</b> shows anti-proliferative potency across different cancer cells with minimal activity in healthy cells. IC<sub>50</sub> values are indicated above each graph and reported in μM. IC<sub>50</sub> values with their 95% confidence intervals are reported in <a href="/doi/suppl/10.1021/acs.jmedchem.0c01922/suppl_file/jm0c01922_si_002.pdf" class="ext-link">Table S3</a>. Citarinostat was not tested in Ramos cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/large/jm0c01922_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01922&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/medium/jm0c01922_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/large/jm0c01922_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. <b>TO-317</b> shows superior HDAC6 selectivity and potency in MV4-11 and MM.1S cells. (A) MV4-11 cells treated with increasing doses (0.25–1 μM) of citarinostat and <b>TO-317</b> show accumulation of Ac-α-tubulin for <b>TO-317</b> at 0.25 μM but not for citarinostat. (B) Similar dose-dependent responses were observed for both inhibitors in MM.1S cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/large/jm0c01922_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01922&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/medium/jm0c01922_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/large/jm0c01922_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Quantification of Ac-α-tubulin and Ac-histone levels in the immunofluorescence assay. DMSO was used as a negative control in each cohort, and citarinostat was the positive control. The result indicates that <b>TO-317</b> induces a clear dose-dependent increase in acetylated α-tubulin with minimal cellular accumulation of acetylated histones under the same dosing concentrations. The data reported above are an average of duplicate experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/large/jm0c01922_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01922&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/medium/jm0c01922_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/large/jm0c01922_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. MV4-11 cells treated with <b>TO-317</b> (A) and citarinostat (B) leads to dose-dependent programmed cell death. Death by necrosis (Q1) is minimal and consistent at all doses. Dose-dependent cell death by <b>TO-317</b> is consistent with a mechanistic approach of cell cycle arrest leading to apoptosis and corroborates the previously observed superior anti-proliferative activity of <b>TO-317</b> over citarinostat, the positive control. The data reported above are an average of duplicate experiments, and quantification of each cell population with the associated standard deviation is reported graphically in <a href="/doi/suppl/10.1021/acs.jmedchem.0c01922/suppl_file/jm0c01922_si_002.pdf" class="ext-link">Figure S8A,B</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/large/jm0c01922_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01922&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/medium/jm0c01922_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/large/jm0c01922_0010.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. ROS generation in MV4-11 cells following incubation with 10 μM <b>TO-317</b> for up to 4 h. <b>TO-317</b> shows markedly increased levels of ROS after 2 h incubation which continue to increase up to the 4 h incubation time tested. Data reported are an average of duplicate studies.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/large/jm0c01922_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01922&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/medium/jm0c01922_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/large/jm0c01922_0011.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. <b>TO-317</b> is stable <i>in vivo</i> with a <i>t</i><sub>1/2 (avg)</sub> = 1.7 h. Male BALB/c mice were dosed with <b>TO-317</b> intraperitoneally (50 mg/mL solution 5% DMSO, 30% PEG400, 1% Tween 80, and 64% saline) and peaks were detected and quantified from collected blood samples at different time concentrations using a triple-quad LC–MS/MS.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01922/20210305/images/large/jm0c01922_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01922&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i30">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10502" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10502" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 60 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hackanson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rimmele, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benkißer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdelkarim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fliegauf, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lübbert, M.</span></span> <span> </span><span class="NLM_article-title">HDAC6 as a Target for Antileukemic Drugs in Acute Myeloid Leukemia</span>. <i>Leuk. Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">1055</span>– <span class="NLM_lpage">1062</span>, <span class="refDoi"> DOI: 10.1016/j.leukres.2012.02.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1016%2Fj.leukres.2012.02.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=22464548" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvFSmsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2012&pages=1055-1062&author=B.+Hackansonauthor=L.+Rimmeleauthor=M.+Benki%C3%9Ferauthor=M.+Abdelkarimauthor=M.+Fliegaufauthor=M.+Jungauthor=M.+L%C3%BCbbert&title=HDAC6+as+a+Target+for+Antileukemic+Drugs+in+Acute+Myeloid+Leukemia&doi=10.1016%2Fj.leukres.2012.02.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC6 as a target for antileukemic drugs in acute myeloid leukemia</span></div><div class="casAuthors">Hackanson, Bjoern; Rimmele, Leander; Benkisser, Marco; Abdelkarim, Mahmoud; Fliegauf, Manfred; Jung, Manfred; Luebbert, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1055-1062</span>CODEN:
                <span class="NLM_cas:coden">LEREDD</span>;
        ISSN:<span class="NLM_cas:issn">0145-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Inhibition of histone deacetylases (HDACs) by drugs such as vorinostat or depsipeptide has become treatment strategy under study in acute myeloid leukemia.  Most preclinically and clin. investigated HDACi target classes I, II and IV, but only few are selective in inhibiting specific HDACs.  Here we analyzed the in vitro antileukemic activity of three novel hydroxamate derivs., the pan-HDAC-inhibitors ST13, ST34 and the known HDAC6 inhibitor ST80, treating leukemia cell lines HL60, Kasumi-1, NB-4, THP-1, K562, U937, Jurkat as well as primary AML blasts.  In cell lines all three compds. exerted a strong growth-inhibitory effect at low micromolar concns.  ST13 increased acetylation of H3, H4 and α-tubulin, while ST34 preferentially acetylated histones H3 and H4.  Interestingly, ST80 preferentially induced α-tubulin acetylation at low micromolar doses, confirming a selective inhibition of HDAC6 by ST80 in leukemic cells.  These observations were also confirmed in primary AML blasts cultured ex vivo.  Growth-inhibition by ST80 was independent of pre-treatment HDAC6 protein expression and in contrast to ST13 and ST34, ST80 did not result in induction of p21/WAF.  Immunofluorescence imaging confirmed that ST80 treatment both increased the abundance and resulted in unilateral local accumulation of acetylated α-tubulin.  In conclusion, the three novel HDACi show potent antileukemic activity in myeloid cell lines and primary AML blasts at low micromolar concns.  Preferential acetylation of α-tubulin implies that ST80 might exert its antileukemic effect not through histone reacetylation but rather through inhibition of HDAC6.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogNxuKC1ZPdrVg90H21EOLACvtfcHk0lhcpX6InWG1TQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvFSmsLo%253D&md5=26085ecb4905806c84bc90900c820db5</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.leukres.2012.02.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.leukres.2012.02.026%26sid%3Dliteratum%253Aachs%26aulast%3DHackanson%26aufirst%3DB.%26aulast%3DRimmele%26aufirst%3DL.%26aulast%3DBenki%25C3%259Fer%26aufirst%3DM.%26aulast%3DAbdelkarim%26aufirst%3DM.%26aulast%3DFliegauf%26aufirst%3DM.%26aulast%3DJung%26aufirst%3DM.%26aulast%3DL%25C3%25BCbbert%26aufirst%3DM.%26atitle%3DHDAC6%2520as%2520a%2520Target%2520for%2520Antileukemic%2520Drugs%2520in%2520Acute%2520Myeloid%2520Leukemia%26jtitle%3DLeuk.%2520Res.%26date%3D2012%26volume%3D36%26spage%3D1055%26epage%3D1062%26doi%3D10.1016%2Fj.leukres.2012.02.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Santo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hideshima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarpe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Duzer, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazitschek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogier, W. C.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Preclinical Activity, Pharmacodynamic, and Pharmacokinetic Properties of a Selective HDAC6 Inhibitor, ACY-1215, in Combination with Bortezomib in Multiple Myeloma</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">2579</span>– <span class="NLM_lpage">2589</span>, <span class="refDoi"> DOI: 10.1182/blood-2011-10-387365</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1182%2Fblood-2011-10-387365" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=22262760" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BC38XltVOntb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2012&pages=2579-2589&author=L.+Santoauthor=T.+Hideshimaauthor=A.+L.+Kungauthor=J.-C.+Tsengauthor=D.+Tamangauthor=M.+Yangauthor=M.+Jarpeauthor=J.+H.+Van+Duzerauthor=R.+Mazitschekauthor=W.+C.+Ogier&title=Preclinical+Activity%2C+Pharmacodynamic%2C+and+Pharmacokinetic+Properties+of+a+Selective+HDAC6+Inhibitor%2C+ACY-1215%2C+in+Combination+with+Bortezomib+in+Multiple+Myeloma&doi=10.1182%2Fblood-2011-10-387365"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma</span></div><div class="casAuthors">Santo, Loredana; Hideshima, Teru; Kung, Andrew L.; Tseng, Jen-Chieh; Tamang, David; Yang, Min; Jarpe, Matthew; van Duzer, John H.; Mazitschek, Ralph; Ogier, Walter C.; Cirstea, Diana; Rodig, Scott; Eda, Homare; Scullen, Tyler; Canavese, Miriam; Bradner, James; Anderson, Kenneth C.; Jones, Simon S.; Raje, Noopur</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2579-2589</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Histone deacetylase (HDAC) enzymic activity has been linked to the transcription of DNA in cancers including multiple myeloma (MM).  Therefore, HDAC inhibitors used alone and in combination are being actively studied as novel therapies in MM.  In the present study, we investigated the preclin. activity of ACY-1215, an HDAC6-selective inhibitor, alone and in combination with bortezomib in MM.  Low doses of ACY-1215 combined with bortezomib triggered synergistic anti-MM activity, resulting in protracted endoplasmic reticulum stress and apoptosis via activation of caspase-3, caspase-8, and caspase-9 and poly (ADP) ribosome polymerase.  In vivo, the anti-MM activity of ACY-1215 in combination with bortezomib was confirmed using 2 different xenograft SCID mouse models: human MM injected s.c. (the plasmacytoma model) and luciferase-expressing human MM injected i.v. (the disseminated MM model).  Tumor growth was significantly delayed and overall survival was significantly prolonged in animals treated with the combination therapy.  Pharmacokinetic data showed peak plasma levels of ACY-1215 at 4 h after treatment coincident with an increase in acetylated α-tubulin, a marker of HDAC6 inhibition, by immunohistochem. and Western blot anal.  These studies provide preclin. rationale for acetylated α-tubulin use as a pharmacodynamic biomarker in future clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoelmsk1wo_LVg90H21EOLACvtfcHk0lggBpczbudP8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XltVOntb4%253D&md5=094298bdd3d5b91c7060d8b294857846</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1182%2Fblood-2011-10-387365&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2011-10-387365%26sid%3Dliteratum%253Aachs%26aulast%3DSanto%26aufirst%3DL.%26aulast%3DHideshima%26aufirst%3DT.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DTseng%26aufirst%3DJ.-C.%26aulast%3DTamang%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DM.%26aulast%3DJarpe%26aufirst%3DM.%26aulast%3DVan%2BDuzer%26aufirst%3DJ.%2BH.%26aulast%3DMazitschek%26aufirst%3DR.%26aulast%3DOgier%26aufirst%3DW.%2BC.%26atitle%3DPreclinical%2520Activity%252C%2520Pharmacodynamic%252C%2520and%2520Pharmacokinetic%2520Properties%2520of%2520a%2520Selective%2520HDAC6%2520Inhibitor%252C%2520ACY-1215%252C%2520in%2520Combination%2520with%2520Bortezomib%2520in%2520Multiple%2520Myeloma%26jtitle%3DBlood%26date%3D2012%26volume%3D119%26spage%3D2579%26epage%3D2589%26doi%3D10.1182%2Fblood-2011-10-387365" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, C.</span></span> <span> </span><span class="NLM_article-title">HDAC6 Promotes Cell Proliferation and Confers Resistance to Gefitinib in Lung Adenocarcinoma</span>. <i>Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">589</span>– <span class="NLM_lpage">597</span>, <span class="refDoi"> DOI: 10.3892/or.2016.4811</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.3892%2For.2016.4811" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=27221381" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtl2mtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2016&pages=589-597&author=Z.+Wangauthor=F.+Tangauthor=P.+Huauthor=Y.+Wangauthor=J.+Gongauthor=S.+Sunauthor=C.+Xie&title=HDAC6+Promotes+Cell+Proliferation+and+Confers+Resistance+to+Gefitinib+in+Lung+Adenocarcinoma&doi=10.3892%2For.2016.4811"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC6 promotes cell proliferation and confers resistance to gefitinib in lung adenocarcinoma</span></div><div class="casAuthors">Wang, Zhihao; Tang, Fang; Hu, Pengchao; Wang, Ying; Gong, Jun; Sun, Shaoxing; Xie, Conghua</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">589-597</span>CODEN:
                <span class="NLM_cas:coden">OCRPEW</span>;
        ISSN:<span class="NLM_cas:issn">1791-2431</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) are promising targets for cancer therapy, and first-generation HDAC inhibitors are currently in clin. trials for the treatment of cancer patients.  HDAC6, which is a key regulator of many signaling pathways that are linked to cancer, has recently emerged as an attractive target for the treatment of cancer.  In the present study, HDAC6 was found to be overexpressed in lung adenocarcinoma cell lines and was neg. correlated with the prognosis of patients with lung adenocarcinoma.  Overexpression of HDAC6 promoted the proliferation of lung adenocarcinoma cells in a deacetylase activity-dependent manner.  HDAC6 overexpression conferred resistance to gefitinib via the stabilization of epidermal growth factor receptor (EGFR).  The inhibition of HDAC6 by CAY10603, a potent and selective inhibitor of HDAC6, inhibited the proliferation of lung adenocarcinoma cells and induced apoptosis.  CAY10603 downregulated the levels of EGFR protein, which in turn inhibited activation of the EGFR signaling pathway.  Moreover, CAY10603 synergized with gefitinib to induce apoptosis of the lung adenocarcinoma cell lines via the destabilization of EGFR.  Taken together, our results suggest that the inhibition of HDAC6 may be a promising strategy for the treatment of lung adenocarcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4lXuah65G6bVg90H21EOLACvtfcHk0lggBpczbudP8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtl2mtLk%253D&md5=3a2778e81b86443b5e4fcc37bc11f11e</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.3892%2For.2016.4811&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For.2016.4811%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DTang%26aufirst%3DF.%26aulast%3DHu%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DGong%26aufirst%3DJ.%26aulast%3DSun%26aufirst%3DS.%26aulast%3DXie%26aufirst%3DC.%26atitle%3DHDAC6%2520Promotes%2520Cell%2520Proliferation%2520and%2520Confers%2520Resistance%2520to%2520Gefitinib%2520in%2520Lung%2520Adenocarcinoma%26jtitle%3DOncol.%2520Rep.%26date%3D2016%26volume%3D36%26spage%3D589%26epage%3D597%26doi%3D10.3892%2For.2016.4811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ho, T. C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, A. H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganesan, A.</span></span> <span> </span><span class="NLM_article-title">Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">12460</span>– <span class="NLM_lpage">12484</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00830</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00830" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlSisrzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=12460-12484&author=T.+C.+S.+Hoauthor=A.+H.+Y.+Chanauthor=A.+Ganesan&title=Thirty+Years+of+HDAC+Inhibitors%3A+2020+Insight+and+Hindsight&doi=10.1021%2Facs.jmedchem.0c00830"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight</span></div><div class="casAuthors">Ho, Terence C. S.; Chan, Alex H. Y.; Ganesan, A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">12460-12484</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  It is now 30 years since the first report of a potent zinc-dependent histone deacetylase (HDAC) inhibitor appeared.  Since then, five HDAC inhibitors have received regulatory approval for cancer chemotherapy while many others are in clin. development for oncol. as well as other therapeutic indications.  This Perspective reviews the biol. and medicinal chem. advances over the past 3 decades with an emphasis on the design of selective inhibitors that discriminate between the 11 human HDAC isoforms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrES4d2gbkB17Vg90H21EOLACvtfcHk0livRmldpJJwng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlSisrzP&md5=1deb2ad5787797a9ee98dcf7bdade52c</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00830%26sid%3Dliteratum%253Aachs%26aulast%3DHo%26aufirst%3DT.%2BC.%2BS.%26aulast%3DChan%26aufirst%3DA.%2BH.%2BY.%26aulast%3DGanesan%26aufirst%3DA.%26atitle%3DThirty%2520Years%2520of%2520HDAC%2520Inhibitors%253A%25202020%2520Insight%2520and%2520Hindsight%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D12460%26epage%3D12484%26doi%3D10.1021%2Facs.jmedchem.0c00830" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span> <span> </span><span class="NLM_article-title">Role of HDACs in Normal and Malignant Hematopoiesis</span>. <i>Mol. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">5</span>, <span class="refDoi"> DOI: 10.1186/s12943-019-1127-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1186%2Fs12943-019-1127-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=31910827" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A280%3ADC%252BB3MbnsVartw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2020&pages=5&author=P.+Wangauthor=Z.+Wangauthor=J.+Liu&title=Role+of+HDACs+in+Normal+and+Malignant+Hematopoiesis&doi=10.1186%2Fs12943-019-1127-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Role of HDACs in normal and malignant hematopoiesis</span></div><div class="casAuthors">Wang Pan; Wang Zi; Wang Pan; Wang Zi; Liu Jing</div><div class="citationInfo"><span class="NLM_cas:title">Molecular cancer</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Normal hematopoiesis requires the accurate orchestration of lineage-specific patterns of gene expression at each stage of development, and epigenetic regulators play a vital role.  Disordered epigenetic regulation has emerged as a key mechanism contributing to hematological malignancies.  Histone deacetylases (HDACs) are a series of key transcriptional cofactors that regulate gene expression by deacetylation of lysine residues on histone and nonhistone proteins.  In normal hematopoiesis, HDACs are widely involved in the development of various lineages.  Their functions involve stemness maintenance, lineage commitment determination, cell differentiation and proliferation, etc.  Deregulation of HDACs by abnormal expression or activity and oncogenic HDAC-containing transcriptional complexes are involved in hematological malignancies.  Currently, HDAC family members are attractive targets for drug design, and a variety of HDAC-based combination strategies have been developed for the treatment of hematological malignancies.  Drug resistance and limited therapeutic efficacy are key issues that hinder the clinical applications of HDAC inhibitors (HDACis).  In this review, we summarize the current knowledge of how HDACs and HDAC-containing complexes function in normal hematopoiesis and highlight the etiology of HDACs in hematological malignancies.  Moreover, the implication and drug resistance of HDACis are also discussed.  This review presents an overview of the physiology and pathology of HDACs in the blood system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQuj8DxhH9_I9LIORRPd5lbfW6udTcc2eYzc7tmXs-rwbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MbnsVartw%253D%253D&md5=96b7cff9ffdde16fca3e2b6e79e51078</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1186%2Fs12943-019-1127-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12943-019-1127-7%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DJ.%26atitle%3DRole%2520of%2520HDACs%2520in%2520Normal%2520and%2520Malignant%2520Hematopoiesis%26jtitle%3DMol.%2520Cancer%26date%3D2020%26volume%3D19%26spage%3D5%26doi%3D10.1186%2Fs12943-019-1127-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase (HDAC) Inhibitors in Cancer: A Patent Review (2017-Present)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">263</span>– <span class="NLM_lpage">274</span>, <span class="refDoi"> DOI: 10.1080/13543776.2020.1725470</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1080%2F13543776.2020.1725470" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=32008402" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BB3cXit1CitbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=263-274&author=C.+Zhaoauthor=H.+Dongauthor=Q.+Xuauthor=Y.+Zhang&title=Histone+Deacetylase+%28HDAC%29+Inhibitors+in+Cancer%3A+A+Patent+Review+%282017-Present%29&doi=10.1080%2F13543776.2020.1725470"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase (HDAC) inhibitors in cancer: a patent review (2017-present)</span></div><div class="casAuthors">Zhao, Chunlong; Dong, Hang; Xu, Qifu; Zhang, Yingjie</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">263-274</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase (HDAC) inhibitors play a crucial role in restoring the balance of acetylation and deacetylation of lysine residues of histones and non-histone proteins, which are applied to treat several diseases including cancer.  This review covers recent efforts in the synthesis and applications of inhibitors and hybrid inhibitors targeting HDAC from 2017 to 2019.  HDACs are important epigenetic targets and HDAC inhibitors have become important biol. active compds. for the treatment of cancers.  Among the recent patents available, most of them place emphasis on HDAC selective inhibitors and multitarget HDAC inhibitors.  Although great accomplishments have been achieved in developing HDAC selective inhibitors, there is still an urgent need for discovery of novel HDAC inhibitors with new zinc-binding groups avoiding the unfavorable pharmacokinetics profiles of hydroxamic acid.  Apart from cancer therapy, HDAC inhibitors have recently been considered as a new strategy in treating other human diseases, such as alc. use disorder (AUD), neurol. disorders, age-related diseases, and so forth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdA-S5sLkahbVg90H21EOLACvtfcHk0ljYJL6hgxY2Kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXit1CitbY%253D&md5=8c3d1f76892b3d33fb6b41d22d561e96</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1080%2F13543776.2020.1725470&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2020.1725470%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DC.%26aulast%3DDong%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DHistone%2520Deacetylase%2520%2528HDAC%2529%2520Inhibitors%2520in%2520Cancer%253A%2520A%2520Patent%2520Review%2520%25282017-Present%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2020%26volume%3D30%26spage%3D263%26epage%3D274%26doi%3D10.1080%2F13543776.2020.1725470" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leipe, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landsman, D.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylases, Acetoin Utilization Proteins and Acetylpolyamine Amidohydrolases Are Members of an Ancient Protein Superfamily</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">3693</span>– <span class="NLM_lpage">3697</span>, <span class="refDoi"> DOI: 10.1093/nar/25.18.3693</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1093%2Fnar%2F25.18.3693" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=9278492" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADyaK2sXmsVahsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1997&pages=3693-3697&author=D.+D.+Leipeauthor=D.+Landsman&title=Histone+Deacetylases%2C+Acetoin+Utilization+Proteins+and+Acetylpolyamine+Amidohydrolases+Are+Members+of+an+Ancient+Protein+Superfamily&doi=10.1093%2Fnar%2F25.18.3693"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylases, acetoin utilization proteins and acetylpolyamine amidohydrolases are members of an ancient protein superfamily</span></div><div class="casAuthors">Leipe, Detlef D.; Landsman, David</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3693-3697</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Searches of several sequence databases reveal that human HD1, yeast HDA1, yeast RPD3 and other eukaryotic histone deacetylases share nine motifs with archaeal and eubacterial enzymes, including acetoin utilization protein (acuC) and acetylpolyamine amidohydrolase.  Histone deacetylase and acetylpolyamine amidohydrolase also share profound functional similarities in that both: (i) recognize an acetylated aminoalkyl group; (ii) catalyze the removal of the acetyl group by cleaving an amide bond; (iii) increase the pos. charge of the substrate.  Stabilization of nucleosomal DNA-histone interaction brought about by the change in charge has been implicated as the underlying cause for histone deacetylase-mediated transcriptional repression.  We speculate that the eukaryotic histone deacetylases originated from a prokaryotic enzyme similar to the acetylpolyamine amidohydrolases that relied on reversible acetylation and deacetylation of the aminoalkyl group of a DNA binding mol. to achieve a gene regulatory effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrN74VTsfnnb7Vg90H21EOLACvtfcHk0ljYJL6hgxY2Kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmsVahsbw%253D&md5=8e62f421b69cbaf52640fdc066ac8df2</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1093%2Fnar%2F25.18.3693&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252F25.18.3693%26sid%3Dliteratum%253Aachs%26aulast%3DLeipe%26aufirst%3DD.%2BD.%26aulast%3DLandsman%26aufirst%3DD.%26atitle%3DHistone%2520Deacetylases%252C%2520Acetoin%2520Utilization%2520Proteins%2520and%2520Acetylpolyamine%2520Amidohydrolases%2520Are%2520Members%2520of%2520an%2520Ancient%2520Protein%2520Superfamily%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D1997%26volume%3D25%26spage%3D3693%26epage%3D3697%26doi%3D10.1093%2Fnar%2F25.18.3693" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gregoretti, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodson, H. V.</span></span> <span> </span><span class="NLM_article-title">Molecular Evolution of the Histone Deacetylase Family: Functional Implications of Phylogenetic Analysis</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>338</i></span>,  <span class="NLM_fpage">17</span>– <span class="NLM_lpage">31</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2004.02.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1016%2Fj.jmb.2004.02.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=15050820" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BD2cXisFyksro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=338&publication_year=2004&pages=17-31&author=I.+Gregorettiauthor=Y.-M.+Leeauthor=H.+V.+Goodson&title=Molecular+Evolution+of+the+Histone+Deacetylase+Family%3A+Functional+Implications+of+Phylogenetic+Analysis&doi=10.1016%2Fj.jmb.2004.02.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Evolution of the Histone Deacetylase Family: Functional Implications of Phylogenetic Analysis</span></div><div class="casAuthors">Gregoretti, Ivan V.; Lee, Yun-Mi; Goodson, Holly V.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">338</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17-31</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) modify core histones and participate in large regulatory complexes that both suppress and enhance transcription.  Recent studies indicate that some HDACs can act on non-histone proteins as well.  Interest in these enzymes is growing because HDAC inhibitors appear to be promising therapeutic agents against cancer and a variety of other diseases.  Thus far, 11 members of the HDAC family have been identified in humans, but few have been characterized in detail.  To better define the biol. function of these proteins, make maximal use of studies performed in other systems, and assist in drug development efforts, we have performed a phylogenetic anal. of all HDAC-related proteins in all fully sequenced free-living organisms.  Previous analyses have divided non-sirtuin HDACs into two groups, classes 1 and 2.  We find that HDACs can be divided into three equally distinct groups: class 1, class 2, and a third class consisting of proteins related to the recently identified human HDAC11 gene.  We term this novel group "class 4" to distinguish it from the unrelated "class 3" sirtuin deacetylases.  Anal. of gene duplication events indicates that the common ancestor of metazoan organisms contained two class 1, two class 2, and a single class 4 HDAC.  Examn. of HDAC characteristics in light of these evolutionary relationships leads to functional predictions, among them that self-assocn. is common among HDAC proteins.  All three HDAC classes (including class 4) exist in eubacteria.  Phylogenetic anal. of bacterial HDAC relatives suggests that all three HDAC classes precede the evolution of histone proteins and raises the possibility that the primary activity of some "histone deacetylase" enzymes is directed against non-histone substrates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVqdtToKvZgLVg90H21EOLACvtfcHk0ljYJL6hgxY2Kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXisFyksro%253D&md5=1748e3b88d8f3b774db50eb19799f63c</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2004.02.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2004.02.006%26sid%3Dliteratum%253Aachs%26aulast%3DGregoretti%26aufirst%3DI.%26aulast%3DLee%26aufirst%3DY.-M.%26aulast%3DGoodson%26aufirst%3DH.%2BV.%26atitle%3DMolecular%2520Evolution%2520of%2520the%2520Histone%2520Deacetylase%2520Family%253A%2520Functional%2520Implications%2520of%2520Phylogenetic%2520Analysis%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2004%26volume%3D338%26spage%3D17%26epage%3D31%26doi%3D10.1016%2Fj.jmb.2004.02.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rossaert, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Den Bosch, L.</span></span> <span> </span><span class="NLM_article-title">HDAC6 Inhibitors: Translating Genetic and Molecular Insights into a Therapy for Axonal CMT</span>. <i>Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>1733</i></span>,  <span class="NLM_fpage">146692</span>, <span class="refDoi"> DOI: 10.1016/j.brainres.2020.146692</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1016%2Fj.brainres.2020.146692" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=32006555" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjsVOksbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1733&publication_year=2020&pages=146692&author=E.+Rossaertauthor=L.+Van+Den+Bosch&title=HDAC6+Inhibitors%3A+Translating+Genetic+and+Molecular+Insights+into+a+Therapy+for+Axonal+CMT&doi=10.1016%2Fj.brainres.2020.146692"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC6 inhibitors: Translating genetic and molecular insights into a therapy for axonal CMT</span></div><div class="casAuthors">Rossaert, Elisabeth; Van Den Bosch, Ludo</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">1733</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">146692</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase 6 (HDAC6) plays a central role in various processes that are key for neuronal survival.  In this review, we summarize the current evidence related to disease pathways in the axonal form of Charcot-Marie-Tooth disease (CMT) and highlight the role of HDAC6 in these pathways.  We hypothesize that HDAC6 might in fact actively contribute to the pathogenesis of certain forms of axonal CMT.  HDAC6 plays a deacetylase activity-dependent, neg. role in axonal transport and axonal regeneration, which are both processes implicated in axonal CMT.  On the other hand, HDAC6 coordinates a protective response during elimination of toxic misfolded proteins, but this is mostly mediated independent of its deacetylase activity.  The current mechanistic insights on these functions of HDAC6 in axonal CMT, along with the selective druggability against its deacetylase activity, make the targeting of HDAC6 particularly attractive.  We elaborate on the preclin. studies that demonstrated beneficial effects of HDAC6 inhibitors in axonal CMT models and outline possible modes of action.  Overall, this overview ultimately provides a rationale for the use of small-mol. HDAC6 inhibitors as a therapeutic strategy for this devastating disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLQPvMw55ppbVg90H21EOLACvtfcHk0lhiNr9Oa71psA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjsVOksbw%253D&md5=3005fe78c94cf2a719d6e031573320c5</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.brainres.2020.146692&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.brainres.2020.146692%26sid%3Dliteratum%253Aachs%26aulast%3DRossaert%26aufirst%3DE.%26aulast%3DVan%2BDen%2BBosch%26aufirst%3DL.%26atitle%3DHDAC6%2520Inhibitors%253A%2520Translating%2520Genetic%2520and%2520Molecular%2520Insights%2520into%2520a%2520Therapy%2520for%2520Axonal%2520CMT%26jtitle%3DBrain%2520Res.%26date%3D2020%26volume%3D1733%26spage%3D146692%26doi%3D10.1016%2Fj.brainres.2020.146692" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Auzmendi-Iriarte, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saenz-Antoñanzas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikelez-Alonso, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrasco-Garcia, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tellaetxe-Abete, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrie, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampron, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortajarena, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matheu, A.</span></span> <span> </span><span class="NLM_article-title">Characterization of a New Small-Molecule Inhibitor of HDAC6 in Glioblastoma</span>. <i>Cell Death Dis.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">417</span>, <span class="refDoi"> DOI: 10.1038/s41419-020-2586-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1038%2Fs41419-020-2586-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=32488056" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFemt7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=417&author=J.+Auzmendi-Iriarteauthor=A.+Saenz-Anto%C3%B1anzasauthor=I.+Mikelez-Alonsoauthor=E.+Carrasco-Garciaauthor=M.+Tellaetxe-Abeteauthor=C.+H.+Lawrieauthor=N.+Sampronauthor=A.+L.+Cortajarenaauthor=A.+Matheu&title=Characterization+of+a+New+Small-Molecule+Inhibitor+of+HDAC6+in+Glioblastoma&doi=10.1038%2Fs41419-020-2586-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of a new small-molecule inhibitor of HDAC6 in glioblastoma</span></div><div class="casAuthors">Auzmendi-Iriarte, Jaione; Saenz-Antonanzas, Ander; Mikelez-Alonso, Idoia; Carrasco-Garcia, Estefania; Tellaetxe-Abete, Maitena; Lawrie, Charles H.; Sampron, Nicolas; Cortajarena, Aitziber L.; Matheu, Ander</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Disease</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">417</span>CODEN:
                <span class="NLM_cas:coden">CDDEA4</span>;
        ISSN:<span class="NLM_cas:issn">2041-4889</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: Histone deacetylase 6 (HDAC6) is an epigenetic modifier that is an attractive pharmacol. target in cancer.  In this work, we show that HDAC6 is elevated in glioblastoma, the most malignant and common brain tumor in adults, in which its high levels correlate with poor patient survival and is more abundant in glioma stem cell subpopulation.  Moreover, we identified a new small-mol. inhibitor of HDAC6, which presents strong sensitivity for HDAC6 inhibition and exerts high cytotoxic activity, alone or in combination with temozolomide.  It is also able to significantly reduce tumor growth in vivo.  Transcriptomic anal. of patient-derived glioma stem cells revealed an increase in cell differentiation and cell death pathways, as well as a decrease in cell-cycle activity and cell division by the treatment with the compd.  Finally, the comparison with a pan-HDAC inhibitor, Vorinostat (SAHA), or HDAC6-specific inhibitor, Tubastatin A, showed higher target specificity and antitumor activity of the new HDAC6 inhibitor.  In conclusion, our data reveal the efficacy of a novel HDAC6 inhibitor in glioblastoma preclin. setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp53nM_XMZC7LVg90H21EOLACvtfcHk0lhiNr9Oa71psA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFemt7%252FM&md5=fd4fad040bffea9191e1a00e9268a3b5</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fs41419-020-2586-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41419-020-2586-x%26sid%3Dliteratum%253Aachs%26aulast%3DAuzmendi-Iriarte%26aufirst%3DJ.%26aulast%3DSaenz-Anto%25C3%25B1anzas%26aufirst%3DA.%26aulast%3DMikelez-Alonso%26aufirst%3DI.%26aulast%3DCarrasco-Garcia%26aufirst%3DE.%26aulast%3DTellaetxe-Abete%26aufirst%3DM.%26aulast%3DLawrie%26aufirst%3DC.%2BH.%26aulast%3DSampron%26aufirst%3DN.%26aulast%3DCortajarena%26aufirst%3DA.%2BL.%26aulast%3DMatheu%26aufirst%3DA.%26atitle%3DCharacterization%2520of%2520a%2520New%2520Small-Molecule%2520Inhibitor%2520of%2520HDAC6%2520in%2520Glioblastoma%26jtitle%3DCell%2520Death%2520Dis.%26date%3D2020%26volume%3D11%26spage%3D417%26doi%3D10.1038%2Fs41419-020-2586-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bae, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ha, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Youn, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. Y.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Therapeutic Potential of CKD-506, a Novel Selective Histone Deacetylase 6 Inhibitor, in a Murine Model of Rheumatoid Arthritis</span>. <i>Arthritis Res. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1</span>, <span class="refDoi"> DOI: 10.1186/s13075-020-02258-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1186%2Fs13075-020-02258-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=31898524" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2020&pages=1&author=J.+K.+Parkauthor=Y.+J.+Jangauthor=B.+R.+Ohauthor=J.+Shinauthor=D.+Baeauthor=N.+Haauthor=Y.+I.+Choiauthor=G.+S.+Younauthor=J.+Parkauthor=E.+Y.+Lee&title=Therapeutic+Potential+of+CKD-506%2C+a+Novel+Selective+Histone+Deacetylase+6+Inhibitor%2C+in+a+Murine+Model+of+Rheumatoid+Arthritis&doi=10.1186%2Fs13075-020-02258-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1186%2Fs13075-020-02258-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13075-020-02258-0%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DJ.%2BK.%26aulast%3DJang%26aufirst%3DY.%2BJ.%26aulast%3DOh%26aufirst%3DB.%2BR.%26aulast%3DShin%26aufirst%3DJ.%26aulast%3DBae%26aufirst%3DD.%26aulast%3DHa%26aufirst%3DN.%26aulast%3DChoi%26aufirst%3DY.%2BI.%26aulast%3DYoun%26aufirst%3DG.%2BS.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DE.%2BY.%26atitle%3DTherapeutic%2520Potential%2520of%2520CKD-506%252C%2520a%2520Novel%2520Selective%2520Histone%2520Deacetylase%25206%2520Inhibitor%252C%2520in%2520a%2520Murine%2520Model%2520of%2520Rheumatoid%2520Arthritis%26jtitle%3DArthritis%2520Res.%2520Ther.%26date%3D2020%26volume%3D22%26spage%3D1%26doi%3D10.1186%2Fs13075-020-02258-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boyault, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadoul, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pabion, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khochbin, S.</span></span> <span> </span><span class="NLM_article-title">HDAC6, at the Crossroads between Cytoskeleton and Cell Signaling by Acetylation and Ubiquitination</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">5468</span>– <span class="NLM_lpage">5476</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1210614</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1038%2Fsj.onc.1210614" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=17694087" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BD2sXovFersrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=5468-5476&author=C.+Boyaultauthor=K.+Sadoulauthor=M.+Pabionauthor=S.+Khochbin&title=HDAC6%2C+at+the+Crossroads+between+Cytoskeleton+and+Cell+Signaling+by+Acetylation+and+Ubiquitination&doi=10.1038%2Fsj.onc.1210614"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination</span></div><div class="casAuthors">Boyault, C.; Sadoul, K.; Pabion, M.; Khochbin, S.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">5468-5476</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase 6 (HDAC6) is a unique enzyme with specific structural and functional features.  It is actively or stably maintained in the cytoplasm and is the only member, within the HDAC family, that harbors a full duplication of its deacetylase homol. region followed by a specific ubiquitin-binding domain at the C-terminus end.  Accordingly, this deacetylase functions at the heart of a cellular regulatory mechanism capable of coordinating various cellular functions largely relying on the microtubule network.  Moreover, HDAC6 action as a regulator of HSP90 chaperone activity adds to the multifunctionality of the protein, and allows the authors to propose a crit. role for HDAC6 in mediating and coordinating various cellular events in response to different stressful stimuli.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9IYNSqbx5pbVg90H21EOLACvtfcHk0lgd158dGSTxkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXovFersrw%253D&md5=3796fc81a6b403bf2c6d08122d3e94c8</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1210614&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1210614%26sid%3Dliteratum%253Aachs%26aulast%3DBoyault%26aufirst%3DC.%26aulast%3DSadoul%26aufirst%3DK.%26aulast%3DPabion%26aufirst%3DM.%26aulast%3DKhochbin%26aufirst%3DS.%26atitle%3DHDAC6%252C%2520at%2520the%2520Crossroads%2520between%2520Cytoskeleton%2520and%2520Cell%2520Signaling%2520by%2520Acetylation%2520and%2520Ubiquitination%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26spage%3D5468%26epage%3D5476%26doi%3D10.1038%2Fsj.onc.1210614" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moreno-Gonzalo, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayor, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sánchez-Madrid, F.</span></span> <span> </span><span class="NLM_article-title">HDAC6 at Crossroads of Infection and Innate Immunity</span>. <i>Trends Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">591</span>– <span class="NLM_lpage">595</span>, <span class="refDoi"> DOI: 10.1016/j.it.2018.05.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1016%2Fj.it.2018.05.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=29937401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFCmtL%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2018&pages=591-595&author=O.+Moreno-Gonzaloauthor=F.+Mayorauthor=F.+S%C3%A1nchez-Madrid&title=HDAC6+at+Crossroads+of+Infection+and+Innate+Immunity&doi=10.1016%2Fj.it.2018.05.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC6 at Crossroads of Infection and Innate Immunity</span></div><div class="casAuthors">Moreno-Gonzalo, Olga; Mayor, Federico; Sanchez-Madrid, Francisco</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Immunology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">591-595</span>CODEN:
                <span class="NLM_cas:coden">TIRMAE</span>;
        ISSN:<span class="NLM_cas:issn">1471-4906</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase 6 (HDAC6) acts by enzyme-dependent and -independent mechanisms to regulate diverse cellular processes including autophagy, the ubiquitin proteasome system, and cell migration.  HDAC6 also has emerging roles in innate immunity, including pathogen sensing and destruction, thus placing this enzyme at the crossroads of infection and innate immunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq57jhEg9ljw7Vg90H21EOLACvtfcHk0lgxGsPs0-AQzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFCmtL%252FJ&md5=06ef7cff747e0af6a67b138ad6ef3074</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.it.2018.05.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.it.2018.05.004%26sid%3Dliteratum%253Aachs%26aulast%3DMoreno-Gonzalo%26aufirst%3DO.%26aulast%3DMayor%26aufirst%3DF.%26aulast%3DS%25C3%25A1nchez-Madrid%26aufirst%3DF.%26atitle%3DHDAC6%2520at%2520Crossroads%2520of%2520Infection%2520and%2520Innate%2520Immunity%26jtitle%3DTrends%2520Immunol.%26date%3D2018%26volume%3D39%26spage%3D591%26epage%3D595%26doi%3D10.1016%2Fj.it.2018.05.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Depetter, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geurs, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Vreese, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goethals, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandoorn, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laevens, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steenbrugge, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Tullio, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bracke, M.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Selective Pharmacological Inhibitors of HDAC6 Reveal Biochemical Activity but Functional Tolerance in Cancer Models</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>145</i></span>,  <span class="NLM_fpage">735</span>– <span class="NLM_lpage">747</span>, <span class="refDoi"> DOI: 10.1002/ijc.32169</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1002%2Fijc.32169" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=30694564" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtlCrsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=145&publication_year=2019&pages=735-747&author=Y.+Depetterauthor=S.+Geursauthor=R.+De+Vreeseauthor=S.+Goethalsauthor=E.+Vandoornauthor=A.+Laevensauthor=J.+Steenbruggeauthor=E.+Meyerauthor=P.+de+Tullioauthor=M.+Bracke&title=Selective+Pharmacological+Inhibitors+of+HDAC6+Reveal+Biochemical+Activity+but+Functional+Tolerance+in+Cancer+Models&doi=10.1002%2Fijc.32169"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Selective pharmacological inhibitors of HDAC6 reveal biochemical activity but functional tolerance in cancer models</span></div><div class="casAuthors">Depetter, Yves; Geurs, Silke; De Vreese, Rob; Goethals, Sophie; Vandoorn, Elien; Laevens, Alien; Steenbrugge, Jonas; Meyer, Evelyne; de Tullio, Pascal; Bracke, Marc; D'hooghe, Matthias; De Wever, Olivier</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">145</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">735-747</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Our study investigates the biochem. and functional impact of selective histone deacetylase 6 (HDAC6) inhibitors, a promising class of novel therapeutics, in several cancer models.  Selective HDAC6 inhibitors (Tubathian A, Tubastatin A, Tubacin and Ricolinostat) and a non-selective HDAC inhibitor (Vorinostat) were evaluated on cancer cell lines derived from multiple tumor types in both an in vitro and in vivo setting as potential cancer therapeutics.  Selective HDAC6 inhibitors resulted in a-tubulin acetylation with no impact on histone acetylation but failed to show any anti-cancer properties.  Only the use of high concns. of selective HDAC6 inhibitors resulted in co-inhibition of other HDAC enzymes and consequently in reduced growth, migratory and/or invasive activity of cancer cells in vitro as well as in vivo.  The specificity of HDAC6 inhibition was confirmed using a CRISPR/Cas9 knockout cell line.  Our results suggest that selective HDAC6 inhibitors may fall short as potential single agent anti-cancer drugs and prove that many previous data regarding this promising class of compds. need to be interpreted with great care due to their use in high concns. resulting in low selectivity and potential off-target effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYUTbDIiyPkLVg90H21EOLACvtfcHk0lgxGsPs0-AQzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtlCrsro%253D&md5=8fd1520da407ccdefed627de78c4ed2a</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1002%2Fijc.32169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.32169%26sid%3Dliteratum%253Aachs%26aulast%3DDepetter%26aufirst%3DY.%26aulast%3DGeurs%26aufirst%3DS.%26aulast%3DDe%2BVreese%26aufirst%3DR.%26aulast%3DGoethals%26aufirst%3DS.%26aulast%3DVandoorn%26aufirst%3DE.%26aulast%3DLaevens%26aufirst%3DA.%26aulast%3DSteenbrugge%26aufirst%3DJ.%26aulast%3DMeyer%26aufirst%3DE.%26aulast%3Dde%2BTullio%26aufirst%3DP.%26aulast%3DBracke%26aufirst%3DM.%26atitle%3DSelective%2520Pharmacological%2520Inhibitors%2520of%2520HDAC6%2520Reveal%2520Biochemical%2520Activity%2520but%2520Functional%2520Tolerance%2520in%2520Cancer%2520Models%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2019%26volume%3D145%26spage%3D735%26epage%3D747%26doi%3D10.1002%2Fijc.32169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase 6 Structure and Molecular Basis of Catalysis and Inhibition</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">741</span>– <span class="NLM_lpage">747</span>, <span class="refDoi"> DOI: 10.1038/nchembio.2134</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1038%2Fnchembio.2134" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=27454933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Kmu7rJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=741-747&author=Y.+Haiauthor=D.+W.+Christianson&title=Histone+Deacetylase+6+Structure+and+Molecular+Basis+of+Catalysis+and+Inhibition&doi=10.1038%2Fnchembio.2134"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase 6 structure and molecular basis of catalysis and inhibition</span></div><div class="casAuthors">Hai, Yang; Christianson, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">741-747</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Histone deacetylase 6 (HDAC6) is a crit. target for drug design because of its role in oncogenic transformation and cancer metastasis, and is unique among all histone deacetylases in that it contains tandem catalytic domains designated CD1 and CD2.  We now report the crystal structures of CD2 from Homo sapiens HDAC6 and of CD1 and CD2 from Danio rerio HDAC6.  We correlated these structures with activity measurements using 13 different substrates.  The catalytic activity of CD2 from both species exhibited broad substrate specificity, whereas that of CD1 was highly specific for substrates bearing C-terminal acetyllysine residues.  Crystal structures of substrate complexes yielded unprecedented snapshots of the catalytic mechanism.  Addnl., crystal structures of complexes with eight different inhibitors, including belinostat and panobinostat (currently used in cancer chemotherapy), the macrocyclic tetrapeptide HC toxin, and the HDAC6-specific inhibitor N-hydroxy-4-(2-((2-hydroxyethyl)(phenyl)amino)-2-oxoethyl)benzamide, revealed surprising new insight regarding changes in Zn2+ coordination and isoenzyme-specific inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqCfziGBHBRLVg90H21EOLACvtfcHk0lgxGsPs0-AQzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Kmu7rJ&md5=e167bc6f66e00923da4f2bced2b306b9</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.2134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.2134%26sid%3Dliteratum%253Aachs%26aulast%3DHai%26aufirst%3DY.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26atitle%3DHistone%2520Deacetylase%25206%2520Structure%2520and%2520Molecular%2520Basis%2520of%2520Catalysis%2520and%2520Inhibition%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2016%26volume%3D12%26spage%3D741%26epage%3D747%26doi%3D10.1038%2Fnchembio.2134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miyake, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keusch, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melancon, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helquist, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gut, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthias, P.</span></span> <span> </span><span class="NLM_article-title">Structural Insights into HDAC6 Tubulin Deacetylation and Its Selective Inhibition</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">748</span>– <span class="NLM_lpage">754</span>, <span class="refDoi"> DOI: 10.1038/nchembio.2140</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1038%2Fnchembio.2140" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=27454931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Kmu7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=748-754&author=Y.+Miyakeauthor=J.+J.+Keuschauthor=L.+Wangauthor=M.+Saitoauthor=D.+Hessauthor=X.+Wangauthor=B.+J.+Melanconauthor=P.+Helquistauthor=H.+Gutauthor=P.+Matthias&title=Structural+Insights+into+HDAC6+Tubulin+Deacetylation+and+Its+Selective+Inhibition&doi=10.1038%2Fnchembio.2140"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Structural insights into HDAC6 tubulin deacetylation and its selective inhibition</span></div><div class="casAuthors">Miyake, Yasuyuki; Keusch, Jeremy J.; Wang, Longlong; Saito, Makoto; Hess, Daniel; Wang, Xiaoning; Melancon, Bruce J.; Helquist, Paul; Gut, Heinz; Matthias, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">748-754</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The authors report crystal structures of zebrafish histone deacetylase 6 (HDAC6) catalytic domains in tandem or as single domains in complex with the (R) and (S) enantiomers of trichostatin A (TSA) or with the HDAC6-specific inhibitor, nexturastat A.  The tandem domains formed, together with the inter-domain linker, an ellipsoid-shaped complex with pseudo-twofold symmetry.  The authors identified important active site differences between both catalytic domains and revealed the binding mode of HDAC6 selective inhibitors.  HDAC inhibition assays with (R)- and (S)-TSA showed that (R)-TSA was a broad-range inhibitor, whereas (S)-TSA had moderate selectivity for HDAC6.  The authors identified a uniquely positioned α-helix and a flexible Trp residue in the loop joining α-helixes H20 to H21 as crit. for deacetylation of the physiol. substrate, tubulin.  Using single-mol. measurements and biochem. assays, the authors demonstrated that HDAC6 catalytic domain 2 deacetylated α-tubulin Lys-40 in the lumen of microtubules, but that its preferred substrate was unpolymd. tubulin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpERJRurS1cC7Vg90H21EOLACvtfcHk0ljtf79FkvvzVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Kmu7rM&md5=4abe529ab89615df33f54350a1a8c69a</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.2140&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.2140%26sid%3Dliteratum%253Aachs%26aulast%3DMiyake%26aufirst%3DY.%26aulast%3DKeusch%26aufirst%3DJ.%2BJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DSaito%26aufirst%3DM.%26aulast%3DHess%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DMelancon%26aufirst%3DB.%2BJ.%26aulast%3DHelquist%26aufirst%3DP.%26aulast%3DGut%26aufirst%3DH.%26aulast%3DMatthias%26aufirst%3DP.%26atitle%3DStructural%2520Insights%2520into%2520HDAC6%2520Tubulin%2520Deacetylation%2520and%2520Its%2520Selective%2520Inhibition%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2016%26volume%3D12%26spage%3D748%26epage%3D754%26doi%3D10.1038%2Fnchembio.2140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haggarty, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koeller, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grozinger, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S. L.</span></span> <span> </span><span class="NLM_article-title">Domain-Selective Small-Molecule Inhibitor of Histone Deacetylase 6 (HDAC6)-Mediated Tubulin Deacetylation</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">4389</span>– <span class="NLM_lpage">4394</span>, <span class="refDoi"> DOI: 10.1073/pnas.0430973100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1073%2Fpnas.0430973100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=12677000" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjt12gtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2003&pages=4389-4394&author=S.+J.+Haggartyauthor=K.+M.+Koellerauthor=J.+C.+Wongauthor=C.+M.+Grozingerauthor=S.+L.+Schreiber&title=Domain-Selective+Small-Molecule+Inhibitor+of+Histone+Deacetylase+6+%28HDAC6%29-Mediated+Tubulin+Deacetylation&doi=10.1073%2Fpnas.0430973100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation</span></div><div class="casAuthors">Haggarty, Stephen J.; Koeller, Kathryn M.; Wong, Jason C.; Grozinger, Christina M.; Schreiber, Stuart L.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4389-4394</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Protein acetylation, esp. histone acetylation, is the subject of both research and clin. investigation.  At least four small-mol. histone deacetylase inhibitors are currently in clin. trials for the treatment of cancer.  These and other inhibitors also affect microtubule acetylation.  A multidimensional, chem. genetic screen of 7392 small mols. was used to discover "tubacin," which inhibits α-tubulin deacetylation in mammalian cells.  Tubacin does not affect the level of histone acetylation, gene-expression patterns, or cell-cycle progression.  We provide evidence that class II histone deacetylase 6 (HDAC6) is the intracellular target of tubacin.  Only one of the two catalytic domains of HDAC6 possesses tubulin deacetylase activity, and only this domain is bound by tubacin.  Tubacin treatment did not affect the stability of microtubules but did decrease cell motility.  HDAC6 overexpression disrupted the localization of p58, a protein that mediates binding of Golgi elements to microtubules.  Our results highlight the role of α-tubulin acetylation in mediating the localization of microtubule-assocd. proteins.  They also suggest that small mols. that selectively inhibit HDAC6-mediated α-tubulin deacetylation, a first example of which is tubacin, might have therapeutic applications as antimetastatic and antiangiogenic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbQBWjEZr47rVg90H21EOLACvtfcHk0ljtf79FkvvzVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjt12gtL0%253D&md5=260da1ede64782ddbddda31b740b9782</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0430973100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0430973100%26sid%3Dliteratum%253Aachs%26aulast%3DHaggarty%26aufirst%3DS.%2BJ.%26aulast%3DKoeller%26aufirst%3DK.%2BM.%26aulast%3DWong%26aufirst%3DJ.%2BC.%26aulast%3DGrozinger%26aufirst%3DC.%2BM.%26aulast%3DSchreiber%26aufirst%3DS.%2BL.%26atitle%3DDomain-Selective%2520Small-Molecule%2520Inhibitor%2520of%2520Histone%2520Deacetylase%25206%2520%2528HDAC6%2529-Mediated%2520Tubulin%2520Deacetylation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2003%26volume%3D100%26spage%3D4389%26epage%3D4394%26doi%3D10.1073%2Fpnas.0430973100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cubizolles, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rousseaux, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kneissel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chua, K.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Mice Lacking Histone Deacetylase 6 Have Hyperacetylated Tubulin but Are Viable and Develop Normally</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">1688</span>– <span class="NLM_lpage">1701</span>, <span class="refDoi"> DOI: 10.1128/mcb.01154-06</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1128%2FMCB.01154-06" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=18180281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BD1cXivVajtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2008&pages=1688-1701&author=Y.+Zhangauthor=S.+Kwonauthor=T.+Yamaguchiauthor=F.+Cubizollesauthor=S.+Rousseauxauthor=M.+Kneisselauthor=C.+Caoauthor=N.+Liauthor=H.-L.+Chengauthor=K.+Chua&title=Mice+Lacking+Histone+Deacetylase+6+Have+Hyperacetylated+Tubulin+but+Are+Viable+and+Develop+Normally&doi=10.1128%2Fmcb.01154-06"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally</span></div><div class="casAuthors">Zhang, Yu; Kwon, SoHee; Yamaguchi, Teppei; Cubizolles, Fabien; Rousseaux, Sophie; Kneissel, Michaela; Cao, Chun; Li, Na; Cheng, Hwei-Ling; Chua, Katrin; Lombard, David; Mizeracki, Adam; Matthias, Gabriele; Alt, Frederick W.; Khochbin, Saadi; Matthias, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1688-1701</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Posttranslational modifications play important roles in regulating protein structure and function.  Histone deacetylase 6 (HDAC6) is a mostly cytoplasmic class II HDAC, which has a unique structure with two catalytic domains and a domain binding ubiquitin with high affinity.  This enzyme was recently identified as a multisubstrate protein deacetylase that can act on acetylated histone tails, α-tubulin and Hsp90.  To investigate the in vivo functions of HDAC6 and the relevance of tubulin acetylation/deacetylation, we targeted the HDAC6 gene by homologous recombination in embryonic stem cells and generated knockout mice.  HDAC6-deficient mice are viable and fertile and show hyperacetylated tubulin in most tissues.  The highest level of expression of HDAC6 is seen in the testis, yet development and function of this organ are normal in the absence of HDAC6.  Likewise, lymphoid development is normal, but the immune response is moderately affected.  Furthermore, the lack of HDAC6 results in a small increase in cancellous bone mineral d., indicating that this deacetylase plays a minor role in bone biol.  HDAC6-deficient mouse embryonic fibroblasts show apparently normal microtubule organization and stability and also show increased Hsp90 acetylation correlating with impaired Hsp90 function.  Collectively, these data demonstrate that mice survive well without HDAC6 and that tubulin hyperacetylation is not detrimental to normal mammalian development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1on7_hqKefrVg90H21EOLACvtfcHk0ljtf79FkvvzVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXivVajtLo%253D&md5=9c83b56ee31ea67a04357b31467ed655</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1128%2FMCB.01154-06&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.01154-06%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DKwon%26aufirst%3DS.%26aulast%3DYamaguchi%26aufirst%3DT.%26aulast%3DCubizolles%26aufirst%3DF.%26aulast%3DRousseaux%26aufirst%3DS.%26aulast%3DKneissel%26aufirst%3DM.%26aulast%3DCao%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DCheng%26aufirst%3DH.-L.%26aulast%3DChua%26aufirst%3DK.%26atitle%3DMice%2520Lacking%2520Histone%2520Deacetylase%25206%2520Have%2520Hyperacetylated%2520Tubulin%2520but%2520Are%2520Viable%2520and%2520Develop%2520Normally%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2008%26volume%3D28%26spage%3D1688%26epage%3D1701%26doi%3D10.1128%2Fmcb.01154-06" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Messaoudi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishaq, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palazzo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sliwa, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bluteau, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Souquère, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diop, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rameau, P.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Critical Role of the HDAC6-Cortactin Axis in Human Megakaryocyte Maturation Leading to a Proplatelet-Formation Defect</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1786</span>, <span class="refDoi"> DOI: 10.1038/s41467-017-01690-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1038%2Fs41467-017-01690-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=29176689" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A280%3ADC%252BC1M3ltV2qsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1786&author=K.+Messaoudiauthor=A.+Aliauthor=R.+Ishaqauthor=A.+Palazzoauthor=D.+Sliwaauthor=O.+Bluteauauthor=S.+Souqu%C3%A8reauthor=D.+Mullerauthor=K.+M.+Diopauthor=P.+Rameau&title=Critical+Role+of+the+HDAC6-Cortactin+Axis+in+Human+Megakaryocyte+Maturation+Leading+to+a+Proplatelet-Formation+Defect&doi=10.1038%2Fs41467-017-01690-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Critical role of the HDAC6-cortactin axis in human megakaryocyte maturation leading to a proplatelet-formation defect</span></div><div class="casAuthors">Messaoudi Kahia; Ali Ashfaq; Ishaq Rameez; Palazzo Alberta; Sliwa Dominika; Bluteau Olivier; Muller Delphine; Godin Isabelle; Droin Nathalie; Vainchenker William; Plo Isabelle; Raslova Hana; Debili Najet; Messaoudi Kahia; Ali Ashfaq; Ishaq Rameez; Palazzo Alberta; Sliwa Dominika; Bluteau Olivier; Muller Delphine; Godin Isabelle; Droin Nathalie; Vainchenker William; Plo Isabelle; Raslova Hana; Debili Najet; Messaoudi Kahia; Ali Ashfaq; Ishaq Rameez; Palazzo Alberta; Sliwa Dominika; Bluteau Olivier; Muller Delphine; Godin Isabelle; Droin Nathalie; Vainchenker William; Plo Isabelle; Raslova Hana; Debili Najet; Messaoudi Kahia; Ali Ashfaq; Ishaq Rameez; Palazzo Alberta; Souquere Sylvie; Pierron Gerard; Diop Khadija M; Droin Nathalie; Rameau Philippe; Lapierre Valerie; Marolleau Jean-Pierre; Matthias Patrick; Thomas Steven G; Watson Stephen P; Thomas Steven G; Watson Stephen P</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1786</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Thrombocytopenia is a major side effect of a new class of anticancer agents that target histone deacetylase (HDAC).  Their mechanism is poorly understood.  Here, we show that HDAC6 inhibition and genetic knockdown lead to a strong decrease in human proplatelet formation (PPF).  Unexpectedly, HDAC6 inhibition-induced tubulin hyperacetylation has no effect on PPF.  The PPF decrease induced by HDAC6 inhibition is related to cortactin (CTTN) hyperacetylation associated with actin disorganization inducing important changes in the distribution of megakaryocyte (MK) organelles.  CTTN silencing in human MKs phenocopies HDAC6 inactivation and knockdown leads to a strong PPF defect.  This is rescued by forced expression of a deacetylated CTTN mimetic.  Unexpectedly, unlike human-derived MKs, HDAC6 and CTTN are shown to be dispensable for mouse PPF in vitro and platelet production in vivo.  Our results highlight an unexpected function of HDAC6-CTTN axis as a positive regulator of human but not mouse MK maturation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQBGBYr4SlFFu_Q9URG6Dx8fW6udTcc2ebbdNrV-Ls3Trntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M3ltV2qsg%253D%253D&md5=919c53df63b715bc6cc3caa7a042981c</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fs41467-017-01690-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-017-01690-2%26sid%3Dliteratum%253Aachs%26aulast%3DMessaoudi%26aufirst%3DK.%26aulast%3DAli%26aufirst%3DA.%26aulast%3DIshaq%26aufirst%3DR.%26aulast%3DPalazzo%26aufirst%3DA.%26aulast%3DSliwa%26aufirst%3DD.%26aulast%3DBluteau%26aufirst%3DO.%26aulast%3DSouqu%25C3%25A8re%26aufirst%3DS.%26aulast%3DMuller%26aufirst%3DD.%26aulast%3DDiop%26aufirst%3DK.%2BM.%26aulast%3DRameau%26aufirst%3DP.%26atitle%3DCritical%2520Role%2520of%2520the%2520HDAC6-Cortactin%2520Axis%2520in%2520Human%2520Megakaryocyte%2520Maturation%2520Leading%2520to%2520a%2520Proplatelet-Formation%2520Defect%26jtitle%3DNat.%2520Commun.%26date%3D2017%26volume%3D8%26spage%3D1786%26doi%3D10.1038%2Fs41467-017-01690-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">A Patent Review of Histone Deacetylase 6 Inhibitors in Neurodegenerative Diseases (2014-2019)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">121</span>– <span class="NLM_lpage">136</span>, <span class="refDoi"> DOI: 10.1080/13543776.2019.1708901</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1080%2F13543776.2019.1708901" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=31865813" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVKnsb3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=121-136&author=S.+Shenauthor=A.+P.+Kozikowski&title=A+Patent+Review+of+Histone+Deacetylase+6+Inhibitors+in+Neurodegenerative+Diseases+%282014-2019%29&doi=10.1080%2F13543776.2019.1708901"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">A patent review of histone deacetylase 6 inhibitors in neurodegenerative diseases (2014-2019)</span></div><div class="casAuthors">Shen, Sida; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">121-136</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase 6 (HDAC6) is unique in comparison with other zinc-dependent HDAC family members.  An increasing amt. of evidence from clin. and preclin. research demonstrates the potential of HDAC6 inhibition as an effective therapeutic approach for the treatment of cancer, autoimmune diseases, as well as neurol. disorders.  The recently disclosed crystal structures of HDAC6-ligand complexes offer further means for achieving pharmacophore refinement, thus further accelerating the pace of HDAC6 inhibitor discovery in the last few years.: This review summarizes the latest clin. status of HDAC6 inhibitors, discusses pharmacol. applications of selective HDAC6 inhibitors in neurodegenerative diseases, and describes the patent applications dealing with HDAC6 inhibitors from 2014-2019 that have not been reported in research articles.: Phenylhydroxamate has proven a very useful scaffold in the discovery of potent and selective HDAC6 inhibitors.  However, weaknesses of the hydroxamate function such as metabolic instability and mutagenic potential limit its application in the neurol. field, where long-term administration is required.  The recent invention of oxadiazole-based ligands by pharmaceutical companies may provide a new opportunity to optimize the druglike properties of HDAC6 inhibitors for the treatment of neurodegenerative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCWThC7SH8r7Vg90H21EOLACvtfcHk0lhcLzqtm1atQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVKnsb3J&md5=926d00ce3a0153953eb2f933599500b9</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1080%2F13543776.2019.1708901&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2019.1708901%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DS.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DA%2520Patent%2520Review%2520of%2520Histone%2520Deacetylase%25206%2520Inhibitors%2520in%2520Neurodegenerative%2520Diseases%2520%25282014-2019%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2020%26volume%3D30%26spage%3D121%26epage%3D136%26doi%3D10.1080%2F13543776.2019.1708901" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mackwitz, M. K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamacher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osko, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Held, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schöler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kassack, M. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, F. K.</span></span> <span> </span><span class="NLM_article-title">Multicomponent Synthesis and Binding Mode of Imidazo[1,2- a]Pyridine-Capped Selective HDAC6 Inhibitors</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">3255</span>– <span class="NLM_lpage">3258</span>, <span class="refDoi"> DOI: 10.1021/acs.orglett.8b01118</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.orglett.8b01118" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpvVCnsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2018&pages=3255-3258&author=M.+K.+W.+Mackwitzauthor=A.+Hamacherauthor=J.+D.+Oskoauthor=J.+Heldauthor=A.+Sch%C3%B6lerauthor=D.+W.+Christiansonauthor=M.+U.+Kassackauthor=F.+K.+Hansen&title=Multicomponent+Synthesis+and+Binding+Mode+of+Imidazo%5B1%2C2-+a%5DPyridine-Capped+Selective+HDAC6+Inhibitors&doi=10.1021%2Facs.orglett.8b01118"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Multicomponent Synthesis and Binding Mode of Imidazo[1,2-a]pyridine-Capped Selective HDAC6 Inhibitors</span></div><div class="casAuthors">Mackwitz, Marcel K. W.; Hamacher, Alexandra; Osko, Jeremy D.; Held, Jana; Schoeler, Andrea; Christianson, David W.; Kassack, Matthias U.; Hansen, Finn K.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3255-3258</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7052</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The multicomponent synthesis of a mini-library of histone deacetylase inhibitors with imidazo[1,2-a]pyridine-based cap groups is presented.  The biol. evaluation led to the discovery of the hit compd. MAIP-032 as a selective HDAC6 inhibitor with promising anticancer activity.  The X-ray structure of catalytic domain 2 from Danio rerio HDAC6 complexed with MAIP-032 revealed a monodentate zinc-binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4rI48LyncTrVg90H21EOLACvtfcHk0lhcLzqtm1atQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpvVCnsbw%253D&md5=0c53331fabd83781717e0678a56dab7e</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Facs.orglett.8b01118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.orglett.8b01118%26sid%3Dliteratum%253Aachs%26aulast%3DMackwitz%26aufirst%3DM.%2BK.%2BW.%26aulast%3DHamacher%26aufirst%3DA.%26aulast%3DOsko%26aufirst%3DJ.%2BD.%26aulast%3DHeld%26aufirst%3DJ.%26aulast%3DSch%25C3%25B6ler%26aufirst%3DA.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26aulast%3DKassack%26aufirst%3DM.%2BU.%26aulast%3DHansen%26aufirst%3DF.%2BK.%26atitle%3DMulticomponent%2520Synthesis%2520and%2520Binding%2520Mode%2520of%2520Imidazo%255B1%252C2-%2520a%255DPyridine-Capped%2520Selective%2520HDAC6%2520Inhibitors%26jtitle%3DOrg.%2520Lett.%26date%3D2018%26volume%3D20%26spage%3D3255%26epage%3D3258%26doi%3D10.1021%2Facs.orglett.8b01118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chia, P. L.</span>; <span class="NLM_string-name">Mukhopadhyay, P.</span>; <span class="NLM_string-name">Kelly, S.</span>; <span class="NLM_string-name">Wu, R.</span>; <span class="NLM_string-name">Fenn, K.</span>; <span class="NLM_string-name">Trivedi, M. S.</span></span> <span> </span><span class="NLM_article-title">Network-Based Assessment of HDAC6 Activity Is Highly Predictive of Pre-Clinical and Clinical Responses to the HDAC Inhibitor Ricolinostat</span>. <span class="NLM_year" style="font-weight: bold;">2020</span>, medRxiv.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=P.+L.+Chia&author=P.+Mukhopadhyay&author=S.+Kelly&author=R.+Wu&author=K.+Fenn&author=M.+S.+Trivedi&title=Network-Based+Assessment+of+HDAC6+Activity+Is+Highly+Predictive+of+Pre-Clinical+and+Clinical+Responses+to+the+HDAC+Inhibitor+Ricolinostat"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChia%26aufirst%3DP.%2BL.%26atitle%3DNetwork-Based%2520Assessment%2520of%2520HDAC6%2520Activity%2520Is%2520Highly%2520Predictive%2520of%2520Pre-Clinical%2520and%2520Clinical%2520Responses%2520to%2520the%2520HDAC%2520Inhibitor%2520Ricolinostat%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jochems, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boulden, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blendy, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarpe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazitschek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Duzer, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berton, O.</span></span> <span> </span><span class="NLM_article-title">Antidepressant-like Properties of Novel HDAC6-Selective Inhibitors with Improved Brain Bioavailability</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">389</span>– <span class="NLM_lpage">400</span>, <span class="refDoi"> DOI: 10.1038/npp.2013.207</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1038%2Fnpp.2013.207" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=23954848" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFyntbjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2014&pages=389-400&author=J.+Jochemsauthor=J.+Bouldenauthor=B.+G.+Leeauthor=J.+A.+Blendyauthor=M.+Jarpeauthor=R.+Mazitschekauthor=J.+H.+Van+Duzerauthor=S.+Jonesauthor=O.+Berton&title=Antidepressant-like+Properties+of+Novel+HDAC6-Selective+Inhibitors+with+Improved+Brain+Bioavailability&doi=10.1038%2Fnpp.2013.207"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Antidepressant-Like Properties of Novel HDAC6-Selective Inhibitors with Improved Brain Bioavailability</span></div><div class="casAuthors">Jochems, Jeanine; Boulden, Janette; Lee, Bridgin G.; Blendy, Julie A.; Jarpe, Matthew; Mazitschek, Ralph; Van Duzer, John H.; Jones, Simon; Berton, Olivier</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">389-400</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">HDAC inhibitors have been reported to produce antidepressant and pro-cognitive effects in animal models, however, poor brain bioavailability or lack of isoform selectivity of current probes has limited our understanding of their mode of action.  We report the characterization of novel pyrimidine hydroxyl amide small mol. inhibitors of HDAC6, brain bioavailable upon systemic administration.  We show that two compds. in this family, ACY-738 and ACY-775, inhibit HDAC6 with low nanomolar potency and a selectivity of 60- to 1500-fold over class I HDACs.  In contrast to tubastatin A, a ref. HDAC6 inhibitor with similar potency and peripheral activity, but more limited brain bioavailability, ACY-738 and ACY-775 induce dramatic increases in α-tubulin acetylation in brain and stimulate mouse exploratory behaviors in novel, but not familiar environments.  Interestingly, despite a lack of detectable effect on histone acetylation, we show that ACY-738 and ACY-775 share the antidepressant-like properties of other HDAC inhibitors, such as SAHA and MS-275, in the tail suspension test and social defeat paradigm.  These effects of ACY-738 and ACY-775 are directly attributable to the inhibition of HDAC6 expressed centrally, as they are fully abrogated in mice with a neural-specific loss of function of HDAC6.  Furthermore, administered in combination, a behaviorally inactive dose of ACY-738 markedly potentiates the anti-immobility activity of a subactive dose of the selective serotonin reuptake inhibitor citalopram.  Our results validate new isoform-selective probes for in vivo pharmacol. studies of HDAC6 in the CNS and reinforce the viability of this HDAC isoform as a potential target for antidepressant development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5yEjJGIv3jbVg90H21EOLACvtfcHk0lgMp2e7jmuXwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFyntbjN&md5=9e0f4d3856c84e629602b589161eb4ab</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2013.207&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2013.207%26sid%3Dliteratum%253Aachs%26aulast%3DJochems%26aufirst%3DJ.%26aulast%3DBoulden%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DB.%2BG.%26aulast%3DBlendy%26aufirst%3DJ.%2BA.%26aulast%3DJarpe%26aufirst%3DM.%26aulast%3DMazitschek%26aufirst%3DR.%26aulast%3DVan%2BDuzer%26aufirst%3DJ.%2BH.%26aulast%3DJones%26aufirst%3DS.%26aulast%3DBerton%26aufirst%3DO.%26atitle%3DAntidepressant-like%2520Properties%2520of%2520Novel%2520HDAC6-Selective%2520Inhibitors%2520with%2520Improved%2520Brain%2520Bioavailability%26jtitle%3DNeuropsychopharmacology%26date%3D2014%26volume%3D39%26spage%3D389%26epage%3D400%26doi%3D10.1038%2Fnpp.2013.207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vergani, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandrone, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ripamonti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cellupica, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galbiati, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caprini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavich, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rocchio, I.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Novel Benzohydroxamate-Based Potent and Selective Histone Deacetylase 6 (HDAC6) Inhibitors Bearing a Pentaheterocyclic Scaffold: Design, Synthesis, and Biological Evaluation</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">10711</span>– <span class="NLM_lpage">10739</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01194</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01194" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFeqs77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=10711-10739&author=B.+Verganiauthor=G.+Sandroneauthor=M.+Marchiniauthor=C.+Ripamontiauthor=E.+Cellupicaauthor=E.+Galbiatiauthor=G.+Capriniauthor=G.+Pavichauthor=G.+Porroauthor=I.+Rocchio&title=Novel+Benzohydroxamate-Based+Potent+and+Selective+Histone+Deacetylase+6+%28HDAC6%29+Inhibitors+Bearing+a+Pentaheterocyclic+Scaffold%3A+Design%2C+Synthesis%2C+and+Biological+Evaluation&doi=10.1021%2Facs.jmedchem.9b01194"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Benzohydroxamate-Based Potent and Selective Histone Deacetylase 6 (HDAC6) Inhibitors Bearing a Pentaheterocyclic Scaffold: Design, Synthesis, and Biological Evaluation</span></div><div class="casAuthors">Vergani, Barbara; Sandrone, Giovanni; Marchini, Mattia; Ripamonti, Chiara; Cellupica, Edoardo; Galbiati, Elisabetta; Caprini, Gianluca; Pavich, Gianfranco; Porro, Giulia; Rocchio, Ilaria; Lattanzio, Maria; Pezzuto, Marcello; Skorupska, Malgorzata; Cordella, Paola; Pagani, Paolo; Pozzi, Pietro; Pomarico, Roberta; Modena, Daniela; Leoni, Flavio; Perego, Raffaella; Fossati, Gianluca; Steinkuhler, Christian; Stevenazzi, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10711-10739</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Histone deacetylase 6 (HDAC6) is a peculiar HDAC isoform whose expression and functional alterations were correlated with a variety of pathologies such as autoimmune disorders, neurodegenerative diseases, and cancer.  It is primarily a cytoplasmic protein, and its deacetylase activity is focused mainly on non-histone substrates such as tubulin, heat shock protein (HSP)90, Foxp3 and cortactin, to name a few.  Selective inhibition of HDAC6 does not show cytotoxic effects in healthy cells, normally assocd. with the inhibition of Class I HDAC isoforms.  Here the authors describe the design and synthesis of a new class of potent and selective HDAC6 inhibitors that bear a pentaheterocyclic central core.  These compds. show a remarkably low toxicity both in vitro and in vivo and are able to increase the function of regulatory T cells (Tregs) at well tolerated concns., suggesting a potential clin. use for the treatment of degenerative, auto-immune diseases and organ transplantation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpV3O384uJCkLVg90H21EOLACvtfcHk0lgMp2e7jmuXwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFeqs77I&md5=efc978e814193713983d2239a821cfd7</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01194&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01194%26sid%3Dliteratum%253Aachs%26aulast%3DVergani%26aufirst%3DB.%26aulast%3DSandrone%26aufirst%3DG.%26aulast%3DMarchini%26aufirst%3DM.%26aulast%3DRipamonti%26aufirst%3DC.%26aulast%3DCellupica%26aufirst%3DE.%26aulast%3DGalbiati%26aufirst%3DE.%26aulast%3DCaprini%26aufirst%3DG.%26aulast%3DPavich%26aufirst%3DG.%26aulast%3DPorro%26aufirst%3DG.%26aulast%3DRocchio%26aufirst%3DI.%26atitle%3DNovel%2520Benzohydroxamate-Based%2520Potent%2520and%2520Selective%2520Histone%2520Deacetylase%25206%2520%2528HDAC6%2529%2520Inhibitors%2520Bearing%2520a%2520Pentaheterocyclic%2520Scaffold%253A%2520Design%252C%2520Synthesis%252C%2520and%2520Biological%2520Evaluation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D10711%26epage%3D10739%26doi%3D10.1021%2Facs.jmedchem.9b01194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shouksmith, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimard, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gawel, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raouf, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geletu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger-Becvar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Araujo, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luchman, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heaton, W. L.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Identification and Characterization of AES-135, a Hydroxamic Acid-Based HDAC Inhibitor That Prolongs Survival in an Orthotopic Mouse Model of Pancreatic Cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">2651</span>– <span class="NLM_lpage">2665</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01957</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01957" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjt1Slu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=2651-2665&author=A.+E.+Shouksmithauthor=F.+Shahauthor=M.+L.+Grimardauthor=J.+M.+Gawelauthor=Y.+S.+Raoufauthor=M.+Geletuauthor=A.+Berger-Becvarauthor=E.+D.+De+Araujoauthor=H.+A.+Luchmanauthor=W.+L.+Heaton&title=Identification+and+Characterization+of+AES-135%2C+a+Hydroxamic+Acid-Based+HDAC+Inhibitor+That+Prolongs+Survival+in+an+Orthotopic+Mouse+Model+of+Pancreatic+Cancer&doi=10.1021%2Facs.jmedchem.8b01957"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and characterization of AES-135, a hydroxamic acid-based HDAC inhibitor that prolongs survival in an orthotopic mouse model of pancreatic cancer</span></div><div class="casAuthors">Shouksmith, Andrew E.; Shah, Fenil; Grimard, Michelle L.; Gawel, Justyna M.; Raouf, Yasir S.; Geletu, Mulu; Berger-Becvar, Angelika; de Araujo, Elvin D.; Luchman, H. Artee; Heaton, William L.; Bakhshinyan, David; Adile, Ashley A.; Venugopal, Chitra; O'Hare, Thomas; Deininger, Michael W.; Singh, Sheila K.; Konieczny, Stephen F.; Weiss, Samuel; Fishel, Melissa L.; Gunning, Patrick T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2651-2665</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Pancreatic ductal adenocarcinoma (PDAC) is an aggressive, incurable cancer with a 20% 1 yr survival rate.  While std.-of-care therapy can prolong life in a small fraction of cases, PDAC is inherently resistant to current treatments, and novel therapies are urgently required.  Histone deacetylase (HDAC) inhibitors are effective in killing pancreatic cancer cells in in vitro PDAC studies, and although there are a few clin. studies investigating combination therapy including HDAC inhibitors, no HDAC drug or combination therapy with an HDAC drug has been approved for the treatment of PDAC.  We developed an inhibitor of HDACs, AES-135, that exhibits nanomolar inhibitory activity against HDAC3, HDAC6, and HDAC11 in biochem. assays.  In a three-dimensional coculture model, AES-135 kills low-passage patient-derived tumor spheroids selectively over surrounding cancer-assocd. fibroblasts and has excellent pharmacokinetic properties in vivo.  In an orthotopic murine model of pancreatic cancer, AES-135 prolongs survival significantly, therefore representing a candidate for further preclin. testing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsx6K4JeAb-bVg90H21EOLACvtfcHk0lgMp2e7jmuXwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjt1Slu78%253D&md5=2b90becae883cc5552a701a614d8c452</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01957&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01957%26sid%3Dliteratum%253Aachs%26aulast%3DShouksmith%26aufirst%3DA.%2BE.%26aulast%3DShah%26aufirst%3DF.%26aulast%3DGrimard%26aufirst%3DM.%2BL.%26aulast%3DGawel%26aufirst%3DJ.%2BM.%26aulast%3DRaouf%26aufirst%3DY.%2BS.%26aulast%3DGeletu%26aufirst%3DM.%26aulast%3DBerger-Becvar%26aufirst%3DA.%26aulast%3DDe%2BAraujo%26aufirst%3DE.%2BD.%26aulast%3DLuchman%26aufirst%3DH.%2BA.%26aulast%3DHeaton%26aufirst%3DW.%2BL.%26atitle%3DIdentification%2520and%2520Characterization%2520of%2520AES-135%252C%2520a%2520Hydroxamic%2520Acid-Based%2520HDAC%2520Inhibitor%2520That%2520Prolongs%2520Survival%2520in%2520an%2520Orthotopic%2520Mouse%2520Model%2520of%2520Pancreatic%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D2651%26epage%3D2665%26doi%3D10.1021%2Facs.jmedchem.8b01957" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Porter, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osko, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diedrich, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hooker, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, F. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase 6-Selective Inhibitors and the Influence of Capping Groups on Hydroxamate-Zinc Denticity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">8054</span>– <span class="NLM_lpage">8060</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01013</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01013" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFansLnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=8054-8060&author=N.+J.+Porterauthor=J.+D.+Oskoauthor=D.+Diedrichauthor=T.+Kurzauthor=J.+M.+Hookerauthor=F.+K.+Hansenauthor=D.+W.+Christianson&title=Histone+Deacetylase+6-Selective+Inhibitors+and+the+Influence+of+Capping+Groups+on+Hydroxamate-Zinc+Denticity&doi=10.1021%2Facs.jmedchem.8b01013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase 6-Selective Inhibitors and the Influence of Capping Groups on Hydroxamate-Zinc Denticity</span></div><div class="casAuthors">Porter, Nicholas J.; Osko, Jeremy D.; Diedrich, Daniela; Kurz, Thomas; Hooker, Jacob M.; Hansen, Finn K.; Christianson, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">8054-8060</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Four crystal structures are presented of histone deacetylase 6 (HDAC6) complexes with para-substituted phenylhydromaxamate inhibitors, including bulky peptoids.  These structures provide insight regarding the design of capping groups that confer selectivity for binding to HDAC6, specifically with regard to interactions in a pocket formed by the L1 loop.  Capping group interactions may also influence hydroxamate-Zn2+ coordination with monodentate or bidentate geometry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq54PM6p6wpnrVg90H21EOLACvtfcHk0ljisfnFjFK1Ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFansLnE&md5=f1d227d7668d09e121e5967b2d65f1a5</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01013%26sid%3Dliteratum%253Aachs%26aulast%3DPorter%26aufirst%3DN.%2BJ.%26aulast%3DOsko%26aufirst%3DJ.%2BD.%26aulast%3DDiedrich%26aufirst%3DD.%26aulast%3DKurz%26aufirst%3DT.%26aulast%3DHooker%26aufirst%3DJ.%2BM.%26aulast%3DHansen%26aufirst%3DF.%2BK.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26atitle%3DHistone%2520Deacetylase%25206-Selective%2520Inhibitors%2520and%2520the%2520Influence%2520of%2520Capping%2520Groups%2520on%2520Hydroxamate-Zinc%2520Denticity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D8054%26epage%3D8060%26doi%3D10.1021%2Facs.jmedchem.8b01013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svoboda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavasin, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Motlova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKinsey, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eubanks, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bařinka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">Structural and in Vivo Characterization of Tubastatin A, a Widely Used Histone Deacetylase 6 Inhibitor</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">706</span>– <span class="NLM_lpage">712</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00560</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00560" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFarsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=706-712&author=S.+Shenauthor=M.+Svobodaauthor=G.+Zhangauthor=M.+A.+Cavasinauthor=L.+Motlovaauthor=T.+A.+McKinseyauthor=J.+H.+Eubanksauthor=C.+Ba%C5%99inkaauthor=A.+P.+Kozikowski&title=Structural+and+in+Vivo+Characterization+of+Tubastatin+A%2C+a+Widely+Used+Histone+Deacetylase+6+Inhibitor&doi=10.1021%2Facsmedchemlett.9b00560"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and in Vivo Characterization of Tubastatin A, a Widely Used Histone Deacetylase 6 Inhibitor</span></div><div class="casAuthors">Shen, Sida; Svoboda, Michal; Zhang, Guangming; Cavasin, Maria A.; Motlova, Lucia; McKinsey, Timothy A.; Eubanks, James H.; Barinka, Cyril; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">706-712</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tubastatin A, a tetrahydro-γ-carboline-capped selective HDAC6 inhibitor (HDAC6i), was rationally designed 10 years ago, and has become the best investigated HDAC6i to date.  It shows efficacy in various neurol. disease animal models, as HDAC6 plays a crucial regulatory role in axonal transport deficits, protein aggregation, as well as oxidative stress.  In this work, we provide new insights into this HDAC6i by investigating the mol. basis of its interactions with HDAC6 through X-ray crystallog., detg. its functional capability to elevate the levels of acetylated α-tubulin in vitro and in vivo, correlating PK/PD profiles to det. EDs in plasma and brain, and finally assessing its therapeutic potential toward psychiatric diseases through use of the SmartCube screening platform.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpi67K0VhCsP7Vg90H21EOLACvtfcHk0ljisfnFjFK1Ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFarsr8%253D&md5=431ff199537a679fc09f19f95e528219</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00560&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00560%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DS.%26aulast%3DSvoboda%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DCavasin%26aufirst%3DM.%2BA.%26aulast%3DMotlova%26aufirst%3DL.%26aulast%3DMcKinsey%26aufirst%3DT.%2BA.%26aulast%3DEubanks%26aufirst%3DJ.%2BH.%26aulast%3DBa%25C5%2599inka%26aufirst%3DC.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DStructural%2520and%2520in%2520Vivo%2520Characterization%2520of%2520Tubastatin%2520A%252C%2520a%2520Widely%2520Used%2520Histone%2520Deacetylase%25206%2520Inhibitor%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26spage%3D706%26epage%3D712%26doi%3D10.1021%2Facsmedchemlett.9b00560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Porter, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahendran, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breslow, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span> <span> </span><span class="NLM_article-title">Unusual Zinc-Binding Mode of HDAC6-Selective Hydroxamate Inhibitors</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">13459</span>– <span class="NLM_lpage">13464</span>, <span class="refDoi"> DOI: 10.1073/pnas.1718823114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1073%2Fpnas.1718823114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=29203661" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFWgsrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2017&pages=13459-13464&author=N.+J.+Porterauthor=A.+Mahendranauthor=R.+Breslowauthor=D.+W.+Christianson&title=Unusual+Zinc-Binding+Mode+of+HDAC6-Selective+Hydroxamate+Inhibitors&doi=10.1073%2Fpnas.1718823114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors</span></div><div class="casAuthors">Porter, Nicholas J.; Mahendran, Adaickapillai; Breslow, Ronald; Christianson, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">51</span>),
    <span class="NLM_cas:pages">13459-13464</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) regulate myriad cellular processes by catalyzing the hydrolysis of acetyl-L-lysine residues in histone and nonhistone proteins.  The Zn2+-dependent class IIb enzyme HDAC6 regulates microtubule function by deacetylating α-tubulin, which suppresses microtubule dynamics and leads to cell cycle arrest and apoptosis.  Accordingly, HDAC6 is a target for the development of selective inhibitors that might be useful in new therapeutic approaches for the treatment of cancer, neurodegenerative diseases, and other disorders.  Here, we present high-resoln. structures of catalytic domain 2 from Danio rerio HDAC6 (henceforth simply "HDAC6") complexed with compds. that selectively inhibit HDAC6 while maintaining nanomolar inhibitory potency: N-hydroxy-4-((N(2-hydroxyethyl)-2-phenylacetamido)methyl)-benzamide (HPB), ACY-1215 (Ricolinostat), and ACY-1083.  These structures reveal that an unusual monodentate Zn2+ coordination mode is exploited by sterically bulky HDAC6-selective phenylhydroxamate inhibitors.  We addnl. report the ultrahigh-resoln. structure of the HDAC6-trichostatin A complex, which reveals two Zn2+-binding conformers for the inhibitor: a major conformer (70%) with canonical bidentate hydroxamate-Zn2+ coordination geometry and a minor conformer (30%) with monodentate hydroxamate-Zn2+ coordination geometry, reflecting a free energy difference of only 0.5 kcal/mol.  The minor conformer is not visible in lower resoln. structure detns.  Structural comparisons of HDAC6-inhibitor complexes with class I HDACs suggest active site features that contribute to the isoenzyme selectivity obsd. in biochem. assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0oUH1X_04p7Vg90H21EOLACvtfcHk0lhOHILu3H0KTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFWgsrbI&md5=07180756239eac4891642cf59a2e6992</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1718823114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1718823114%26sid%3Dliteratum%253Aachs%26aulast%3DPorter%26aufirst%3DN.%2BJ.%26aulast%3DMahendran%26aufirst%3DA.%26aulast%3DBreslow%26aufirst%3DR.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26atitle%3DUnusual%2520Zinc-Binding%2520Mode%2520of%2520HDAC6-Selective%2520Hydroxamate%2520Inhibitors%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2017%26volume%3D114%26spage%3D13459%26epage%3D13464%26doi%3D10.1073%2Fpnas.1718823114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gawel, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shouksmith, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raouf, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nawar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toutah, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bukhari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manaswiyoungkul, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olaoye, O. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Israelian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radu, T. B.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">PTG-0861: A Novel HDAC6-Selective Inhibitor as a Therapeutic Strategy in Acute Myeloid Leukaemia</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>201</i></span>,  <span class="NLM_fpage">112411</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112411</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1016%2Fj.ejmech.2020.112411" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=32615502" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlSht73E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=201&publication_year=2020&pages=112411&author=J.+M.+Gawelauthor=A.+E.+Shouksmithauthor=Y.+S.+Raoufauthor=N.+Nawarauthor=K.+Toutahauthor=S.+Bukhariauthor=P.+Manaswiyoungkulauthor=O.+O.+Olaoyeauthor=J.+Israelianauthor=T.+B.+Radu&title=PTG-0861%3A+A+Novel+HDAC6-Selective+Inhibitor+as+a+Therapeutic+Strategy+in+Acute+Myeloid+Leukaemia&doi=10.1016%2Fj.ejmech.2020.112411"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">PTG-0861: A novel HDAC6-selective inhibitor as a therapeutic strategy in acute myeloid leukaemia</span></div><div class="casAuthors">Gawel, Justyna M.; Shouksmith, Andrew E.; Raouf, Yasir S.; Nawar, Nabanita; Toutah, Krimo; Bukhari, Shazreh; Manaswiyoungkul, Pimyupa; Olaoye, Olasunkanmi O.; Israelian, Johan; Radu, Tudor B.; Cabral, Aaron D.; Sina, Diana; Sedighi, Abootaleb; de Araujo, Elvin D.; Gunning, Patrick T.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">201</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112411</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Dysregulated Histone Deacetylase (HDAC) activity across multiple human pathologies have highlighted this family of epigenetic enzymes as crit. druggable targets, amenable to small mol. intervention.  While efficacious, current approaches using non-selective HDAC inhibitors (HDACi) have been shown to cause a range of undesirable clin. toxicities.  To circumvent this, recent efforts have focused on the design of highly selective HDACi as a novel therapeutic strategy.  Beyond roles in regulating transcription, the unique HDAC6 (with two catalytic domains) regulates the deacetylation of α-tubulin; promoting growth factor-controlled cell motility, cell division, and metastatic hallmarks.  Recent studies have linked aberrant HDAC6 function in various hematol. cancers including acute myeloid leukemia and multiple myeloma.  Herein, we report the discovery, in vitro characterization, and biol. evaluation of PTG-0861 (JG-265), a novel HDAC6-selective inhibitor with strong isoenzyme-selectivity (∼36x ) and low nanomolar potency (IC50 = 5.92 nM) against HDAC6.  This selectivity profile was rationalized via in silico docking studies and also obsd. in cellulo through cellular target engagement.  Moreover, PTG-0861 achieved relevant potency against several blood cancer cell lines (e.g. MV4-11, MM1S), while showing limited cytotoxicity against non-malignant cells (e.g. NHF, HUVEC) and CD-1 mice.  In examg. compd. stability and cellular permeability, PTG-0861 revealed a promising in vitro pharmacokinetic (PK) profile.  Altogether, in this study we identified a novel and potent HDAC6-selective inhibitor (∼4x more selective than current clin. stds. - citarinostat, ricolinostat), which achieves cellular target engagement, efficacy in hematol. cancer cells with a promising safety profile and in vitro PK.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGUpACNMyWt7Vg90H21EOLACvtfcHk0lhOHILu3H0KTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlSht73E&md5=c5b2e399be96a785b52019f04e1c08b8</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112411&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112411%26sid%3Dliteratum%253Aachs%26aulast%3DGawel%26aufirst%3DJ.%2BM.%26aulast%3DShouksmith%26aufirst%3DA.%2BE.%26aulast%3DRaouf%26aufirst%3DY.%2BS.%26aulast%3DNawar%26aufirst%3DN.%26aulast%3DToutah%26aufirst%3DK.%26aulast%3DBukhari%26aufirst%3DS.%26aulast%3DManaswiyoungkul%26aufirst%3DP.%26aulast%3DOlaoye%26aufirst%3DO.%2BO.%26aulast%3DIsraelian%26aufirst%3DJ.%26aulast%3DRadu%26aufirst%3DT.%2BB.%26atitle%3DPTG-0861%253A%2520A%2520Novel%2520HDAC6-Selective%2520Inhibitor%2520as%2520a%2520Therapeutic%2520Strategy%2520in%2520Acute%2520Myeloid%2520Leukaemia%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D201%26spage%3D112411%26doi%3D10.1016%2Fj.ejmech.2020.112411" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shouksmith, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gawel, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nawar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sina, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raouf, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bukhari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johns, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manaswiyoungkul, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olaoye, O. O.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">56</span>– <span class="NLM_lpage">64</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00471</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00471" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlygtLrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=56-64&author=A.+E.+Shouksmithauthor=J.+M.+Gawelauthor=N.+Nawarauthor=D.+Sinaauthor=Y.+S.+Raoufauthor=S.+Bukhariauthor=L.+Heauthor=A.+E.+Johnsauthor=P.+Manaswiyoungkulauthor=O.+O.+Olaoye&title=Class+I%2FIIb-Selective+HDAC+Inhibitor+Exhibits+Oral+Bioavailability+and+Therapeutic+Efficacy+in+Acute+Myeloid+Leukemia&doi=10.1021%2Facsmedchemlett.9b00471"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia</span></div><div class="casAuthors">Shouksmith, Andrew E.; Gawel, Justyna M.; Nawar, Nabanita; Sina, Diana; Raouf, Yasir S.; Bukhari, Shazreh; He, Liying; Johns, Alexandra E.; Manaswiyoungkul, Pimyupa; Olaoye, Olasunkanmi O.; Cabral, Aaron D.; Sedighi, Abootaleb; de Araujo, Elvin D.; Gunning, Patrick T.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">56-64</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The HDAC inhibitor 4-tert-butyl-N-(4-(hydroxycarbamoyl)phenyl)benzamide (AES-350, I) was identified as a promising preclin. candidate for the treatment of acute myeloid leukemia (AML), an aggressive malignancy with a meagre 24% 5-yr survival rate.  Through screening of low-mol.-wt. analogs derived from the previously discovered novel HDAC inhibitor, AES-135 (II), compd. I demonstrated greater HDAC isoform selectivity, higher cytotoxicity in MV4-11 cells, an improved therapeutic window, and more efficient absorption through cellular and lipid membranes.  Compd. I also demonstrated improved oral bioavailability compared to SAHA in mouse models.  A broad spectrum of expts., including FACS, ELISA, and Western blotting, were performed to support our hypothesis that I dose-dependently triggers apoptosis in AML cells through HDAC inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8ikqWn7KZc7Vg90H21EOLACvtfcHk0lhOHILu3H0KTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlygtLrK&md5=3c21f11cda2a27e00f30a7cd3c700785</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00471&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00471%26sid%3Dliteratum%253Aachs%26aulast%3DShouksmith%26aufirst%3DA.%2BE.%26aulast%3DGawel%26aufirst%3DJ.%2BM.%26aulast%3DNawar%26aufirst%3DN.%26aulast%3DSina%26aufirst%3DD.%26aulast%3DRaouf%26aufirst%3DY.%2BS.%26aulast%3DBukhari%26aufirst%3DS.%26aulast%3DHe%26aufirst%3DL.%26aulast%3DJohns%26aufirst%3DA.%2BE.%26aulast%3DManaswiyoungkul%26aufirst%3DP.%26aulast%3DOlaoye%26aufirst%3DO.%2BO.%26atitle%3DClass%2520I%252FIIb-Selective%2520HDAC%2520Inhibitor%2520Exhibits%2520Oral%2520Bioavailability%2520and%2520Therapeutic%2520Efficacy%2520in%2520Acute%2520Myeloid%2520Leukemia%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26spage%3D56%26epage%3D64%26doi%3D10.1021%2Facsmedchemlett.9b00471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Osko, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span> <span> </span><span class="NLM_article-title">Structural Basis of Catalysis and Inhibition of HDAC6 CD1, the Enigmatic Catalytic Domain of Histone Deacetylase 6</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">4912</span>– <span class="NLM_lpage">4924</span>, <span class="refDoi"> DOI: 10.1021/acs.biochem.9b00934</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.9b00934" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1Snsb3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2019&pages=4912-4924&author=J.+D.+Oskoauthor=D.+W.+Christianson&title=Structural+Basis+of+Catalysis+and+Inhibition+of+HDAC6+CD1%2C+the+Enigmatic+Catalytic+Domain+of+Histone+Deacetylase+6&doi=10.1021%2Facs.biochem.9b00934"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis of Catalysis and Inhibition of HDAC6 CD1, the Enigmatic Catalytic Domain of Histone Deacetylase 6</span></div><div class="casAuthors">Osko, Jeremy D.; Christianson, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">4912-4924</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Histone deacetylase 6 (HDAC6) is emerging as a target for inhibition in therapeutic strategies aimed at treating cancer, neurodegenerative disease, and other disorders.  Among the metal-dependent HDAC isoenzymes, HDAC6 is unique in that it contains two catalytic domains, CD1 and CD2.  CD2 is a tubulin deacetylase and a tau deacetylase, and the development of HDAC6-selective inhibitors has focused exclusively on this domain.  In contrast, there is a dearth of structural and functional information regarding CD1, which exhibits much narrower substrate specificity in comparison with CD2.  As the first step in addressing the CD1 information gap, we now present X-ray crystal structures of seven inhibitor complexes with wild-type, Y363F, and K330L HDAC6 CD1.  These structures broaden our understanding of mol. features important for catalysis and inhibitor binding.  The active site of HDAC6 CD1 is wider than that of CD2, which is unexpected in view of the narrow substrate specificity of CD1.  Amino acid substitutions between HDAC6 CD1 and CD2, as well as conformational differences in conserved residues, define striking differences in active site contours.  Catalytic activity measurements with HDAC6 CD1 confirm the preference for peptide substrates contg. C-terminal acetyllysine residues.  However, these measurements also show that CD1 exhibits weak activity for peptide substrates bearing certain small amino acids on the carboxyl side of the scissile acetyllysine residue.  Taken together, these results establish a foundation for understanding the structural basis of HDAC6 CD1 catalysis and inhibition, pointing to possible avenues for the development of HDAC6 CD1-selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrk6bd_6kU9erVg90H21EOLACvtfcHk0lib6CpWE5LoyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1Snsb3P&md5=4bebfc15825270bceeb7b87ca61c0f10</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.9b00934&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.9b00934%26sid%3Dliteratum%253Aachs%26aulast%3DOsko%26aufirst%3DJ.%2BD.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26atitle%3DStructural%2520Basis%2520of%2520Catalysis%2520and%2520Inhibition%2520of%2520HDAC6%2520CD1%252C%2520the%2520Enigmatic%2520Catalytic%2520Domain%2520of%2520Histone%2520Deacetylase%25206%26jtitle%3DBiochemistry%26date%3D2019%26volume%3D58%26spage%3D4912%26epage%3D4924%26doi%3D10.1021%2Facs.biochem.9b00934" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Osko, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span> <span> </span><span class="NLM_article-title">Structural Determinants of Affinity and Selectivity in the Binding of Inhibitors to Histone Deacetylase 6</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">127023</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2020.127023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1016%2Fj.bmcl.2020.127023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=32067866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjtFGqs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=127023&author=J.+D.+Oskoauthor=D.+W.+Christianson&title=Structural+Determinants+of+Affinity+and+Selectivity+in+the+Binding+of+Inhibitors+to+Histone+Deacetylase+6&doi=10.1016%2Fj.bmcl.2020.127023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Structural determinants of affinity and selectivity in the binding of inhibitors to histone deacetylase 6</span></div><div class="casAuthors">Osko, Jeremy D.; Christianson, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">127023</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review. Digest.  Histone deacetylase 6 (HDAC6) is assocd. with multiple neurol. disorders as well as aggressive cancers, making its selective inhibition highly desirable for therapeutic purposes.  The basic mol. design of an effective HDAC6 inhibitor consists of a zinc-binding group, a linker, and a capping group capable of making interactions at the mouth of the active site.  To date, more than 50 high-resoln. X-ray crystal structures of HDAC6-inhibitor complexes have been reported, many of which reveal intermol. interactions that contribute to isoenzyme affinity and selectivity.  Here, we review the key features of HDAC6 inhibitor design illuminated by these structural studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEHMdvmF9TPLVg90H21EOLACvtfcHk0lib6CpWE5LoyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjtFGqs70%253D&md5=df46fa5e4720d8340d728e6269dadb90</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2020.127023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2020.127023%26sid%3Dliteratum%253Aachs%26aulast%3DOsko%26aufirst%3DJ.%2BD.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26atitle%3DStructural%2520Determinants%2520of%2520Affinity%2520and%2520Selectivity%2520in%2520the%2520Binding%2520of%2520Inhibitors%2520to%2520Histone%2520Deacetylase%25206%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D30%26spage%3D127023%26doi%3D10.1016%2Fj.bmcl.2020.127023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ali, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gómez-Biagi, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosa, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, P.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heaton, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eiring, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vellore, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Araujo, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ball, D. P.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Disarming an Electrophilic Warhead: Retaining Potency in Tyrosine Kinase Inhibitor (TKI)-Resistant CML Lines While Circumventing Pharmacokinetic Liabilities</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">850</span>– <span class="NLM_lpage">861</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201600021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1002%2Fcmdc.201600021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=27028877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BC28XltVOitL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=850-861&author=A.+M.+Aliauthor=R.+F.+G%C3%B3mez-Biagiauthor=D.+A.+Rosaauthor=P.-S.+Laiauthor=W.+L.+Heatonauthor=J.+S.+Parkauthor=A.+M.+Eiringauthor=N.+A.+Velloreauthor=E.+D.+de+Araujoauthor=D.+P.+Ball&title=Disarming+an+Electrophilic+Warhead%3A+Retaining+Potency+in+Tyrosine+Kinase+Inhibitor+%28TKI%29-Resistant+CML+Lines+While+Circumventing+Pharmacokinetic+Liabilities&doi=10.1002%2Fcmdc.201600021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Disarming an Electrophilic Warhead: Retaining Potency in Tyrosine Kinase Inhibitor (TKI)-Resistant CML Lines While Circumventing Pharmacokinetic Liabilities</span></div><div class="casAuthors">Ali, Ahmed M.; Gomez-Biagi, Rodolfo F.; Rosa, David A.; Lai, Ping-Shan; Heaton, William L.; Park, Ji Sung; Eiring, Anna M.; Vellore, Nadeem A.; de Araujo, Elvin D.; Ball, Dan P.; Shouksmith, Andrew E.; Patel, Ami B.; Deininger, Michael W.; O'Hare, Thomas; Gunning, Patrick T.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">850-861</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Pharmacol. blockade of the activation of signal transducer and activator of transcription 3 (STAT3) in tyrosine kinase inhibitor (TKI)-resistant chronic myeloid leukemia (CML) cell lines characterized by kinase-independent resistance was shown to re-sensitize CML cells to TKI therapy, suggesting that STAT3 inhibitors in combination with TKIs are an effective combinatorial therapeutic for the treatment of CML.  Benzoic acid- and hydroxamic acid-based STAT3 inhibitors SH-4-054 and SH-5-007, developed previously in our lab., demonstrated promising activity against these resistant CML cell lines.  However, pharmacokinetic studies in murine models (CD-1 mice) revealed that both SH-4-054 and SH-5-007 are susceptible to glutathione conjugation at the para position of the pentafluorophenyl group via nucleophilic arom. substitution (SNAr).  To det. whether the electrophilicity of the pentafluorophenyl sulfonamide could be tempered, an in-depth structure-activity relationship (SAR) study of the SH-4-054 scaffold was conducted.  These studies revealed that AM-1-124, possessing a 2,3,5,6-tetrafluorophenylsulfonamide group, retained STAT3 protein affinity (Ki=15 μm), as well as selectivity over STAT1 (Ki>250 μm).  Moreover, in both hepatocytes and in in vivo pharmacokinetic studies (CD-1 mice), AM-1-124 was found to be dramatically more stable than SH-4-054 (t1/2=1.42 h cf. 10 min, resp.).  AM-1-124 is a promising STAT3-targeting inhibitor with demonstrated bioavailability, suitable for evaluation in preclin. cancer models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqS38duOD8NmLVg90H21EOLACvtfcHk0lib6CpWE5LoyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XltVOitL4%253D&md5=f356ee9c2078e878e2756c885f099d55</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201600021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201600021%26sid%3Dliteratum%253Aachs%26aulast%3DAli%26aufirst%3DA.%2BM.%26aulast%3DG%25C3%25B3mez-Biagi%26aufirst%3DR.%2BF.%26aulast%3DRosa%26aufirst%3DD.%2BA.%26aulast%3DLai%26aufirst%3DP.-S.%26aulast%3DHeaton%26aufirst%3DW.%2BL.%26aulast%3DPark%26aufirst%3DJ.%2BS.%26aulast%3DEiring%26aufirst%3DA.%2BM.%26aulast%3DVellore%26aufirst%3DN.%2BA.%26aulast%3Dde%2BAraujo%26aufirst%3DE.%2BD.%26aulast%3DBall%26aufirst%3DD.%2BP.%26atitle%3DDisarming%2520an%2520Electrophilic%2520Warhead%253A%2520Retaining%2520Potency%2520in%2520Tyrosine%2520Kinase%2520Inhibitor%2520%2528TKI%2529-Resistant%2520CML%2520Lines%2520While%2520Circumventing%2520Pharmacokinetic%2520Liabilities%26jtitle%3DChemMedChem%26date%3D2016%26volume%3D11%26spage%3D850%26epage%3D861%26doi%3D10.1002%2Fcmdc.201600021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Porter, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span> <span> </span><span class="NLM_article-title">Structure, Mechanism, and Inhibition of the Zinc-Dependent Histone Deacetylases</span>. <i>Curr. Opin. Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">9</span>– <span class="NLM_lpage">18</span>, <span class="refDoi"> DOI: 10.1016/j.sbi.2019.01.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1016%2Fj.sbi.2019.01.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=30743180" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVGit7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2019&pages=9-18&author=N.+J.+Porterauthor=D.+W.+Christianson&title=Structure%2C+Mechanism%2C+and+Inhibition+of+the+Zinc-Dependent+Histone+Deacetylases&doi=10.1016%2Fj.sbi.2019.01.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Structure, mechanism, and inhibition of the zinc-dependent histone deacetylases</span></div><div class="casAuthors">Porter, Nicholas J.; Christianson, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Structural Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">9-18</span>CODEN:
                <span class="NLM_cas:coden">COSBEF</span>;
        ISSN:<span class="NLM_cas:issn">0959-440X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Zinc-dependent histone deacetylases (HDACs) regulate the biol. function of histone and non-histone proteins through the hydrolysis of acetyllysine side chains to yield free lysine and acetate.  Certain HDAC isoenzymes exhibit alternative catalytic activities, such as polyamine deacetylase or lysine fatty acid deacylase activity.  To date, crystal structures have been reported for class I HDACs (1-3, and 8), class IIa HDACs (4 and 7), and class IIb HDACs (6 and 10).  Conserved active site residues mediate the chem. of substrate activation and hydrolysis in these isoenzymes through a metal-activated water mol. assisted by general base-general acid catalysis.  Upregulated HDAC activity is obsd. in cancer and neurodegenerative disease, and four HDAC inhibitors are currently approved for use in cancer chemotherapy.  Crystal structures of HDAC-inhibitor complexes guide the design of new inhibitors with high affinity and selectivity for specific HDAC isoenzymes implicated in human disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2Vx86t86y6rVg90H21EOLACvtfcHk0lgaPFWR1PPsAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVGit7o%253D&md5=1dd392837f88a1f079861d44a3f529f5</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.sbi.2019.01.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.sbi.2019.01.004%26sid%3Dliteratum%253Aachs%26aulast%3DPorter%26aufirst%3DN.%2BJ.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26atitle%3DStructure%252C%2520Mechanism%252C%2520and%2520Inhibition%2520of%2520the%2520Zinc-Dependent%2520Histone%2520Deacetylases%26jtitle%3DCurr.%2520Opin.%2520Struct.%2520Biol.%26date%3D2019%26volume%3D59%26spage%3D9%26epage%3D18%26doi%3D10.1016%2Fj.sbi.2019.01.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Porter, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span> <span> </span><span class="NLM_article-title">Entropy as a Driver of Selectivity for Inhibitor Binding to Histone Deacetylase 6</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">3916</span>– <span class="NLM_lpage">3924</span>, <span class="refDoi"> DOI: 10.1021/acs.biochem.8b00367</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.8b00367" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BC1cXps1Onsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=3916-3924&author=N.+J.+Porterauthor=F.+F.+Wagnerauthor=D.+W.+Christianson&title=Entropy+as+a+Driver+of+Selectivity+for+Inhibitor+Binding+to+Histone+Deacetylase+6&doi=10.1021%2Facs.biochem.8b00367"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Entropy as a Driver of Selectivity for Inhibitor Binding to Histone Deacetylase 6</span></div><div class="casAuthors">Porter, Nicholas J.; Wagner, Florence F.; Christianson, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">3916-3924</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Among the metal-dependent histone deacetylases, the class IIb isoenzyme HDAC6 is remarkable due to its role in the regulation of microtubule dynamics in the cytosol.  Selective inhibition of HDAC6 results in microtubule hyperacetylation, leading to cell cycle arrest and apoptosis, which is a validated strategy for cancer chemotherapy and the treatment of other disorders.  HDAC6 inhibitors generally consist of a Zn2+-binding group such as a hydroxamate, a linker, and a capping group; the capping group is a crit. determinant of isoenzyme selectivity.  Surprisingly, however, even "capless" inhibitors exhibit appreciable HDAC6 selectivity.  To probe the chem. basis for this selectivity, we now report high-resoln. crystal structures of HDAC6 complexed with capless cycloalkylhydroxamate inhibitors 1-4.  Each inhibitor hydroxamate group coordinates to the catalytic Zn2+ ion with canonical bidentate geometry.  Addnl., the olefin moieties of compds. 2 and 4 bind in an arom. crevice between the side chains of F583 and F643.  Reasoning that similar binding could be achieved in the representative class I isoenzyme HDAC8, we employed isothermal titrn. calorimetry to study the thermodn. of inhibitor binding.  These measurements indicate that the entropy of inhibitor binding is generally pos. for binding to HDAC6 and neg. for binding to HDAC8, resulting in up to 313-fold selectivity for binding to HDAC6 relative to HDAC8.  Thus, favorable binding entropy contributes to HDAC6 selectivity.  Notably, cyclohexenylhydroxamate 2 represents a promising lead for derivatization with capping groups that may further enhance its impressive 313-fold thermodn. selectivity for HDAC6 inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5MmbdoXXUqrVg90H21EOLACvtfcHk0lgaPFWR1PPsAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXps1Onsrg%253D&md5=0da8abf0ee7f012db41c620101551442</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.8b00367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.8b00367%26sid%3Dliteratum%253Aachs%26aulast%3DPorter%26aufirst%3DN.%2BJ.%26aulast%3DWagner%26aufirst%3DF.%2BF.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26atitle%3DEntropy%2520as%2520a%2520Driver%2520of%2520Selectivity%2520for%2520Inhibitor%2520Binding%2520to%2520Histone%2520Deacetylase%25206%26jtitle%3DBiochemistry%26date%3D2018%26volume%3D57%26spage%3D3916%26epage%3D3924%26doi%3D10.1021%2Facs.biochem.8b00367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fierke, C. A.</span></span> <span> </span><span class="NLM_article-title">Carbonic Anhydrase: Evolution of the Zinc Binding Site by Nature and by Design</span>. <i>Acc. Chem. Res.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">331</span>– <span class="NLM_lpage">339</span>, <span class="refDoi"> DOI: 10.1021/ar9501232</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ar9501232" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADyaK28Xjs1GktLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=1996&pages=331-339&author=D.+W.+Christiansonauthor=C.+A.+Fierke&title=Carbonic+Anhydrase%3A+Evolution+of+the+Zinc+Binding+Site+by+Nature+and+by+Design&doi=10.1021%2Far9501232"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Carbonic anhydrase: Evolution of the zinc binding site by nature and by design</span></div><div class="casAuthors">Christianson, David W.; Fierke, Carol A.</div><div class="citationInfo"><span class="NLM_cas:title">Accounts of Chemical Research</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">331-339</span>CODEN:
                <span class="NLM_cas:coden">ACHRE4</span>;
        ISSN:<span class="NLM_cas:issn">0001-4842</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review and discussion with 89 refs., of the evolution of the Zn-binding site of erythrocyte carbonic anhydrase II and its redesign by protein engineering.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGCjLbhEYyq7Vg90H21EOLACvtfcHk0lgRvrS4LsgpWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xjs1GktLk%253D&md5=e86dc0ab1affce3505364767ad3efcb9</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Far9501232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Far9501232%26sid%3Dliteratum%253Aachs%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26aulast%3DFierke%26aufirst%3DC.%2BA.%26atitle%3DCarbonic%2520Anhydrase%253A%2520Evolution%2520of%2520the%2520Zinc%2520Binding%2520Site%2520by%2520Nature%2520and%2520by%2520Design%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D1996%26volume%3D29%26spage%3D331%26epage%3D339%26doi%3D10.1021%2Far9501232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dudev, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudev, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, C.</span></span> <span> </span><span class="NLM_article-title">First-Second Shell Interactions in Metal Binding Sites in Proteins: A PDB Survey and DFT/CDM Calculations</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">3168</span>– <span class="NLM_lpage">3180</span>, <span class="refDoi"> DOI: 10.1021/ja0209722</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja0209722" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BD3sXht1Sgt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2003&pages=3168-3180&author=T.+Dudevauthor=Y.+Linauthor=M.+Dudevauthor=C.+Lim&title=First-Second+Shell+Interactions+in+Metal+Binding+Sites+in+Proteins%3A+A+PDB+Survey+and+DFT%2FCDM+Calculations&doi=10.1021%2Fja0209722"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">First-Second Shell Interactions in Metal Binding Sites in Proteins: A PDB Survey and DFT/CDM Calculations</span></div><div class="casAuthors">Dudev, Todor; Lin, Yen-lin; Dudev, Minko; Lim, Carmay</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3168-3180</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The role of the second shell in the process of metal binding and selectivity in metalloproteins has been elucidated by combining Protein Data Bank (PDB) surveys of Mg, Mn, Ca, and Zn binding sites with d. functional theory/continuum dielec. methods (DFT/CDM).  Peptide backbone groups were found to be the most common second-shell ligand in Mg, Mn, Ca, and Zn binding sites, followed (in decreasing order) by Asp/Glu, Lys/Arg, Asn/Gln, and Ser/Thr side chains.  Arom. oxygen- or nitrogen-contg. side chains (Tyr, His, and Trp) and sulfur-contg. side chains (Cys and Met) are seldom found in the second coordination layer.  The backbone and Asn/Gln side chain are ubiquitous in the metal second coordination layer as their carbonyl oxygen and amide hydrogen can act as a hydrogen-bond acceptor and donor, resp., and can therefore partner practically every first-shell ligand.  The second most common outer-shell ligand, Asp/Glu, predominantly hydrogen bonds to a metal-bound water or Zn-bound histidine and polarizes the H-O or H-N bond.  In certain cases, a second-shell Asp/Glu could affect the protonation state of the metal ligand.  It could also energetically stabilize a pos. charged metal complex more than a neutral ligand such as the backbone and Asn/Gln side chain.  As for the first shell, the second shell is predicted to contribute to the metal selectivity of the binding site by discriminating between metal cations of different ionic radii and coordination geometries.  The first-shell-second-shell interaction energies decay rapidly with increasing solvent exposure of the metal binding site.  They are less favorable but are of the same order of magnitude as compared to the resp. metal-first-shell interaction energies. Altogether, the results indicate that the structure and properties of the second shell are dictated by those of the first layer.  The outer shell is apparently designed to stabilize/protect the inner-shell and complement/enhance its properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGof_Unc1bR69rVg90H21EOLACvtfcHk0lgRvrS4LsgpWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXht1Sgt7w%253D&md5=6f36bae58c3d9f8b4d4ffb3dd5efaceb</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fja0209722&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja0209722%26sid%3Dliteratum%253Aachs%26aulast%3DDudev%26aufirst%3DT.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DDudev%26aufirst%3DM.%26aulast%3DLim%26aufirst%3DC.%26atitle%3DFirst-Second%2520Shell%2520Interactions%2520in%2520Metal%2520Binding%2520Sites%2520in%2520Proteins%253A%2520A%2520PDB%2520Survey%2520and%2520DFT%252FCDM%2520Calculations%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2003%26volume%3D125%26spage%3D3168%26epage%3D3180%26doi%3D10.1021%2Fja0209722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ray, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hideshima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tai, Y.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chauhan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. C.</span></span> <span> </span><span class="NLM_article-title">Combination of a Novel HDAC6 Inhibitor ACY-241 and Anti-PD-L1 Antibody Enhances Anti-Tumor Immunity and Cytotoxicity in Multiple Myeloma</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">843</span>– <span class="NLM_lpage">846</span>, <span class="refDoi"> DOI: 10.1038/leu.2017.322</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1038%2Fleu.2017.322" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=29104288" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjvFWrtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2018&pages=843-846&author=A.+Rayauthor=D.+S.+Dasauthor=Y.+Songauthor=T.+Hideshimaauthor=Y.-T.+Taiauthor=D.+Chauhanauthor=K.+C.+Anderson&title=Combination+of+a+Novel+HDAC6+Inhibitor+ACY-241+and+Anti-PD-L1+Antibody+Enhances+Anti-Tumor+Immunity+and+Cytotoxicity+in+Multiple+Myeloma&doi=10.1038%2Fleu.2017.322"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma</span></div><div class="casAuthors">Ray, A.; Das, D. S.; Song, Y.; Hideshima, T.; Tai, Y.-T.; Chauhan, D.; Anderson, K. C.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">843-846</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) are attractive therapeutic targets, and selective HDAC inhibitors (HDACi), alone or in combination with other anti-cancer agents, are promising treatment strategies in multiple myeloma (MM).1234To date, however, the effect of HDACi on immune regulation in the MM bone marrow (BM) microenvironment, as well as the therapeutic potential of combining selective HDACi with immune-based therapies, is undefined.  Recent studies showed that besides histone modification, HDACs also modulate non-histone targets including immune regulatory mols.5, 6 For example, blockade of HDACs upregulates immunecheckpoints such as PD-1 ligand (PD-L1).6 Moreover, the combination of HDACi with PD-1/PD-L1 checkpoint blockade significantly improves immunotherapy in a murine B16F10 model.6 In MM, PD-L1 expression directly correlates with progression of disease, with highest levels in patients with relapsed/refractory MM.7, 8 Here, we utilized an orally bioavalable HDAC6 selective inhibitor ACY-241, currently in clin. trials,9 to examine whether the combination of ACY-241 with anti-PD-L1 antibody enhances anti-MM immunity in the MM BM microenvironment.  For our studies, we utilized a co-culture model of immune effector cells (plasmacytoid dendritic cells (pDCs), T cells, NK cells) and MM cells.7, 10 Specifically, we have identified that interactions of MM cells with innate and adaptive immune cells in the BM milieu confer immune suppression via PD-1/PD-L1 signaling axis (Figure 1a: Schema).7, 10 This is exemplified in our studies demonstrating a novel functional interaction between pDCs (Lin- MHC-II+ CD123+ CD4+ CD303/BDCA-2+ CD304/BDCA-4+) and MM cells, implicating pDCs in both MM pathogenesis and immune suppression.  We showed that increased nos. of pDCs are present in MM patient BM vs. normal BM.  Importantly, pDCs in MM BM are relatively resistant to current therapies; protect tumor cells from therapy-induced cytotoxicity; promote tumor growth and survival; and confer immune dysfunction.7, 10 Using our co-culture model, we further delineated the immunosuppressive mechanism(s) that have a role during pDC-T-NK cell interactions with tumor cells.  Specifically, we found that: (1) MM cells and pDCs expressed high surface levels of PD-L1, whereas T cells showed high PD-1 levels; and (2) PD-L1 on MM pDCs suppresses PD-1 expressing T-cell and NK cell immune function; and (3) blockade of PD-L1-PD-1 signaling axis by anti-PD-L1 Ab generates MM-specific CD8+ ctotoxic T lymphocyte (CTL) activity, as well as enhances NK cell-mediated MM cell cytolytic activity.  Importantly, our co-culture model allows for evaluation of the effect of anti-MM drugs on immune regulatory mols. expressed on immune cells and tumor cells, as well as provides a platform for validating all immune-based combination strategies, esp. in the context of immune cells within the MM BM microenvironment.  In the current study, we utilized these models to specifically examine whether the combination of ACY-241 with anti-PD-L1 Ab increases anti-tumor immunity and cytotoxicity in MM.  We first evaluated whether the combination of ACY-241 and anti-PD-L1 Ab enhances MM patient NK cell-mediated cytolytic activity.  For these studies, we utilized low concn. of ACY-241 that do not significantly affect the viability of pDCs, T cells or NK cells (Supplementary Figure 1 A-C).  Freshly isolated NK cells from MM patient BM (n=7) were co-cultured with autologous pDCs in the presence of anti-PD-L1 Ab (5 μg/mL), ACY-241 (0.2 μ) or ACY-241 plus anti-PD-L1 Ab for 5 days.  Cells were washed and resuspended in complete medium without drugs and cultured with autologous MM cells prestained with Celltrace violet for 24 h, followed by 7-AAD staining and quantification of MM cell lysis by flow cytometry.  The combination of ACY-241 and anti-PD-L1 Ab triggered a more robust NK cell-mediated cytotlytic activity against MM cells than either agent alone (Figure 1b and c).  No significant NK cell-mediated cytotoxicity was noted in the absence of pDCs in these expts. (Supplementary Figure 2B), confirming a key role of pDCs in NK cell functioning in response to treatment with ACY-241 and/or anti-PD-L1 Ab.  To further confirm our findings, we next performed anal. of CD107a as a marker of NK cell function.  MM patient pDCs and autologous NK cells were treated with ACY-241, anti-PD-L1 Ab or ACY-241 plus anti-PD-L1 Ab, followed by degranulation assay to assess surface CD107a expressing CD3-/CD56+ NK cells by multi-parameter flow cytometry.  In concert with our finding shown in Figures 1b and c, ACY-241 plus anti-PD-L1 Ab increases CD107a+ degranulated cytolytic NK cells (Supplementary Figure 3).  As in our prior study,7 anti-PD-L1 Ab alone restored NK cell-mediated anti-MM activity.  Interestingly, treatment of pDC-NK cells co-cultured with ACY-241 alone triggerred NK cell cytolytic activity against MM cells (Figures 1b and c).  In this context, a recent study showed a role of HDAC6 in the regulation of PD-L1 in melanoma.11 We hypothesized that ACY-241 may downregulate PD-L1/PD-1-mediated NK cell immune suppression during pDC-NK cell interactions.  Indeed, ACY-241 significantly decreases PD-L1 expression on pDCs (Supplementary Figure 5), which in turn attentuates PD-L1/PD-1-mediated NK suppression and thereby enhances NK cell-mediated MM cell cytotoxicity.  Although not examd. here, other possibilities may account for ACY-241 activity.  Similar to immunomodulatory agent Lenalidomide, ACY-241 may skew effector cytokine (IFN-γ; TNFα) prodn. toward enhancing NK cell anti-MM activity.  Alternatively, ACY-241 may act as reported for HDACi LBH589, which upregulates activation marker CD69 on NK cells.12 Finally, ACY-241 may enhance NK cell anti-MM activity by altering receptor-ligand (for example, NKG2D or KIR) expression-mediated tumor cell killing.  These issues remain to be examd.  Nonetheless, we here show that: (1) pDC-MM cell interactions modulate NK cell cytotoxic activity; (2) combined ACY-241 and anti-PD-L1 Ab enhances MM patient pDC-induced NK cell-mediated cytolytic activities against autologous MM cells; (3) ACY-241 or anti-PD-L1 alone have the ability to stimulate NK cell effector function, albiet to a lesser extent than in combination; and (4) ACY-241 is an immune-modulating agent as it triggers significant NK cell anti-MM activity.  A recent study showed that a HDAC6i ricolinostat triggers T-cell activation and APC function.13 We therefore next examd. whether ACY-241, anti-PD-L1 or their combination triggers the generation of MM-specific CTLs ex vivo.  MM patient BM CD8+T cells (n=7) were co-cultured with autologous pDCs (pDC:T; 1:10 ratio) in the presence of anti-PD-L1 Ab, ACY-241 or ACY-241 plus anti-PD-L1 Ab for 5 days.  Cells were washed and resuspended in complete medium without drugs and cultured with autologous MM cells that were prestained with CellTracker Green for 24 h, followed by 7-AAD staining and quantification of CTLs-mediated MM cell lysis by FACS.  The combination of ACY-241 and anti-PD-L1 Ab triggered a more robust autologous MM-specific CD8+ CTL activity than either agent alone, evidenced by decreased no. of viable CellTracker Green-pos. MM cells (Figure 2a and Supplementary Figure 4).  MM cells were also cultured alone without immune effector cells for the same time period, and data obtained from flow anal. were used for normalization to account for the spontaneous MM cells death.  We next performed CD107a degranulation assays to confirm the generation of CD8+ T-cell cytolytic activity.  MM patient pDCs were co-cultured with autologous T cells and treated with ACY-241, anti-PD-L1 Ab, or ACY-241 plus anti-PD-L1 Ab, followed by degranulation assay to measure CD107a on the cell surface of activated CD3+/CD8+ T cells using flow cytometry.  In agreement with our findings from CTL assays (Figure 2a and Supplementary Figure 4), a more robust increase in surface CD107a+ cytotoxic T cells was noted upon treatment with combined ACY-241 and anti-PD-L1 Ab vs. either ACY-241 or anti-PD-L1 Ab alone (Figure 2b).  No significant MM patient CTL activity was noticed in the absence of pDCs (Supplementary Figure 2C).  Collectively, our data show that combination of selective HDAC6 inhibitor ACY-241 with anti-PD-L1 Ab triggers both CTLs- and NK cells-mediated MM cell killing (Supplementary Figures 6 and 7; Schema).  Mechanistic studies show that combined activity of ACY-241 and anti-PD-L1 is due to downregulation of immunosuppressive PD-L1/PD-1 signaling during pDC-T cells and pDC-NK cells interactions.  It is likely that besides blockade of PD-L1/PD-1, this combination regimen also abrogates other immunosuppressive mechanisms and/or activates immune-activating pathways among pDCs, NK or T cells that together contribute in restoration of anti-MM immunity.  Ongoing studies are focused on investigating these immune mechanism(s).  Finally, recent data indicate potential toxicity assocd. with checkpoint inhibitors in MM.  However, in contrast to inhibitor of checkpoint PD-1 (pembrolizumab), clin. trials of anti-PD-L1 Abs to date show safety, without any significant adverse events in MM patients.14 Moreover, a recent study found a better response rate in patients with higher PD-L1 levels on MM cells, and PD-1 expression on lymphocytes correlated weakly with progression-free survival in a small subset of patients.15 These findings, coupled with our data, support translation of combined ACY-241 and anti-PD-L1 Ab into clin. trials to restore immune function, enhance MM cytotoxicity and improve patient outcome in MM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiLF586f3pxrVg90H21EOLACvtfcHk0lgRvrS4LsgpWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjvFWrtr0%253D&md5=b186fa9563c1e48519b4831dc3cebc3e</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fleu.2017.322&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2017.322%26sid%3Dliteratum%253Aachs%26aulast%3DRay%26aufirst%3DA.%26aulast%3DDas%26aufirst%3DD.%2BS.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DHideshima%26aufirst%3DT.%26aulast%3DTai%26aufirst%3DY.-T.%26aulast%3DChauhan%26aufirst%3DD.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26atitle%3DCombination%2520of%2520a%2520Novel%2520HDAC6%2520Inhibitor%2520ACY-241%2520and%2520Anti-PD-L1%2520Antibody%2520Enhances%2520Anti-Tumor%2520Immunity%2520and%2520Cytotoxicity%2520in%2520Multiple%2520Myeloma%26jtitle%3DLeukemia%26date%3D2018%26volume%3D32%26spage%3D843%26epage%3D846%26doi%3D10.1038%2Fleu.2017.322" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yee, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bensinger, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voorhees, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berdeja, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Supko, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wheeler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markelewicz, R. J.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, in Combonation with Lenalidomide and Dexamethasone in Patients with Relapsed and Relapsed-and-Refractory Multiple Myeloma: Phase 1b Results (ACE-MM-101 Study)</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">3055</span>, <span class="refDoi"> DOI: 10.1182/blood.v126.23.3055.3055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1182%2Fblood.V126.23.3055.3055" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2015&pages=3055&author=A.+J.+Yeeauthor=W.+Bensingerauthor=P.+M.+Voorheesauthor=J.+G.+Berdejaauthor=P.+G.+Richardsonauthor=J.+Supkoauthor=D.+Tamangauthor=S.+S.+Jonesauthor=C.+Wheelerauthor=R.+J.+Markelewicz&title=Ricolinostat+%28ACY-1215%29%2C+the+First+Selective+HDAC6+Inhibitor%2C+in+Combonation+with+Lenalidomide+and+Dexamethasone+in+Patients+with+Relapsed+and+Relapsed-and-Refractory+Multiple+Myeloma%3A+Phase+1b+Results+%28ACE-MM-101+Study%29&doi=10.1182%2Fblood.v126.23.3055.3055"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1182%2Fblood.V126.23.3055.3055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.V126.23.3055.3055%26sid%3Dliteratum%253Aachs%26aulast%3DYee%26aufirst%3DA.%2BJ.%26aulast%3DBensinger%26aufirst%3DW.%26aulast%3DVoorhees%26aufirst%3DP.%2BM.%26aulast%3DBerdeja%26aufirst%3DJ.%2BG.%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26aulast%3DSupko%26aufirst%3DJ.%26aulast%3DTamang%26aufirst%3DD.%26aulast%3DJones%26aufirst%3DS.%2BS.%26aulast%3DWheeler%26aufirst%3DC.%26aulast%3DMarkelewicz%26aufirst%3DR.%2BJ.%26atitle%3DRicolinostat%2520%2528ACY-1215%2529%252C%2520the%2520First%2520Selective%2520HDAC6%2520Inhibitor%252C%2520in%2520Combonation%2520with%2520Lenalidomide%2520and%2520Dexamethasone%2520in%2520Patients%2520with%2520Relapsed%2520and%2520Relapsed-and-Refractory%2520Multiple%2520Myeloma%253A%2520Phase%25201b%2520Results%2520%2528ACE-MM-101%2520Study%2529%26jtitle%3DBlood%26date%3D2015%26volume%3D126%26spage%3D3055%26doi%3D10.1182%2Fblood.v126.23.3055.3055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hideshima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paranal, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colling, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estiu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazitschek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, J. A.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Discovery of Selective Small-Molecule HDAC6 Inhibitor for Overcoming Proteasome Inhibitor Resistance in Multiple Myeloma</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">13162</span>– <span class="NLM_lpage">13167</span>, <span class="refDoi"> DOI: 10.1073/pnas.1608067113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1073%2Fpnas.1608067113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=27799547" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslKnu73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2016&pages=13162-13167&author=T.+Hideshimaauthor=J.+Qiauthor=R.+M.+Paranalauthor=W.+Tangauthor=E.+Greenbergauthor=N.+Westauthor=M.+E.+Collingauthor=G.+Estiuauthor=R.+Mazitschekauthor=J.+A.+Perry&title=Discovery+of+Selective+Small-Molecule+HDAC6+Inhibitor+for+Overcoming+Proteasome+Inhibitor+Resistance+in+Multiple+Myeloma&doi=10.1073%2Fpnas.1608067113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma</span></div><div class="casAuthors">Hideshima, Teru; Qi, Jun; Paranal, Ronald M.; Tang, Weiping; Greenberg, Edward; West, Nathan; Colling, Meaghan E.; Estiu, Guillermina; Mazitschek, Ralph; Perry, Jennifer A.; Ohguchi, Hiroto; Cottini, Francesca; Mimura, Naoya; Gorgun, Gullu; Tai, Yu-Tzu; Richardson, Paul G.; Carrasco, Ruben D.; Wiest, Olaf; Schreiber, Stuart L.; Anderson, Kenneth C.; Bradner, James E.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">46</span>),
    <span class="NLM_cas:pages">13162-13167</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Multiple myeloma (MM) has proven clin. susceptible to modulation of pathways of protein homeostasis.  Blockade of proteasomal degrdn. of polyubiquitinated misfolded proteins by the proteasome inhibitor bortezomib (BTZ) achieves responses and prolongs survival in MM, but long-term treatment with BTZ leads to drug-resistant relapse in most patients.  In a proof-of-concept study, the authors previously demonstrated that blocking aggresomal breakdown of polyubiquitinated misfolded proteins with the histone deacetylase 6 (HDAC6) inhibitor tubacin enhances BTZ-induced cytotoxicity in MM cells in vitro.  However, these foundational studies were limited by the pharmacol. liabilities of tubacin as a chem. probe with only in vitro utility.  Emerging from a focused library synthesis, a potent, selective, and bioavailable HDAC6 inhibitor, WT161, was created to study the mechanism of action of HDAC6 inhibition in MM alone and in combination with BTZ.  WT161 in combination with BTZ triggers significant accumulation of polyubiquitinated proteins and cell stress, followed by caspase activation and apoptosis.  More importantly, this combination treatment was effective in BTZ-resistant cells and in the presence of bone marrow stromal cells, which have been shown to mediate MM cell drug resistance.  The activity of WT161 was confirmed in the human MM cell xenograft mouse model and established the framework for clin. trials of the combination treatment to improve patient outcomes in MM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxE_VYaPFUSbVg90H21EOLACvtfcHk0lgQcNUMYOe3sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslKnu73M&md5=2515fcba03631917d0ca7656d1f62a7e</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1608067113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1608067113%26sid%3Dliteratum%253Aachs%26aulast%3DHideshima%26aufirst%3DT.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DParanal%26aufirst%3DR.%2BM.%26aulast%3DTang%26aufirst%3DW.%26aulast%3DGreenberg%26aufirst%3DE.%26aulast%3DWest%26aufirst%3DN.%26aulast%3DColling%26aufirst%3DM.%2BE.%26aulast%3DEstiu%26aufirst%3DG.%26aulast%3DMazitschek%26aufirst%3DR.%26aulast%3DPerry%26aufirst%3DJ.%2BA.%26atitle%3DDiscovery%2520of%2520Selective%2520Small-Molecule%2520HDAC6%2520Inhibitor%2520for%2520Overcoming%2520Proteasome%2520Inhibitor%2520Resistance%2520in%2520Multiple%2520Myeloma%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2016%26volume%3D113%26spage%3D13162%26epage%3D13167%26doi%3D10.1073%2Fpnas.1608067113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, C.</span></span> <span> </span><span class="NLM_article-title">HDAC6 Promotes Cell Proliferation and Confers Resistance to Temozolomide in Glioblastoma</span>. <i>Canc. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>379</i></span>,  <span class="NLM_fpage">134</span>– <span class="NLM_lpage">142</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2016.06.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1016%2Fj.canlet.2016.06.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=27267806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BC28Xptl2hu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=379&publication_year=2016&pages=134-142&author=Z.+Wangauthor=P.+Huauthor=F.+Tangauthor=H.+Lianauthor=X.+Chenauthor=Y.+Zhangauthor=X.+Heauthor=W.+Liuauthor=C.+Xie&title=HDAC6+Promotes+Cell+Proliferation+and+Confers+Resistance+to+Temozolomide+in+Glioblastoma&doi=10.1016%2Fj.canlet.2016.06.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC6 promotes cell proliferation and confers resistance to temozolomide in glioblastoma</span></div><div class="casAuthors">Wang, Zhihao; Hu, Pengchao; Tang, Fang; Lian, Haiwei; Chen, Xiong; Zhang, Yingying; He, Xiaohua; Liu, Wanhong; Xie, Conghua</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">379</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">134-142</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Histone deacetylases are considered to be among the most promising targets in drug development for cancer therapy.  Histone deacetylase 6 (HDAC6) is a unique cytoplasmic enzyme that regulates many biol. processes involved in tumorigenesis through its deacetylase and ubiquitin-binding activities.  Here, we report that HDAC6 is overexpressed in glioblastoma tissues and cell lines.  Overexpression of HDAC6 promotes the proliferation and spheroid formation of glioblastoma cells.  HDAC6 overexpression confers resistance to temozolomide (TMZ) mediated cell proliferation inhibition and apoptosis induction.  Conversely, knockdown of HDAC6 inhibits cell proliferation, impairs spheroid formation and sensitizes glioblastoma cells to TMZ.  The inhibition of HDAC6 deacetylase activity by selective inhibitors inhibits the proliferation of glioblastoma cells and induces apoptosis.  HDAC6 selective inhibitors can sensitize glioblastoma cells to TMZ.  Moreover, we showed that HDAC6 mediated EGFR stabilization might partly account for its oncogenic role in glioblastoma.  TMZ resistant glioblastoma cells showed higher expression of HDAC6 and more activation of EGFR.  HDAC6 inhibitors decrease EGFR protein levels and impair the activation of the EGFR pathway.  Taken together, our results suggest that the inhibition of HDAC6 may be a promising strategy for the treatment of glioblastoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6MAz69kW6cLVg90H21EOLACvtfcHk0lhFEemrAMw1yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xptl2hu7o%253D&md5=683ba6217cf86e9834fc826be4ddc4fd</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2016.06.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2016.06.001%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DHu%26aufirst%3DP.%26aulast%3DTang%26aufirst%3DF.%26aulast%3DLian%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DXie%26aufirst%3DC.%26atitle%3DHDAC6%2520Promotes%2520Cell%2520Proliferation%2520and%2520Confers%2520Resistance%2520to%2520Temozolomide%2520in%2520Glioblastoma%26jtitle%3DCanc.%2520Lett.%26date%3D2016%26volume%3D379%26spage%3D134%26epage%3D142%26doi%3D10.1016%2Fj.canlet.2016.06.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maharaj, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Achille, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fonseca, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pabon-Saldana, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quayle, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villagra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotomayor, E. M.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Silencing of HDAC6 as a Therapeutic Target in Chronic Lymphocytic Leukemia</span>. <i>Blood Adv.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">3012</span>– <span class="NLM_lpage">3024</span>, <span class="refDoi"> DOI: 10.1182/bloodadvances.2018020065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1182%2Fbloodadvances.2018020065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=30425065" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1aqu7fF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2018&pages=3012-3024&author=K.+Maharajauthor=J.+J.+Powersauthor=A.+Achilleauthor=S.+Dengauthor=R.+Fonsecaauthor=M.+Pabon-Saldanaauthor=S.+N.+Quayleauthor=S.+S.+Jonesauthor=A.+Villagraauthor=E.+M.+Sotomayor&title=Silencing+of+HDAC6+as+a+Therapeutic+Target+in+Chronic+Lymphocytic+Leukemia&doi=10.1182%2Fbloodadvances.2018020065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Silencing of HDAC6 as a therapeutic target in chronic lymphocytic leukemia</span></div><div class="casAuthors">Maharaj, Kamira; Powers, John J.; Achille, Alex; Deng, Susan; Fonseca, Renee; Pabon-Saldana, Mibel; Quayle, Steven N.; Jones, Simon S.; Villagra, Alejandro; Sotomayor, Eduardo M.; Sahakian, Eva; Pinilla-Ibarz, Javier</div><div class="citationInfo"><span class="NLM_cas:title">Blood Advances</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">3012-3024</span>CODEN:
                <span class="NLM_cas:coden">BALDBA</span>;
        ISSN:<span class="NLM_cas:issn">2473-9537</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">We report for the first time that expression of epigenetic modifier histone deacetylase 6 (HDAC6) is upregulated in CLL patient samples, cell lines, and euTCL1 transgenic mouse models compared with HDAC6 in normal controls.  Genetic silencing of HDAC6 conferred survival benefit in euTCL1 mice.  Administration of isoform-specific HDAC6 inhibitor ACY738 in the euTCL1 aging and adoptive transfer models deterred proliferation of CLL B cells, delayed disease onset via disruption of B-cell receptor signaling, and sensitized CLL B cells to apoptosis.  Furthermore, coadministration of ACY738 and ibrutinib displayed synergistic cell kill against CLL cell lines and improved overall survival compared with either single agent in vivo.  These results demonstrate for the first time the therapeutic efficacy of selective HDAC6 inhibition in preclin. CLL models and suggest a rationale for the clin. development of HDAC6 inhibitors for CLL treatment, either alone or in combination with Bruton tyrosine kinase inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0IBtltKjkVrVg90H21EOLACvtfcHk0lhFEemrAMw1yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1aqu7fF&md5=14a25be6448658246df510db8259c20c</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1182%2Fbloodadvances.2018020065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fbloodadvances.2018020065%26sid%3Dliteratum%253Aachs%26aulast%3DMaharaj%26aufirst%3DK.%26aulast%3DPowers%26aufirst%3DJ.%2BJ.%26aulast%3DAchille%26aufirst%3DA.%26aulast%3DDeng%26aufirst%3DS.%26aulast%3DFonseca%26aufirst%3DR.%26aulast%3DPabon-Saldana%26aufirst%3DM.%26aulast%3DQuayle%26aufirst%3DS.%2BN.%26aulast%3DJones%26aufirst%3DS.%2BS.%26aulast%3DVillagra%26aufirst%3DA.%26aulast%3DSotomayor%26aufirst%3DE.%2BM.%26atitle%3DSilencing%2520of%2520HDAC6%2520as%2520a%2520Therapeutic%2520Target%2520in%2520Chronic%2520Lymphocytic%2520Leukemia%26jtitle%3DBlood%2520Adv.%26date%3D2018%26volume%3D2%26spage%3D3012%26epage%3D3024%26doi%3D10.1182%2Fbloodadvances.2018020065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cosenza, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Civallero, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quayle, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pozzi, S.</span></span> <span> </span><span class="NLM_article-title">Ricolinostat (ACY-1215), a Selective HDAC6 Inhibitor, Alone and in Combination with Bendamustine Is Effective in Preclinical Studies in Lymphoma Cell Lines</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">2772</span>, <span class="refDoi"> DOI: 10.1182/blood.v128.22.2772.2772</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1182%2Fblood.V128.22.2772.2772" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2016&pages=2772&author=M.+Cosenzaauthor=M.+Civalleroauthor=S.+N.+Quayleauthor=S.+Sacchiauthor=S.+Pozzi&title=Ricolinostat+%28ACY-1215%29%2C+a+Selective+HDAC6+Inhibitor%2C+Alone+and+in+Combination+with+Bendamustine+Is+Effective+in+Preclinical+Studies+in+Lymphoma+Cell+Lines&doi=10.1182%2Fblood.v128.22.2772.2772"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1182%2Fblood.V128.22.2772.2772&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.V128.22.2772.2772%26sid%3Dliteratum%253Aachs%26aulast%3DCosenza%26aufirst%3DM.%26aulast%3DCivallero%26aufirst%3DM.%26aulast%3DQuayle%26aufirst%3DS.%2BN.%26aulast%3DSacchi%26aufirst%3DS.%26aulast%3DPozzi%26aufirst%3DS.%26atitle%3DRicolinostat%2520%2528ACY-1215%2529%252C%2520a%2520Selective%2520HDAC6%2520Inhibitor%252C%2520Alone%2520and%2520in%2520Combination%2520with%2520Bendamustine%2520Is%2520Effective%2520in%2520Preclinical%2520Studies%2520in%2520Lymphoma%2520Cell%2520Lines%26jtitle%3DBlood%26date%3D2016%26volume%3D128%26spage%3D2772%26doi%3D10.1182%2Fblood.v128.22.2772.2772" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cosenza, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Civallero, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcheselli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pozzi, S.</span></span> <span> </span><span class="NLM_article-title">Ricolinostat, a Selective HDAC6 Inhibitor, Shows Anti-Lymphoma Cell Activity Alone and in Combination with Bendamustine</span>. <i>Apoptosis</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">827</span>– <span class="NLM_lpage">840</span>, <span class="refDoi"> DOI: 10.1007/s10495-017-1364-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1007%2Fs10495-017-1364-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=28315173" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkslKktr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=827-840&author=M.+Cosenzaauthor=M.+Civalleroauthor=L.+Marcheselliauthor=S.+Sacchiauthor=S.+Pozzi&title=Ricolinostat%2C+a+Selective+HDAC6+Inhibitor%2C+Shows+Anti-Lymphoma+Cell+Activity+Alone+and+in+Combination+with+Bendamustine&doi=10.1007%2Fs10495-017-1364-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine</span></div><div class="casAuthors">Cosenza, Maria; Civallero, Monica; Marcheselli, Luigi; Sacchi, Stefano; Pozzi, Samantha</div><div class="citationInfo"><span class="NLM_cas:title">Apoptosis</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">827-840</span>CODEN:
                <span class="NLM_cas:coden">APOPFN</span>;
        ISSN:<span class="NLM_cas:issn">1360-8185</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Histone deacetylase inhibitors (HDACis) have emerged as a new class of anticancer agents, targeting the biol. process including cell cycle and apoptosis.  We investigated and explained the anticancer effects of an HDAC6 inhibitor, ricolinostat alone and in combination with bendamustine in lymphoma cell lines.  Cell viability was measured by MTT assay.  Apoptosis, reactive oxygen species (ROS) generation, Bcl-2 protein expression, cell cycle progression and tubuline expression were detd. by flow cytometry.  The effects of ricolinostat alone and in combination on the caspases, PI3K/Akt, Bcl-2 pathways, ER stress and UPR were assessed by immunoblotting.  Ricolinostat shows anti lymphoma activity when used as single agent and its capability to induce apoptosis is synergistically potentiated by the bendamustine in lymphoma cell lines.  Drug combination reduced the proportion of cells in the G0/G1 and S phases and caused an increase of "sub-G0/G1" peak.  The synergistic effect accompanied with the increased ROS, activation of caspase-8, -9, and -3, the cleavage of PARP and modulated by Bcl-2 proteins family.  In addn., the exposure of ricolinostat induced the acetylation level of α-tubulin, the extend of which was not further modified by bendamustine.  Finally, the apoptosis effect of ricolinostat/bendamustine may be mediated by a corresponding effect on microtubule stabilization.  Our data suggest that ricolinostat in combination with bendamustine may be a novel combination with potential for use as an antitumor agent in lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhV5zrMw5A6rVg90H21EOLACvtfcHk0lggjAxeZGB29g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkslKktr8%253D&md5=6ac58def2f10c37fe434c78dd074dcfd</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1007%2Fs10495-017-1364-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10495-017-1364-4%26sid%3Dliteratum%253Aachs%26aulast%3DCosenza%26aufirst%3DM.%26aulast%3DCivallero%26aufirst%3DM.%26aulast%3DMarcheselli%26aufirst%3DL.%26aulast%3DSacchi%26aufirst%3DS.%26aulast%3DPozzi%26aufirst%3DS.%26atitle%3DRicolinostat%252C%2520a%2520Selective%2520HDAC6%2520Inhibitor%252C%2520Shows%2520Anti-Lymphoma%2520Cell%2520Activity%2520Alone%2520and%2520in%2520Combination%2520with%2520Bendamustine%26jtitle%3DApoptosis%26date%3D2017%26volume%3D22%26spage%3D827%26epage%3D840%26doi%3D10.1007%2Fs10495-017-1364-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guha, M.</span></span> <span> </span><span class="NLM_article-title">HDAC Inhibitors Still Need a Home Run, despite Recent Approval</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">225</span>– <span class="NLM_lpage">226</span>, <span class="refDoi"> DOI: 10.1038/nrd4583</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1038%2Fnrd4583" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=25829268" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BC2MXls1artLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=225-226&author=M.+Guha&title=HDAC+Inhibitors+Still+Need+a+Home+Run%2C+despite+Recent+Approval&doi=10.1038%2Fnrd4583"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC inhibitors still need a home run, despite recent approval</span></div><div class="casAuthors">Guha, Malini</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">225-226</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A beleaguered class of epigenetic modulators continues to struggle for oncol. success, but new insights into their mechanisms in cancer may yet offer hope.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotdd1X74wEP7Vg90H21EOLACvtfcHk0lggjAxeZGB29g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXls1artLs%253D&md5=011db36451b31bc7d19e8ffab8281af8</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Fnrd4583&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4583%26sid%3Dliteratum%253Aachs%26aulast%3DGuha%26aufirst%3DM.%26atitle%3DHDAC%2520Inhibitors%2520Still%2520Need%2520a%2520Home%2520Run%252C%2520despite%2520Recent%2520Approval%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26spage%3D225%26epage%3D226%26doi%3D10.1038%2Fnrd4583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hubbert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guardiola, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawaguchi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nixon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, T.-P.</span></span> <span> </span><span class="NLM_article-title">HDAC6 Is a Microtubule-Associated Deacetylase</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>417</i></span>,  <span class="NLM_fpage">455</span>– <span class="NLM_lpage">458</span>, <span class="refDoi"> DOI: 10.1038/417455a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1038%2F417455a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=12024216" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BD38XjvVersr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=417&publication_year=2002&pages=455-458&author=C.+Hubbertauthor=A.+Guardiolaauthor=R.+Shaoauthor=Y.+Kawaguchiauthor=A.+Itoauthor=A.+Nixonauthor=M.+Yoshidaauthor=X.-F.+Wangauthor=T.-P.+Yao&title=HDAC6+Is+a+Microtubule-Associated+Deacetylase&doi=10.1038%2F417455a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC6 is a microtubule-associated deacetylase</span></div><div class="casAuthors">Hubbert, Charlotte; Guardiola, Amaris; Shao, Rong; Kawaguchi, Yoshiharu; Ito, Akihiro; Nixon, Andrew; Yoshida, Minoru; Wang, Xiao-Fan; Yao, Tso-Pang</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">417</span>
        (<span class="NLM_cas:issue">6887</span>),
    <span class="NLM_cas:pages">455-458</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Reversible acetylation of α-tubulin has been implicated in regulating microtubule stability and function.  The distribution of acetylated α-tubulin is tightly controlled and stereotypic.  Acetylated α-tubulin is most abundant in stable microtubules but is absent from dynamic cellular structures such as neuronal growth cones and the leading edges of fibroblasts.  However, the enzymes responsible for regulating tubulin acetylation and deacetylation are not known.  Here we report that a member of the histone deacetylase family, HDAC6, functions as a tubulin deacetylase.  HDAC6 is localized exclusively in the cytoplasm, where it assocs. with microtubules and localizes with the microtubule motor complex contg. p150glued.  In vivo, the overexpression of HDAC6 leads to a global deacetylation of α-tubulin, whereas a decrease in HDAC6 increases α-tubulin acetylation.  In vitro, purified HDAC6 potently deacetylates α-tubulin in assembled microtubules.  Furthermore, overexpression of HDAC6 promotes chemotactic cell movement, supporting the idea that HDAC6-mediated deacetylation regulates microtubule-dependent cell motility.  Our results show that HDAC6 is the tubulin deacetylase, and provide evidence that reversible acetylation regulates important biol. processes beyond histone metab. and gene transcription.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp76Er3MrWtO7Vg90H21EOLACvtfcHk0lggjAxeZGB29g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjvVersr4%253D&md5=f18cbb0af388925c606e822358ba3da6</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2F417455a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F417455a%26sid%3Dliteratum%253Aachs%26aulast%3DHubbert%26aufirst%3DC.%26aulast%3DGuardiola%26aufirst%3DA.%26aulast%3DShao%26aufirst%3DR.%26aulast%3DKawaguchi%26aufirst%3DY.%26aulast%3DIto%26aufirst%3DA.%26aulast%3DNixon%26aufirst%3DA.%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DX.-F.%26aulast%3DYao%26aufirst%3DT.-P.%26atitle%3DHDAC6%2520Is%2520a%2520Microtubule-Associated%2520Deacetylase%26jtitle%3DNature%26date%3D2002%26volume%3D417%26spage%3D455%26epage%3D458%26doi%3D10.1038%2F417455a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Catley, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiziltepe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tai, Y.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hideshima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tassone, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atadja, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chauhan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munshi, N. C.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Aggresome Induction by Proteasome Inhibitor Bortezomib and α-Tubulin Hyperacetylation by Tubulin Deacetylase (TDAC) Inhibitor LBH589 Are Synergistic in Myeloma Cells</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">3441</span>– <span class="NLM_lpage">3449</span>, <span class="refDoi"> DOI: 10.1182/blood-2006-04-016055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1182%2Fblood-2006-04-016055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=16728695" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1ahsLzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2006&pages=3441-3449&author=L.+Catleyauthor=E.+Weisbergauthor=T.+Kiziltepeauthor=Y.-T.+Taiauthor=T.+Hideshimaauthor=P.+Neriauthor=P.+Tassoneauthor=P.+Atadjaauthor=D.+Chauhanauthor=N.+C.+Munshi&title=Aggresome+Induction+by+Proteasome+Inhibitor+Bortezomib+and+%CE%B1-Tubulin+Hyperacetylation+by+Tubulin+Deacetylase+%28TDAC%29+Inhibitor+LBH589+Are+Synergistic+in+Myeloma+Cells&doi=10.1182%2Fblood-2006-04-016055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Aggresome induction by proteasome inhibitor bortezomib and α-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells</span></div><div class="casAuthors">Catley, Laurence; Weisberg, Ellen; Kiziltepe, Tanyel; Tai, Yu-Tzu; Hideshima, Teru; Neri, Paola; Tassone, Pierfrancesco; Atadja, Peter; Chauhan, Dharminder; Munshi, Nikhil C.; Anderson, Kenneth C.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3441-3449</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Histone deacetylase (HDAC) inhibitors have shown cytotoxicity as single agents in preclin. studies for multiple myeloma (MM) cells.  LBH589 is a novel hydroxamic acid deriv. that at low nanomolar concns. induces apoptosis in MM cells resistant to conventional therapies via caspase activation and poly-(ADP-ribose) polymerase (PARP) cleavage.  Significant synergistic cytotoxicity was obsd. with LBH589 in combination with bortezomib against MM cells that were sensitive and resistant to dexamethasone (Dex), as well as primary patient MM cells.  LBH589 at low nanomolar concns. also induced α-tubulin hyperacetylation.  Aggresome formation was obsd. in the presence of bortezomib, and the combination of LBH589 plus bortezomib induced the formation of abnormal bundles of hyeracetylated α-tubulin but with diminished aggresome size and apoptotic nuclei.  These data confirm the potential clin. benefit of combining HDAC inhibitors with proteasome inhibitors, and provide insight into the mechanisms of synergistic anti-MM activity of bortezomib in combination with LBH589.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoc6Qs12jXniLVg90H21EOLACvtfcHk0lggjAxeZGB29g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1ahsLzM&md5=3e50cf4c9f257e27dc9beb422963c99d</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1182%2Fblood-2006-04-016055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2006-04-016055%26sid%3Dliteratum%253Aachs%26aulast%3DCatley%26aufirst%3DL.%26aulast%3DWeisberg%26aufirst%3DE.%26aulast%3DKiziltepe%26aufirst%3DT.%26aulast%3DTai%26aufirst%3DY.-T.%26aulast%3DHideshima%26aufirst%3DT.%26aulast%3DNeri%26aufirst%3DP.%26aulast%3DTassone%26aufirst%3DP.%26aulast%3DAtadja%26aufirst%3DP.%26aulast%3DChauhan%26aufirst%3DD.%26aulast%3DMunshi%26aufirst%3DN.%2BC.%26atitle%3DAggresome%2520Induction%2520by%2520Proteasome%2520Inhibitor%2520Bortezomib%2520and%2520%25CE%25B1-Tubulin%2520Hyperacetylation%2520by%2520Tubulin%2520Deacetylase%2520%2528TDAC%2529%2520Inhibitor%2520LBH589%2520Are%2520Synergistic%2520in%2520Myeloma%2520Cells%26jtitle%3DBlood%26date%3D2006%26volume%3D108%26spage%3D3441%26epage%3D3449%26doi%3D10.1182%2Fblood-2006-04-016055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunker, E. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karman, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azofeifa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnett, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wheeler, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toomey, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Genome-Wide Dose-Dependent Inhibition of Histone Deacetylases Studies Reveal Their Roles in Enhancer Remodeling and Suppression of Oncogenic Super-Enhancers</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">1756</span>– <span class="NLM_lpage">1776</span>, <span class="refDoi"> DOI: 10.1093/nar/gkx1225</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1093%2Fnar%2Fgkx1225" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=29240919" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlGisbbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2018&pages=1756-1776&author=G.+J.+Sanchezauthor=P.+A.+Richmondauthor=E.+N.+Bunkerauthor=S.+S.+Karmanauthor=J.+Azofeifaauthor=A.+T.+Garnettauthor=Q.+Xuauthor=G.+E.+Wheelerauthor=C.+M.+Toomeyauthor=Q.+Zhang&title=Genome-Wide+Dose-Dependent+Inhibition+of+Histone+Deacetylases+Studies+Reveal+Their+Roles+in+Enhancer+Remodeling+and+Suppression+of+Oncogenic+Super-Enhancers&doi=10.1093%2Fnar%2Fgkx1225"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Genome-wide dose-dependent inhibition of histone deacetylases studies reveal their roles in enhancer remodeling and suppression of oncogenic super-enhancers</span></div><div class="casAuthors">Sanchez, Gilson J.; Richmond, Phillip A.; Bunker, Eric N.; Karman, Samuel S.; Azofeifa, Joseph; Garnett, Aaron T.; Xu, Quanbin; Wheeler, Graycen E.; Toomey, Cathryn M.; Zhang, Qinghong; Dowell, Robin D.; Liu, Xuedong</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1756-1776</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">1362-4962</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Histone deacetylase inhibitors (HDACIs) are known to alter gene expression by both up- and downregulation of protein-coding genes in normal and cancer cells.  However, the exact regulatory mechanisms of action remain uncharacterized.  Here we investigated genome wide dose-dependent epigenetic and transcriptome changes in response to HDACI largazole in a transformed and a non-transformed cell line.  Exposure to low nanomolar largazole concns. (<GI50) predominantly resulted in upregulation of gene transcripts whereas higher largazole doses (≥GI50) triggered a general decrease in mRNA accumulation.  Largazole induces elevation of histone H3 acetylation at Lys-9 and Lys-27 along many gene bodies but does not correlate with upor down-regulation of the assocd. transcripts.  A higher dose of largazole results in more RNA polymerase II pausing at the promoters of actively transcribed genes and cell death.  The most prevalent changes assocd. with transcriptional regulation occur at distal enhancer elements.  Largazole promotes H3K27 acetylation at a subset of poised enhancers and unexpectedly, we also found active enhancers that become decommissioned in a dose and cell type-dependent manner.  In particular, largazole decreases RNA polymerase II accumulation at superenhancers (SEs) and preferentially suppresses SEdriven transcripts that are assocd. with oncogenic activities in transformed cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2YBkoOboN_LVg90H21EOLACvtfcHk0lhb6Vmz9byI7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlGisbbN&md5=12517cc4cf615407f6f9698cde886e38</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkx1225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkx1225%26sid%3Dliteratum%253Aachs%26aulast%3DSanchez%26aufirst%3DG.%2BJ.%26aulast%3DRichmond%26aufirst%3DP.%2BA.%26aulast%3DBunker%26aufirst%3DE.%2BN.%26aulast%3DKarman%26aufirst%3DS.%2BS.%26aulast%3DAzofeifa%26aufirst%3DJ.%26aulast%3DGarnett%26aufirst%3DA.%2BT.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DWheeler%26aufirst%3DG.%2BE.%26aulast%3DToomey%26aufirst%3DC.%2BM.%26aulast%3DZhang%26aufirst%3DQ.%26atitle%3DGenome-Wide%2520Dose-Dependent%2520Inhibition%2520of%2520Histone%2520Deacetylases%2520Studies%2520Reveal%2520Their%2520Roles%2520in%2520Enhancer%2520Remodeling%2520and%2520Suppression%2520of%2520Oncogenic%2520Super-Enhancers%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2018%26volume%3D46%26spage%3D1756%26epage%3D1776%26doi%3D10.1093%2Fnar%2Fgkx1225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lue, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prabhu, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mundi, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abshiru, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camarillo, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, E. I.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">5271</span>– <span class="NLM_lpage">5283</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.ccr-18-3989</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1158%2F1078-0432.CCR-18-3989" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=30979734" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BB3cXltVegt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2019&pages=5271-5283&author=J.+K.+Lueauthor=S.+A.+Prabhuauthor=Y.+Liuauthor=Y.+Gonzalezauthor=A.+Vermaauthor=P.+S.+Mundiauthor=N.+Abshiruauthor=J.+M.+Camarilloauthor=S.+Mehtaauthor=E.+I.+Chen&title=Precision+Targeting+with+EZH2+and+HDAC+Inhibitors+in+Epigenetically+Dysregulated+Lymphomas&doi=10.1158%2F1078-0432.ccr-18-3989"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Precision targeting with EZH2 and HDAC inhibitors in epigenetically dysregulated lymphomas</span></div><div class="casAuthors">Lue, Jennifer K.; Prabhu, Sathyen A.; Liu, Yuxuan; Gonzalez, Yulissa; Verma, Akanksha; Mundi, Prabhjot S.; Abshiru, Nebiyu; Camarillo, Jeannie M.; Mehta, Swasti; Chen, Emily I.; Qiao, Changhong; Nandakumar, Renu; Cremers, Serge; Kelleher, Neil L.; Elemento, Olivier; Amengual, Jennifer E.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5271-5283</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Both gain-of-function enhancer of zeste homolog 2 (EZH2) mutations and inactivating histone acetyltransferases mutations, such as CREBBP and EP300, have been implicated in the pathogenesis of germinal center (GC)-derived lymphomas.  We hypothesized that direct inhibition of EZH2 and histone deacetyltransferase (HDAC) would be synergistic in GC-derived lymphomas.  Exptl. Design: Lymphoma cell lines (n = 21) were exposed to GSK126, an EZH2 inhibitor, and romidepsin, a pan-HDAC inhibitor.  Synergy was assessed by excess over bliss.  Western blot, mass spectrometry, and coimmunopptn. were performed.  A SU-DHL-10 xenograft model was utilized to validate in vitro findings.  Pretreatment RNA-sequencing of cell lines was performed.  MetaVIPER anal. was used to infer protein activity.  Results: Exposure to GSK126 and romidepsin demonstrated potent synergy in lymphoma cell lines with EZH2 dysregulation.  Combination of romidepsin with other EZH2 inhibitors also demonstrated synergy suggesting a class effect of EZH2 inhibition with romidepsin.  Dual inhibition of EZH2 and HDAC led to modulation of acetylation and methylation of H3K27.  The synergistic effects of the combination were due to disruption of the PRC2 complex secondary to acetylation of RbAP 46/48.  A common basal gene signature was shared among synergistic lymphoma cell lines and was characterized by upregulation in chromatin remodeling genes and transcriptional regulators.  This finding was supported by metaVIPER anal. which also revealed that HDAC 1/2 and DNA methyltransferase were assocd. with EZH2 activation.  Conclusions: Inhibition of EZH2 and HDAC is synergistic and leads to the dissocn. of PRC2 complex.  Our findings support the clin. translation of the combination of EZH2 and HDAC inhibition in EZH2 dysregulated lymphomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqpLROkJyGLLVg90H21EOLACvtfcHk0lhb6Vmz9byI7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXltVegt7c%253D&md5=c0a9c8babc8838b2b1c629e6578f9456</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-18-3989&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-18-3989%26sid%3Dliteratum%253Aachs%26aulast%3DLue%26aufirst%3DJ.%2BK.%26aulast%3DPrabhu%26aufirst%3DS.%2BA.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DGonzalez%26aufirst%3DY.%26aulast%3DVerma%26aufirst%3DA.%26aulast%3DMundi%26aufirst%3DP.%2BS.%26aulast%3DAbshiru%26aufirst%3DN.%26aulast%3DCamarillo%26aufirst%3DJ.%2BM.%26aulast%3DMehta%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DE.%2BI.%26atitle%3DPrecision%2520Targeting%2520with%2520EZH2%2520and%2520HDAC%2520Inhibitors%2520in%2520Epigenetically%2520Dysregulated%2520Lymphomas%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2019%26volume%3D25%26spage%3D5271%26epage%3D5283%26doi%3D10.1158%2F1078-0432.ccr-18-3989" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villani, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, X.</span></span> <span> </span><span class="NLM_article-title">The Role of Cellular Reactive Oxygen Species in Cancer Chemotherapy</span>. <i>J. Exp. Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">266</span>, <span class="refDoi"> DOI: 10.1186/s13046-018-0909-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1186%2Fs13046-018-0909-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=30382874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BC1MXptlWnsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2018&pages=266&author=H.+Yangauthor=R.+M.+Villaniauthor=H.+Wangauthor=M.+J.+Simpsonauthor=M.+S.+Robertsauthor=M.+Tangauthor=X.+Liang&title=The+Role+of+Cellular+Reactive+Oxygen+Species+in+Cancer+Chemotherapy&doi=10.1186%2Fs13046-018-0909-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">The role of cellular reactive oxygen species in cancer chemotherapy</span></div><div class="casAuthors">Yang, Haotian; Villani, Rehan M.; Wang, Haolu; Simpson, Matthew J.; Roberts, Michael S.; Tang, Min; Liang, Xiaowen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental & Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">266</span>CODEN:
                <span class="NLM_cas:coden">JECRDN</span>;
        ISSN:<span class="NLM_cas:issn">1756-9966</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Most chemotherapeutics elevate intracellular levels of reactive oxygen species (ROS), and many can alter redox-homeostasis of cancer cells.  It is widely accepted that the anticancer effect of these chemotherapeutics is due to the induction of oxidative stress and ROS-mediated cell injury in cancer.  However, various new therapeutic approaches targeting intracellular ROS levels have yielded mixed results.  Since it is impossible to quant. detect dynamic ROS levels in tumors during and after chemotherapy in clin. settings, it is of increasing interest to apply math. modeling techniques to predict ROS levels for understanding complex tumor biol. during chemotherapy.  This review outlines the current understanding of the role of ROS in cancer cells during carcinogenesis and during chemotherapy, provides a crit. anal. of the methods used for quant. ROS detection and discusses the application of math. modeling in predicting treatment responses.  Finally, we provide insights on and perspectives for future development of effective therapeutic ROS-inducing anticancer agents or antioxidants for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq93LfhPJogR7Vg90H21EOLACvtfcHk0liCeiMvmfmT4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXptlWnsbg%253D&md5=f790a63bc1d67df0a465872a166fa378</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1186%2Fs13046-018-0909-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13046-018-0909-x%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DH.%26aulast%3DVillani%26aufirst%3DR.%2BM.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DSimpson%26aufirst%3DM.%2BJ.%26aulast%3DRoberts%26aufirst%3DM.%2BS.%26aulast%3DTang%26aufirst%3DM.%26aulast%3DLiang%26aufirst%3DX.%26atitle%3DThe%2520Role%2520of%2520Cellular%2520Reactive%2520Oxygen%2520Species%2520in%2520Cancer%2520Chemotherapy%26jtitle%3DJ.%2520Exp.%2520Clin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D37%26spage%3D266%26doi%3D10.1186%2Fs13046-018-0909-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jayavelu, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Böhmer, S.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lässig, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerny-Reiterer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sperr, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valent, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriggl, R.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">NOX4-Driven ROS Formation Mediates PTP Inactivation and Cell Transformation in FLT3ITD-Positive AML Cells</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">473</span>– <span class="NLM_lpage">483</span>, <span class="refDoi"> DOI: 10.1038/leu.2015.234</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1038%2Fleu.2015.234" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=26308771" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsF2ru7rJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=473-483&author=A.+K.+Jayaveluauthor=J.+P.+M%C3%BCllerauthor=R.+Bauerauthor=S.-A.+B%C3%B6hmerauthor=J.+L%C3%A4ssigauthor=S.+Cerny-Reitererauthor=W.+R.+Sperrauthor=P.+Valentauthor=B.+Maurerauthor=R.+Moriggl&title=NOX4-Driven+ROS+Formation+Mediates+PTP+Inactivation+and+Cell+Transformation+in+FLT3ITD-Positive+AML+Cells&doi=10.1038%2Fleu.2015.234"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">NOX4-driven ROS formation mediates PTP inactivation and cell transformation in FLT3ITD-positive AML cells</span></div><div class="casAuthors">Jayavelu, A. K.; Mueller, J. P.; Bauer, R.; Boehmer, S.-A.; Laessig, J.; Cerny-Reiterer, S.; Sperr, W. R.; Valent, P.; Maurer, B.; Moriggl, R.; Schroeder, K.; Shah, A. M.; Fischer, M.; Scholl, S.; Barth, J.; Oellerich, T.; Berg, T.; Serve, H.; Frey, S.; Fischer, T.; Heidel, F. H.; Boehmer, F.-D.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">473-483</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Activating mutations of FMS-like tyrosine kinase 3 (FLT3), notably internal tandem duplications (ITDs), are assocd. with a grave prognosis in acute myeloid leukemia (AML).  Transforming FLT3ITD signal transduction causes formation of reactive oxygen species (ROS) and inactivation of the protein-tyrosine phosphatase (PTP) DEP-1/PTPRJ, a neg. regulator of FLT3 signaling.  Here we addressed the underlying mechanisms and biol. consequences.  NADPH oxidase 4 (NOX4) mRNA and protein expression was found to be elevated in FLT3ITD-pos. cells and to depend on FLT3ITD signaling and STAT5-mediated activation of the NOX4 promoter.  NOX4 knockdown reduced ROS levels, restored DEP-1 PTP activity and attenuated FLT3ITD-driven transformation.  Moreover, Nox4 knockout (Nox4-/-) murine hematopoietic progenitor cells were refractory to FLT3ITD-mediated transformation in vitro.  Development of a myeloproliferative-like disease (MPD) caused by FLT3ITD-transformed 32D cells in C3H/HeJ mice, and of a leukemia-like disease in mice transplanted with MLL-AF9/ FLT3ITD-transformed murine hematopoietic stem cells were strongly attenuated by NOX4 downregulation.  NOX4-targeting compds. were found to counteract proliferation of FLT3ITD-pos. AML blasts and MPD development in mice.  These findings reveal a previously unrecognized mechanism of oncoprotein-driven PTP oxidn., and suggest that interference with FLT3ITD-STAT5-NOX4-mediated overprodn. of ROS and PTP inactivation may have therapeutic potential in a subset of AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlyRxwdJm4YLVg90H21EOLACvtfcHk0liCeiMvmfmT4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsF2ru7rJ&md5=c002a51936b7f1fad8c49b2a2910dfab</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1038%2Fleu.2015.234&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2015.234%26sid%3Dliteratum%253Aachs%26aulast%3DJayavelu%26aufirst%3DA.%2BK.%26aulast%3DM%25C3%25BCller%26aufirst%3DJ.%2BP.%26aulast%3DBauer%26aufirst%3DR.%26aulast%3DB%25C3%25B6hmer%26aufirst%3DS.-A.%26aulast%3DL%25C3%25A4ssig%26aufirst%3DJ.%26aulast%3DCerny-Reiterer%26aufirst%3DS.%26aulast%3DSperr%26aufirst%3DW.%2BR.%26aulast%3DValent%26aufirst%3DP.%26aulast%3DMaurer%26aufirst%3DB.%26aulast%3DMoriggl%26aufirst%3DR.%26atitle%3DNOX4-Driven%2520ROS%2520Formation%2520Mediates%2520PTP%2520Inactivation%2520and%2520Cell%2520Transformation%2520in%2520FLT3ITD-Positive%2520AML%2520Cells%26jtitle%3DLeukemia%26date%3D2016%26volume%3D30%26spage%3D473%26epage%3D483%26doi%3D10.1038%2Fleu.2015.234" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claret, F. X.</span></span> <span> </span><span class="NLM_article-title">Novel Roles of Reactive Oxygen Species in the Pathogenesis of Acute Myeloid Leukemia</span>. <i>J. Leukocyte Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">423</span>– <span class="NLM_lpage">429</span>, <span class="refDoi"> DOI: 10.1189/jlb.0113006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1189%2Fjlb.0113006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=23715741" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlyqu7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2013&pages=423-429&author=F.+Zhouauthor=Q.+Shenauthor=F.+X.+Claret&title=Novel+Roles+of+Reactive+Oxygen+Species+in+the+Pathogenesis+of+Acute+Myeloid+Leukemia&doi=10.1189%2Fjlb.0113006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Novel roles of reactive oxygen species in the pathogenesis of acute myeloid leukemia</span></div><div class="casAuthors">Zhou, Fuling; Shen, Qiang; Claret, Francois X.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Leukocyte Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">423-429</span>CODEN:
                <span class="NLM_cas:coden">JLBIE7</span>;
        ISSN:<span class="NLM_cas:issn">0741-5400</span>.
    
            (<span class="NLM_cas:orgname">Society for Leukocyte Biology</span>)
        </div><div class="casAbstract">A review.  It has become apparent that regulation of ROS is important in cell signaling and homeostasis.  Accumulation of ROS triggers oxidative stress in various cell types and contributes to the development, progression, and persistence of cancer.  Recent research has demonstrated that redox dysregulation caused by ROS promotes proliferation, differentiation, genomic, and epigenetic alterations; immune evasion; and survival in leukemic cells.  ROS act as signaling mols. to regulate redox-sensitive transcriptional factors, enzymes, oncogenes, and other downstream effectors.  Thus, a thorough understanding the role of ROS as key mediators in leukemogenesis is likely to provide opportunities for improved pharmacol. intervention.  In this review, we summarize the recent findings that support a role for ROS in the pathogenesis of AML and outline innovative approaches in the implementation of redox therapies for myeloid malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEUyDAttsKZrVg90H21EOLACvtfcHk0liCeiMvmfmT4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlyqu7nK&md5=b72a5fde8eb9a10bca275795f9ce3d2e</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1189%2Fjlb.0113006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1189%252Fjlb.0113006%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DF.%26aulast%3DShen%26aufirst%3DQ.%26aulast%3DClaret%26aufirst%3DF.%2BX.%26atitle%3DNovel%2520Roles%2520of%2520Reactive%2520Oxygen%2520Species%2520in%2520the%2520Pathogenesis%2520of%2520Acute%2520Myeloid%2520Leukemia%26jtitle%3DJ.%2520Leukocyte%2520Biol.%26date%3D2013%26volume%3D94%26spage%3D423%26epage%3D429%26doi%3D10.1189%2Fjlb.0113006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eckschlager, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stiborova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hrabeta, J.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase Inhibitors as Anticancer Drugs</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1414</span>, <span class="refDoi"> DOI: 10.3390/ijms18071414</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.3390%2Fijms18071414" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=28671573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVGgt73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=1414&author=T.+Eckschlagerauthor=J.+Plchauthor=M.+Stiborovaauthor=J.+Hrabeta&title=Histone+Deacetylase+Inhibitors+as+Anticancer+Drugs&doi=10.3390%2Fijms18071414"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors as anticancer drugs</span></div><div class="casAuthors">Eckschlager, Tomas; Plch, Johana; Stiborova, Marie; Hrabeta, Jan</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1414/1-1414/25</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Carcinogenesis cannot be explained only by genetic alterations, but also involves epigenetic processes.  Modification of histones by acetylation plays a key role in epigenetic regulation of gene expression and is controlled by the balance between histone deacetylases (HDAC) and histone acetyltransferases (HAT).  HDAC inhibitors induce cancer cell cycle arrest, differentiation and cell death, reduce angiogenesis and modulate immune response.  Mechanisms of anticancer effects of HDAC inhibitors are not uniform; they may be different and depend on the cancer type, HDAC inhibitors, doses, etc.  HDAC inhibitors seem to be promising anti-cancer drugs particularly in the combination with other anti-cancer drugs and/or radiotherapy.  HDAC inhibitors vorinostat, romidepsin and belinostat have been approved for some T-cell lymphoma and panobinostat for multiple myeloma.  Other HDAC inhibitors are in clin. trials for the treatment of hematol. and solid malignancies.  The results of such studies are promising but further larger studies are needed.  Because of the reversibility of epigenetic changes during cancer development, the potency of epigenetic therapies seems to be of great importance.  Here, we summarize the data on different classes of HDAC inhibitors, mechanisms of their actions and discuss novel results of preclin. and clin. studies, including the combination with other therapeutic modalities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPNVhoLBAHnrVg90H21EOLACvtfcHk0ljYbXJftLkS5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVGgt73P&md5=6018c7709a09548214bfe34bd91107a9</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.3390%2Fijms18071414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms18071414%26sid%3Dliteratum%253Aachs%26aulast%3DEckschlager%26aufirst%3DT.%26aulast%3DPlch%26aufirst%3DJ.%26aulast%3DStiborova%26aufirst%3DM.%26aulast%3DHrabeta%26aufirst%3DJ.%26atitle%3DHistone%2520Deacetylase%2520Inhibitors%2520as%2520Anticancer%2520Drugs%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2017%26volume%3D18%26spage%3D1414%26doi%3D10.3390%2Fijms18071414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Debeb, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacerda, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolfe, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnamurthy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reuben, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueno, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilcrease, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodward, W. A.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase Inhibitor-Induced Cancer Stem Cells Exhibit High Pentose Phosphate Pathway Metabolism</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">28329</span>– <span class="NLM_lpage">28339</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.8631</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.18632%2Foncotarget.8631" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=27078845" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A280%3ADC%252BC28fpvVeiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=28329-28339&author=B.+G.+Debebauthor=L.+Lacerdaauthor=R.+Larsonauthor=A.+R.+Wolfeauthor=S.+Krishnamurthyauthor=J.+M.+Reubenauthor=N.+T.+Uenoauthor=M.+Gilcreaseauthor=W.+A.+Woodward&title=Histone+Deacetylase+Inhibitor-Induced+Cancer+Stem+Cells+Exhibit+High+Pentose+Phosphate+Pathway+Metabolism&doi=10.18632%2Foncotarget.8631"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitor-induced cancer stem cells exhibit high pentose phosphate pathway metabolism</span></div><div class="casAuthors">Debeb Bisrat G; Lacerda Lara; Larson Richard; Wolfe Adam R; Woodward Wendy A; Debeb Bisrat G; Lacerda Lara; Larson Richard; Wolfe Adam R; Krishnamurthy Savitri; Reuben James M; Ueno Naoto T; Woodward Wendy A; Krishnamurthy Savitri; Gilcrease Michael; Reuben James M; Ueno Naoto T</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">28329-39</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  We recently demonstrated that histone deacetylase (HDAC) inhibitors can "reprogram" differentiated triple-negative breast cancer cells to become quiescent stem-like cancer cells.  We hypothesized that the metabolic state of such cells differs from that of their differentiated progeny.  RESULTS:  In untreated cells, glucose uptake was higher in ALDH+ cells than in ALDH- cells (p = 0.01) but lactate production was not different; treating ALDH- or ALDH+ cells with VA or SAHA similarly increased glucose uptake without changing lactate production but upregulated G6PD, a rate-limiting enzyme in pentose phosphate pathway metabolism.  NADPH production was higher in HDAC inhibitor-treated stem-like cells than in vehicle-treated cells (p < 0.05).  Two G6PD inhibitors, 6-aminonicotinamide and dehydroepiandrosterone, decreased mammosphere formation efficiency and ALDH activity and 6-aminonicotinamide reduced the VA-induced increase in ALDH+ cells.  Finally, patients expressing high G6PD mRNA had significantly worse overall survival (p < 0.001), and patients with high G6PD protein showed a similar trend towards worse disease-specific survival (p = 0.06).  METHODS:  Glucose consumption, lactate and NADPH production, and reactive oxygen species generation were compared in aldehyde dehydrogenase (ALDH)-positive and -negative cells in the presence or absence of the HDAC inhibitors valproic acid (VA) or suberoylanilide hydroxamic acid (SAHA).  Glucose-6-phosphate dehydrogenase (G6PD) expression was evaluated in a tissue microarray from 94 patients with node-positive invasive breast carcinoma and in two publically available databases and correlated with overall survival.  CONCLUSIONS:  Energy metabolism in HDAC inhibitor-induced stem-like cancer cells differed sharply from that of differentiated cell types.  HDAC inhibitor-induced dedifferentiation promoted metabolic reprogramming into the pentose phosphate pathway, which is targeted effectively by G6PD inhibition.  These findings highlight a potential dual-therapy approach to targeting bulk differentiated cells with HDAC inhibitors and CSCs with G6PD inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcReIsQmOZOPkzW1zwg2yUK5fW6udTcc2eZU0G2IdETE8Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28fpvVeiuw%253D%253D&md5=4570baed154999960cf18e0478566516</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.8631&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.8631%26sid%3Dliteratum%253Aachs%26aulast%3DDebeb%26aufirst%3DB.%2BG.%26aulast%3DLacerda%26aufirst%3DL.%26aulast%3DLarson%26aufirst%3DR.%26aulast%3DWolfe%26aufirst%3DA.%2BR.%26aulast%3DKrishnamurthy%26aufirst%3DS.%26aulast%3DReuben%26aufirst%3DJ.%2BM.%26aulast%3DUeno%26aufirst%3DN.%2BT.%26aulast%3DGilcrease%26aufirst%3DM.%26aulast%3DWoodward%26aufirst%3DW.%2BA.%26atitle%3DHistone%2520Deacetylase%2520Inhibitor-Induced%2520Cancer%2520Stem%2520Cells%2520Exhibit%2520High%2520Pentose%2520Phosphate%2520Pathway%2520Metabolism%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26spage%3D28329%26epage%3D28339%26doi%3D10.18632%2Foncotarget.8631" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Valdez, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brammer, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosing, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nieto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Champlin, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, B. S.</span></span> <span> </span><span class="NLM_article-title">Romidepsin Targets Multiple Survival Signaling Pathways in Malignant T Cells</span>. <i>Blood Canc. J.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>, <span class="NLM_elocation-id">e357</span> <span class="refDoi"> DOI: 10.1038/bcj.2015.83</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1038%2Fbcj.2015.83" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=26473529" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&author=B.+C.+Valdezauthor=J.+E.+Brammerauthor=Y.+Liauthor=D.+Murrayauthor=Y.+Liuauthor=C.+Hosingauthor=Y.+Nietoauthor=R.+E.+Champlinauthor=B.+S.+Andersson&title=Romidepsin+Targets+Multiple+Survival+Signaling+Pathways+in+Malignant+T+Cells&doi=10.1038%2Fbcj.2015.83"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1038%2Fbcj.2015.83&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbcj.2015.83%26sid%3Dliteratum%253Aachs%26aulast%3DValdez%26aufirst%3DB.%2BC.%26aulast%3DBrammer%26aufirst%3DJ.%2BE.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DMurray%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DHosing%26aufirst%3DC.%26aulast%3DNieto%26aufirst%3DY.%26aulast%3DChamplin%26aufirst%3DR.%2BE.%26aulast%3DAndersson%26aufirst%3DB.%2BS.%26atitle%3DRomidepsin%2520Targets%2520Multiple%2520Survival%2520Signaling%2520Pathways%2520in%2520Malignant%2520T%2520Cells%26jtitle%3DBlood%2520Canc.%2520J.%26date%3D2015%26volume%3D5%26doi%3D10.1038%2Fbcj.2015.83" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Freisleben, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brudny-Klöppel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulder, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Vries, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Zwart, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timmerman, P.</span></span> <span> </span><span class="NLM_article-title">Blood Stability Testing: European Bioanalysis Forum View on Current Challenges for Regulated Bioanalysis</span>. <i>Bioanalysis</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1333</span>– <span class="NLM_lpage">1336</span>, <span class="refDoi"> DOI: 10.4155/bio.11.121</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.4155%2Fbio.11.121" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=21679027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BC3MXns1Shtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=1333-1336&author=A.+Freislebenauthor=M.+Brudny-Kl%C3%B6ppelauthor=H.+Mulderauthor=R.+De+Vriesauthor=M.+De+Zwartauthor=P.+Timmerman&title=Blood+Stability+Testing%3A+European+Bioanalysis+Forum+View+on+Current+Challenges+for+Regulated+Bioanalysis&doi=10.4155%2Fbio.11.121"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Blood stability testing: European Bioanalysis Forum view on current challenges for regulated bioanalysis</span></div><div class="casAuthors">Freisleben, Achim; Brudny-Kloeoeppel, Margarete; Mulder, Hans; de Vries, Ronald; de Zwart, Marcel; Timmerman, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Bioanalysis</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1333-1336</span>CODEN:
                <span class="NLM_cas:coden">BIOAB4</span>;
        ISSN:<span class="NLM_cas:issn">1757-6180</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">Since 2008, blood stability testing has gained considerable attention in the European Bioanal. Forum (EBF) with discussions aiming to align processes, timing and reporting of analyte stability testing in blood as part of method development and validation.  In this recommendation, EBF summarizes the conclusions reached to date and aims to provide recommendation for the exptl. conduct of such assays as well as the inclusion of stability testing into the scope of method development and validation.  Besides considering a step-wise approach for blood stability testing, recommendation is made to analyze the blood fraction using a qualified assay in order to circumvent important exptl. hurdles.  This article will provide an increased understanding of the impact of blood stability testing but furthermore invites scientists to share their views in order to refine the thinking to reach a global harmonized view.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmPhqXZlITKbVg90H21EOLACvtfcHk0lhgH0drgW96UQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXns1Shtrc%253D&md5=366af8b550deb578f763c77e4d84b899</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.4155%2Fbio.11.121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Fbio.11.121%26sid%3Dliteratum%253Aachs%26aulast%3DFreisleben%26aufirst%3DA.%26aulast%3DBrudny-Kl%25C3%25B6ppel%26aufirst%3DM.%26aulast%3DMulder%26aufirst%3DH.%26aulast%3DDe%2BVries%26aufirst%3DR.%26aulast%3DDe%2BZwart%26aufirst%3DM.%26aulast%3DTimmerman%26aufirst%3DP.%26atitle%3DBlood%2520Stability%2520Testing%253A%2520European%2520Bioanalysis%2520Forum%2520View%2520on%2520Current%2520Challenges%2520for%2520Regulated%2520Bioanalysis%26jtitle%3DBioanalysis%26date%3D2011%26volume%3D3%26spage%3D1333%26epage%3D1336%26doi%3D10.4155%2Fbio.11.121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sugihara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitamura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatsumi, K.</span></span> <span> </span><span class="NLM_article-title">Reduction of Hydroxamic Acids to the Corresponding Amides Catalyzed by Rabbit Blood</span>. <i>Xenobiotica</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">457</span>– <span class="NLM_lpage">467</span>, <span class="refDoi"> DOI: 10.1080/004982500237479</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1080%2F004982500237479" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10875680" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BD3cXktF2ltbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2000&pages=457-467&author=K.+Sugiharaauthor=S.+Kitamuraauthor=S.+Ohtaauthor=K.+Tatsumi&title=Reduction+of+Hydroxamic+Acids+to+the+Corresponding+Amides+Catalyzed+by+Rabbit+Blood&doi=10.1080%2F004982500237479"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Reduction of hydroxamic acids to the corresponding amides catalyzed by rabbit blood</span></div><div class="casAuthors">Sugihara, K.; Kitamura, S.; Ohta, S.; Tatsumi, K.</div><div class="citationInfo"><span class="NLM_cas:title">Xenobiotica</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">457-467</span>CODEN:
                <span class="NLM_cas:coden">XENOBH</span>;
        ISSN:<span class="NLM_cas:issn">0049-8254</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">The hydroxamic acids N-hydroxyphenacetin and N-hydroxy-2-acetylamino-fluorene were reduced to the corresponding amides, phenacetin and 2-acetylaminofluorene resp. by rabbit blood supplemented with both NAD(P)H and FAD.  These reducing activities were found in erythrocytes but not in plasma, and were sensitive to inhibition by carbon monoxide and oxygen.  When blood or erythrocytes were boiled, these activities were not abolished.  Hemoproteins such as Hb and catalase exhibited the reductase activity in the presence of both NAD(P)H and FAD under anaerobic conditions.  The activity was not abolished when the hemoproteins were boiled.  Hematin showed a significant reducing activity in the presence of these cofactors.  The activity of hematin was also obsd. with the photochem. reduced form of FAD.  The redn. system in blood was composed of NAD(P)H, FAD and Hb.  Redn. appears to proceed in two steps, i.e. the redn. of FAD by NADH or NADPH, followed by the non-enzymic redn. of the hydroxamic acids to the amides by reduce FAD, catalyzed by the hem group of Hb in rabbit erythrocytes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgLx6hWIY9CLVg90H21EOLACvtfcHk0lhgH0drgW96UQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXktF2ltbk%253D&md5=4c17b4499a670cb515c3c94edc4757ef</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1080%2F004982500237479&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F004982500237479%26sid%3Dliteratum%253Aachs%26aulast%3DSugihara%26aufirst%3DK.%26aulast%3DKitamura%26aufirst%3DS.%26aulast%3DOhta%26aufirst%3DS.%26aulast%3DTatsumi%26aufirst%3DK.%26atitle%3DReduction%2520of%2520Hydroxamic%2520Acids%2520to%2520the%2520Corresponding%2520Amides%2520Catalyzed%2520by%2520Rabbit%2520Blood%26jtitle%3DXenobiotica%26date%3D2000%26volume%3D30%26spage%3D457%26epage%3D467%26doi%3D10.1080%2F004982500237479" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hermant, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosc, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piveteau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gealageas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ronco, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roignant, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolojanahary, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jean, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renard, P.-Y.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Controlling Plasma Stability of Hydroxamic Acids: A MedChem Toolbox</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">9067</span>– <span class="NLM_lpage">9089</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01444</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01444" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1amurbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=9067-9089&author=P.+Hermantauthor=D.+Boscauthor=C.+Piveteauauthor=R.+Gealageasauthor=B.+Lamauthor=C.+Roncoauthor=M.+Roignantauthor=H.+Tolojanaharyauthor=L.+Jeanauthor=P.-Y.+Renard&title=Controlling+Plasma+Stability+of+Hydroxamic+Acids%3A+A+MedChem+Toolbox&doi=10.1021%2Facs.jmedchem.7b01444"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Controlling Plasma Stability of Hydroxamic Acids: A MedChem Toolbox</span></div><div class="casAuthors">Hermant, Paul; Bosc, Damien; Piveteau, Catherine; Gealageas, Ronan; Lam, BaoVy; Ronco, Cyril; Roignant, Matthieu; Tolojanahary, Hasina; Jean, Ludovic; Renard, Pierre-Yves; Lemdani, Mohamed; Bourotte, Marilyne; Herledan, Adrien; Bedart, Corentin; Biela, Alexandre; Leroux, Florence; Deprez, Benoit; Deprez-Poulain, Rebecca</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9067-9089</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Hydroxamic acids are outstanding zinc chelating groups that can be used to design potent and selective metalloenzyme inhibitors in various therapeutic areas.  Some hydroxamic acids display a high plasma clearance resulting in poor in vivo activity, though they may be very potent compds. in vitro.  The authors designed a 57-member library of hydroxamic acids to explore the structure-plasma stability relationships in these series and to identify which enzyme(s) and which pharmacophores are crit. for plasma stability.  Arylesterases and carboxylesterases were identified as the main metabolic enzymes for hydroxamic acids.  Finally, the authors suggest structural features to be introduced or removed to improve stability.  This work thus provides the first medicinal chem. toolbox (exptl. procedures and structural guidance) to assess and control the plasma stability of hydroxamic acids and realize their full potential as in vivo pharmacol. probes and therapeutic agents.  This study is particularly relevant to preclin. development as it allows obtaining compds. equally stable in human and rodent models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpp13iDBW5DnrVg90H21EOLACvtfcHk0lh8KmNCin17mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1amurbE&md5=a7314d840db2c12c7fb769d0b8d52236</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01444&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01444%26sid%3Dliteratum%253Aachs%26aulast%3DHermant%26aufirst%3DP.%26aulast%3DBosc%26aufirst%3DD.%26aulast%3DPiveteau%26aufirst%3DC.%26aulast%3DGealageas%26aufirst%3DR.%26aulast%3DLam%26aufirst%3DB.%26aulast%3DRonco%26aufirst%3DC.%26aulast%3DRoignant%26aufirst%3DM.%26aulast%3DTolojanahary%26aufirst%3DH.%26aulast%3DJean%26aufirst%3DL.%26aulast%3DRenard%26aufirst%3DP.-Y.%26atitle%3DControlling%2520Plasma%2520Stability%2520of%2520Hydroxamic%2520Acids%253A%2520A%2520MedChem%2520Toolbox%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D9067%26epage%3D9089%26doi%3D10.1021%2Facs.jmedchem.7b01444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flipo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hocine, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dassonneville, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deprez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deprez-Poulain, R.</span></span> <span> </span><span class="NLM_article-title">Hydroxamates: Relationships between Structure and Plasma Stability</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">6790</span>– <span class="NLM_lpage">6802</span>, <span class="refDoi"> DOI: 10.1021/jm900648x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900648x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1GgsbnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6790-6802&author=M.+Flipoauthor=J.+Chartonauthor=A.+Hocineauthor=S.+Dassonnevilleauthor=B.+Deprezauthor=R.+Deprez-Poulain&title=Hydroxamates%3A+Relationships+between+Structure+and+Plasma+Stability&doi=10.1021%2Fjm900648x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Hydroxamates: Relationships between Structure and Plasma Stability</span></div><div class="casAuthors">Flipo, Marion; Charton, Julie; Hocine, Akila; Dassonneville, Sandrine; Deprez, Benoit; Deprez-Poulain, Rebecca</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6790-6802</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Hydroxamates are valuable tools for chem. biol. as well as interesting leads for medicinal chem.  Although many hydroxamates display nanomolar activities against metalloproteases, only three hydroxamates have reached the market, among which is the HDAC inhibitor vorinostat.  Failures in development are generally attributed to lack of selectivity, toxicity, or poor stability.  To help medicinal chemists with respect to plasma stability, the authors have performed the first and preliminary study on structure-plasma stability for hydroxamates.  The authors define some structural rules to predict or improve the plasma stability in the preclin. stage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrk66ooWU1NhbVg90H21EOLACvtfcHk0lh8KmNCin17mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1GgsbnJ&md5=069a87988fbeb68a248d006c7f6307a0</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Fjm900648x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900648x%26sid%3Dliteratum%253Aachs%26aulast%3DFlipo%26aufirst%3DM.%26aulast%3DCharton%26aufirst%3DJ.%26aulast%3DHocine%26aufirst%3DA.%26aulast%3DDassonneville%26aufirst%3DS.%26aulast%3DDeprez%26aufirst%3DB.%26aulast%3DDeprez-Poulain%26aufirst%3DR.%26atitle%3DHydroxamates%253A%2520Relationships%2520between%2520Structure%2520and%2520Plasma%2520Stability%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D6790%26epage%3D6802%26doi%3D10.1021%2Fjm900648x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarantopoulos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juric, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connarn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruchec, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harvey, R. D.</span></span> <span> </span><span class="NLM_article-title">A Phase 1b Study of the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Citarinostat (ACY-241) in Combination with Paclitaxel (Pac) in Patients (Pts) with Advanced Solid Tumors (AST)</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">2547</span>, <span class="refDoi"> DOI: 10.1200/JCO.2018.36.15_suppl.2547</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;key=10.1200%2FJCO.2018.36.15_suppl.2547" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2018&pages=2547&author=M.+S.+Gordonauthor=G.+Shapiroauthor=J.+Sarantopoulosauthor=D.+Juricauthor=B.+Luauthor=P.+Chenauthor=J.+Connarnauthor=Y.+L.+Bruchecauthor=R.+D.+Harvey&title=A+Phase+1b+Study+of+the+Safety%2C+Pharmacokinetics%2C+and+Preliminary+Antitumor+Activity+of+Citarinostat+%28ACY-241%29+in+Combination+with+Paclitaxel+%28Pac%29+in+Patients+%28Pts%29+with+Advanced+Solid+Tumors+%28AST%29&doi=10.1200%2FJCO.2018.36.15_suppl.2547"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1200%2FJCO.2018.36.15_suppl.2547&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2018.36.15_suppl.2547%26sid%3Dliteratum%253Aachs%26aulast%3DGordon%26aufirst%3DM.%2BS.%26aulast%3DShapiro%26aufirst%3DG.%26aulast%3DSarantopoulos%26aufirst%3DJ.%26aulast%3DJuric%26aufirst%3DD.%26aulast%3DLu%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DConnarn%26aufirst%3DJ.%26aulast%3DBruchec%26aufirst%3DY.%2BL.%26aulast%3DHarvey%26aufirst%3DR.%2BD.%26atitle%3DA%2520Phase%25201b%2520Study%2520of%2520the%2520Safety%252C%2520Pharmacokinetics%252C%2520and%2520Preliminary%2520Antitumor%2520Activity%2520of%2520Citarinostat%2520%2528ACY-241%2529%2520in%2520Combination%2520with%2520Paclitaxel%2520%2528Pac%2529%2520in%2520Patients%2520%2528Pts%2529%2520with%2520Advanced%2520Solid%2520Tumors%2520%2528AST%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2018%26volume%3D36%26spage%3D2547%26doi%3D10.1200%2FJCO.2018.36.15_suppl.2547" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5WGI" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5WGI','PDB','5WGI'); return false;">PDB: 5WGI</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4A69" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4A69','PDB','4A69'); return false;">PDB: 4A69</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T64" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T64','PDB','1T64'); return false;">PDB: 1T64</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EDU" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EDU','PDB','5EDU'); return false;">PDB: 5EDU</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5WGL" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5WGL','PDB','5WGL'); return false;">PDB: 5WGL</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7JOM" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7JOM','PDB','7JOM'); return false;">PDB: 7JOM</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i26"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01922">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_47566"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01922?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01922</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01922/suppl_file/jm0c01922_si_001.csv">CSV</a>)</p></li><li><p class="inline">HDAC binding and inhibition profiles using FP and enzymatic activity assays; PAMPA, kinetic solubility, and pharmacokinetic data; cell population sorting; cell viability screens; mass spectrometry; immunofluorescence; and synthetic schemes, experimental procedures, and compound characterization (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01922/suppl_file/jm0c01922_si_002.pdf">PDF</a>)</p></li><li><p class="inline">Docking of <b>TO-317</b> with drHDAC6 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01922/suppl_file/jm0c01922_si_003.pdb">PDB</a>)</p></li><li><p class="inline">Docking of 1 with drHDAC6 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01922/suppl_file/jm0c01922_si_004.pdb">PDB</a>)</p></li><li><p class="inline">Docking of 2 with drHDAC6 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01922/suppl_file/jm0c01922_si_005.pdb">PDB</a>)</p></li><li><p class="inline">Docking of citarinostat with drHDAC6 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01922/suppl_file/jm0c01922_si_006.pdb">PDB</a>)</p></li><li><p class="inline">Docking of <b>TO-317</b> with HDAC8 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01922/suppl_file/jm0c01922_si_007.pdb">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01922/suppl_file/jm0c01922_si_001.csv">jm0c01922_si_001.csv (2.29 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01922/suppl_file/jm0c01922_si_002.pdf">jm0c01922_si_002.pdf (11.59 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01922/suppl_file/jm0c01922_si_003.pdb">jm0c01922_si_003.pdb (60.23 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01922/suppl_file/jm0c01922_si_004.pdb">jm0c01922_si_004.pdb (4.92 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01922/suppl_file/jm0c01922_si_005.pdb">jm0c01922_si_005.pdb (5.05 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01922/suppl_file/jm0c01922_si_006.pdb">jm0c01922_si_006.pdb (5.11 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01922/suppl_file/jm0c01922_si_007.pdb">jm0c01922_si_007.pdb (6.31 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01922&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-5%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01922%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01922" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679938a6dae43cf4","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
